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 Daptomycin is a calcium-dependent cyclic lipodepsipeptide that is used clinically in 
the treatment of infections caused by pathogenic Gram-positive organisms, such as methicillin-
resistant Staphylococcus aureus. Another calcium-dependent cyclic lipodepsipeptide 
antibiotic, A54145D, also has biological activity against Gram-positive pathogenic organisms, 
but is not used clinically because it is approximately 4-fold less active than daptomycin. Unlike 
daptomycin, however, A54145D is not inhibited by lung surfactant in vitro, which makes 
A54145D a suitable lead compound for the development of other antibiotics that may find use 
in medical practice as an alternative treatment for community-acquired pneumonia caused by 
Streptococcus pneumoniae. 
 While the total synthesis of daptomycin has been reported, thus allowing for an 
efficient method for the generation of analogs of daptomycin, no similar synthesis for 
A54145D was reported at the start of these studies. To facilitate the development of future 
antibiotics, a total synthesis of A54145D was developed employing Fmoc-based solid-phase-
peptide synthesis. This synthesis enabled us to confirm that the 3-hydroxyasparagine residue 
has the (2S,3S)-configuration (threo), and the 3-methoxyaspartate residue has the (2S,3R)-
configuration (erythro) instead of the (2S,3S)-configuration (threo). Additional analogs of 
A54145D and A54145A1 were synthesized to study the structure-activity relationships of these 
antibiotics, and it was determined that the threonine residue is not amenable for substitution, 
in that replacement of threonine caused a dramatic loss in biological activity. Furthermore, it 




aspartate, and 3-hydroxyasparagine with asparagine resulted in a 16-fold reduction of 
biological activity. 
 To further elucidate the mechanism of action of cyclic lipodepsipeptide antibiotics, 
which is a matter of some controversy in the scientific literature, ten fluorinated analogs of 
daptomycin were constructed by semi-synthesis or total synthesis to study their interaction 
with model membranes using 19F-NMR. These analogs exhibited activity against Bacillus 
subtilis equal to or approaching that of daptomycin. 19F-NMR studies with a peptide that 
contained a trifluoromethyl moiety at the end of the lipid tail indicate that at concentrations of 
daptomycin and calcium that are representative of in vivo conditions, daptomycin does not 
aggregate in solution. Preliminary 19F-NMR studies with a daptomycin analog containing the 
CF3 group appended to the ornithine residue at position 6 in the presence of model membranes 
and varying amounts of calcium suggest that the ornithine residue of daptomycin interacts with 
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Chapter 1 – Introduction 
 
1.0 – Antibiotics and Antibiotic Resistance 
 
 Sulfonamides were deployed as antibacterial agents in the 1930s, and ever since then, 
antibiotics have been used clinically to aid in the treatment of bacterial infections.1,2 Antibiotics 
are compounds that kill bacteria (bactericidal) or prevent their proliferation (bacteriostatic). 
They can act on various cellular targets, including the cell wall, cell membrane, proteins, and 
even nucleic acids. Penicillin, for example, inhibits the final step in cell wall biosynthesis in 
Gram-positive bacteria.3 
 Many infections that were once fatal have become easily treatable through antibiotics. 
The introduction of antibiotics for the rapid treatment of pathogenic bacteria is easily one of 
the most important advances ever made in the field of medicine. Many antibiotics were 
discovered or developed between 1940 and 1960, and this time interval has been called the 
“Golden Age” of antibiotic development.4 Between 1962 and 2000, no new major classes of 
antibiotics were introduced to clinic, until linezolid (2000), daptomycin (2003), and 
retapamulin (2007) were approved for clinical use (Figure 1.1).4 More recently, fixadomycin 
and bedaquiline (Figure 1.1) were approved for clinical use (2012).5,6 Regrettably, the search 
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for new antibiotics is not very economically profitable, and despite the urgent and on-going 
need for new antibiotics, limited research is underway.7 
 
Figure 1.1: Novel antibiotics released in the 21st century. Each structure represents a different 
class. Linezolid, retapamulin, and fidaxomicin inhibit ribosomal protein synthesis.8–10 
Bedaquiline inhibits ATP synthase.11 
 
 The lack of research toward new antibiotics is concerning, as bacterial antibiotic 
resistance has been observed within several years of the deployment of any novel antibiotic 
(Figure 1.2).1 Indeed, Clatworthy et al. discussed this trend in 2007, noting the dates of 
deployment and the dates of resistance observed. As an antibiotic is deployed to target a 
cellular component or function, bacteria adapt to their environment under selective pressure, 




Figure 1.2: Timeline of antibiotic deployment and observed resistance. The year the antibiotic 
was deployed is depicted above the timeline, and the year resistance was observed is below. 
Figure taken from Clatworthy et al. and used with permission.1 
 
 The widespread resistance to antibiotics has led some to claim that we are living in a 
“post-antibiotic era”.12 The extensive use of antibiotics has led to the emergence of multi-drug 
resistant strains of bacteria including Staphylococcus aureus, Mycobacterium tuberculosis, and 
Streptococcus pneumoniae. Accordingly, humanity and bacteria are currently in an 
evolutionary arms race: as bacteria evolve resistance against our current arsenal of antibiotics, 
we must be continually developing new antibiotics, and this cycle will inevitably continue ad 
infinitum. Thus, overcoming antibiotic-resistant bacteria is not merely an end-goal, but a 
perpetual journey, and the issue of antibiotic resistance is an issue that is expected to become 
much more serious in the not-too-distant future. 
 Fortunately, physicians have at their disposal a handful of antibiotics for which 
widespread resistance has not yet developed. These are used as a last resort when all other 
antibiotics fail. One of these so-called last resort antibiotics is daptomycin.13 
4 
 
1.1 – Introduction to Cyclic Lipodepsipeptide Antibiotics 
 
 Daptomycin (Figures 1.1 and 1.3) is a cyclic lipodepsipeptide antibiotic (cLPA) that is 
used to treat serious skin infections caused by Gram-positive bacteria. It is a member of the 
A21978C family of antibiotics and is clinically approved for the treatment of infections caused 
by methicillin-resistant and methicillin-susceptible S. aureus (MRSA and MSSA, 
respectively), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, 
and vancomycin-resistant Enterococci faecalis.13,14 Notably, daptomycin is not used clinically 
against Streptococcus pneumoniae, the source of community-acquired pneumonia. Although 
daptomycin is biologically active in vitro against S. pneumonia, daptomycin is suspected to be 
inhibited by lung surfactant in vivo.  
 Daptomycin consists of a macrocyclic peptide core containing ten amino acids, with an 
ester bond between the side-chain of Thr4 and the α-carboxylic acid of Kyn13. Attached to 
Thr4 is an exocyclic portion which contains an additional three amino acids and a lipid tail. 
The peptide contains three non-proteinogenic L-amino acids: ornithine at position 6 (Orn6), 
(2S,3R)-3-methylglutamate at position 12 (MeGlu12), and kynurenine at position 13 (Kyn13). 
Additionally, there are three non-proteinogenic D-amino acids (D-Asn2, D-Ala8, and D-
Ser11). It is produced using non-ribosomal peptide synthetases (NRPSs) by Streptomyces 
roseosporus (See section 1.4 for a brief discussion on non-ribosomal peptide synthesis) and 




Figure 1.3: The structure of daptomycin (1.2). D-amino acids are shown in blue, and non-
proteinogenic amino acids are shown in green. The depsi-bond between the side-chain of Thr4 
and the α-carboxylic acid of Kyn13 is shown in red. 
 
 Members of the Calcium-Dependent Antibiotic (CDA) and A54145 families of 
antibiotics (Figure 1.4) are structurally related to daptomycin. The A54145 family also 
contains a macrocyclic peptide core containing ten amino acids, an exocyclic tripeptide and a 
lipid tail. In A54145, the depsi-bond is formed between the side-chain of Thr4 and the α-
carboxylic acid of Ile13 or Val13. Three non-proteinogenic D-amino acids are found at the 
same locations as for daptomycin (D-Glu2, D-Lys8, and D-Asn11). The A54145 family of 
antibiotics consists of 8 different factors, whose structures vary at three different locations. 
Common to all A54145 factors are the non-proteinogenic amino acids hydroxyasparagine at 
position 3 (HOAsn3), sarcosine at position 4 (Sar4), and methoxyaspartate at position 9 
(MeOAsp9). The factors vary at the lipid tail, which may be n-decanoyl, iso-decanoyl, or 
anteiso-undecanoyl; at position 12, which may be Glu or 3MeGlu; and at position 13, which 
may be Ile or Val. The A54145 family of antibiotics is synthesized non-ribosomally by 




Figure 1.4: The structure of the A54145 family of antibiotics. D-amino acids are shown in 
blue, and non-proteinogenic amino acids are shown in green. The depsi-bond between the side-
chain of Thr4 and the α-carboxylic acid of Ile13/Val13 is shown in red. 
 
 No members of the A54145 family have been approved for clinical use. Factors that 
contain MeGlu12 are about 2-fold less active than daptomycin but are too toxic to mice.15 
Factors that contain Glu12 are about 2-fold less active than those containing MeGlu12 but are 
substantially less toxic. A54145 Factor D (A54145D), which contains Glu12, Ile13, and an 
anteiso-undecanoyl tail, has lower biological activity than daptomycin, but, somewhat 
surprisingly, in vitro studies demonstrate that A54145D retains most of its biological activity 
in the presence of lung surfactant.16,17 Since inhibition by lung surfactant is the suspected 
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reason why daptomycin failed to meet non-inferiority criteria as a treatment for community-
acquired pneumonia during clinical trials, A54145D’s in vitro efficacy in the presence of lung 
surfactant makes it a promising starting point in the development of antibiotics that can be used 
to treat community-acquired pneumonia (CAP), a leading cause of death worldwide.18,19 
1.2 – Proposed Mechanisms of Action of Cyclic Lipodepsipeptide Antibiotics 
 
 Most of the research to date pertaining to the mechanism of action of cLPAs has been 
done on daptomycin. It is assumed that A54145 behaves in a similar fashion. Despite over 30 
years of studies to elucidate its mode of action, the exact mechanism by which daptomycin 
elicits its bactericidal effect is a matter of some controversy. The main proposed mechanisms 
are pore formation within the cell membrane, disruption of cell wall synthesis, and disruption 
of proper cell membrane function. 
 In 1985, the first reported study of the bacterial activity of the A21978C family of 
antibiotics was published. Eliopoulos et al. discovered that A21978C1, which is daptomycin 
with an 8-methyldecanoyl tail instead of a decanoyl tail, only exhibited anti-bacterial activity 
if the growth medium was supplemented with calcium (Ca2+).20 Lakey et al. reported in 1986 
that subjecting lipid membranes to A21978C (daptomycin) increased their conductivity and 
rendered them permeable to potassium, and that conductivity was proportional to the amount 
of Ca2+ added.21 Finally, in 2004, researchers in the Hancock group used daptomycin’s intrinsic 
fluorescence to show that daptomycin binds to membranes only in the presence of Ca2+, and 
only when the membranes contain phosphatidylglycerol (PG) lipids.22 Further, based upon 
circular dichroism studies (CD) studies, the Hancock group established that daptomycin 
undergoes a significant structural change upon membrane-binding.22 While the exact 
mechanism by which daptomycin elicits its bactericidal activity is still controversial, it has 
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been well established that daptomycin requires calcium and phosphatidyl glycerol for 
biological activity, and that depolarization of the cell membrane occurs after being subjected 
to daptomycin.  
1.2.1 – Disruption of Cell Wall Synthesis 
 
 There are several differences between Gram-positive and Gram-negative bacteria. 
Firstly, Gram-negative bacteria have two separate cell membranes: an inner membrane and an 
outer membrane (Figure 1.5). Secondly, Gram-positive bacteria have a much thicker 
peptidoglycan (also termed murein) layer, which acts as a cell wall. It is the synthesis of this 
peptidoglycan layer that is thought by some to be the site of action of daptomycin. 
 
Figure 1.5: Structure of Gram-negative and Gram-positive membranes. Murein is referred to 
as peptidoglycan in this thesis. Figure taken and modified from Dr. Palmer’s Biochemical 
Pharmacology course notes with permission.23 
 
 In 1985, Eliopoulos et al. studied A21978C1 and observed that upon subjecting 
Staphylococcus aureus and Streptococcus faecalis to this compound for 180 minutes,  
incorporation of radio-labelled [14C]-alanine was reduced by up to 50% of the control.20 Since 
alanine is a precursor to D-alanine, which is incorporated into peptidoglycan during its 
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biosynthesis, the researchers concluded that daptomycin inhibits the peptidoglycan synthesis.20 
The same effect was also observed with authentic daptomycin (at the time named LY146032) 
by Allen et al.24 Similarly, Mengin-Lecreulx et al. also reported in 1990 that daptomycin likely 
interferes in peptidoglycan synthesis, as treatment with daptomycin reduced the incorporation 
of another precursor, [14C]-GlcNAc (N-acetylglucosamine), into peptidoglycan.25 
 In 1990 and 1993, researchers in the Satta group further refined this proposed 
mechanism of action.26 In this work, the researchers determined that daptomycin was still 
active against Enterococcus faecium protoplasts (living cells which notably lack a cell wall, 
and are grown in osmotically protective media).26,27 By comparing the number of colony 
forming units (CFUs) observed after treatment with daptomycin with the number of CFUs 
observed after treatment with vancomycin (a known peptidoglycan synthesis inhibitor), it was 
clearly demonstrated that inhibition of peptidoglycan synthesis alone cannot account for 
daptomycin’s biological activity, as vancomycin was rendered ineffective, yet daptomycin still 
retained biological activity. The researchers determined that treating both S. aureus and E. 
faecium protoplasts with daptomycin reduced the incorporation of [14C]-glycerol into 
lipoteichoic acid (LTA), the synthesis of which is known to occur in the cell membrane.26,27 
This led to the alternative hypothesis that daptomycin also inhibits the biosynthesis of LTA. 
 Further research by Boaretti and Canepari towards daptomycin’s inhibition of LTA 
synthesis allowed for the isolation of so-called daptomycin-binding proteins in 1995, and the 
further purification of these proteins in 2000.28,29 These isolated proteins, however, are only 
speculated to be related to LTA biosynthesis, and no direct evidence of daptomycin’s binding 
and their subsequent inhibition was obtained. Further, these proteins were never characterized 
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or identified, and no research on the topic of daptomycin-binding proteins has been published 
since.28 
 Many of the studies which conclude that daptomycin inhibits peptidoglycan synthesis 
or LTA synthesis relied on the observation that radiolabeled precursors to peptidoglycan and 
LTA are not incorporated by cells subjected to daptomycin. However, protoplasts lacking a 
peptidoglycan-containing cell wall were killed by daptomycin, which would not be expected 
if daptomycin acted exclusively on peptidoglycan synthesis. Furthermore, Laganas et al. 
demonstrated in 2003 that rifampin-treated S. aureus were susceptible to daptomycin 
treatment.30 Rifampin is a bacteriostatic antibiotic that causes the cessation of macromolecular 
synthesis including synthesis of LTA through RNA polymerase inhibition.31 However, 
treatment with rifampin does not significantly affect cellular viability. If daptomycin’s 
mechanism of action involved the inhibition of LTA biosynthesis, one might then expect that 
treating rifampin-arrested cells with daptomycin would not cause cell death. However, Laganas 
et al. found that daptomycin does indeed cause cell death of rifampin-arrested cells.30 Thus, 
current evidence pointing to the hypothesis that daptomycin’s mechanism of action involves 
inhibition of cell-wall biosynthesis does not completely explain daptomycin’s mode of action. 
1.2.2 – Disruption of Proper Cell Membrane Function 
 
 In 1986, Lakey and Lea observed that treatment of membranes with daptomycin 
increased their conductivity, proportional to the amount of calcium ions present, and from this 
proposed that daptomycin’s activity involved incorporation into the bilayer membrane.21 
Several studies have offered some support to the idea that daptomycin acts directly on 
membranes of its target bacteria, causing adverse effects. For example, scanning electron 
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microscopy of daptomycin-treated S. aureus by Wale et al. resulted in gross morphological 
changes to the surface of the bacteria.32 
 Researchers at Cubist Pharmaceuticals in 2008 were able to isolate cells after 
daptomycin treatment and examine them intact using electron microscopy, and demonstrated 
that daptomycin, regardless of its interaction with lipid bilayers, does not result in bacterial 
cell lysis (up to concentrations of 4 µg/mL, 8 x the MIC), however does result in aberrant cell 
division septa.33 In the same year, research in the Straus and Hancock groups demonstrated 
that the addition of daptomycin and Ca2+ to liposomes (model membranes) containing 
dioleoylphosphatidylglycerol (DOPG) and dioleoylphosphatidylcholine (DOPC) resulted in 
the fusion of large unilamellar vesicles (LUVs).34 Despite the evidence of membrane fusion in 
model membranes, this is unlikely to be the mechanism of action in vivo, since the presence of 
the cell well would prevent membrane fusion of live cells. 
 In 2012, Pogliano et al. in collaboration with Cubist Pharmaceuticals studied the 
interaction of BODIPY-daptomycin with B. subtilis.35 BODIPY-daptomycin is a synthetic 
variant of daptomycin which contains the BODIPY fluorophore, and can therefore be observed 
in live cells. The researchers noticed that BODIPY-daptomycin localizes in the cell membrane 
at nascent septa but is absent from pre-existing septa. Further, patches of daptomycin were 
found to co-localize with DivIVA-GFP, or the DivIVA protein with a green fluorescent protein 
(GFP) covalently attached. The authors proposed that daptomycin forms patches that attract 
the cell division protein DivIVA and incorrectly induce cell division. Further, sub-lethal 
concentrations of daptomycin resulted in abnormal membrane morphology, in that typically 
cylindrical B. subtilis appeared bent or curved following treatment with daptomycin. Finally, 
BODIPY-daptomycin co-localized with GFP-vancomycin, which is known to localize at 
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locations of peptidoglycan synthesis, further suggesting daptomycin’s possible role in 
abnormal cell wall morphology. In accordance with these observations, a new mechanism of 
action was proposed that involved the abnormal functioning of the cell membrane (Figure 1.6). 
In this proposed mechanism of action, daptomycin at sub-lethal concentrations causes changes 
in cell-membrane curvature as a result of the large head-group volume of daptomycin and the 
small-volume tail. It was postulated that this negative membrane curvature is compensated on 
the inner leaflet by cardiolipin, which has a small-volume head group and a large-volume lipid 
volume. Patches of daptomycin recruit the DivIVA protein, incorrectly signaling the 
daptomycin-patch as a site of cell division. At above-lethal concentrations of daptomycin, 
discontinuities in the membrane result in the slow leakage of ions and the loss of membrane 
potential. 
 
Figure 1.6: Proposed mechanism of action involving discontinuities in the membrane. Shown 
in the image is daptomycin (light blue cups with yellow circles), PG lipids (green lipids), 
cardiolipin (yellow lipids), potassium ions (green circles), and DivIVA (blue ovals). Taken 
from Pogliano et al. and used with permission.35 
 
 A novel hypothesis to the mechanism of action was also proposed by Chen et al. in 
2014, which involved daptomycin-mediated lipid-extraction.36 In this proposed mechanism of 
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action, the insertion of daptomycin into the model membrane displaces a pair of lipid molecules 
from the membrane, resulting in a major rearrangement of neighbouring lipids, called water 
pore defects, and these water pore defects allow for the permeation of ions through the 
membrane.36 To support this hypothesis, the researchers analyzed giant unilamellar vesicles 
(GUVs) partially aspirated into a micropipette at constant vacuum, effectively producing a 
spherical part and cylindrical part of the vesicle (Figure 1.7). Treatment with daptomycin at 
concentrations above the minimum inhibitory concentration resulted in an initial increase in 
the volume of the cylindrical part of the vesicle, indicating association of daptomycin with the 
membrane, followed by a decrease in the cylindrical volume, indicating an increase in surface 
tension that could be caused by the loss of lipids from the membrane. This study fails to 
address, however, the results from Pogliano et al., who observed membrane curvature as the 
result of daptomycin treatment.35 It is possible that daptomycin’s ability to adjust membrane 
curvature might also increase the surface tension observed in this lipid-extraction study. 
                         
Figure 1.7: Membrane surface area changes of GUVs with treatment of daptomycin. 
Daptomycin concentrations are indicated. The top row represents sub-MIC concentrations, and 
the middle and bottom rows represent supra-MIC concentrations. Taken from Chen et al. and 







 Very recently, Müller et al. observed that daptomycin completely dislodges MurG and 
PlsX from the bacterial membrane, and based upon this, suggested an alternative mechanism 
of action.37 It was proposed that daptomycin binds to fluid micro-domains (regions of increased 
fluidity), distorting the membrane resulting in even more fluid lipids at the site of membrane 
insertion (A,B Figure 1.8). The recruitment of other fluid lipids in the inner leaflet allows for 
daptomycin flipping from the outer to the inner leaflet, displacing the MurG protein, 
responsible for catalyzing the last synthesis step of peptidoglycan precursor lipid II, and PlsX, 
which is involved in phospholipid synthesis (C, Figure 1.8). Daptomycin present at the inner 
leaflet prevents the reassociation of MurG (D, Figure 1.8). Interestingly, this proposed 
mechanism of action relates the disruption of proper membrane function to the disruption of 
cell wall synthesis. Membrane depolarization is explained as a secondary effect of 
daptomycin’s activity, instead of its primary effect: the boundaries between regions of 
increased fluidity and more rigid micro-domains are assumed to be weak spots that allow for 
leaking of protons through the membrane. Interestingly, this work observed the lysis of cell 




Figure 1.8: Proposed mechanism of action involving MurG and PlsX dislocation. Daptomycin 
inserts into fluidic domains of the membrane (A, B), dislodging peripheral proteins such as 
MurG and PlsX (C,D). MurG and PlsX (green) are involved in peptidoglycan synthesis and 
phospholipid synthesis. Figure taken from Müller et al. and used with permission.37 
 
 Additionally, it was demonstrated by Lee et al. in 2018 that daptomycin bound to 
membranes that contained cholesterol less effectively.38 Since cholesterol increases the rigidity 
of biological membranes, this offers further support to the notion that daptomycin binds to 
regions of the membrane with increased fluidity.  
 A third mechanism of action widely accepted and supported by available evidence is 
the idea that daptomycin oligomerizes on bacterial membranes and forms a pore. This pore 
allows the leakage of cations from the cytosol, causing membrane depolarization and 




1.2.3 – Oligomerization and Pore Formation 
 
 Initial studies by Lakey and Lea in 1986 demonstrated that treatment of biological 
membranes in the presence of calcium ions resulted in increased conductivity of model 
membranes.21 Generally, increasing the calcium ion concentrations resulted in increased 
conductivity, suggesting that charged molecules or atoms were able to pass through the 
membrane. Lakey and Ptak in 1988 reconfirmed that daptomycin requires calcium for activity 
by observing the fluorescence changes of the intrinsically fluorescent kynurenine amino acid 
in lipids at increasing calcium concentrations.39  
 In 1991, researchers at Eli Lilly demonstrated on live cells that daptomycin disrupts 
membrane potential in S. aureus in a calcium-dependent fashion.40 In this report, it was also 
observed that the greatest biological activity of daptomycin was observed when the membrane 
potential of growing cells was at its largest, suggesting that the energized membrane potential 
is a target of the antibiotic’s action mechanism. Later that year, researchers at Eli Lilly reported 
that treatment by daptomycin reduced the potential-dependent uptake of glutamic acid and 
alanine, further suggesting that the energized membrane was the target for biological activity.41 
Expanding upon these results, in 2003 Jared Silverman et al. of Cubist Pharmaceuticals 
correlated the cell viability of daptomycin-treated S. aureus with a loss in membrane potential, 
and additionally, through the loss of potassium ions using a PBFI indicator (PBFI is a 
fluorescence ion indicator specific for potassium (K+) ions).42 Notably, the release of 
exclusively potassium from the cells would result in membrane hyperpolarization, so it is likely 
that daptomycin allows for the leakage of other ions from the cell in addition to potassium.13 
Additionally, recent research published by the Fišer group demonstrated that membranes with 
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higher potential were dissipated faster than membranes with lower potential when subjected to 
daptomycin, further suggesting that daptomycin’s target is an energized membrane.43 
 The above observations support the mechanism of action which involves membrane 
depolarization, but they do not provide insights into how it exactly this biological activity is 
effected. In the 2003 work by Silverman et al., it was proposed that daptomycin oligomerizes 
on biological membranes, which ultimately leads to membrane depolarization, although no 
evidence was presented to support daptomycin oligomerization. 
 It wasn’t until 2011 when researchers in the Palmer group reported that daptomycin 
oligomerizes on biological membranes.44,45 Based on observed self-quenching of the NBD-
fluorophore on NBD-daptomycin (NBD is 7-nitrobenzo-2-oxa-1,3-diazole, covalently 
attached to the Orn6 residue), and reduced self-quenching in the presence of native 
daptomycin, the presence of oligomers were deduced. Formation of oligomers were calcium 
ion dependent, and further, dependent upon the presence of DOPG lipids in the model 
membranes. Additionally, a daptomycin with a perylene moiety on its lipid tail formed 
excimers in the presence of PG membranes and calcium, further suggesting aggregation. 
 Researchers in the Palmer group in 2012 further estimated the subunit stoichiometry of 
membrane-associated daptomycin oligomers to be between 6 and 7 by quantifying 
fluorescence and fluorescence-resonance energy transfer (FRET) of the kynurenine of native 
daptomycin and the NBD-group of NBD-daptomycin.46 Then, in 2014, members of the Palmer 
group utilized a pore-forming assay to further elucidate the mechanism of action of 
daptomycin. In this assay, daptomycin and CCCP (carbonyl cyanide m-chlorophenyl 
hydrazine, a known protonophore) are exposed to pyranine-containing liposomes with both  
pH and salt gradient, and these pore-formers mutually allow dissipation of both gradients. The 
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fluorescence of pyranine is pH-sensitive and increases at higher pH (Figure 1.9). Accordingly, 
antibiotics that allow for the dissipation of the membrane through ion leakage will incite a 
fluorescence increase. 
 
Figure 1.9: Schematic representation of the pyranine-based liposome permeabilization assay. 
Addition of CCCP alone (Panel B) allows for slow diffusion of protons, but addition of CCCP 
and daptomycin (Panel C) allows for rapid dissipation of both gradients. Taken from Zhang et 
al. and used with permission.47 
 
 A control for this assay employed valinomycin instead of daptomycin, an antibiotic 
which is selective for translocating potassium through the membrane. With daptomycin, it was 
observed that other cations, including sodium, magnesium, and cesium in addition to potassium 
could pass through the membrane, but larger cations such as choline or hexamethonium were 
translocated at a much slower rate, and anions such as chloride and cysteine were not 
translocated at all, suggesting that daptomycin forms pores selective for cations, with a 
preference for smaller, monoatomic ions over larger, molecular ions.  
 Also in 2014, the Palmer group proposed that the fully functioning pore formed by 
daptomycin involves the oligomerization of daptomycin on each leaflet of the biological 
membrane.48 The study involved the use of the NBD fluorophore, which can be quenched in 
the presence of dithionite. When model membranes containing NBD-labelled phosphatidyl-
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ethanolamine (NBD-PE) were subjected to dithionite, approximately half of the fluorescence 
was quenched, as would be expected since only the outer leaflet of the membrane contained 
the NBD label (Figure 1.10). Upon addition of detergent, which dissolves the model 
membranes, the remaining NBD signal was quenched. When NBD-daptomycin in model 
membranes was exposed to dithionite in the absence of cardiolipin, initially 50% of the NBD 
signal was quenched, and over the time-frame of six additional minutes, the remaining sample 
was slowly quenched. The presence of 10% or more cardiolipin (CL), a phospholipid derived 
from phosphatidyl glycerol which contains a single polar head group and four lipid tails, 
resulted in greater than 75% initial quenching the NBD signal upon addition of dithionite. 
Taken together, it suggests that cardiolipin prevents the translocation of daptomycin from the 
outer to the inner leaflet, and thus prevents the formation of a fully functioning pore (See 
resistance mechanisms, section 1.3.2).  
 
Figure 1.10: Evidence of daptomycin found on the inner- and outer- leaflets of model 
membranes through NBD fluorescence quenching by dithionite. Taken from Zhang et al. and 
used with permission.48  
 
 These data, combined with additional quantitative FRET studies as performed by the 
Palmer group in 2012,46 allowed for a new model for daptomycin’s mechanism of action to be 
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proposed (Figure 1.11). In this model, daptomycin binds to membranes in a Ca2+- and PG-
dependent fashion, and the acyl tail void volume caused by daptomycin having a single lipid 
tail and phospholipids having usually two causes deep insertion of the tetrameric leaflet to the 
membrane (Figure 1.11C). Spontaneous membrane translocation and then combination with a 
tetramer in the opposite leaflet forms the fully functional octameric pore (Figure 1.11D). In 
this proposed model, cardiolipin would indeed produce the observed effect – the extra acyl tail 
groups present because of cardiolipin would act to alleviate the void volume produced by 
daptomycin binding to membranes, which would reduce the deeper membrane insertion and 
therefore membrane translocation.  
 
Figure 1.11: Updated model of daptomycin’s action mechanism. Taken from Zhang et al. and 
used with permission.48  
 
 This model was further refined when Taylor et al. deduced that daptomycin and 
A54145D membrane binding involve the successive binding of two calcium ions.49 Both 
isothermal titration calorimetry (ITC) and fluorescence techniques were used to establish that 
daptomycin binds to two equivalents of calcium in a stepwise fashion: after binding one 
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equivalent of calcium (at ~0.1 mM Ca2+), acrylodan fluorophores appended to Orn6 of 
daptomycin and D-Lys8 of A54145D demonstrated localization in a membrane. With 
increased calcium present (~0.5 to 1.0 mM Ca2+), an additional fluorescence change is 
observed, this time with the intrinsically fluorescent Trp1 residue of A54145D, or Kyn13 
residue of daptomycin. Related to this is the research of Zhang et al., who studied an A54145D 
analog with a pyrene-butanoyl lipid tail.50 The results of these studies suggest that the pyrene 
moiety forms an excimer (requiring close proximity, implying mutual presence and therefore 
oligomerization in the membrane) at calcium concentrations similar to the second transition 
proposed by Taylor et al.49 These data suggest that the first interaction between daptomycin 
and biological membranes occurs at the Orn6 residue, and following this, the hydrophobic lipid 
tail and additional hydrophobic Trp1 and Kyn13 residues insert into the membrane. Similarly, 
these results suggest that the first interaction between A54145D and biological membranes 
occurs at the D-Lys8 residue, followed by the Trp1 and hydrophobic lipid tail. 
 In 2017, Taylor et al. further discovered that membrane permeabilization by 
daptomycin depends not only on the head groups of the membrane lipids, but also the acyl 
chain component of the lipids.51 Functional octameric oligomers were formed only with 
DMPC/DMPG (dimyristoylphosphatidylcholine / dimyristoylphosphatidylglycerol) lipids. In 
the presence of DOPC/DOPG lipids, or POPC/POPG lipids 
(palmitoyloleoylphosphatidylcholine / palmitoyloleoylphosphatidylglycerol), membrane 
binding occurs, but instead of forming the octameric oligomer and properly functioning pore, 
tetrameric oligomerization on each leaflet is observed by FRET quantification, and no 
membrane permeabilization was observed. Additionally, a greater degree of NBD-daptomycin 
quenching by dithionite is observed in DOPC/DOPG membranes relative to DMPC/DMPG 
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membranes, suggesting an uneven distribution of daptomycin across the leaflets with a greater 
preference for the outer leaflet, indicating less membrane translocation. Further, in 2018, it was 
shown that as little as 10% DOPC in membranes containing DMPG and DMPC could inhibit 
proper pore formation.52 Taken together, these studies may refute some of the recent action 
mechanism studies performed on DOPC/DOPG or POPC/POPG lipids signifying that 
daptomycin does not form a pore. Lee et al. studied the effect of daptomycin on DOPG/DOPC 
membranes and observed only a transient ion leakage upon binding of daptomycin.38 Because 
of the temporary nature of ion leakage, they concluded that daptomycin does not form pores. 
Additionally, Kreutzberger et al. observed that giant unilamellar vesicles (GUVs) made of 
POPG and POPC that encapsulated smaller vesicles did not allow for daptomycin to translocate 
from the outer membrane to the inner membrane, on the basis that daptomycin was only 
observed on the outer vesicle membranes and not on the membranes of the interior vesicles.53  
 Direct evidence for the formation of an ion channel was observed by Seydlová et al. in 
2018.43 The researchers performed conductance measurements on planar lipid membranes, 
which allow for the analysis of pore-forming activities on membranes. In this assay, a single 
lipid bilayer separates two aqueous reservoirs. An external voltage is applied to the membrane, 
and the opening of a pore in the membrane is indicated by a jump in current through the 
membrane; conversely, the closing of a pore is indicated by a reduction in membrane current. 
Indeed, planar lipid membranes demonstrated clear evidence of pore formation, only after 
being subjected to daptomycin. Interestingly, the membrane pores formed by daptomycin had 
varying degrees of current fluctuation and were dependent upon the applied voltage across the 
membrane. The varying currents indicated that pores of varying diameters were formed, 
suggesting that pores can have varying subunit stoichiometry.   
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1.3 – Proposed Mechanisms of Resistance of cLPAs 
 
 Some studies attempt to directly elucidate the mechanism of action of antibiotics, but 
a more indirect approach is also sometimes used: studying the mechanisms of resistance that 
bacteria employ. By studying the mechanisms of resistance, some insights may be gained on 
how antibiotics function. 
 While resistance to daptomycin is not yet widespread, there have been numerous 
reports of reduced susceptibility of pathogenic bacteria to daptomycin. A growing body of 
literature is dedicated to the resistance mechanisms employed against daptomycin due to its 
current use as a last-resort antibiotic. It is possible that these studies can provide information 
on daptomycin’s mode of action. 
1.3.1 – Resistance by Changes to the Membrane Lipid Composition 
 
 Various genomic analyses have been performed on clinical isolates with reduced 
susceptibility to daptomycin. In a genomic analysis of S. aureus isolates with decreased 
susceptibility to daptomycin, Friedman et al. discovered several single-nucleotide 
polymorphisms (SNPs) in the mprF gene, which is associated with the multipeptide resistance 
factor (mprF) protein responsible for converting PG into lysyl-PG.54 Peleg et al. also correlated 
daptomycin resistance with mutations in the pgsA and cls2 genes, which are involved in the 
first step of PG synthesis and the synthesis of cardiolipin, respectively.55 Notably, all of these 
genes involve to some extent the composition of the lipid bilayer, which is well-accepted to be 
the target of daptomycin’s activity.  
 The mprF gene encodes for the multipeptide resistance factor protein, which appends 
a lysine into PG, forming lysyl-PG (Figure 1.12). Additionally, the mprF protein flips lysyl-
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PG from the inner membrane leaflet to the outer membrane leaflet.56,57 This protein has been 
correlated with reduced daptomycin susceptibility in several reports.58,59 Mutations in this gene 
may result in increased lysyl-PG formation, or lysyl-PG translocation to the outer leaflet, which 
in turn may have effects on daptomycin’s activity. 
 
 
Figure 1.12: Dimyristoyl phosphatidyl glycerol (DMPG), lysyl-DMPG, and 
tetramyristoylcardiolipin (TMCL). Anionic DMPG is required for daptomycin’s activity. 
TMCL and overall cationic lysyl-DMPG may reduce daptomycin’s activity. 
 
 It is known that daptomycin requires PG for biological activity, and this may be due to 
the charge of the lipid. At physiological pH levels, daptomycin is trianionic, and upon binding 
to two equivalents of calcium, the Dap-2Ca2+ complex becomes cationic, and charge attraction 
between the daptomycin-calcium complex and negatively charged PG can be expected. 
However, when lysine is appended to PG, there may be charge repulsion between cationic 
lysyl-PG and cationic Dap-2Ca2+. Hence, the presence of lysyl-PG in the membrane may be a 
resistance mechanism employed by bacteria. Indeed, Mishra et al. in 2013 noticed a significant 
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increase in lysyl-PG of isolates of S. aureus with reduced daptomycin susceptibility.60 
Admittedly, most of this lysyl-PG was located in the inner membrane leaflet, which may have 
an effect in reducing the translocation of daptomycin from the outer membrane leaflet to the 
inner membrane leaflet and therefore the formation of a properly functioning pore. In any case, 
the amount of PG present in the species analyzed invariably decreased, which may suggest that 
resistance is caused by increased presence of lysyl-PG in the membrane, or simply decreased 
PG-content. 
 Although the mprF gene is widely implicated in cases of increased resistance to 
daptomycin, Pillai et al. discovered that reduced susceptibility to daptomycin does not 
necessarily involve mutations to the mprF gene.61 Another possible mechanism of increased 
resistance to daptomycin involves cardiolipin. It was demonstrated by the Palmer group that 
cardiolipin inhibits the translocation of daptomycin tetramers from the outer leaflet of the 
membrane to the inner leaflet.48 Accordingly, it is to be expected that mutations in the cls2 
gene, which encodes cardiolipin synthase, an enzyme that forms cardiolipin from PG, are 
correlated with reduced susceptibility to daptomycin.55 Indeed, Davlieva et al. in 2013 
observed in isolates of daptomycin-resistant Enterococci that select mutations to cls2 resulted 
in cardiolipin synthase with increased enzymatic activity, suggesting that the increased 
presence of cardiolipin is a mechanism of resistance employed by bacteria.62 
1.3.2 – Resistance via Cell Wall Thickening 
 
 In 2017, Taylor et al. in the Palmer group studied the biological activity of a covalently 
linked daptomycin dimer (1.14, Figure 1.13).63 The peptide, which consisted of two 
daptomycin nuclei (daptomycin less the lipid tail) tethered together by a linear C18 alkane with 
two carboxylic acid functional groups on either end. Peptide 1.14 was able to form pores on 
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model membranes similar to authentic daptomycin but had MIC’s against B. subtilis 1046 that 
were at least 100-fold less active than authentic daptomycin. Interestingly, when the 
daptomycin dimer was assayed against B. subtilis PDC134 L-forms (variants of the bacteria 
that lack a cell wall), biological activity returned to levels approaching those of authentic 
daptomycin (0.2 µg/mL for daptomycin-dimer compared to 0.075 µg/mL for daptomycin). 
Taken all together, this suggests that the cell wall may have some effect on resistance to 
daptomycin, as the covalent daptomycin dimer may have had difficulty diffusing through the 
peptidoglycan layer. 
 
Figure 1.13: Covalently-linked daptomycin-dimer 1.14. 
 
 It was also observed by Peleg et al. in 2012 with transmission electron microscopy that 
isolates of daptomycin-non-susceptible S. aureus demonstrated increased cell wall thickness 
relative to their daptomycin-susceptible counterparts.55 In agreement with Taylor et al.’s 
results, it would seem that a thicker peptidoglycan layer may result in less effective diffusion 
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of daptomycin to the cell membrane, and since the cell membrane is the active target of 
daptomycin, this would subsequently reduce its biological activity. Again, it should also be 
noted that increased cell wall thickness is not a requirement of daptomycin resistance. Yang et 
al. in 2010 observed a daptomycin-resistant strain of MRSA which did not display a thicker 
cell wall, once again suggesting that there may be multiple mechanisms by which bacteria 
evolve resistance to daptomycin.64   
1.3.3 – Resistance by Direct Inactivation of Daptomycin 
 
 In 2012, D’Costa et al. observed that antibiotic-producing soil bacteria are remarkably 
resistant to antibiotics and performed mechanistic studies on these resistances.65 A library of 
soil bacteria demonstrated that daptomycin was almost universally ineffective against soil 
bacteria, and antibiotic inactivation was exceptionally high. It is worth noting that these 
mechanisms of resistance have not been observed in clinical isolates of daptomycin-resistant 
pathogenic bacteria but represent possible resistance mechanisms to daptomycin in general. 
 One resistance mechanism displayed by approximately 29% of species in the soil-
bacterium library was removal of the acyl tail of daptomycin. As increased length of the lipid 
tail is associated with increased biological activity, it can be expected that complete removal 
of the tail would abolish it.66 Additionally, 44% of soil-bacterium species demonstrated 
hydrolysis of the ester-bond in daptomycin, which was further shown to abolish biological 
activity. 
 In summary, the mechanisms of action associated with daptomycin, and the 
mechanisms of resistance to daptomycin displayed by bacteria, are complex, and the precise 
nature of daptomycin’s biological activity is still a topic of some controversy.  
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1.4 – Natural synthesis of Daptomycin and A54145 
 
 In biological systems, proteins and peptides are typically translated from a primary 
mRNA transcript which was transcribed from DNA. Translation is mediated by organelles 
called ribosomes and amino acids are bought in close-proximity of the growing peptide through 
tRNAs. On the other hand, cLPAs are produced using non-ribosomal peptide synthetases 
(NRPSs), which are enzymes that synthesize peptides without the use of ribosomes.66,67 
Daptomycin’s NRPSs are encoded by three different genes (dptA, dptBC, and dptD), and 
A54145’s NRPSs are encoded by four genes (lptA, lptB, lptC, and lptD), each of which is 
responsible for the incorporation of several amino acids (Figure 1.14).66–68  
 
Figure 1.14: Core peptide structure and gene map of daptomycin and A54145 biosynthesis. 
(Top) Core peptide structures of daptomycin and A54145. The NRPS of each boxed region is 
encoded by a different gene. (Bottom) Gene maps for daptomycin and A54145. A – 
adenylation domain; T – thiolation domain; E – epimerase domain; M – methylation domain; 
TE – thioesterase domain. Images taken and modified with permission from Baltz et al.66 and 
Miao et al.67 
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 The gene maps in Figure 1.14 are labelled with appropriate domains that catalyze specific 
reactions in the synthesis of cLPAs, further described for daptomycin in Figure 1.15. Amino acids 
are activated by the adenylation domain (A), followed by tethering to the thiolation domain (T), 
forming a thioester (Figure 1.15A). The condensation domain (C) of the subsequent amino acid 
then catalyzes the formation of the peptide bond between this thioester and the following amino 
acid (Figure 1.15B). This cycle continues until the final amino acid (Kyn13 for daptomycin, Ile13 
for A54145D) is adenylated and tethered by the T-domain, after which the peptide is cyclized 
between the Thr4 side-chain and the terminal amino acid by a thioesterase domain (Te). Within 
this synthesis, epimerase domains (E) are responsible for inverting the stereochemistry of standard 
L-amino acids to form D-amino acids, and in the case of A54145, a methylation domain (M) is 
responsible for the methylation of the α-amino group of Sar5. It is worth noting that these domains 
promote some degree of flexibility: the daptomycin NRPS can accommodate several lipid tails: n-
decanoyl, anteiso-undecanoyl, iso-dodecanoyl, and anteiso-tridecanoyl tails.68 A54145 has even 
more flexibility. Lipid tail incorporation can tolerate n-decanoyl, iso-decanoyl, and anteiso-
decanoyl; position 12 can tolerate glutamic acid and 3-methylglutamic acid; and position 13 can 






Figure 1.15: Schematic of the modular daptomycin synthase. (A) Each amino acid is activated 
by the adenylation domain, and converted to a thioester by a T domain. (B) The condensation 
domain acquires the growing peptide sequence from the previous module, forming a new 
peptide bond. (C) Synthesis of daptomycin is performed by three large enzymes, each 
responsible for the addition of multiple amino acids. Figure taken from Taylor and Palmer with 
permission.13 
 
1.5 – Daptomycin and A54145 analogs 
 
1.5.1 – Synthesis of Daptomycin analogs via Semi-Synthesis 
 
 Since the discovery of the A21978C family of antibiotics, researchers have attempted 
to introduce modifications to its structure to ascertain how biological activity is affected 
(structure-activity relationships, SARs) and to produce yet more effective antibiotics. 
Researchers at Lilly Research Laboratories obtained the A21978C complex, containing a 
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common peptide nucleus, and were able to modify its acyl tail.69 First, a Boc-protecting group 
was added to the ornithine residue, followed by bacteria-assisted acyl tail removal, which was 
found to be most effective using Actinoplanes utahensis NRRL 12052 (Scheme 1.1). The 
product, Orn(Boc)DeacylDap (1.15), was then reacylated by treatment with activated esters in 
N,N-dimethylformamide (DMF), and the Boc-group removed with a short treatment with 
trifluoroacetic acid (TFA). Tails ranging from six carbons (hexanoyl) to sixteen carbons 
(hexadecanoyl) were added, and it was observed that increasing the tail length caused a marked 
increase in biological activity with a concurrent increase in toxicity against mice (Table 1.1).69 
The compound with the most favourable activity/toxicity profile possessed a decanoyl (Dec) 
tail, and was ultimately named daptomycin. Analogous studies on A54145A1 published by the 
same company in 1990 also demonstrated increased biological activity as acyl tail length 
increased.15,70  
 




Table 1.1: Minimum inhibitory concentrations (MICs) of daptomycin and A54145A analogs 
with alternative lipid tails.15,69,71 
Original 
antibiotic 
New lipid tail MIC (ug/mL)a 
LD50 against mice 
(mg/kg, iv) 
A21978C1 
n-heptanoyl 8 > 600 
n-octanoyl 4 > 600 
n-nonanoyl 8 > 600 
n-decanoyl 0.5 600 
n-undecanoyl 0.25 450 
n-dodecanoyl 0.5 144 
n-tridecanoyl 0.125 112.5 
n-tetradecanoyl 0.5 62.5 
n-pentadecanoyl 1 56.3 
n-hexadecanoyl 1 50 
A54145A1 
n-hexanoyl >128 N.D. 
n-nonanoyl 32 >500 
iso-decanoyl 16 >500 
n-decanoyl 8 >500 
n-undecanoyl 2 >500 
n-dodecanoyl 1 321 
 
a MICs performed against S. aureus. 
 In an effort to create even more potent and effective cLPAs, in 2003, researchers at 
Cubist Pharmaceuticals Inc. created 46 different analogs of daptomycin by appending various 
acyl groups to the side-chain of ornithine through nucleophilic acyl substitution with 
pentafluorophenyl esters (Scheme 1.2).72,73 It was discovered that the ornithine residue is 
particularly amenable to substitution, resulting in minimal loss of bactericidal activity. Most 
interesting in this study is perhaps that these modifications to daptomycin’s structure also 
modify the charge of daptomycin: by converting the basic amine to a non-basic amide 
functional group, the overall charge of these daptomycin analogs at physiological pH becomes 
-4 instead of -3. Nevertheless, biological activity remained: synthesized analogs were 1.6 to 




Scheme 1.2: General synthesis of Orn6-substituted daptomycin analogs by Hill et al.72 
 
 Researchers at Cubist Pharmaceuticals in 2012 developed an additional approach for 
modifying native daptomycin.74 In this approach, the ornithine residue was protected with a 
carboxybenzyl (CBz) group and the lipid tail removed enzymatically using the previously 
patented deacylase protocol, yielding CBz-protected peptide 1.16 (Scheme 1.3).75 Then, Trp1 
was removed using Edman degradation with phenyl isothiocyanate. Boc-protected non-
proteinogenic amino acids were then coupled to the resulting free amine as pentafluorophenyl 
esters, followed by Boc-deprotection and additional coupling to add the lipid tail. Finally, the 
CBz group was removed by hydrogenolysis, and the resulting peptide assessed for biological 
activity. Using this approach, 22 additional daptomycin analogs were obtained, which retained 
considerable biological activity as long as Trp1 was replaced with an amino acid with a highly 
lipophilic side-chain. Further, some modifications produced daptomycin analogs that retained 
biological activity in the presence of lung surfactant. These results suggest that the tryptophan 
residue of daptomycin may be interacting with a hydrophobic target and may also interact with 




Scheme 1.3: Synthesis of Trp1→Xaa1 daptomycin analogs performed by He et al.74 
 
 Although direct modification of daptomycin via appending groups on to the Orn6 
residue, modifying the lipid tail, and changing the Trp1 residue can provide valuable 
information on the structure-activity relationship of daptomycin and its analogs, its scope in 
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the synthesis of daptomycin analogs is limited to three different positions. For further probing 
the mechanism of action, it would be beneficial if there was an alternative synthesis that would 
allow for additional amino acid substitutions of daptomycin. 
1.5.2 – Chemoenzymatic Synthesis of Daptomycin and A54145 Analogs 
 
 In 2004, researchers in the Marahiel group developed a chemoenzymatic route to the 
synthesis of daptomycin analogs.76 In this approach, linear peptides bearing a C-terminal 
thioester, synthesized using solid-phase peptide synthesis, were subjected to CDA cyclase, 
which is the cyclization domain of the non-ribosomal peptide synthetase from Streptomyces 
coelicolor used to synthesize CDA in vivo (similar to Figure 1.14). The CDA cyclase domain 
effectively formed the macrocyclic core of daptomycin, and additional coupling of the Dec-
Trp-Asn building block allowed for the generation of nine analogs of daptomycin. In all of 
these analogs, MeGlu12 was replaced with Glu12 and D-Asn2 was replaced with L-Asn2, as 
the correct D configuration of Asn2 was unknown at the time. All synthesized analogs were 
noticeably less biologically active than authentic daptomycin (probably in part due to the 
replacement of D-Asn2 with L-Asn2), but nevertheless this new approach allowed for 
increased flexibility when designing daptomycin analogs beyond lipid-tail substitution and 
appending groups to the Orn6 sidechain.  
 In 2006, the Marahiel group refined their chemo-enzymatic approach through 
biochemical isolation and characterization of the peptide cyclase domains from the daptomycin 
and A54145 non-ribosomal peptide synthetases, and with the added knowledge of the proper 
stereochemistry of D-Asn2,77 the researchers synthesized a total of nine additional 
daptomycin-A54145 hybrids and assessed them for biological activity.78 The researchers 
reported the chemoenzymatic synthesis of the single-mutant of daptomycin in which MeGlu12 
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is replaced with Glu12 (Dap-Glu12), and this analog was 5.5-fold less active than authentic 
daptomycin against Bacillus subtilis PY79. Further, this work also reported the synthesis of an 
A54145A1 analog in which the uncommon amino acids HOAsn3 and MeOAsp9 were replaced 
with their proteinogenic counterparts, Asn3 and Asp9, and a second analog in which, in 
addition to these modifications, the Thr residue at position 4 was replaced with 
diaminopropionic acid (DAPA). These two analogs were adequately cyclized by the excised 
peptide cyclase domains and their MICs were both reported to be 25 µg/mL, a 12.5-fold 
decrease from that of authentic daptomycin.  
 Key limitations in the chemoenzymatic approach used in these studies is that 
synthesized linear peptides must be purified both before and after cyclization – from the point 
of view of developing a large number of analogs of daptomycin or A54145, it would be more 
advantageous if each analog required only one purification. Further, as the cyclase domain 
used is an enzyme, presumably with some sort of substrate specificity, it is unknown whether 
it would be completely effective in cyclizing any peptide sequence, which further limits is 
application to the synthesis of analogs of these antibiotics.  
1.5.3 – Biosynthetic Approach to Daptomycin and A54145 Analogs 
 
 Between 2010 and 2014, the Baltz group synthesized analogs of daptomycin and 
A54145 using an enzymatic approach, in which the NRPSs of daptomycin and A54145 were 
modified to produce different antimicrobial products.16,17,79 The biological activity of these 
analogs were assessed in the absence and presence of 1% bovine lung surfactant. Relative to 
native daptomycin, all daptomycin analogs had reduced activity in the absence of lung 
surfactant, although some analogs demonstrated increased activity in the presence of lung 
surfactant, again, relative to daptomycin’s activity in the presence of lung surfactant. 
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 A total of 25 analogs of A54145D and A54145E were synthesized with alternative 
amino acids at several positions throughout the peptide resulting in peptides with varying 
biological activities (Table 1.2), depending on the substitutions used. It seems that A54145E 
is significantly inhibited by lung surfactant, and many modifications to A54145E resulted in 
peptides with a more favourable biological activity profile (Table 1.2, entries 3 to 13). Most 
notably, the activity in the presence of lung surfactant increased by a factor of 16 when D-Glu2 
and HOAsn3 were replaced with D-Asn2 and Asp3, respectively (Table 1.2, entry 4). Most 
modifications to A54145D resulted in a loss of biological activity both in the presence and 
absence of lung surfactant (Table 1.2, entries 14 to 27), however, replacement of Ile13 in 
A54145D with Kyn13 produced an analog that was 2-fold more biologically active than 
A54145D both in the presence and absence of lung surfactant, although it was still 2-fold less 
active than daptomycin in the absence of lung surfactant (Table 1.2, entry 28). A single 
substitution of MeOAsp with Asp in A54145D resulted in a drastic loss in biological activity 
(Table 1.2, entry 25), although some activity was restored slightly if HOAsn was also replaced 
with Asn (Table 1.2, entry 19). 
 While unable to produce analogs with improved biological activity relative to 
daptomycin, the Baltz group did synthesize two analogs with improved biological activity 
relative to A54145D. While these two derivatives would appear to have some potential for 
clinical application, they were not sufficiently active in mouse models, and thus were not 






Table 1.2: MICs of A54145D and A54145E analogs synthesized by the Baltz group.16,17,79 
Entry Peptide 
Amino acid at position S. aureus MIC a 





1 Daptomycin D-Asn Asp Gly D-Ala Asp D-Ser MeGlu Kyn 0.5 64 
2 A54145E D-Glu HOAsn Sar D-Lys MeOAsp D-Asn MeGlu Ile 1 32 
3 CB-182,575 D-Asn HOAsn Sar D-Lys MeOAsp D-Asn MeGlu Ile 2 4 
4 CB-182,561 D-Asn Asp Sar D-Lys MeOAsp D-Asn MeGlu Ile 1 2 
5 CB-182,363 D-Glu Asn Sar D-Lys MeOAsp D-Asn MeGlu Ile 2 16 
6 CB-182,597 D-Glu Asn Sar D-Lys HOAsp D-Asn MeGlu Ile 1 16 
7 CB-182,390 D-Glu Asn Sar D-Lys Asp D-Asn MeGlu Ile 2 2 
8 CB-182,571 D-Glu HOAsn Sar D-Ala MeOAsp D-Asn MeGlu Ile 1 32 
9 CB-182,549 D-Glu HOAsn Sar D-Ser MeOAsp D-Asn MeGlu Ile 1 16 
10 CB-182,510 D-Glu HOAsn Sar D-Asn MeOAsp D-Asn MeGlu Ile 8 64 
11 CB-182,443 D-Glu HOAsn Sar D-Lys Asp D-Asn MeGlu Ile 2 4 
12 CB-182,548 D-Glu HOAsn Sar D-Lys MeOAsp D-Ala MeGlu Ile 1 16 
13 CB-182,332 D-Glu HOAsn Sar D-Lys MeOAsp D-Ser MeGlu Ile 2 16 
14 A54145D D-Glu HOAsn Sar D-Lys MeOAsp D-Asn Glu Ile 2 4 
15 CB-182,444 D-Asn HOAsn Sar D-Lys MeOAsp D-Asn Glu Ile 8 8 
16 CB-182,560 D-Asn Asp Sar D-Lys MeOAsp D-Asn Glu Ile 8 16 
17 CB-182,325 D-Glu Asn Sar D-Lys MeOAsp D-Asn Glu Ile 32 32 
18 CB-182,349 D-Glu Asn Sar D-Lys HOAsp D-Asn Glu Ile 32 64 
19 CB-182,348 D-Glu Asn Sar D-Lys Asp D-Asn Glu Ile 16 32 
20 CB-182,391 D-Glu HOAsn Gly D-Lys MeOAsp D-Asn Glu Ile 16 32 
21 CB-182,567 D-Glu HOAsn Sar D-Ala MeOAsp D-Asn Glu Ile 4 8 
22 CB-182,532 D-Glu HOAsn Sar D-Ser MeOAsp D-Asn Glu Ile 8 8 
23 CB-182,531 D-Glu HOAsn Sar D-Asn MeOAsp D-Asn Glu Ile 16 16 
24 CB-182,350 D-Glu HOAsn Sar D-Lys HOAsp D-Asn Glu Ile 8 16 
25 CB-182,333 D-Glu HOAsn Sar D-Lys Asp D-Asn Glu Ile 32 64 
26 CB-182,509 D-Glu HOAsn Sar D-Lys MeOAsp D-Ala Glu Ile 8 16 
27 CB-182,336 D-Glu HOAsn Sar D-Lys MeOAsp D-Ser Glu Ile 64 128 
28 CB-183,296 D-Glu HOAsn Sar D-Lys MeOAsp D-Asn Glu Kyn 1 2 
Modifications from A54145E and A54145D are indicated in red. 
a Against S. aureus 42 
 
 This approach has proven effective in generating new daptomycin and A54145 analogs, 
but is ultimately limited by the repertoire of synthetase modules and their substrate 
specificities, similar to the chemoenzymatic approach previously discussed (section 1.5.2). 
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Changes to the growing peptide sequence may result in peptides that are not processed by the 
other domains in the NRPSs due to incompatibility of recombinantly adjoined modules. 
Additionally, to obtain a single analog in significant yields, bacterial genomes must be edited, 
and the resulting strains must be isolated and cultured. With the ultimate goal of developing 
new antibiotics that may find use in clinic, it would be advantageous in the screening stage to 
develop a more high-throughput method for synthesis, which allows for rapid synthesis and 
isolation, and avoids the use of genetic modifications and culturing of individual strains of 
bacteria. To that end, the total synthesis of antimicrobial peptides would be advantageous, as 
it would allow for a higher throughput method by which analogs can be synthesized and 
assayed for biological activity. 
1.6 – The Total Synthesis of Daptomycin 
 
1.6.1 – Fmoc-based Solid-Phase Peptide Synthesis 
 
 As a considerable part of this thesis deals with the synthesis of peptides using Fmoc-
based solid-phase peptide synthesis (Fmoc-SPPS), a brief discussion of Fmoc-SPPS is 
warranted. Fmoc-SPPS is a technique used to synthesize peptides in which the growing peptide 
is covalently attached to an insoluble polystyrene (PS) resin. Attachment of the first amino 
acid is accomplished variously using carboxylic acids or amines, and the peptide is grown 
stepwise (Scheme 1.4). Each amino acid coupled to the resin is suitably protected by various 




Scheme 1.4: General strategy for solid-phase peptide synthesis. In this scheme, PG = 
protecting group, AA = amino acid. 
 
 In Fmoc-SPPS, the α-amino groups of amino acids are protected with a 
fluorenylmethoxycarbonyl (Fmoc) group, which is base-labile and easily removed in the 
presence of 20% piperidine in DMF. Since piperidine is costly, 2-methylpiperidine (2-MP) or 
4-methylpiperidine (4-MP) are often used as replacements. Commercially available amino 
acids with an Fmoc-protecting group on the α-amine group may also require a side-chain 
protecting group. There are many different protecting groups available to the organic chemist, 
but common protecting groups include butyloxycarbonyl (Boc) groups for amines, tert-butyl 
(tBu) groups for carboxylic acids, and tert-butyldimethylsilyl (TBDMS) groups or trityl (Trt) 
groups for alcohols (Figure 1.16). Boc-, tBu-, and Trt-protecting groups are easily removed by 
treatment with a strong acid such as TFA, and TBDMS groups can be removed by treatment 




Figure 1.16: Common protecting groups in SPPS. 
 
 Several different linkers attaching the peptide to the PS resin can be used in SPPS, and 
chosen linkages chosen must be stable to the conditions used in forming the desired peptide. 
The Taylor lab most often uses the 2-chlorotrityl-chloride (2-ClTrt-Cl-PS) resin, which is a 2-
ClTrt-Cl group attached to a polystyrene solid support (Figure 1.17). This 2-ClTrt-Cl group is 
stable to treatments of base but labile to weak acids. Other resins include the Wang resin, which 
possesses a benzyl alcohol linker that is resistant to weak acids but labile to strong acids such 
as TFA, and also the Merrifield resin, which is resistant to acids and bases, but labile to 
hydrogen fluoride and hydrogenolysis. In the case of 2-ClTrt-Cl-PS resin and Merrifield resin, 
attachment to the resin occurs by nucleophilic displacement of the chloride leaving group, but 
for the Wang resin, the alcohol acts as a nucleophile toward an activated ester of a carboxylic 
acid. 
 
Figure 1.17: Commonly used linkers used in SPPS. The shaded circle represents the 
polystyrene solid support. 
 
 A variant of the 2-ClTrt-Cl-PS resin used occasionally in the Taylor lab is the TentaGel 
Trt-Cl resin, which contains a polystyrene matrix with a polyethylene glycol (PEG) linker 
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attached to the trityl chloride group (Figure 1.17). The PEG linker allows for more space 
between the polystyrene support and the peptide, which reduces peptide aggregation during 
SPPS and improves coupling yields. Both daptomycin and A54145D possess an ester bond 
between the side-chain of Thr4 and the α-carboxylic acid of Kyn13 (daptomycin) or Ile13 
(A54145D), and in past syntheses of daptomycin and analogs, it was observed that the 
challenging depsi-bond formation could be made more efficient through the use of TentaGel 
Trt-Cl resin.81,82  
 Solid-phase peptide synthesis allows for the synthesis of complex peptides, and its main 
advantage is the ease of purification after each successive coupling step. Treating the solid 
support with excess coupling reagents or deprotection reagents facilitates the desired reaction, 
and the excess, unreacted reagents are simply rinsed away through a filter, leaving only the 
peptide-bound solid resin remaining. Accordingly, solid-phase peptide synthesis generally 
avoids the use of other purification methods such as column chromatography until the 
completion of last step of the synthesis. 
1.6.2 – First Total Synthesis of Daptomycin by the Li Group 
 
 In 2013, the first total synthesis of daptomycin was reported by the Li group.83 They 
started their synthesis by attaching the peptide to the support via the α-carboxylic acid of Gly10 
(1.18, Scheme 1.5). The group employed Fmoc-SPPS to yield linear peptide 1.19, containing 
the lipid tail and residues 1 to 10, after which the crucial ester-bond was to be formed yielding 
peptide 1.20. However, the formation of the depsi-bond proved problematic and could not be 




Scheme 1.5: First proposed route to daptomycin by the Li group.83 
 
 The researchers ultimately overcame the issue and achieved the synthesis of 
daptomycin by coupling on a tetra-amino acid building block 1.22 (with residues 13, 3, 4, and 
5) to linear peptide 1.21 with the ester-bond pre-formed (Scheme 1.6), which was synthesized 
in solution. Fmoc-based SPPS from peptide 1.23 allowed for the incorporation of residues 12 
and 11, yielding peptide 1.24, and the azido protecting group on Asp3 was reduced with 
dithiothreitol (DTT) and N,N-diisopropylethylamine (DIPEA) in DMF. The azido group is 
sometimes used in addition to Fmoc-SPPS as it is completely orthogonal to the Fmoc-
protecting group. Further Fmoc-based SPPS allows for the lipid tail and residues 1 and 2 to be 




Scheme 1.6: Second route to daptomycin by the Li group, part 1.83 
 
 Linear precursor 1.25 was cleaved from the peptide with weakly acidic acetic acid 
(AcOH), trifluoroethanol (TFE) and dichloromethane (DCM) to keep side-chain protecting 
groups intact, yielding peptide 1.26 (Scheme 1.7). Coupling of the dimethyl acetal of 
salicylaldehyde mediated by benzotriazol-1-yl-oxy-tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) and DIPEA followed by global deprotection yielded branched 
peptide 1.27 in 17% yield, based on initial resin loading. Aldehyde 1.27 was converted to 
hemiaminal ether 1.28 with pyridine acetate buffer via chemoselective serine ligation and 
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macrocyclization, and further cleavage of the hemiaminal ether 1.28 with TFA and H2O 
yielded daptomycin in 67% yield from aldehyde 1.27. 
 The synthetic approach by the Li group was the first total synthesis of daptomycin 
reported. The main advantage of synthesizing analogs by total synthesis is that it enables the 
synthesis of many analogs in a relatively quick time-frame. The Li group’s strategy, however, 
is not very conducive to the synthesis of analogs of daptomycin for multiple reasons. Firstly, 
without being able to form the depsi-bond on-resin, the researchers are required to synthesize 
a tetrapeptide building block in solution with the ester-bond pre-formed, and a new tetrapeptide 
building block must by synthesized whenever one of these four amino acid residues is to be 
substituted with an alternative amino acid. Secondly, the synthesis required two purifications 
by reverse-phase-(RP) high performance liquid chromatography (HPLC): one purification of 
intermediate 1.27 prior to serine ligation, and an additional purification at the end of the 
synthesis, making the strategy much more labour-intensive. Finally, the synthesis involves four 
separate in-solution steps to convert resin-bound peptide 1.25 to daptomycin, which would be 
extremely labour-intensive if large numbers of analogs were to be synthesized in this way. It 
would be far more advantageous if the ester bond of daptomycin could be formed on-resin, in 









1.6.3 – Synthesis of Daptomycin Analogs by the Martin Group 
 
 In 2014, the Martin group reported a synthesis of daptomycin analogs which also 
involved an off-resin cyclization.84 In one analog, MeGlu12 was replaced with Glu12, and 
Thr4 was replaced with DAPA4 (diaminopropionic acid), resulting in the conversion of the 
depsi-bond to a synthetically less challenging amide bond. A second analog contained both of 
these modifications, and moreover a Trp instead of Kyn13. Their strategy involved attaching 
the peptide to the solid-support by the α-carboxylic acid of Gly5 and employing Fmoc-SPPS 
to incorporate residues 1 through 4 plus the lipid tail (Scheme 1.8). DAPA4 was incorporated 
in the form of FmocDAPA(Alloc). Selective deprotection of the Alloc (allyloxycarbonyl) 
protecting group of peptide 1.29 with Pd(PPh3)4 and phenylsilane (PhSiH3) provided a new 
branch point for further peptide elaboration of free amine 1.30. Incorporation of residues 13 to 
6 using Fmoc-SPPS yielded uncyclized Dap-DAPA4-Glu12 precursor 1.31, which was 
cleaved from the resin with weakly acidic 20% hexafluoroisopropanol (HFIP) in DCM. The 
peptide, with protecting groups still intact, was subjected to off-resin cyclization followed by 
global deprotection of Boc-protecting groups with TFA, yielding Fmoc-DAPA4-Glu12 (1.32). 
In this strategy, the formation of the depsi-bond was not an inherent challenge as it was 
replaced with the less synthetically challenging amide bond. Further, it was observed that these 
two analogs were considerably less active than daptomycin (Dap-DAPA4-Glu12 was 80-fold 
less active, and Dap-DAPA4-Glu12-Trp13 was 160-fold less active when assayed against S. 
aureus ATCC 29213). Several amino acid substitutions were made in these analogs, so it is 
difficult to pin-point the exact cause of such a drastic reduction in biological activity. However, 
it is likely that the conversion of the depsi-bond to an amide bond resulted in a significant loss 
of activity, as Dap-Glu12, which contains an ester bond but otherwise resembles Dap-DAPA4-
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Glu12, has been reported to be only 5.5-fold less active than native daptomycin when assayed 
against B. subtilis PY79.78 
 
Scheme 1.8: Synthesis of Dap-DAPA4-Glu12 (1.32) by the Martin group.84 Dap-DAPA4-




1.6.4 – Total Synthesis of Daptomycin by the Taylor Group 
 
 Despite the advances of the Li group and the Martin group, a total synthesis of 
daptomycin suitable for the rapid generation of many analogs had not yet been achieved. In 
the Li group’s synthesis, the use of solution-phase chemistry to synthesize their amino acid 
building blocks makes the rapid development of analogs more challenging and more time-
consuming. In the Martin group’s synthesis, the ester-bond crucial for daptomycin activity was 
completely omitted and replaced with an amide bond. These challenges were tackled by the 
Taylor group in 2015, who published the first entirely on-resin synthesis of daptomycin and 
analogs.85 
 The approach pioneered by Lohani et al. employed Fmoc- and N3-SPPS, and the 
peptide was attached to the resin by the sidechain of Asp9 using DIPEA and 
FmocAsp(OH)Oallyl forming resin-bound FmocAspOallyl 1.33 (Scheme 1.9). Removal of the 
allyl group with Pd(PPh3)4 and N,N’-dimethylbarbituric acid (DMBA) and incorporation of 
Gly10 via the tosylate salt of allyl glycine produced resin-bound dipeptide 1.34. In the first 
attempted synthesis, Fmoc-SPPS was used to introduce the lipid tail along with residues 1 to 
8, but formation of the depsi-bond on complete linear peptide 1.35 with FmocKyn(CHO, 




Scheme 1.9: First attempted route to daptomycin by the Taylor group.85 
 
 To resolve the challenging issue of depsi-bond formation, it was attempted on truncated 
peptide 1.37 containing azido-protected Asp3, which allowed for facile depsi-bond formation 
with Fmoc-Kyn(CHO, Boc)-OH when N,N’-diisopropylcarbodiimide (DIC) and N,N-
dimethyl-4-aminopyridine (DMAP) were used as coupling reagents (Scheme 1.10), yielding 
peptide 1.38. Residues 1 and 2 were introduced via azido acids N3-D-Asn(Trt)OH and 
N3Trp(Boc)OH, and their azido groups were converted to amino groups with 
trimethylphosphine (PMe3) in dioxane and H2O, followed by the incorporation of the lipid tail 
to yield branched peptide 1.36. Further Fmoc-based SPPS yielded the uncyclized peptide 1.39, 
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and removal of the allyl group with Pd(PPh3)4 and DMBA followed by on-resin cyclization 
with PyBOP, 1-hydroxy-7-azabenzotriazole (HOAt), and DIPEA, and finally global 
deprotection and resin cleavage with TFA resulted in daptomycin in a 9% overall yield.  
 




 This synthesis was applied to three additional daptomycin analogs, and these analogs 
demonstrated that the non-proteinogenic amino acids MeGlu12 and Kyn13 could be replaced 
with Glu12 and Trp13 (Dap-Glu12-Trp13) with activity approaching that of native daptomycin 
(only 5-fold less active at 1.8 mM Ca2+). Further, an analog was synthesized in which the 
stereochemistry of the β-methyl group of MeGlu12 was changed from 3R to 3S, and this was 
found to reduce biological activity by about 50-fold when assayed against B. subtilis ATCC 
1046 at 5 mM Ca2+, demonstrating that inversion of a single stereocenter in daptomycin can 
be detrimental to biological activity. In a subsequent publication, a similar approach was used 
to obtain Dap-Ser4-Glu12-Trp13, an analog in which the Thr4 residue was replaced with a 
Ser4 residue.86 This modified approach involved the use of FmocSer(Trt)OH, whose trityl 
group was removed under weakly acidic 20% dichloroacetic acid (DCA) in DCM (v/v). 
Accordingly, a more acid-resistant Wang resin was used in its synthesis. Dap-Ser4-Glu12-
Trp13 was at least 100-fold less active than daptomycin, and at least 20-fold less active than 
Dap-Glu12-Trp13. This approach, however effective in the development of daptomycin 
analogs, suffered in its use of three azido acids, N3Trp(Boc)OH, N3-D-Asn(Trt)OH, and 
N3Asp(tBu)OH, which are not commercially available and therefore require in-lab synthesis. 
This makes the approach less amenable for a large-scale daptomycin library generation. 
 The Taylor group improved their synthesis of Dap-Glu12-Trp13 in 2016.87 In the new 
approach, ester bond formation on truncated Fmoc-protected peptide 1.40 with 
N3Trp(Boc)OH, DIC, and DMAP was achieved, thereby only requiring one azido acid in the 
synthesis of daptomycin analogs (Scheme 1.11). Branched peptide 1.41 was further elaborated 
with Fmoc-SPPS yielding peptide 1.42. Reduction of azido-peptide 1.42 was achieved with 
DTT and DIPEA in DMF. Following this, Fmoc-SPPS yielded resin-bound, uncyclized peptide 
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1.43. Dap-Glu-12-Trp13 (1.44) was obtained analogously to the approach used in Scheme 
1.10. 
 
Scheme 1.11: Second strategy toward daptomycin analogs reported by the Taylor group.87 
 
 In 2018, the Taylor group improved their synthetic approach even further, obviating 
the need for azido acids altogether.82 This new approach used Fmoc-SPPS on TentaGel Trt-Cl 
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resin, which contains a polystyrene matrix with a polyethylene glycol linker attached to the 
trityl chloride group (Section 1.6.1). It was observed that this resin choice facilitates the 
formation of the depsi-bond, which allowed for an entirely Fmoc-based synthesis of 
daptomycin and analogs (Scheme 1.12). Dipeptide 1.34 underwent Fmoc-SPPS to form linear 
peptide 1.45, and depsi-bond formation proceeded via treatment with 10 equiv of 
FmocTrp(Boc)OH, 10 equiv of DIC, and 0.1 equiv of DMAP in DCM containing Triton X-
100 (1%, v/v) yielding peptide 1.46. Further elaboration of peptide 1.46 using the same 
conditions presented in Schemes 1.10 and 1.11 afforded Dap-Glu12-Trp13 (1.44). This 
synthetic approach also allowed for the synthesis of Dap-Lys6-Glu12-Trp13 (1.47, Figure 
1.18), an analog in which the uncommon amino acids Orn6, MeGlu12 and Kyn13 are replaced 
with Lys6, Glu12, and Trp13. The biological activity of this compound was examined and 
determined to be only 2-fold less active than daptomycin against B. subtilis, and thus serves as 
a valuable starting point in the synthesis of a library of antibiotics. 
 





Figure 1.18: Daptomycin (1.2) compared with Dap-Lys6-Glu12-Trp13 (1.47) 
 
 With the optimized total synthesis of daptomycin, researchers in the Taylor group were 
able to conduct an alanine scan (replacement of individual amino acids of daptomycin with 
alanine) to probe attempt to determine which amino acid residues are tolerant to 
substitution.81,82 It was determined that residues 6 and 11 are amenable to substitution with 
alanine or D-alanine, respectively, with a 2-fold loss of activity, and also that position 2 is 
somewhat amenable to substitution with D-alanine, with a 4-fold loss in activity, relative to 
Dap-Lys6-Glu12-Trp13. On the basis of these results, positions 2, 6, and 11 may be amenable 
to substitutions with other amino acids, yielding daptomycin analogs with improved biological 
activity. This is part of the long-term goals in the Taylor group: to develop of libraries of 
antibiotics using a split-and-pool solid-phase peptide approach (see section 3.1 for a 
description of the split-and-pool approach). 
1.7 – Project Goals 
 
1.7.1 – Total Synthesis of A54145D and analogs 
 
 From Section 1.5 and 1.6, it is clear that the development of a total synthesis of 
daptomycin enables the development of analogs which can provide information on biological 
activity and may have activity profiles similar to or better than that of authentic daptomycin. 
This may ultimately allow for the possible generation of new antibiotics which may find 
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clinical use. No analogous total chemical synthesis of A54145 had been reported prior to the 
studies presented in this thesis. 
 In Chapter 2, the objective is to achieve an efficient synthesis of A54145D using Fmoc-
based peptide synthesis on solid-support. The synthesis of A54145D was achieved, and the 
results of these studies demonstrate a stereochemical revision in the side-chain of MeOAsp9 
from L-threo-MeOAsp to L-erythro-MeOAsp. Additionally, it was determined that the 
stereochemistry of the methyl group on the 8-methyldecanoyl tail does not affect biological 
activity. 
 In Chapter 3, the objective is to conduct further structure-activity relationship studies 
of A54145 analogs. Two new syntheses for A54145 analogs were developed, and these studies 
indicate that Thr4 of A54145 is not amenable to substitution. Further, structure-activity 
relationship studies confirm previously reported results that substitution of HOAsn3 or 
MeOAsp9 results in a 16-fold loss of biological activity, but that the 8-methyldecanoyl tail of 
A54145D can be replaced with a decanoyl tail (yielding A54145A1) with only slightly reduced 
biological activity against B. subtilis. Additionally, replacing the anteiso-undecanoyl tail, 
HOAsn, and MeOAsp with a decanoyl tail, Asn, and Asp, respectively, produces an analog 
with also a 16-fold loss in biological activity relative to A54145D, and a mere 4-fold loss in 
biological activity relative to A54145A1. 
1.7.2 – Probing the mechanism of action of Daptomycin using 19F-NMR 
 
 From Section 1.3, it is evident that the exact mechanism by which daptomycin elicits 
its bactericidal mode of action it not completely elucidated, but that it involves association with 
the biological membrane in a PG- and Ca2+-dependent fashion. One technique often used to 
probe interactions of biomolecules with lipid membranes involves 19F-NMR. The fluorine 
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nucleus is sensitive to its chemical environment and known to adopt different chemical shifts 
and peak shapes in hydrophilic and hydrophobic environments. In Chapter 4, the synthesis of 
a total of ten fluorinated analogs of daptomycin is discussed, as are preliminary NMR studies 
that probe the nature of daptomycin’s interaction with biological membranes. These 
preliminary findings indicate that the ornithine residue interacts with model membranes prior 
to the lipid tail, and that aggregation of daptomycin analogs does not occur in solution at 










Chapter 2 – The Total Synthesis of A54145D 
 
2.1 – Introduction  
 
 No members of the A54145 family have been developed into clinically useful drugs. 
The most potent natural factors (Factors B, B1, and E) contain MeGlu12, and while they are 
only 2-fold less active than daptomycin (1.2, Figure 2.1), they are found to be toxic to mice.15,17 
For example, the LD50 for A54145B is low, at only 28 mg/kg.
15,80 Factors containing Glu12, 
such as A54145D (1.11, Figure 2.1), are about 2-fold less potent than those containing MeGlu, 
but are substantially less toxic in mouse models (>500 mg/kg).15,17 
 




 Daptomycin did not meet non-inferiority standards in clinical trials for treating 
community-acquired pneumonia (CAP). A possible cause for this failure is its inhibition by 
lung surfactant.19 Unlike daptomycin, A54145D is not severely inhibited by lung surfactant. 
This characteristic of A54145D prompted the development of combinatorial biosynthesis 
methodologies for preparing cLPAs based on the A54145D peptide core.16,17 Although several 
A54145D analogs were obtained that exhibited good activity, low toxicity, and low inhibition 
by surfactant, none were sufficiently active in mouse models for S. pneumoniae to pursue 
clinically.80 Nevertheless, these results are promising when one considers that the key in vitro 
criteria (good activity, low toxicity, and low inhibition by surfactant) were met even though 
the number of analogs prepared represented only a very small fraction of the potential chemical 
space. It is possible that the development of an efficient chemical approach to the synthesis of 
A54145D and its analogs will enable researchers to access a larger portion of the available 
chemical space, which could ultimately lead to the development of a cLPA suitable for the 
treatment of CAP that is resistant to conventional therapy.  
2.1.1 – Research Objectives 
 
 The main objectives of the work described in this chapter are to synthesize A54145D 
and elucidate the stereochemistry of the side chains of HOAsn and MeOAsp. An additional 
objective is to establish the importance of the stereochemistry of the 8-methyldecanoyl lipid 
tail to biological activity. It would also be desirable if the synthesis of A54145D was amenable 
to the synthesis of large numbers of analogs. 
2.1.2 – Stereochemical Considerations for A54145D 
 
 A54145 Factor D contains four amino acids with two stereogenic centers. Both 
isoleucine at position 13 and threonine at position 4 have known stereochemistry. However, at 
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positions 3 and 9 are HOAsn and MeOAsp, respectively, and although they are often depicted 
in the literature as having the 2S,3S-configuration, the absolute configuration of the position 3 
stereocenter was not unambiguously established at the start of these studies. It was suggested 
by Strieker et al. that the HOAsn of CDA was likely (2R,3S) based upon bioinformatic studies 
of the CDA NRPSs.88 Notably, the NRPSs for CDA include an epimerase domain (Section 
1.4) which converts L-HOAsn (2S,3S) to D-HOAsn (2R,3S). The analogous A54145 NRPSs 
lack this epimerase domain for HOAsn3, and since the two antibiotics are both produced by 
two Streptomyces species (S. fradiae for A54145, and S. coelicolor for CDA), we proceeded 
with the assumption that A54145 contains HOAsn with a (2S,3S) configuration, or L-threo-
HOAsn. Unfortunately, no bioinformatic studies have been performed for MeOAsp. 
Nevertheless, we further assumed that the amino acids were synthesized in vivo through a 
common intermediate and that both amino acids were of the L-threo configuration. 
2.2 – Results and Discussion 
 
2.2.1 – First Proposed Synthesis of A54145D 
 
 In our first approach for the synthesis of A54145D, we envisioned attaching the resin 
to the side-chain of MeOAsp9 via Fmoc-L-threo-MeOAspOallyl (Fmoc-tMeOAspOallyl) 
(Scheme 2.1), which resembles the approach used by Lohani et al. and Barnawi et al. (Scheme 
1.9, Section 1.6.4).82,85 Removal of the allyl group of resin-bound Fmoc-tMeOAspOallyl (2.1) 
with Pd(PPh3)4 and DMBA followed by the coupling of the tosylate salt of allyl glycine (TsO
- 
H3N
+GlyOallyl) would produce dipeptide 2.2. The reason for choosing this particular dipeptide 
is two-fold. Firstly, final cyclization steps of cyclic peptides can cause racemization of the C-
terminal amino acid during activation of the carboxylic acid. By employing Gly10 as the C-
terminal amino acid in this cyclization step, we can avoid the formation of two epimers 
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entirely, as glycine is inherently achiral. Secondly, this dipeptide would permit on-resin 
cyclization, which, from the perspective of ultimately generating a multitude of peptides via a 
split-and-pool SPPS approach on macro-beads, is advantageous for library genesis. While off-
resin cyclization is possible, it would require a separate reaction flask for each macro-bead 
(each individual peptide in the library), whereas on-resin cyclization can be done with limitless 
macro-beads in the same reaction cartridge. For a description of Fmoc-SPPS on macro-beads, 
refer to section 3.1. 
 Elaboration of peptide 2.2 via Fmoc-SPPS employing DIC/hydroxybenzotriazole 
(HOBt) would yield linear peptide 2.3, which contains the unprotected hydroxyl group of Thr4 
as the branch point for depsi-bond formation. Forming the depsi-bond with N3IleOH and 
DIC/DMAP would produce peptide 2.4, which would further undergo elaboration via Fmoc 
SPPS yielding peptide 2.5. We expected that reduction of the azido group with 
tributylphosphine (PBu3) in the presence of the symmetric anhydride of FmocGlu(tBu)OH in 
tetrahydrofuran (THF)/H2O, followed by further Fmoc-SPPS, would yield the uncyclized 
peptide 2.6, which, after removal of the allyl protecting group with Pd(PPh3)4 and DMBA, 
would allow for an on-resin cyclization. Global deprotection and resin cleavage using 




Scheme 2.1: First proposed synthesis of A54145D (i.e., A54145-tHOAsn3-tMeOAsp9). 
 
 For this synthesis, suitably protected amino acids were required. Attachment of the 
peptide by the side-chain of MeOAsp9 would require Fmoc-tMeOAspOallyl, and subsequent 





2.2.1.1 – Synthesis of Non-Commercially Available Amino Acids and the Lipid Tail 
 
 For the synthesis of Fmoc-tMeOAspOallyl, an asymmetric aminohydroxylation 
reaction, performed by Professor Scott Taylor, using the conditions of von Eckardstein et al.89 
was performed on ester 2.790 to give compound 2.8 in excellent yield (Scheme 2.2). 
Methylation of the free hydroxyl group using MeI/Ag2O gave compound 2.9 in good yield. 
Oxidation of the phenyl ring followed by esterification of the resulting acid using allyl bromide 
gave compound 2.10 in 52% yield (2 steps). Finally, removal of the tert-butyl and Boc-
protecting groups using acid followed by Fmoc protection of the free amino group gave 
compound 2.11 in 87% yield.  
 
Scheme 2.2: Synthesis of Fmoc-tMeOAspOallyl (2.11). 
 
 Fmoc-tHOAsn(Trt, TBDMS)OH was synthesized by Ryan Moreira, a graduate student 
in the Taylor group, by tritylation of Fmoc-tHOAsn(TBDMS)OH.91 The 8-methyldecanoyl 
lipid tail of A54145D is not commercially available and therefore also required synthesis. We 
elected to use a racemic tail, and so (±)-8-methyldecanoic (2.14) was prepared (Scheme 2.3). 
This involved a Wittig reaction between phosphonium bromide salt 2.12, produced using the 
procedure by Motoshima et al.92, and (±)-2-methylbutanal which gave alkene 2.13 in 66% 
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yield. Lipid 2.14 was obtained in good yield by subjecting 2.13 to hydrogenation and then 
NaOH (aq).   
 
Scheme 2.3: Synthesis of (±)-8-methyldecanoic acid (2.14). 
  
2.2.2 – First Approach to A54145D 
 
 Fmoc-tMeOAspOallyl (2.11) was attached to TentaGel-TrtCl resin via its side chain 
COOH group (Scheme 2.4). Removal of the allyl group of amino acid 2.1 followed by 
installation of TsO-H3N
+GlyOallyl gave dipeptide 2.2. However, when the peptide was 
elongated using standard Fmoc-SPPS, it was found that the amount of peptide remaining 
attached to the resin decreased with each successive amino acid coupling. Specifically, 
following resin cleavage with TFA, tripeptide 2.17 was observed by HPLC (Figure 2.2) and 
by low-resolution mass spectrometry (LRMS), but further elaboration using Fmoc-SPPS to 
produce peptide 2.18 yielded an HPLC chromatogram almost devoid of any peaks after 
cleavage of the peptide from the resin. We suspected that aspartimide formation had occurred 
during Fmoc-SPPS, in the presence of 4-MP as a base. This would cause the peptide to be 
cleaved slowly from the resin throughout the synthesis. This result was unexpected, because 
similar side-reactions were not observed in the total synthesis of daptomycin and its analogs 
by other researchers.82,85 It is likely that the presence of the electron-withdrawing methoxy 








Figure 2.2: HPLC Chromatograms demonstrating loss of peptide from the resin. It was 
suspected that aspartimide formation between Gly10 and tMeOAsp9 cleaved the peptide from 
the resin. 
 
 To overcome the issue of aspartimide formation, we prepared dipeptide 2.19, in which 
the amide nitrogen of Gly10 was protected with a dimethoxybenzyl (DMB) group (Scheme 
2.5).84 Unfortunately, we found that upon removal of the Fmoc group, the resulting dipeptide 
2.20 underwent extremely rapid diketopiperazine (DKP) formation (2.21), as indicated by 
HPLC analysis and LRMS, in which the free amine produced upon Fmoc-deprotection engages 
in nucleophilic acyl substitution of the nearby allyl ester, forming a highly stable, six-
membered ring product. DKP-formation is a common side reaction when N-alkylated amino 




Scheme 2.5: DKP formation upon Fmoc-deprotection of peptide 2.19. 
 
 In 2018, researchers in the Brimble group synthesized jahanyne, 2.22, which is a highly 
N-methylated natural product (Figure 2.3).93 In their synthesis, the peptide was attached to the 
resin by the α-carboxylic acid of proline, which is extremely susceptible to DKP formation. 
The researchers were able to avoid DKP formation between N-methylphenylalanine and 
proline with shortened treatments of 2-MP in DMF (20%, v/v). Encouraged by this 
observation, we assessed whether this strategy would be feasible in our synthesis of tripeptide 
2.23. 
 
Figure 2.3: Structure of jahanyne, a highly N-methylated natural product. 
 
 Dipeptide 2.19 was subjected to a single 1-minute treatment of 20% 2-MP in DMF 
(v/v) before the coupling of Fmoc-D-Lys(Boc)OH with DIC/HOBt. The resulting HPLC trace 
demonstrated unpromising results, in that the major peak corresponded to starting material 
(2.26), and two peaks corresponding to DKP product (2.24) and desired product (2.17) were 
observed, with the DKP product being more significant (Figure 2.4). Thus, it was concluded 





Figure 2.4: HPLC chromatogram after one minute of Fmoc-deprotection of peptide 2.19 and 
subsequent resin cleavage. Reduced deprotection times were not effective in eliminating the 
formation of DKP side-product 2.21/2.24. 
 
 Due to the difficulties encountered using the on-resin cyclization route, we decided to 
pursue an off-resin cyclization strategy, in which the peptide would be attached to the resin by 
the α-carboxylic acid of Gly10 (Scheme 2.6). One significant difference between this strategy 
and the strategy presented in Scheme 2.1 is that following the incorporation of all amino acids, 
the peptide would be cleaved from the resin with a weakly acidic solution of TFA in DCM 
(1%, v/v), keeping the side-chain protecting groups intact. Off-resin cyclization would then 





Scheme 2.6: Alternative proposed synthesis of A54145-tHOAsn3-tMeOAsp9. 
 
 Resin-bound glycine (1.18) was subjected to 20% 4-MP in DMF, and Fmoc-L-threo-
MeOAsp(tBu)OH (2.33, prepared by Ryan Moreira of the Taylor group)91 was introduced with 
DIC/HOBt, yielding dipeptide 2.34 (Scheme 2.7). After coupling of the third amino acid (D-
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Lys8), we considered it prudent to check if the desired tripeptide 2.35 was obtained, since we 
had already observed that aspartimide formation could occur upon Fmoc-deprotection of the 
resin-bound dipeptide. RP-HPLC analysis of the cleaved tripeptide revealed two peaks (Figure 
2.5), both with a mass corresponding to the desired product as indicated by LRMS. In the 
mechanism of aspartimide formation shown in Scheme 2.8, two isomeric products are formed: 
an α-MeOAsp product and a β-MeOAsp product. The presence of these closely eluting peaks 
with the same target mass further supports the supposition that the methoxy group of MeOAsp9 
promotes aspartimide formation. 
 










Figure 2.5: Aspartimide formation indicated by RP-HPLC. Peptide 2.35 was cleaved from the 
resin and analyzed by RP-HPLC. Both closely eluting peaks above had a mass corresponding 
to the desired peptide, suggestive of aspartimide formation (See Scheme 2.8). 
 
 In another attempt, DMB-protected Gly was attached to the resin followed by the 
addition of Fmoc-tMeOAsp(tBu)OH, yielding dipeptide 2.36 (Scheme 2.9). Unsurprisingly, 
attempts to incorporate Fmoc-D-Lys(Boc)OH also resulted in DKP formation, which is evident 
from almost complete absence of peaks in the HPLC chromatogram of the cleaved product 
(Figure 2.6). DKP formation had resulted in cleavage of the peptide from the resin.  
 
 





Figure 2.6: HPLC chromatogram showing very little peptide product after attempted coupling 
of Fmoc-D-Lys(Boc)OH to dipeptide 2.37. Following resin cleavage, very little of any product 
was detected, indicating DKP formation upon deprotection of dipeptide 2.36. 
 
 The strategy employed thus far involved final cyclization of the peptide between D-
Asn11 and Gly10, chosen because glycine is achiral and thus immune to epimerization during 
the cyclization step. Attachment of the peptide to the resin by the sidechain of MeOAsp9 or by 
the α-carboxylic acid of Gly10 had proven unsuccessful due to aspartimide formation in the 
absence of a DMB protecting group, and DKP formation in the presence of one. We reasoned 
that DKP formation might be avoided if tripeptide 2.23 was obtained by the coupling of 
DMBGlyOallyl to dipeptide 2.39 (Scheme 2.10). In this approach, there would never be a free 
amino group capable of DKP formation with the allyl ester of Gly10. It should be noted, 
however, that the activated ester of the C-terminal end of a peptide chain is more susceptible 
to racemization than a single carbamate-protected amino acid, and epimerized products may 
be expected. 
 




 Dipeptide 2.39 was obtained in excellent purity employing Fmoc-SPPS, with an HPLC 
chromatogram consisting of a single peak following resin cleavage. After attempting to 
introduce DMBGlyOallyl to dipeptide 2.39, the HPLC chromatogram revealed several 
different peaks (Figure 2.7), and one minor peak (tr = 27.5 min) corresponded to the desired 
tripeptide 2.23 as indicated by LRMS. Another expected peak (tr = 18.6 min) corresponded to 
the DMB-alcohol cleavage by-product, 2.40. No evidence of the starting material Fmoc-D-
Lys-tMeOAspOallyl or its allyl-deprotected Fmoc-D-Lys-tMeOAspOH counterpart was 
observed, indicating that the first step of the reaction sequence involving allyl deprotection 
goes to completion, as is expected using these conditions,82,85 and further, that the allyl 
deprotected product Fmoc-D-Lys-tMeOAspOH necessarily underwent a subsequent reaction. 
The question remained, which reaction corresponded to the major product observed by HPLC? 
 While Fmoc-D-Lys-tMeOAspOH was not observed, we were surprised to find that the 
major peak (tr = 22.5 min) on the HPLC chromatogram corresponded to Fmoc-D-Lys-
DHAsp-
OH, 2.41 (Figure 2.7), where DHAsp is dehydroaspartic acid, formed by the elimination of the 
methoxy group. Further, an additional peak (tr = 32.0) was found to correspond to tripeptide 
Fmoc-D-Lys-DHAsp-(DMB)Gly-OH, 2.42. Taken together, the presence of these peaks led us 
to conclude that the methoxy group had been eliminated in a side reaction during activation of 
the allyl deprotected peptide. We propose that O-acyl urea intermediate 2.43 underwent an 
intramolecular acid-base reaction and removed the proton from the α-position of tMeOAsp 
(Scheme 2.11). Elimination of the methoxy group, likely by an E1CB mechanism, yielded 
Fmoc-D-Lys-DHAsp-OH after cleavage from the resin (2.41). Dipeptide 2.43 could also 
undergo the expected amino acid coupling, yielding tripeptide 2.23 (Scheme 2.11). By HPLC 
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and LRMS, it was also demonstrated that the DMB-protecting group of tripeptide 2.42 was not 
removed during resin-cleavage involving a 1-hour treatment of 95:2.5:2.5 TFA/TIPS/H2O.  
 While it may have been possible to avoid this side reaction by using different coupling 
reagents, the high probability that this route would lead to, at the very least, epimerization of 
the MeOAsp residue via oxazalone formation or via direct α-deprotonation prompted us to 
explore an alternative route. 
 
Figure 2.7: HPLC chromatogram of cleaved products after attempted synthesis of 2.23. 
 
 




2.2.3 – Second Approach to A54145D 
 
  The key advantage of our previously attempted routes to A54145D was that the final 
cyclization was to take place between D-Asn11 and Gly10, thus avoiding issues of 
epimerization, as Gly10 is achiral. This strategy was successfully employed by Lohani et al. in 
their total synthesis of daptomycin.85 A54145D has an additional achiral amino acid: Sar5. 
With this in mind, we envisioned a total synthesis of A54145D which would begin with 
attachment of Sar5 to the resin through its α-carboxyl group, yielding 2.45 (Scheme 2.12). 
Incorporation of residue 4 would yield dipeptide 2.46, and residue 3 would yield tripeptide 
2.47. Formation of the depsi-bond with N3IleOH would yield branched peptide 2.48, and 
subsequent Fmoc-SPPS would yield 2.49. Reduction of the azido group followed by further 
Fmoc-SPPS would yield uncyclized peptide 2.50, and resin cleavage, off-resin cyclization, and 




Scheme 2.12: Proposed synthesis of A54145D via Sar5 resin-attachment. 
 
 This approach was expected to be advantageous for several reasons. Firstly, the Taylor 
lab had shown that formation of the ester bond in daptomycin became more difficult with 
increasing length of the peptide containing the Thr residue, and it was very difficult when the 
lipid tail was present.85 We therefore expected that forming the ester-bond in 2.48 would be 
less synthetically challenging than the initial approaches discussed above, which involved 
forming a depsi bond on octapeptide 2.3 (Scheme 2.1). Additionally, aspartimide formation 
between Gly10 and tMeOAsp9 could be avoided with the use of a DMB-protecting group, 
while simultaneously avoiding DKP formation between tMeOAsp9 and Gly10. However, a 
disadvantage of attaching the peptide to the resin by Sar5 is that FmocAA-Sar esters (where 
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AA is any amino acid) can also undergo DKP formation of the terminal amino group upon 
deprotection of the Fmoc group.95 Nevertheless, we expected that DKP formation during the 
deprotection of peptide 2.46 could be reduced using carefully selected deprotection conditions.  
2.2.3.1 – Attempts to Avoid DKP Formation between Thr4 and Sar5 
 
 Knowing that DKP formation might be an issue in our synthesis, we spent some time 
optimizing a method for the determination of exactly how much DKP was being formed, 
through Fmoc loading checks at each stage of the synthesis. In all our studies, resin-loading 
was estimated using a procedure modified from Gude et al.96 
 In 2002, Gude et al. reported a method for the quantification of Fmoc-derivatized solid 
phase supports.96 In their approach, an aliquot of the resin is treated with 20 mL 2% DBU in 
DMF to remove the Fmoc group. The reaction mixture is subsequently diluted in acetonitrile 
and the dibenzofulvene product quantified by absorbance based on a molar coefficient of 7624 
mol-1  L cm-1 at 304 nm. Employing Beer-Lambert’s law, A = εbc, where A is the absorbance, 
ε is the molar extinction coefficient, b is the path-length of the cuvette, and c is the 
concentration of dibenzofulvene deprotection product, and accounting for the dilution factor 
and the initial volume, the researchers were able to quantify resin-loading according to the 
following equation: 




 This equation is used to estimate the loading of a peptide on resin when the substitution 
of the resin is low, as is the case for TentaGel TrtCl resin (theoretical loading = 0.23 mmol/g). 
However, when the theoretical loading is high, with 2-ClTrt-Cl resin (theoretical loading = 1.5 
mmol/g), the equation above fails to accurately assess the loading.  
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 Consider the situation where 2-ClTrt-Cl-PS with a theoretical loading of 1.5 mmol/g is 
used in peptide synthesis. Choosing an initial scale of 0.1 mmol would require 66 mg of resin, 
and if the loading of the first amino acid (FmocSarOH) was 95% efficient, then the amount of 
FmocSarOH present on the resin after the initial coupling would be approximately 30 mg (311 
g/mol * 0.1 mmol * 0.95 = 30 mg). Therefore, an aliquot of resin chosen for loading is 
approximately 31% amino acid by mass, and 69% of the mass corresponds to the original resin 
(30 mg / (30 + 66) mg *100% = 31%), meaning that a large portion of the aliquot chosen for 
Fmoc quantification should not be considered in the resin-loading calculation. On the other 
hand, if low-loading TentaGel Trt-Cl resin with a theoretical loading of 0.23 mmol/g was used, 
an initial scale of 0.1 mmol would require 435 mg of resin. If the loading of the first amino 
acid was 95% efficient, the mass of FmocSarOH present after the initial coupling would still 
be 30 mg, which accounts for approximately 6% of the resin’s new total mass (30 mg / (30 + 
435) mg *100% = 6%). In practice, the mass of the resin does increase significantly when 2-
ClTrt-Cl-PS resin is used (as is expected, given that all amino acids have a higher mass than 
chlorine), further demonstrating that the mass of the peptide must be accounted for when 
determining the amount of resin-loading. 
 The equation presented by Gude et al.96 makes no consideration of the mass of the 
peptide in its calculation. In our approach to quantifying resin loading, we used 2 mL of 2% 
DBU in DMF, and accounting for the mass of the peptide, a new equation was developed: 
 𝐿𝑜𝑎𝑑𝑖𝑛𝑔(𝑚𝑚𝑜𝑙𝑒/𝑔) =
𝐴𝑏𝑠304 ∗ 16.396
(𝑚𝑔 𝑟𝑒𝑠𝑖𝑛) − 𝐴𝑏𝑠304 ∗ (
𝑀𝑊 − 35.45
1000 ) ∗ 16.396
 
 
 In this new equation, where MW = molecular weight of the amino acid, the actual mass 
of the resin is corrected with the additional term in the denominator, which removes the portion 
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of mass that is the direct result of coupling an amino acid to the resin. The other advantage of 
this modified equation is that it can be used to determine the loading of the resin at multiple 
stages of the synthesis, since the increased mass of the peptide is accounted for. The loading 
of a tripeptide can be determined just as easily as the loading of a single amino acid. This is 
advantageous, as it allows for the determination of DKP formation, simply by quantifying the 
amount of Fmoc signal present both before and after amino acid coupling attempts. 
 Efforts to circumvent DKP formation were reported by Thieriet et al. in 1997.97 In this 
approach, the N-terminus of dipeptides bearing an N-terminal Alloc protecting group were 
deprotected under neutral conditions using Pd(PPh3)4 and PhSiH3 as the allyl scavenger, in the 
presence of an activated amino acid. This tandem deprotection-coupling procedure was 
reported to reduce DKP formation to as little as 2%. In 2001, Zorn et al. reported that Pd(PPh3)4 
and DABCO (1,4-diazabicyclo[2.2.2]octane) could also be used, and successfully applied 
these conditions to the deprotection and subsequent coupling of an activated amino acid to an 
N-terminal Alloc-protected proline-proline dipeptide on a Wang resin, which is highly prone 
to DKP formation when deprotected.98 Inspired by these observations, we attempted to 
synthesize model tripeptide 2.51 (FmocAsn(Trt)ThrSarOH) by coupling FmocAsn(Trt)OH to 
resin-bound AllocThrSar (2.46a, Table 2.1, entries 1-4). Following the attempted amino acid 
coupling, a portion of the peptide was cleaved from the resin with 95:2.5:2.5 TFA/TIPS/H2O 
and analyzed by RP-HPLC to detect the desired peptide. If desired peptide was present, the 
quantity was then determined by performing a resin-loading analysis. 
 Initial attempts to form tripeptide 2.51 using the approaches of Thieriet et al. and Zorn 
et al. were unsuccessful (Table 2.1, entry 1). On both TentaGel Trt-Cl resin and 2-ClTrt-Cl-PS 
resin, deprotection of the Alloc group using these tandem conditions failed to yield the desired 
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peptide. It is unknown whether DKP formation had caused cleavage of the peptide from the 
resin, or if the deprotected peptide simply failed to react with the activated ester under these 
conditions, because DCM was used as the solvent. Deallylations using DMBA as the allyl 
scavenger and DCM as a solvent for both the deallylation and the coupling reactions, 
performed either in tandem or sequentially, produced only trace amounts of desired tripeptide 
(entries 2 and 3). However, when allyl deprotection was performed using Pd(PPh3)4/DMBA in 
DCM, followed by coupling of activated FmocAsn(Trt)OH in DMF, the desired tripeptide was 
obtained in a 44% yield on TentaGel Trt-Cl resin, and 49% on 2-ClTrt-Cl resin (Table 2.1, 
entry 4). This supports the notion that DCM is ineffective as a solvent for peptide coupling 
reactions. No further attempts for tandem deprotection-coupling were made, although it may 
be of interest to attempt tandem Alloc-deprotections and Fmoc-amino acid couplings with 
DMF as the solvent in an attempt to ameliorate this issue. 
 Siow et al. in their synthesis of jahanyne reported that DKP formation could be 
minimized using 2-MP and short Fmoc deprotection times. Accordingly, we attempted to 
reduce DKP formation using 2-MP and carefully controlled reaction times. When three 10-
minute iterations of 2-MP in DMF were used for Fmoc deprotection of Fmoc-protected 
dipeptide 2.47b, none of the desired peptide was obtained when the peptide was attached to 
TentaGel Trt-Cl resin (Table 2.1, entry 5). Surprisingly, when 2-ClTrt-Cl-PS resin was used, 
with three 10-minute iterations of 20% 2-MP treatment, the desired peptide was obtained in a 
26% yield. Reducing the deprotection to two 5-minute iterations (entry 6) formed the desired 
peptide in 34% yield with TentaGel, and 73% yield with 2-ClTrt-Cl. When the deprotection 
time was reduced to only two 1-minute iterations of 20% 2-MP in DMF, the desired tripeptide 
2.51 was obtained in almost quantitative yield (Entry 7). 
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Table 2.1: Conditions examined for coupling FmocAsn(Trt)OH to peptides 2.46a or 2.46b. 
 






12 equiv of DABCO or PhSiH3, 0.2 
equiv of Pd(PPh3)4, DCM 




10 equiv of DMBA, 0.2 equiv of 
Pd(PPh3)4, DCM 
4 equiv of AA/HOBt/DIC tandemb 0d 
3 Alloc 
10 equiv of DMBA, 0.2 equiv of 
Pd(PPh3)4, DCM, 1 h 




10 equiv of DMBA, 0.2 equiv of 
Pd(PPh3)4, DCM, 1 h 
4 equiv of AA/HOBt/DIC  
in DMF 
sequential 44d, 49e 
5 Fmoc 20% 2-MP in DMF, 3 x 10 min 
4 equiv of AA/HOBt/DIC  
in DMF 
sequential 0d, 26e 
6 Fmoc 20% 2-MP in DMF, 2 x 5 min 
4 equiv of AA/HOBt/DIC  
in DMF 
sequential 34d, 73e 
7 Fmoc 20% 2-MP in DMF, 2 x 1 min 
4 equiv of AA/HOBt/DIC  
in DMF 
sequential 99e 
a Tandem reaction conducted for 2 h. bTandem reaction conducted for 4 h. c TentaGel or 2-
ClTrt-Cl resin. dTentaGel resin. e2-ClTrt-Cl resin. 
 
 It is possible that the ester bond between sarcosine and the resin is more susceptible to 
attack by the amino group of the unprotected threonine residue with TentaGel resin than 2-
ClTrt-Cl-PS resin. Because of the PEG linker found in TentaGel, the peptide attached to 
TentaGel is expected to have more mobility in solution, and this could increase the rate of DKP 
formation.  
 We initially used Fmoc-tHOAsn(Trt, TBDMS)OH for the synthesis of A54145D. Thus, 
peptide 2.46b was deprotected using the conditions outlined in entry 7 in Table 2.1 and Fmoc-
tHOAsn(Trt, TBDMS)OH was coupled to the resulting deprotected dipeptide using 
DIC/HOBt.  However, the coupling was sluggish and, based upon the lower than expected 
signal intensities by analytical RP-HPLC of subsequent amino acid couplings, we suspected 
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that increased DKP formation was again an issue. Therefore, we decided to try the less 
sterically encumbered Fmoc-tHOAsn(TBDMS)OH building block.91  In this case, the coupling 
proceeded smoothly and tripeptide 2.53 was formed in almost quantitative yield (Scheme 
2.13). 
 
Scheme 2.13: Synthesis of tripeptide 2.53 after shortened deprotection times. 
 
2.2.3.2 – Difficulties in Deprotection of Resin-bound FmocSar 
 
 While DKP formation could be avoided using reduced deprotection times on 2-ClTrt-
Cl-PS resin, it is worth mentioning the difficulty experienced in attempting to remove the Fmoc 
group of resin-bound FmocSar (2.45, Scheme 2.13). Typically, the Fmoc-group can be 
removed without issue from resin-bound amino acids using two 10-minute treatments with 
20% piperidine in DMF, and this was indeed the case for FmocSarOH bound to TentaGel Trt-
Cl resin. Unfortunately, attempts to remove the Fmoc group from 2.45 proved problematic, 
which has received little mention in the literature. 
 In the first attempted synthesis of dipeptide 2.46a, 2.45 was subjected to 20% 4-MP in 
DMF (1 x 5 min, 1 x 20 min) and the resulting unprotected sarcosine allowed to react with 
AllocThrOH with DIC/HOBt. After Alloc-removal and coupling of FmocAsn(Trt)OH in DCM 
(Table 2.1, entry 3), a portion of the resin was cleaved for HPLC analysis, revealing a single 
peak as shown in Figure 2.8. While the presence of a single peak in an analytical RP-HPLC 
83 
 
chromatogram is generally desired during HPLC analysis, we were dismayed when LRMS 
revealed this peak to correspond to FmocSarOH. The presence of this protected amino acid 
indicated that when FmocSarOH is the only amino acid attached to 2-ClTrt-Cl resin, it is more 
resistant to Fmoc-deprotection than other amino acids, and this observation was only slightly 
ameliorated when the resin was allowed to swell for longer periods of time. We were initially 
surprised by this result, but came upon the work of Malakoutikhah et al., who reported in 2008 
alternative Fmoc-deprotection conditions to remove the Fmoc group from resin-bound Fmoc-
N-methylphenylalanine (Fmoc-N-MePheOH).99 In their work, most Fmoc-groups were 
removed by simple treatment of 20% piperidine in DMF (2 x 1 min, 1 x 10 min), but this was 
not the case for resin-bound Fmoc-N-MePheOH. Removal of the Fmoc-group in resin-bound 
Fmoc-N-MePheOH required an additional 5-minute treatment with 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), toluene, and piperidine in DMF (5%, 5%, 20%, v/v).  
 
Figure 2.8: Presence of FmocSarOH observed after attempted formation of tripeptide 2.51. 
 
 To resolve this issue, 2.45 was subjected to conditions similar to those reported by 
Malakoutikhah et al., except 4-MP was used in place of piperidine. Nevertheless, protected 
FmocSarOH was still observed by HPLC and LRMS (Figure 2.9A). However, treatment of the 
peptide with an extended 75-minute treatment of DBU, toluene and 4-MP in DMF (5%, 5%, 
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20%, v/v) effectively removed the Fmoc-group quantitatively (Figure 2.9B). Furthermore, 
extended deprotection times (3 x 30 min) with 20% 4-MP in DMF (Figure 2.9C) or with 5% 
DBU (3 x 30 min) in DMF (Figure 2.9D) were also effective in removing the Fmoc-group. It 
is worth noting that the HPLC chromatograms in Figures 2.8 and 2.9 can detect FmocSarOH 
because of the presence of the chromophoric fluorenyl group. However, the product of Fmoc-
deprotection, unprotected sarcosine, possesses no chromophore, and therefore is not detectable 
by HPLC analysis using a UV detector. Accordingly, these HPLC chromatograms will only 
show the lack of starting material, and not the presence of product. Having finally established 
conditions suitable for completely removing the Fmoc-group of FmocSarOH while avoiding 




Figure 2.9: Attempted Fmoc-deprotections of FmocSar on 2-ClTrt-Cl resin. (A) partial 
deprotection observed when employing the conditions used by Malakoutikhah et al.99 (B) 
Complete deprotection observed after extended treatment with 5:5:20:70 DBU/Toluene/ 4-
MP/DMF. (C) Complete deprotection observed after extended treatment with 20% 4-MP in 






2.2.3.3 – Total Synthesis of A54145D-tHOAsn-tMeOAsp 
 
 Tripeptide 2.53 was obtained in almost quantitative yield from 2.46b employing two 
1-minute iterations of 20% 2-MP in DMF, followed by coupling of Fmoc-
tHOAsn(OTBDMS)OH with DIC and DMAP (Scheme 2.14). Ester bond formation between 
tripeptide 2.53 and N3IleOH (synthesized according to the procedure of Kim et al.,
100 except 
that imidazole-1-sulfonyl azide hydrochloride101,102 was used in place of triflic azide) with 
DIC/DMAP was performed without issue after one 12 h coupling, and no subsequent 
epimerization of Ile13 was observed. Fmoc-SPPS was used to incorporate D-Glu2, Trp1, and 
racemic lipid 2.14 into peptide 2.54 to give peptide 2.55. At this point, we noticed that the 
cleavage cocktail 95:2.5:2.5 TFA/TIPS/H2O was no longer effective in removing the TBDMS 
protecting group from tHOAsn(OTBDMS), indicating that at a later point in the synthesis, it 
would need to be removed by treatment with TBAF. 
 
Scheme 2.14: Unsuccessful synthesis of peptide 2.56. 
 
 Reduction of the N3 group of peptide 2.55 was attempted with PBu3 in 95:5 THF/H2O 
in the presence of the symmetric anhydride of FmocGlu(tBu)OH,103 but HPLC analysis of the 
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reduced product indicated a complex mixture of products (Figure 2.10). The major product (tr 
= 30 min) could not be identified, and the desired product (tr = 40 min, 2.57) was only present 
in minute amounts. Reduction of the azido group using alternative conditions of DTT and 
DIPEA was sluggish. In fact, two overnight attempts of azido reduction using DTT and DIPEA 
resulted in less than 50% reduction as indicated by HPLC.  
                   .                        / 
Figure 2.10: HPLC chromatogram of crude peptide after azido-reduction of 2.55 with PBu3 
and resin cleavage. 
 
 Fortunately, we found that if the TBDMS group was removed with TBAF and AcOH 
in THF prior to N3 reduction, the desired peptide 2.58 could be obtained almost quantitatively, 
suggesting that the TBDMS group participates in unknown side reactions under our reduction 
conditions (Scheme 2.15). Furthermore, it was suspected that the TBDMS protecting group 
participated in side-reactions during TFA cleavage conditions. When the progress of the 
reaction was analyzed by HPLC, it was found that the presence of the TBDMS protecting 
group resulted in somewhat complex HPLC chromatograms. However, once the TBMDS 
group was removed with TBAF, the apparent purities of the compounds as judged by HPLC 
significantly improved. Presumably, the silyl ether underwent some side reactions during the 
resin-cleavage step with 95:2.5:2.5 TFA/TIPS/H2O, although the nature of these side reactions 
is unknown.  
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 It is worth noting that, despite the presence of the symmetric anhydride of 
FmocGlu(tBu)OH during N3 group reduction, the major product was indeed peptide 2.58 and 
not the FmocGlu(tBu)-coupled counterpart, consistent with previous studies in the Taylor 
lab.103 The presence of the symmetric anhydride of FmocGlu(tBu)OH during azido group 
reduction prevents cleavage of the ester bond during this step. Accordingly, subsequent Fmoc-
SPPS still required standard coupling of FmocGlu(tBu)OH using DIC/HOBt.  
 Standard Fmoc-SPPS from 2.58 was used to introduce residues 12 to 6 to give peptide 
2.59 (Scheme 2.15). A DMB-protecting group on Gly10 was used to prevent aspartimide 
formation between tMeOAsp9 and Gly10. Peptide 2.59 was cleaved from the resin using 1% 
TFA in DCM (v/v) to give peptide 2.60, which was cyclized using PyAOP/HOAt/2,4,6-
collidine, followed by global deprotection with TFA/TIPS/H2O to yield crude A54145-
tHOAsn3-tMeOAsp9. Purification by semi-preparative RP-HPLC gave the target peptide in 




Scheme 2.15: Successful synthesis of A54145-tHOAsn3-tMeOAsp9. 
 
 The antimicrobial activity of authentic A54145D, generously provided by Jared 
Silverman previously of Cubist Pharmaceuticals, now owned by Merck and Co., and the 
activity of our synthesized A54145D-tHOAsn3-tMeOAsp9 were determined against B. subtilis 
ATCC 1046 (Table 2.2). The synthesized A54145D-tHOAsn3-tMeOAsp9 exhibited an MIC 
that was at least 64 times greater than that of authentic A54145D, signifying poorer biological 
activity, which suggested to us that the configuration of the side chain of the HOAsn3 residue 
and/or the MeOAsp9 residue in the synthetic peptide was incorrect. Since bioinformatics 
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studies strongly suggested that the HOAsn residue is the L-threo isomer,88 we assumed that 
the problem was most likely with the MeOAsp residue. 
Table 2.2: MICs of A54145D peptides. 
entry peptide MIC (g/mL)a 
1 Authentic A54145D 0.5 
2 A54145D-tHOAsn3-tMeOAsp9b >32 
3 A54145D-tHOAsn3-eMeOAsp9c 0.5 
4 A54145D-(8R)-anteiso 0.5 
5 A54145D-(8S)-anteiso 0.5 
aAgainst B. subtilis ATCC 1046. 1.25 mM Ca2+ present. 
bPutative structure of A54145D 
cActual structure of A54145D (see below) 
 
2.2.3.4 – Total Synthesis of A54145D-tHOAsn3-eMeOAsp9 
 
 To test whether the low biological activity was indeed due to incorrect stereochemistry 
at the MeOAsp residue, Fmoc-L-erythro-MeOAsp(tBu)OH (Fmoc-eMeOAsp(tBu)OH, 2.65 
in Scheme 2.16) was prepared by Ryan Moreira. The configuration of the alcohol in 2.6191 was 
inverted by first treating 2.61 with diisopropyl azodicarboxylate (DIAD), triphenylphosphine 
(PPh3) and p-nitrobenzoic acid (PNBCOOH), and the resulting PNB ester 2.62 was then 
subjected to NaN3.
104 This gave the corresponding erythro isomer 2.63 in excellent yield. 
Methylation of the alcohol in 2.63 with MeI/Ag2O in diethyl ether at reflux gave ether 2.64 in 
almost quantitative yield. Removal of the benzyl group in 2.64 using Bobbit’s salt91 and 
oxidation of the in situ generated alcohol using NaO2Cl/NaOCl gave acid Fmoc-





Scheme 2.16: Synthesis of Fmoc-L-erythro-MeOAsp(tBu)OH, 2.65. 
 
 A54145D-tHOAsn3-eMeOAsp9 was prepared using the same route that was used for 
the threo isomer (Schemes 2.13, 2.14, and 2.15). After purification, the synthesized peptide 
was co-injected with authentic A54145D for HPLC analysis, and the two compounds co-eluted 
(Figure 2.11). The biological activity of A54145D-tHOAsn3-eMeOAsp9 was identical to the 
biological activity of authentic A54145D (Table 2.2, entry 3), indicating that this newly 










2.2.3.5 – Characterization of A54145D-tHOAsn3-eMeOAsp9 
 
 The 1H-NMR spectrum of A54145D had been reported previously by Cubist 
Pharmaceuticals in the patent literature.105 As an additional confirmation that our synthesized 
compound was indeed the same as authentic A54145D, we obtained a 1H-NMR spectrum in 
D2O. However, a direct comparison was challenging because of line-broadening issues that 




Figure 2.12: 1H-NMR of A54145D-tHOAsn3-eMeOAsp9 (300 MHz, D2O). As is the case 
with the literature 1H-NMR spectrum of A54145D,105 severe line broadening is observed. 
 
 To address the line-broadening problem, the nucleus of A54145D (A54145D without 
the lipid tail) was synthesized in the same manner as A54145D (Schemes 2.13, 2.14, and 2.15), 
except that Trp1 was incorporated into the resin as BocTrp(Boc)OH, no lipid tail was attached, 
and Fmoc-eMeOAsp(tBu)OH was used instead of Fmoc-tMeOAsp(tBu)OH. The 1H-NMR of 
the synthetic nucleus was a good match to its literature spectrum (Figure 2.13),106 which further 
indicated that we had indeed produced authentic A54145D, and that MeOAsp9 is of the L-
erythro-configuration and not the L-threo-configuration as is often depicted in the literature. 
Additionally, this also confirmed that HOAsn in A54145D is of the L-threo-configuration.  
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Figure 2.13: 1H-NMR of synthetic A54145D-nucleus (300 MHz, D2O, top) and literature 
spectrum (270 MHz, D2O, bottom).
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 After the comparison of the 1H-NMR of our synthesized nucleus to the 1H-NMR data 
found in the patent literature,106 we then proceeded to completely characterize it by 1D and 2D 
NMR spectroscopy. An aliquot of 5 mg of the peptide was dissolved in 0.5 mL of D2O and 
analyzed with 1D NMR experiments including 1H-NMR, and 2D NMR experiments including 
1H-13C HSQC, 1H-13C HMBC, 1H-COSY, 1H-TOCSY and 1H-ROESY (See Figures A.1 to 
A.6, and Table A.1 in Appendix A).  
 In assigning the chemical shifts of each amino acid residue, the 1H-13C HSQC, 1H-13C 
HMBC, 1H-COSY spectra were used to assign the chemical shifts of Trp1, Thr4, and Ile13. 
The 1H-COSY was used to assign the chemical shifts of Sar5 and Ala6, and subsequently, 1H-
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13C HMBC was used to assign the chemical shifts of the methyl groups of Sar5 and eMeOAsp9. 
Both the 1H-COSY and the 1H-TOCSY spectra were used to assign the chemical shifts of the 
remaining amino acids, and the 1H-ROESY spectra was used to distinguish between D-Glu2 
and Glu12, Asp7 and D-Asn11, and tHOAsn3 and eMeOAsp9. Following the assignments of 
each proton signal, the assignments of each carbon signal were made using the 1H-13C HSQC 
spectrum. Additionally, with DMSO-d6 as the solvent, line broadening issues observed for 
synthesized A54145D-tHOAsn3-tMeOAsp9 and A54145D-tHOAsn3-eMeOAsp9 were 
avoided, and therefore, we also completely characterized these two compounds with 1H-NMR, 
and 2D experiments 1H-13C HSQC, 1H-13C HMBC, 1H-COSY, 1H-TOCSY and 1H-ROESY 
(Figures A.7 to A.12 for A54145D-tHOAsn3-eMeOAsp9, Figures A.13 to A.18 for A54145D-
tHOAsn3-tMeOAsp9; and Table A.2 in Appendix A). Additionally, synthetic A54145D was 
characterized by MS/MS peptide sequencing (See Figure D.1 and Figure D.2 in Appendix D). 
2.2.4 – Assessing the Role of Lipid Tail Stereochemistry in Biological Activity of A54145D 
 
 Although the configuration of the anteiso-lipid in A54145D has never been determined, 
Kaneda has reported that anteiso-lipids in Gram-positive bacteria have the S-configuration.107 
Furthermore, it was also established by Boeck and Wetzel that supplementing S. fradiae with 
isoleucine in the growth medium significantly increased the output of A54145 factors C, D and 
E (those with the anteiso-undecanoyl tail) from 17% of the total antibiotic to 66% of the total 
antibiotic.108 From these data, it may be inferred that the side chain of isoleucine ultimately 
ends up in the anteiso-decanoyl lipid tail, and since the side-chain of isoleucine possesses S-
stereochemistry, the notion that the lipid tail may be of the S-configuration is further 
substantiated. The fact that our synthetic A54145D, which contained a racemic lipid, exhibited 
the same activity as authentic A54145D suggests that the stereochemistry of the lipid does not 
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affect activity or that the lipid in A54145D is actually racemic. To determine if this is indeed 
the case, we prepared A54145D (containing the correct L-erythro-MeOAsp isomer) bearing 
either (R)-8-methyldecanoic or (S)-8-methyldecanoic acid (A54145D-(8R)-anteiso and 
A54145D-(8S)-anteiso, respectively). (8R)- and (8S)-methyldecanoic acid were prepared using 
the same route used to prepare (±)-8-methyldecanoic (Scheme 2.3, Section 2.2.1.1) except (R)- 
or (S)-2-methylbutanal was used instead of (±)-2-methylbutanal. (S)-2-Methylbutanal was 
readily prepared by (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl (TEMPO) oxidation of 
commercially available (S)-2-methylbutanol.109 However, (R)-2-methylbutanol and (R)-2-
methylbutanal are either not commercially available or prohibitively expensive. Ryan Moreira 
prepared (R)-2-methylbutanal using a route similar to that developed by Yang et al. for the 
synthesis of (R)-2-methylpentanal (Scheme 2.17).110 (1S)-2,10-camphorsultam, 2.66, was 
treated with butyryl chloride in the presence of triethylamine (TEA) and DMAP which gave 
sulfonamide 2.67 in 69% yield. Methylation at the 2-position of the butyryl portion of 2.67 
with sodium hexamethyldisilazide (NaHMDS)/methyl iodide (MeI) gave compound 2.68 in 
79 % yield. Treatment of 2.68 with diisobutylaluminum hydride (DIBAL) gave (R)-2-
methylbutanal (2.69) in 33 % yield. The yield obtained for compound 2.69 was quite low, due 
to the volatility of this compound. We found it best to not remove all the solvent after 
chromatography, but instead to use it as a 40% solution in DCM in the subsequent Wittig 





Scheme 2.17: Synthesis of (R)-2-methylbutanal (2.69). 
 
 With the enantiomerically pure lipid tails in hand, two more A54145D peptides were 
synthesized using the same route outlined in Schemes 2.13, 2.14 and 2.15, except that Fmoc-
eMeOAsp(tBu)OH, and (8R)- or (8S)-methyldecanoic acid were used. The biological activities 
of A54145D-(8R)-anteiso and A54145D-(8S)-anteiso were determined against B. subtilis 
ATCC 1046 (Table 2.2, entries 4 and 5), and it was found that the biological activities of these 
two compounds were identical to those of authentic A54145D and A54145D-tHOAsn3-
eMeOAsp9. While these results fail to ascertain the true stereochemistry of the lipid tail in 
A54145D, they nevertheless demonstrate that the biological activity of A54145D is unaffected 
by the stereochemistry of the lipid tail.  
2.3 – Conclusions 
 
 Very recently, and while the work described here was nearing completion, Chen et al. 
reported the total synthesis of A54145 factors A, A1, B, B1 and F, the stereochemical revision 
of the MeOAsp, and also confirmed that the HOAsn3 residue is the L-threo isomer.111 Their 
approach was to attach the peptide to the resin via Gly10 (1.18 in Scheme 2.6, Section 2.2.2); 
however, the yields obtained were low (3 %). Our studies suggest that the low yields may have 
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been due to aspartimide formation. Having to make the ester bond on a 10-mer containing the 
lipid tail may also have contributed to the low yields. In contrast, we have devised a more 
efficient synthesis of A54145D.  Consistent with the studies of Chen et al.,111 we found that 
the MeOAsp9 residue has the 2S,3R configuration. In addition, we demonstrated that the 
stereochemistry of the anteiso-undecanoyl lipid tail does not affect biological activity. 
 





 The total synthesis of A54145D reported here is more efficient than that of Chen et 
al.,111 and key challenges in the synthesis have been overcome. This total synthesis opens the 
door for the synthesis of A54145D analogs to establish SARs, which could lead to the 
development of novel antibiotics for treating CAP. For example, can the non-proteinogenic 
amino acids be replaced with more commercially available ones? Are other amino acids in the 
structure of A54145D amenable to substitution without loss of activity? With a successful 
approach for the synthesis of A54145D analogs in hand, we turned our attention to the 
synthesis of A54145D analogs. This research is presented in Chapter 3. 
 
2.4 – Experimental 
 
2.4.1 – General Experimental 
 
 All reagents used for peptide synthesis were obtained from commercial sources 
including coupling reagents, resins, and Fmoc amino acids. ACS grade N,N’-
dimethylformamide (DMF), 4-methylpiperidine (4-MP), 2-methylpiperidine (2-MP), TFA, 
dimethylbarbituric acid (DMBA), and triisopropylsilane (TIPS) were purchased from 
commercial suppliers and used without further purification. CH2Cl2 (DCM) was distilled from 
calcium hydride under nitrogen. THF was distilled from sodium metal and benzophenone 
under nitrogen. Peptide synthesis was performed manually using a rotary mixer for agitation. 
 Peptide syntheses were monitored by treating small aliquots of resin with 95:2.5:2.5 
TFA/TIPS/H2O for 1.5 h, removing the solvent by N2 stream, re-dissolving the peptide in 1:1 
MeCN/H2O and analyzing by RP-HPLC and LRMS.  
 Analytical HPLC was accomplished with a reversed-phase C18 column (10 µm, 250 
mm × 4.6 mm, 1 mL/min flow rate). Peptides were purified by reversed phase semi-preparative 
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HPLC using a C18 column (10 µm, 150 mm × 20 mm, 10 mL/min flow rate). High resolution 
positive ion electrospray (ESI+) mass spectra were obtained using an orbitrap mass 
spectrometer, dissolving samples in 1:1 MeOH/H2O + 0.1% formic acid. 
 Resin loading was estimated using a procedure modified from Gude et al.96 Resin 
containing the first amino acid, di- or tripeptide were subjected to 2 mL of 2% DBU in DMF 
(v/v) for 30 minutes. The suspension was diluted to 10 mL with acetonitrile, of which 1 mL 
was further diluted to 12.5 mL with acetonitrile. Absorbance of this solution was observed in 
triplicate at 304 nm with a reference solution as a blank. Resin loading was estimated by 
substitution of appropriate values into the equation in section 2.2.3.1.  
2.4.2 – Procedure for Assessing Minimum Inhibitory Concentrations (MICs) 
 
 The antibacterial activity of the synthetic peptides and authentic A54145D was 
determined using a broth microdilution assay.112 Overnight bacterial cultures were grown in 
Luria-Bertani (LB) broth and then diluted to approximately 1 × 106 CFU/mL according to the 
measured optical density at 600 nm (OD600). Twofold serial dilutions were used to prepare a 
series of peptide solutions in LB broth, which were then inoculated with an equal volume of 
diluted bacterial culture in 96-well microplates. Plates were incubated for 24 h at 37 °C, and 
then the MIC was determined by the lowest concentration at which there was no visible growth 
of bacteria. 
2.4.3 – General Procedures for Fmoc-SPPS 
 
Procedure for resin activation and resin attachment: 2-ClTrt-Cl-PS resin or TentaGel Trt-Cl 
resin was treated with 3.6 equiv of thionyl chloride and 7.2 equiv of pyridine in dry DCM at 
reflux for 2 h. Following the reflux, the resin was transferred to a disposable polyethylene 
cartridge equipped with a filter and rinsed extensively (6 x 30 s) with dry DCM. To this was 
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added the first amino acid (4 equiv) and DIPEA (8 equiv) in dry DCM, and the peptide was 
agitated for 4 h. Following the reaction time, the cartridge was rinsed with DCM (3 x 3 min) 
and capped with DCM/methanol (MeOH)/DIPEA (17:2:1, v/v, 3 x 10 min). The resin was then 
rinsed with DCM (3 x 5 min). 
General procedure for Fmoc-Removal: The resin was swelled in DMF for 5 min before the 
addition of 20% 4-MP in DMF (v/v, 1 x 5 min, 1 x 20 min). For the removal of Fmoc groups 
after the formation of the depsi bond, the resin was treated with 20% 2-MP in DMF (v/v, 3 x 
10 min). Following Fmoc-deprotection, the resin was rinsed with DMF (3 x 5 min) and DCM 
(3 x 5 min). 
General procedure for Amino Acid Coupling: The resin was swelled in DMF for 5 min before 
the addition of FmocAAOH (4 equiv), HOBt (4 equiv), and DIC (4 equiv) in DMF. The 
cartridge was agitated for 4 h at room temperature before the reagents were filtered and the 
resin subsequently rinsed with DMF (3 x 5 min) and DCM (3 x 5 min). 
General procedure for Allyl Group Removal: The resin was swelled in dry DCM. The solvent 
was removed by filtration, and to the cartridge was added DMBA (10 equiv) and Pd(PPh3)4 
(0.2 equiv) in 3:1 DCM/DMF (v/v). The mixture was mixed by N2 stream for 1 h, and following 
the reaction time, the unreacted Pd(PPh3)4 was quenched by further rinses with 1% sodium 
diethyldithiocarbamate trihydrate in DMF (m/v, 5 x 5 min). The resin was further rinsed with 
DMF (3 x 5 min) and DCM (3 x 5 min). 
General procedure for Amino Acid Coupling in the N → C direction: The resin was swelled 
in DMF for 5 min, and HOBt (4 equiv) and DIC (4 equiv) added as a solution in DMF. The 
free carboxylic acid was allowed to activate for 5 min before the addition of H2NAAOAllyl (4 
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equiv), and the cartridge was agitated for 4 h. Following the reaction, the resin was rinsed with 
DMF (3 x 5 min) and DCM (3 x 5 min). 
General procedure for Depsi-Bond Formation: FmocIleOH or N3IleOH (10 equiv) were 
dissolved in dry DCM followed by the addition of DIC (10 equiv). The suspension was mixed 
for 1 h before filtration and transfer to the peptide containing an unprotected alcohol of Thr4. 
Following the addition of the amino acid and DIC, DMAP (0.1 equiv) was added to the 
cartridge, and the cartridge was agitated overnight (12 h). The following day, the resin was 
rinsed with DCM (3 x 5 min), DMF (3 x 5 min), and finally with DCM (3 x 5 min). 
 
2.4.4 – Experimental Procedures for Synthesized Compounds 
 
 
(6-Ethoxy-6-oxohexyl)triphenylphosphonium bromide (2.12). Compound 2.12 was 
synthesized according using a procedure by Motoshima and coworkers.92 To a 50 mL round-
bottom flask was added ethyl 6-bromohexanoate (2.01 mL, 11.3 mmol, 1.07 eq.), 
triphenylphosphine (2.77 g, 10.5 mmol, 1 eq.), and dry acetonitrile (15 mL). The mixture was 
refluxed for 7 h, concentrated, and purified by column chromatography employing a slow 
gradient of chloroform to 19:1 chloroform-methanol. The desired product was obtained as a 
beige, amorphous solid (3.43 g, 67%).  1H-NMR (300 MHz, CDCl3) δ: 7.79-7.65 (m, 15H), 
3.99 (q, 2H, J = 7.1 Hz), 3.73-3.69 (m, 2H), 2.19 (t, 2H, J = 7.1 Hz), 1.61-1.56 (m, 6H), 1.14 
(t, 2H, J = 7.1 Hz). 13C-NMR (75 MHz, CDCl3) δ: 173.5, 135.1, 133.6, 130.5, 118.2, 60.2, 
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33.7, 29.7, 24.3, 22.9, 22.3, 14.2. 31P-NMR (121 MHz, CDCl3) δ: 25.3. HRMS (ESI+): m/z 
[M]+ calcd for C26H30O2P: 405.19779; found: 405.19741. 
 
(±)-Ethyl (Z)-8-methyldec-6-enoate ((±)-2.13).  The following procedure was used to prepare 
(±)-2.13, (S)-2.13 and (R)-2.13 using either (±)- or (S)-2-methylbutanal, or (R)-2-
methylbutanal (2.69). To a 100 mL round-bottom flask was added 2.12 (1.02 g, 2.10 mmol, 1 
equiv) and the flask was purged with argon gas. Dry THF (50 mL) was added and the mixture 
was cooled to -78 oC in a slurry of dry ice in acetone. A 1.0 M solution of NaHMDS in THF 
(2.1 mL, 2.1 mmol, 1 equiv) was slowly added over 5 min and the resulting orange solution 
was stirred for 30 min at -78 oC. A solution of (±)-2-methylbutanal (231 µL, 2.00 mmol, 0.95 
equiv) in THF (5 mL) was transferred to the reaction mixture. The solution was allowed to 
warm to room temperature and stirred overnight. The reaction was quenched with saturated 
sodium bicarbonate and the product was extracted with ethyl acetate (2 x 50 mL). The organic 
layers were combined, dried with sodium sulfate, and concentrated in vacuo. The residue was 
subjected to flash chromatography (95% hexane/5% ethyl acetate, Rf = 0.3) which provided 
pure (±)-2.13 as a colorless oil (0.305 g, 66% yield). The yields of (S)-2.13 and (R)-2.13 were 
71% and 69% respectively. 1H-NMR (300 MHz, CDCl3) δ: 5.22 (1H, td, J = 7.2, 10.8 Hz), 
5.04 (1H, app. t, J = 9.9 Hz), 4.04 (2H, q, J = 7.2 Hz), 2.22 (2H, t, J = 7.5 Hz), 1.97 (2H, q, J 
= 7.3 Hz), 1.57 (2H, app. quint, J = 7.6 Hz), 1.36-1.04 (7H, m), 0.85 (3H, d, J = 6.7 Hz), 0.76 
(3H, t, J = 7.4 Hz). 13C-NMR (75 MHz, CDCl3) δ: 173.5, 136.4, 127.8, 60.0, 34.1, 33.3, 30.2, 
29.3, 27.0, 24.5, 20.9, 14.1, 11.8. HRMS-ESI+: m/z [M + H]+ calcd for C13H25O2: 213.1849; 
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found 213.1849. The 1H-NMR spectra of (S)-2.13 and (R)-2.13 were identical to that of (±)-
2.13.  
 
(±)-8-Methyldecanoic acid ((±)-2.14). The following procedure was used to prepare (±)-2.14, 
(S)-2.14, and (R)-2.14 using either (±)-2.13, (S)-2.13, or (R)-2.13. Compound (±)-2.13 (201 
mg, 0.95 mmol) was added to a 50 mL round-bottom flask equipped with a stir bar. To this 
was added ethanol (25 mL) and 10% Pd/C (40 mg, 0.04mmole, 0.04 equiv) and the flask was 
purged with argon gas. The flask was then flushed with H2 and allowed to stir overnight at 
room temperature. The mixture was filtered over celite and the filtrate was concentrated 
yielding a colorless oil {1H-NMR (300 MHz, CDCl3) δ: 4.06 (2H, q, J = 7.0 Hz), 2.22 (2H, t, 
J = 7.4 Hz), 1.56 (2H, m), 1.35-0.95 (15H, m), 0.88-0.72 (6H, m). 13C-NMR (75 MHz, CDCl3) 
δ: 173.7, 60.0, 36.5, 34.3, 29.5, 29.4, 29.1, 26.8, 24.9, 19.1, 14.1, 11.3. HRMS-ESI+: m/z [M + 
H]+ calcd for C13H27O2: 215.20056; found 215.20134}. The oil (176 mg, 0.82 mmol) was 
dissolved in a solution of 1:1 MeOH and 0.6 M NaOH (aq) (25 mL). After 3 h, the reaction 
was acidified to pH 1 with 1 M HCl and the product extracted into ethyl acetate (2 x 50 mL). 
The organic layers were dried with Na2SO4 and the solvent removed by rotary evaporation 
yielding pure (±)-2.14 as a colorless oil (153 mg, 77%). The yields of (S)-2.14 and (R)-2.14 
were 78% and 79% respectively. 1H-NMR (300 MHz, CDCl3) δ: 11.74 (1H, br. s), 2.33 (2H, 
t, J = 7.5 Hz), 1.59 (2H, app. quint, J = 7.3 Hz), 1.39-1.00 (11H, m), 0.88-0.76 (6H, m); 13C-
NMR (75 MHz, CDCl3) δ: 183.6, 39.4, 37.2, 37.0, 32.5, 32.3, 32.0, 29.7, 27.5, 22.0, 14.2; 




of (S)-2.14 and (R)-2.14 were identical to that of (±)-2.14. (S)-2.14: [α]22D +4.7
o (c 0.20, 
CHCl3) (lit.,
113 [α]25D +6.1
o (1.14, CHCl3)).  (R)-2.14: [α]
22
D -4.4
o (c 0.20, CHCl3). 
 
TsO-H3N+GlyOAllyl (2.73). Glycine (21 g, 0.280 mol, 1 equiv) was added to a solution of 
toluene (75 mL) and allyl alcohol (66.6 mL, 0.979 mol, 3.5 equiv). To this solution was added 
p-toluenesulfonic acid monohydrate (p-TsOH·H2O, 55.9 g, 0.294 mol, 1.05 equiv). The 
solution was stirred under reflux equipped with a Dean-Stark trap overnight. Following the 
reaction, the mixture was concentrated to obtain a dark oil. This was triturated with ethyl 
acetate overnight and the resulting solid was rinsed with chilled ethyl acetate yielding the 
desired product as beige crystals (80.4 g, 88%). 1H-NMR (300 MHz, CD3OD) δ: 7.69 (2H, d, 
J = 7.9 Hz), 7.22 (2H, d, J = 7.8 Hz), 5.95 (1H, m), 5.36 (1H, d, J = 17.2 Hz), 5.26 (1H, d, J = 
10.4 Hz), 4.71 (2H, d, J = 5.5 Hz), 3.85 (2H, s), 2.36 (3H, s). 13C-NMR (75 MHz, CD3OD): δ: 
166.8, 142.0, 140.3, 131.3, 128.4, 125.5, 118.1, 66.3, 39.6, 19.9.  HRMS (ESI+): m/z [M+H]+ 
calcd for C5H10NO2: 116.07061, found 116.07093. 
 
Allyl (2,4-dimethoxybenzyl)glycinate (2.74). Compound 2.74 was synthesized based upon a 
procedure by the Martin Group.84 To 1,2-dichloroethane (100 mL) was added 2,4-
dimethoxybenzaldehyde (3.0 g, 18 mmol, 1 equiv) and triethylamine (7.5 mL, 54 mmol, 3 
equiv), and the solution was stirred vigorously. To the stirring solution was added compound 
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2.73 (7.24 g, 27 mmol, 1.5 equiv), followed by the portion-wise addition of STAB-H (7.69 g, 
36.2 mmol, 2.1 equiv). The resulting mixture was stirred overnight. Following the reaction, 
the mixture was quenched with the addition of sat. NaHCO3 (aq) (30 mL), and the desired 
product extracted with DCM (3 x 15 mL).  The organic layers were dried and concentrated, 
and the residue was further purified by flash chromatography (1:1 EtOAc/DCM containing 
0.5% NH4OH). Fractions containing the desired product were pooled and concentrated 
yielding the desired product as a clear oil (4.79 g, quant.). 1H-NMR (300 MHz, CDCl3) δ: 7.06 
(1H, d, J = 7.9 Hz), 6.39-6.33 (2H, m), 5.88 (1H, ddt, J = 16.3, 10.7, 5.8 Hz), 5.24 (1H, dd, J 
= 1.2 Hz, 17.2 Hz), 5.22 (1H, d, J = 10.4 Hz), 4.53 (2H, d, J = 5.8 Hz), 3.76 (3H, s), 3.73 (3H, 
s), 3.69 (2H, s), 2.03 (1H, s). 13C-NMR (75 MHz, CDCl3) δ: 175.0, 163.1, 161.6, 134.9, 133.4, 
122.9, 121.3, 106.5, 101.3, 68.1, 58.15, 58.13, 52.8, 50.9. HRMS (ESI+): m/z [M+H]+ calcd 
for C14H20NO4: 266.1387; found: 266.1395. 
 
FmocDMBGlyOH (2.75). Compound 2.74 (4.79 g, 18 mmol, 1 equiv) was suspended in 1,4-
dioxane (20 mL). To this was added 1M NaOH (aq) (20 mL) portionwise, 4 mL added every 
five min. After 1 h, hydrolysis of the allyl ester was confirmed by TLC. The reaction mixture 
was diluted with sat. NaHCO3 (aq) (50 mL), and a suspension of 9-fluorenylmethyl N-
succinimidyl carbonate (Fmoc-OSu, 6.39 g, 19 mmol, 1.05 equiv) in 1,4-dioxane (25 mL) was 
added to the stirring mixture dropwise. The mixture was allowed to stir overnight at room 
temperature. Following the reaction, the mixture was concentrated in vacuo to remove the 
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dioxane, and water was added to achieve a total volume of 100 mL. Solid citric acid was added 
to achieve neutral pH. The mixture was extracted with EtOAc (3 x 100 mL), and the organic 
layers were combined and dried over Na2SO4 before concentration by rotary evaporation. The 
product was then purified by column chromatography with a slow gradient of DCM to 10% 
MeOH in DCM. Fractions containing the desired product were pooled and concentrated to 
obtain compound 2.75 (6.66 g, 76%) as a beige solid. Characterization data agreed with 
literature.84 1H NMR (300 MHz, CDCl3) δ: 7.74 (2H, t, J = 7.4 Hz), 7.53 (2H, d, J = 7.4 Hz), 
7.38-7.25 (4H, m), 6.78 (1H, d, J = 7.7), 6.42 (1H, s), 6.34 (1H, d, J = 7.9 Hz), 4.54-4.40 (4H, 
m), 4.27-4.21 (1H, m), 4.06 (1H, s), 3.91 (1H, s), 3.78 (3H, s), 3.75 (3H, s). 13C NMR (75 
MHz, CDCl3) δ: 178.4, 163.4, 161.4, 159.8, 146.8, 144.2, 134.5, 133.5, 130.6, 130.0, 127.9, 
127.8, 122.8, 120.2, 120.0, 107.1, 101.2, 70.7, 58.3, 58.1, 51.2, 50.1, 49.1. HRMS (ESI+): m/z 
[M+H+]+ calcd for C26H26NO6: 448.17546; found 448.17594. 
 
AllocThrOH (2.76). To saturated Na2CO3 (aq) (39 mL) was added unprotected threonine (3.0 
g, 25 mmol, 1.0 equiv). To the ice-cooled stirring solution was added a solution of allyl 
chloroformate (2.94 mL, 28 mmol, 1.1 equiv) in 1,4-dioxane (60 mL) dropwise over 1 h. The 
ice-bath was removed and the mixture stirred at room temperature for an additional 2 h. 
Following the reaction, the mixture was diluted with 150 mL of water and washed with ether 
(3 x 150 mL). The aqueous layer was acidified to pH 2 with 1 M HCl, and the product extracted 
with EtOAc (3 x 100 mL). The organic phase was dried (Na2SO4), and concentrated. The 
residue was then dissolved in saturated NaHCO3 (aq) (150 mL), washed with ether (3 x 100 
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mL), and reacidified to pH 2 with 1 M HCl (aq). A final extraction with EtOAc (3 x 100 mL), 
followed by the drying of the organic phase with Na2SO4 and subsequent solvent removal by 
rotary evaporation yielded compound 2.76 as a clear oil (3.74g, 73%). Characterization data 
matched the literature.114 1H NMR (300 MHz, CD3OD) δ: 5.98 (1H, m), 5.31 (1H, d, J = 17.2 
Hz), 5.18 (1H, d, J = 10.5 Hz), 4.55 (2H, d, J = 5.1 Hz), 4.29-4.24 (1H, m), 4.13 (1H, d, J = 
2.8 Hz), 1.20 (3H, d, J = 6.4 Hz). 13C NMR (75 MHz, CD3OD) δ: 177.0, 160.3, 135.6, 119.6, 
70.1, 68.5, 62.3, 22.2. HRMS (ESI+): m/z [M+H+]+ calcd for C8H14NO5: 204.08665; found: 
204.08704. 
 
Imidazole-1-sulfonyl azide hydrochloride (2.77). According to a procedure by Goddard-
Borger et al., and Ji and coworkers101,102, sulfuryl chloride (16.1 mL, 200 mmol, 1 equiv) was 
added dropwise to an ice-chilled suspension of sodium azide (13 g, 200 mmol, 1 equiv) in 
acetonitrile (200 mL). The ice-bath was removed and the mixture was stirred overnight at room 
temperature. The mixture was chilled in a new ice-bath, after which imidazole (25.9 g, 380 
mmol, 1.9 equiv) was added portion-wise over 10 min. The resulting slurry was stirred for 3 h 
at room temperature. The mixture was diluted with EtOAc (400 mL), washed with water (2 x 
400 mL), and finally washed with saturated NaHCO3 (aq) (2 x 200 mL). The organic phase 
was dried over Na2SO4 and filtered. To this organic phase was added a solution of HCl in EtOH 
[obtained by adding acetyl chloride (21.3 mL, 300 mmol) drop-wise to ice-cooled dry ethanol 
(75 mL)] dropwise while stirring. The precipitate was filtered and rinsed with ethyl acetate (3 
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x 50 mL) to give 2.77 as white needles (27.7 g, 66%). 1H-NMR (D2O) δ: 9.38 (1H, s), 7.94 
(1H, s), 7.53 (1H, s). HRMS (ESI+): m/z [M]+ calcd for C3H4N5O2S, 174.00802; found, 
174.00815. 
 
N3IleOH (2.78). To a stirring solution of methanol (14 mL) and water (7 mL) was added 
isoleucine (1.0 g, 7.6 mmol, 1 equiv). To this was added compound 2.77 (1.93 g, 9.2 mmol, 
1.2 equiv) and copper(II) sulfate pentahydrate (20 mg, 0.076 mmol, 0.01 equiv). To the stirring 
suspension was added potassium carbonate (2.83 g, 20.5 mmol, 2.7 equiv) and the reaction 
was stirred overnight at room temperature excluding light. After the reaction time, the mixture 
was concentrated to one-third its volume, diluted with water (25 mL) and acidified to pH 1 
with 1 M HCl (aq). The aqueous solution was extracted with DCM (3 x 25 mL), and the 
combined organic layers were dried over Na2SO4 and subsequently the organic solvent 
removed in vacuo. The crude oil was then diluted in saturated NaHCO3 (aq) (25 mL) and 
washed with diethyl ether (1 x 30 mL). The aqueous phase was again adjusted to pH 1 with 1 
M HCl (aq) and further extracted with DCM (3 x 30 mL). The combined organic layers were 
dried over Na2SO4, and the solvent removed by rotary evaporation yielding compound 2.78 
(890 mg, 74%) as a clear oil. Characterization data agreed with the literature.100 1H-NMR (300 
MHz, CDCl3) δ: 11.1 (br. s), 3.76 (1H, d, J = 5.9 Hz), 1.98-1.89 (1H, m), 1.54-1.18 (2H, m), 
0.96 (3H, d, J = 6.8 Hz), 0.86 (3H, t, J = 7.4 Hz). 13C-NMR (75 MHz, CDCl3) δ: 179.2, 69.9, 




A54145D-tHOAsn3-tMeOAsp9. The following describes the optimized synthesis of A54145-
tHOAsn3-tMeOAsp9. 2-Cl-TrtCl-PS (theoretical substitution = 1.5 mmol/g, 66.7 mg, 0.1 
mmol, 1 equiv) was activated in dry DCM with thionyl chloride (26 µL, 3.6 equiv) and pyridine 
(58 µL, 7.2 equiv) under reflux for 2 h. The resin was transferred to a disposable peptide 
cartridge and rinsed 6 x with dry DCM, followed by loading with FmocSarOH (4 equiv) and 
DIPEA (8 equiv) in 1 mL dry DCM for 2 h, twice. The resin was capped with 17:2:1 
DCM/MeOH/DIPEA (3 x 10 min) and the loading efficiency determined to be 1.40 mmol/g. 
Removal of the Fmoc group from resin-bound FmocSar was performed with four 30-min 
iterations of 20% 4-methylpiperidine in DMF (v/v). All Fmoc-amino acids (4 equiv) and the 
lipid tail (4 equiv) were activated for 5 min using HOBt (4 equiv) and DIC (4 equiv) in DMF 
(2 mL) and then coupled for 4 h, except for Fmoc-tMeOAsp(tBu)-OH, which was coupled for 
12 h. Removal of the Fmoc-group from resin-bound FmocThrSar was performed with two 1-
min iterations of 20% 2-methylpiperidine in DMF (v/v), and all other Fmoc-removals were 
performed with three 10-min iterations of 20% 2-methylpiperidine in DMF. Following 
installation of FmocHOAsn(TBDMS)OH, yielding peptide 2.53, synthesis of peptide 2.54 was 
achieved by treating peptide 2.53 with N3IleOH (10 equiv), pre-activated with DIC (10 equiv) 
by stirring in DCM (2 mL) for 1 h, followed by the addition of  DMAP (0.1 equiv). Depsi-
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bond completion was monitored by HPLC. The next amino acids, D-Glu2, Trp1, and 8-
methyldecanoic acid ((±)-2.14), were introduced using the above general procedure, yielding 
peptide 2.55. The removal of the TBDMS group of Asn(OTBDMS) was afforded by treating 
the resin with TBAF (3 equiv), and acetic acid (3 equiv) in THF (2 mL) for 1 h. After the 
removal of the TBDMS group, the azido group was reduced by treatment of the peptide with 
PBu3 (3 equiv), and (FmocGlu(tBu)CO)2O (5 equiv, formed by the addition of 10 equiv 
FmocGlu(tBu)OH and 5 equiv DIC to 2 mL dry THF and stirring for 1 h) in THF for 5 minutes, 
followed by the addition of 0.1 mL H2O and further stirring for 16 h, yielding peptide 2.58. 
The remaining amino acids were introduced using the coupling and deprotection protocol 
mentioned above, affording peptide 2.59. The peptide was cleaved from the resin by treatment 
with 1% TFA in DCM (5 x 10 mins) affording peptide 2.60 after solvent removal by rotary 
evaporation. Peptide 2.60 was subjected to PyAOP (5 equiv), HOAt (5 equiv), and 2,4,6-
collidine (10 equiv) in DMF (100 mL, 1 mM) overnight for cyclization. The solvent was 
removed by high-vacuum rotary evaporation, and the crude solid was treated with 95:2.5:2.5 
TFA/TIPS/H2O (v/v, 15 mL) for global deprotection of side-chain protecting groups for 1.5 h. 
The TFA was removed under stream of N2, and the peptide precipitated with diethyl ether. The 
suspension was centrifuged, and the pellet was redissolved in 9:1 H2O/CH3CN. The target 
compound was purified by preparative RP-HPLC employing an isocratic gradient of 40:60 
CH3CN / H2O (+0.1% TFA). Fractions containing the target product were pooled and 
lyophilized giving A54145D-tHOAsn3-tMeOAsp9 as a white powder (12.3 mg, 8% yield 
based on resin loading), judged to be > 95% pure by analytical RP-HPLC (Figure B.1 in 
Appendix B). HRMS-ESI+ (m/z): calcd for C73H113N17O27 [M+2H]
2+, 829.8990; found 
829.8992 (Figure C.1 in Appendix C). The peptide was also characterized by NMR (1H, as 
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well as 2D: HSQC, HMBC, COSY, TOCSY, ROESY. See Figures A.13-A.18 and Table A.2 
in Appendix A). 
 
A54145D-tHOAsn3-eMeOAsp9: A54145D-tHOAsn3-eMeOAsp9 was synthesized 
according to the procedure used for A54145D-tHOAsn3-tMeOAsp9, except that Fmoc-
eMeOAsp(tBu)OH was used in place of Fmoc-tMeOAsp(tBu)OH. The desired compound was 
isolated as a white powder (12.4 mg, 8% yield), judged to be >95% pure by analytical RP-
HPLC (Figure B.2 in Appendix B). HRMS-ESI+ (m/z): calcd for C73H113N17O27 [M+2H]
2+, 
829.8990; found 829.9010 (Figure C.2 in Appendix C). The peptide was also characterized by 
NMR (1H, as well as 2D: HSQC, HMBC, COSY, TOCSY, ROESY. See Figures A.7-A.12 and 
Table A.2 in Appendix A), and its sequence characterized by MS/MS (See Figures D.1 and 




A54145D-(8S)-anteiso: A54145D-(8S)-anteiso was synthesized according to the procedure 
used for A54145D-tHOAsn3-tMeOAsp9, except that Fmoc-eMeOAsp(tBu)OH was used in 
place of Fmoc-tMeOAsp(tBu)OH, and (S)-8-methyldecanoic acid were used in place of (±)-8-
methyldecanoic acid. A54145D-(8S)-anteiso was isolated as a white powder (16.6 mg, 11% 
yield based on resin loading), judged to be >95% pure by analytical RP-HPLC (Figure B.3 in 
Appendix B). HRMS-ESI+ (m/z): calcd for C73H113N17O27 [M+2H]
2+, 829.8990; found 
829.8986 (Figure C.3 in Appendix C).  
 
A54145D-(8R)-anteiso: A54145D-(8R)-anteiso was synthesized according to the procedure 
used for A54145D-tHOAsn3-tMeOAsp9, except that Fmoc-eMeOAsp(tBu)OH was used in 
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place of Fmoc-tMeOAsp(tBu)OH, and (R)-8-methyldecanoic acid were used in place of (±)-
8-methyldecanoic acid. A54145D-(8R)-anteiso was isolated as a white powder (16.7 mg, 11% 
yield based on resin loading), judged to be >95% pure by analytical RP-HPLC (Figure B.4 in 
Appendix B). HRMS-ESI+ (m/z): calcd for C73H113N17O27 [M+2H]
2+, 829.8990; found 
829.8991 (Figure C.4 in Appendix C). 
 
A54145D-nucleus: The nucleus of A54145D, used for characterization purposes, was 
synthesized according to the procedure used for A54145D-tHOAsn3-tMeOAsp9, except that 
Fmoc-eMeOAsp(tBu)OH was used in place of Fmoc-tMeOAsp(tBu)OH, and BocTrp(Boc)OH 
was used instead of FmocTrp(Boc)OH. No lipid tail was coupled to the peptide. The peptide 
was purified using preparative RP-HPLC employing an isocratic solution of 16:84 CH3CN / 
H2O (+ 0.1% TFA), yielding A54145D-nucleus as a white powder (12.0 mg, 9% based on 
resin-loading). The compound was judged to be >95% pure based on analytical HPLC (Figure 
B.5 in Appendix B). HRMS-ESI+ (m/z): calcd for C62H93N17O26 [M+2H]
2+, 745.8233; found 
745.8244 (Figure C.5 in Appendix C). The peptide was also characterized by NMR (1H, as 














Chapter 3 – Structure Activity Relationships of A54145 
 
3.1 – Introduction 
 
 The development of new drugs often involves performing structure-activity 
relationship (SAR) studies on known drugs or known biologically active compounds to learn 
more about the mechanism of action of the drug and identify moieties which are amenable to 
substitution or modification. Such studies sometimes result in the development of new, more 
active, or differently-acting drugs. Various SAR studies have been performed on daptomycin, 
which include modification to the lipid tail, appending groups onto the ornithine residue, and 
substituting different amino acids (see sections 1.5 and 1.6). Except for some work by the Baltz 
group in between 2010 and 2014 (Table 1.2, section 1.5.3), much less research is available for 
A54145D. In this chapter we report our initial studies on the synthesis of several analogs of 
A54145D and A54145A1 and their in vitro biological activity. 
3.1.1 – Split-and-Pool Method of Fmoc-SPPS Employing Macro-beads 
 
 A long-term goal in the Taylor lab is to synthesize large numbers of daptomycin and 
A54145 analogs and evaluate these analogs for their biological activity. Such studies might 
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provide non-toxic daptomycin or A54145 analogs that are highly active in both the absence 
and presence of lung surfactant and would also be useful for mechanism of action studies. 
 One method that enables rapid synthesis of large numbers of peptides is the split-and-
pool approach. This approach to peptide synthesis is illustrated in Figure 3.1. In this example, 
the beads are split into three different reaction vials. The first amino acid is attached to the 
beads using a different amino acid (AA1, AA2, or AA3) for each vial. The beads from all three 
vials are then pooled and then equally split back into three separate vials. Then, the second 
amino acid is coupled, again, using a different amino acid (AA4, AA5, AA6) for each vial. 
When this process is repeated a third time (with AA7, AA8, AA9), each vial contains nine 
different peptides attached to the beads, and each resin bead contains multiple copies of only 
one peptide. In Figure 3.1, three iterations of three amino acids yields a library of 27 variants 
(33 = 27). This process can be repeated as often as desired, and exponential growth results in a 
large library of analogs synthesized, in a relatively short time-frame, with each macro-bead 
possessing a single peptide. Just three iterations applied to all 20 proteinogenic amino acids 
would yield 8000 different variants (203 = 8000).  
 One of the challenges of applying the split-and-pool approach to synthesizing 
daptomycin or A54145 analogs is assessing the synthesized peptides for biological activity. 
Since A54145 and daptomycin function by first inserting into the bacterial cell membrane, the 
peptides will have to be cleaved off of the beads in order to assess their biological activity. 
This means that individual beads must be picked out of the mixture, and the peptide cleaved 
from the resin, and then assessed for activity. This also means that each individual bead must 
produce enough peptide for biological screening and spectral identification. Solid-phase 
combinatorial synthesis is typically performed on beads with diameters of 50-500 µm with a 
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loading of 0.1 to 0.5 mmol/g.115 If such beads were used for daptomycin or A54145 library 
construction, then only pmol or low nmol amounts of peptide would be produced per bead, 
which is not enough for our purposes. Consequently, high loading macro-beads (500-560 µm 
or higher in diameter, 1.0-1.5 mmol/g loading) will have to be used to make the daptomycin 
and A54145 libraries. Unfortunately, reaction rates decrease with increasing resin bead 
diameter, since library preparation on macro-beads is hindered by slow reagent diffusion into 
the polymer matrix and sluggish reaction rates.115 Consequently, we are aware of only one 
report describing the synthesis of a cyclic peptide library on macrobeads.116 
 The problem of slow reaction rates on macro-beads can be overcome by using longer 
reaction times and a large excess of reagents. However, as depsi-bond formation is already 
very challenging on “regular” resin beads, we expected that it will be particularly challenging 
on macro-beads. Therefore, it would be advantageous if the ester bond in A54145 could be 
replaced with an amide bond, as amide bonds are easier to form than ester bonds. It would also 
be advantageous for the cyclization of the peptides to be done on-resin. With an on-resin 
cyclization, each individual peptide at the end of the synthesis need only be cleaved from the 
resin and purified by HPLC. However, a synthesis employing an off-resin cyclization would 
involve extra steps: each peptide would have to be cleaved from the resin while keeping 
protecting groups intact, the peptide would then be cyclized, and then the side-chain protecting 
groups removed, followed by purification. Most problematically, these steps would require a 
different reaction vessel for each peptide (each different macro-bead), and this accordingly 
would make the synthesis significantly more laborious. In Chapter 2, the total synthesis of 
A54145D was reported, and while this opens the door to the generation of many more 
A54145D analogs, the strategy cannot be applied to synthesis on macro-beads using a split-
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3.1.2 – Previous A54145 Analogs Synthesized as a Starting Point for Library Genesis 
 
 In 2006, Kopp et al. reported the chemoenzymatic synthesis of an A54145A1 analog in 
which the non-proteinogenic amino acids HOAsn3 and MeOAsp9 were replaced with their 
proteinogenic counterparts, Asn3 and Asp9 (3.1), as well as a second analog in which, in 
addition to these modifications, the Thr residue at position 4 was replaced with (2S)-2,3-
diaminopropionic acid (DAPA) (3.2, Figure 3.2).78 The MICs of these two peptides were both 
reported to be 25 µg/mL against B. subtilis PY79. Although notably less active than both 
daptomycin and A54145D, this result suggests that replacing the ester bond in A54145D with 
an amide linkage has no effect on biological activity. The identical biological activities of these 
two analogs were surprising to us, since, as we and others have shown, when the ester bond in 
daptomycin analogs is replaced with an amide bond, the biological activity is significantly 
reduced.84,117  If Kopp et al.’s result is correct, it is significant for two reasons. First, it would 
be expected that the chemical synthesis of A54145 analogs containing an amide bond would 
be less challenging than analogs containing an ester bond at this position. This would be 
advantageous for library construction on macro-beads. Second, a study by D’Costa et al. has 
shown that resistance to daptomycin can occur by enzymatic hydrolysis of the ester bond 
(section 1.3.3).65 It is likely that such a resistance mechanism could also result in the 
deactivation of other cyclic lipodepsipeptide antibiotics such as A54145 and its analogs.  It is 
possible that this mechanism of resistance could be circumvented by replacing the ester bond 




Figure 3.2: Structures of analogs 3.1 and 3.2. Deviations from A54145A1 are shown in green. 
 
3.1.3 – Research Objectives 
 
 The main objectives of the work described in this chapter is to synthesize peptides 3.1 
and 3.2, as well as other analogs that contain Asn and/or Asp in place of HOAsn and MeOAsp, 
and to use these analogs to determine the roles of the ester bond in A54145’s biological 
activity. Additionally, another objective of this work is to evaluate the importance of the ester 
bond and these two uncommon amino acids on the activity of A54145D or A54145A1.  
3.2 – Results and Discussion 
 
3.2.1 – A54145A1-Asn3-DAPA4-Asp9 (Peptide 3.2) 
 
 In Chapter 2, the total synthesis of A54145D was discussed (Schemes 2.13, 2.14, and 
2.15). The peptide was attached to the resin via Sar5 and the ester bond was formed between 
the side chain of the Thr residue in resin-bound tripeptide 2.53 and N3IleOH to give peptide 
2.54. Fmoc SPPS was used to introduce residues 1 and 2 and the lipid tail into peptide 2.54 to 
give peptide 2.55. Upon removal of the TBDMS group and reduction of the azido group in 
peptide 2.55, the resulting peptide 2.58 was further elaborated via Fmoc-SPPS to give peptide 
2.59, which was  cleaved from the resin, yielding 2.60, cyclized in solution, and then globally 
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deprotected to give A54145D. An on-resin cyclization strategy, which involved attaching the 
peptide to the resin via the side chain COOH of a MeOAsp9-Gly10 dipeptide (Scheme 2.4) 
was attempted but was unsuccessful due to aspartimide formation between Gly10 and 
MeOAsp9. Attempts to circumvent this problem by protecting the amide nitrogen of Gly10 
with a dimethoxybenzyl (DMB) group were unsuccessful due to very rapid diketopiperazine 
formation.  This is in contrast to previous work in the Taylor lab, whose successful syntheses 
of daptomycin and its analogs were readily achieved using an on-resin cyclization strategy by 
attaching the peptide to the resin via the side chain of an Asp9-GlyOallyl10 dipeptide (1.34, 
Scheme 1.10, Section 1.6.4).82,85,87,103  The finding that aspartimide formation occurs with 
MeOAsp but not Asp suggests that the presence of the electron withdrawing 3-methoxy group 
was promoting aspartimide formation. As A54145A1-Asn3-Asp9 (3.1) and A54145A1-Asn3-
DAPA4-Asp9 (3.2) contain Asp and not MeOAsp at position 9, we reasoned that an on-resin 
cyclization strategy could be used for the synthesis of these two analogs. 
3.2.1.1 – Proposed Synthesis of A54145A1-Asn3-DAPA4-Asp9 (3.2) 
 
 In the first proposed synthesis of compound 3.2, we envisioned attaching the peptide 
to 2-ClTrt-Cl-PS resin by the side-chain of Asp9, using FmocAsp(OH)GlyOallyl as the initial 
building block, yielding dipeptide 1.34 (Scheme 3.1), analogous to the synthesis of daptomycin 
by Lohani et al.82,85 Fmoc-based SPPS with commercially available amino acids and Fmoc-β-
azidoAlaOH118,119 would yield peptide 3.3. The azido group in Fmoc-β-azidoAlaOH would be 
used as a protecting group for the amino group in the DAPA residue, as the azido group is 
orthogonal to Fmoc-, Boc-, and allyl protecting groups. After the completion of linear peptide 
3.3, the azido group would be reduced, yielding amine 3.4. Peptide 3.4 would undergo further 
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Fmoc-SPPS yielding branched peptide 3.5. Removal of the allyl group followed by on-resin 
cyclization and then resin cleavage and global deprotection would afford target compound 3.2. 
 




3.2.1.2 – Total Synthesis of A54145A1-Asn3-DAPA4-Asp9 (3.2) 
 
 Dipeptide 3.8 was synthesized using our previously reported procedure.86 First, 
FmocAsp(tBu)OH was coupled to TsO-H3N
+GlyOallyl (2.73) yielding dipeptide 3.7 (Scheme 
3.2). The tert-butyl group in dipeptide 3.7 was removed using TFA. FmocAspGlyOallyl (3.8) 
was coupled to 2-ClTrt-Cl resin with DIPEA without issue, yielding dipeptide 1.34. The 
loading levels attained for this initial coupling typically were determined to be 60-70%. 
Standard Fmoc-based SPPS employing DIC and HOBt as coupling reagents transformed 
dipeptide 1.34 into linear peptide 3.3 without issue. 
 
Scheme 3.2: Synthesis of dipeptide 3.8. 
 
 DAPA was introduced into peptide 3.3 as Fmoc-β-azidoAla, which was synthesized by 
slightly modified literature procedures (Scheme 3.3).118,119 Lau and Spring reported the 
synthesis of Fmoc-β-azidoAla, 3.10, through a Hofmann rearrangement starting from 
FmocAsnOH yielding FmocDAPAOH (3.9). FmocDAPAOH was converted to Fmoc-β-
azidoAla through the use of a diazo transfer reagent, imidazole-1-sulfonyl azide hydrochloride 
(2.77). In Lau and Spring’s synthesis, bis(trifluoroacetoxy)iodobenzene was used to achieve 
the Hofmann rearrangement. We found that the reaction also worked when 
diacetoxyiodobenzene was used, but with a lower yield (57% versus 80%) (Scheme 3.3). Since 





Scheme 3.3: Synthesis of Fmoc β-azidoAla (3.10). 
 
 At this point we should mention an observation that we made when cleaving Trp(Boc)-
bearing peptides from resins using TFA/TIPS/H2O. Upon cleavage of such peptides from the 
resin using TFA/TIPS/H2O, two peaks were sometimes observed in the analytical HPLC 
chromatogram, one of which corresponded to the target peptide, and the second, which 
consistently eluted 1-2 minutes before the target peptide, and which had a mass that was 44 
amu larger than the target peptide as determined by LRMS. This additional peak was also 
temporary; repeated injections on the same day showed different relative peak areas of these 
two signals (Figure 3.3), and subsequent injection the following day showed a complete 
absence of the additional peak. Consistent with this observation is the hypothesis of a 
temporary CO2-adduct of the Trp-containing peptide, in which the Boc-protected tryptophan 
residue undergoes a stepwise deprotection (Scheme 3.4). The first step is fast, involving the 
loss of the tert-butyl group, and the second step is slow, involving decarboxylation.  
 






Figure 3.3: RP-HPLC chromatograms of the crude mixture obtained after treating peptide 3.3 
with TFA/TIPS/H2O. Both spectra correspond to the same sample, but the bottom spectrum 
was injected several hours after the first. 
 
 Following the successful synthesis of linear peptide 3.3, the azido group in peptide 3.3 
was reduced using PMe3 in a 1:1 mixture of THF and H2O, yielding peptide 3.4. Surprisingly, 
subsequent coupling of FmocIleOH employing DIC and HOBt were inefficient, producing 
some of the desired compound, but a considerable amount of unreacted starting material 
remained. To remedy this, we attempted the conditions developed by Thakkar et al., which 
involved using HOBt/PyBOP/DIPEA as coupling reagents in DMF/DCM/NMP (N-
methylpyrrolidinone) (3:2:2) containing 1% Triton X-100 (called “Magic Mixture”).120 It was 
suspected that the lipid in the peptide was promoting aggregation, or perhaps causing the 
peptide to adopt a tertiary structure that shielded the branch point from reacting efficiently, and 
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that the detergent, Triton X-100, might prevent or minimize this problem. Of note, Magic 
Mixture was originally developed to assist with challenging on-resin cyclizations. To our 
delight, Magic Mixture was effective in the incorporation of Ile13 and Glu12. 
 However, the use of Magic Mixture was not effective for the incorporation of D-Asn11. 
HPLC analysis of the crude uncyclized peptide 3.5 by RP-HPLC and LRMS indicated the 
presence of an undesired side-product that was 18 amu less than the target product, which was 
consistent with asparagine dehydration (Figure 3.4). To alleviate this problem, peptide 3.15 
was constructed in which D-Asn11 was incorporated with a Trt protecting group (Scheme 3.5). 
It is interesting to note that asparagine dehydration was not observed when incorporating Asn3 
to the peptide using DIC/HOBt, signifying that the dehydration of asparagine may be 
dependent upon the coupling reagents used. 
 
 
Figure 3.4: RP-HPLC chromatograms demonstrating D-Asn11 dehydration. The peptide was 
analyzed by HPLC one day after cleavage with TFA/TIPS/H2O to avoid spectrum convolution 




 Fmoc-deprotection of 3.15 yielded corresponding amine 3.16. The next two steps in 
the synthesis of compound 3.2 involved removing the allyl protecting group and the on-resin 
cyclization. The allyl group was removed without issue with 0.2 equiv of Pd(PPh3)4 and 
DMBA (10 equiv) in 3:1 DCM/DMF (v/v). The mixture was treated with several rinses of 1% 
sodium diethyldithiocarbamate trihydrate in DMF (w/v) to remove the palladium catalyst. 
Cyclization using Magic Mixture was expected to be successful (as these conditions were 
initially developed for challenging cyclizations); however, it was observed that these 
conditions resulted in the incomplete formation of the final amide bond. After one cyclization 
attempt, cyclization efficiency was estimated to be 30% by HPLC, and after two cyclization 
attempts, cyclization efficiency was estimated to be 60%. Despite incomplete cyclization, the 
peptide was then cleaved from the resin with TFA/TIPS/H2O and then purified by semi-
preparative RP-HPLC, affording compound 3.2 in a 6% yield based on initial resin loading. 
 Although compound 3.2 was successfully synthesized, the strategy suffered from an 
inefficient cyclization. With the long-term goal to develop an approach amenable for library 
generation, it would be advantageous to develop cyclization conditions that can consistently 
and reliably result in quantitative cyclization. We decided to examine the cyclization 
conditions used by Knerr and van der Donk, who employed PyAOP/HOAt/2,4,6-collidine in 
DMF, to form several macrolactams of Epilancin 15X analogs.121 It was found that we could 
quantitatively cyclize peptide 3.16 with these alternative conditions. Using these conditions, 
peptide 3.2 was obtained in a 13% yield based on initial resin loading (Scheme 3.5). Analysis 
by MS/MS was attempted on the cyclic peptide, and the spectrum obtained very closely 










3.2.1.3 – Assessing the Biological Activity of Peptide 3.2 
 
 The biological activity of peptide 3.2 was assessed as reported by Kopp et al., against 
B. subtilis PY79 at 1.8 mM Ca2+. Peptide 3.2 was not biologically active up to tested 
concentrations of 128 µg/mL; however, Kopp et al. reported an MIC of 25 µg/mL for this 
peptide.78 The reason for the discrepancy between our work and the work of Kopp et al. is 
unknown. Our results are consistent with previous research reported by the Taylor group and 
the Martin group, who both found a significant reduction in biological activity when the ester 
bond of daptomycin is replaced with an amide bond.84,117 
 Some of the biological activity of peptide 3.2 could be restored if the minimum 
inhibitory concentrations are measured at elevated calcium concentrations. While the 
synthesized analog was not active at lower calcium concentrations (1.8 mM), at 100 mM 
calcium, the MIC was reduced to 10 µg/mL, which suggests that this compound may have a 
reduced affinity for calcium. Such observations have been observed with many moderately 
active daptomycin analogs synthesized in the Taylor group,82 although the increased biological 
activity at higher levels of calcium is irrelevant to potential antibiotic leads in vivo, as the free 
concentration of calcium in blood plasma is 1.25 mM. 
 Peptide 3.2 was also subjected to a membrane binding assay routinely performed by 
members of the Taylor and Palmer groups.49,50,117 The structures of daptomycin and A54145D 
possess intrinsic fluorophores in the form of Trp1 and Kyn13 in daptomycin, and Trp1 in 
A54145D. Upon insertion into a hydrophobic environment such as a model membrane, the 
fluorescence signals of these amino acids undergo a characteristic blue shift, or a hypsochromic 
shift. In this assay, solutions of analogs in the presence of model membranes are subjected to 
increasing amounts of calcium, and the fluorescence emission spectrum is observed. Plotting 
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the fluorescence spectra as a function of calcium concentration (Figure 3.5) demonstrates that 
membrane binding depends on calcium concentration.  
 For native A54145D, calcium concentrations between 0.1 and 0.5 mM result in an 
observable blue shift in the presence of 1:1 DMPC/DMPG lipids, signifying membrane 
insertion.48,49 However, for peptide 3.2, insertion into the model membranes is never observed, 
even at calcium concentrations up to 50 mM, consistent with the lack of biological activity of 
this compound. 
 
Figure 3.5: Membrane binding curves of native A54145D49 and peptide 3.2. Between 0.1 and 
0.5 mM Ca2+, the Trp1 of native A54145D undergoes a hypsochromic shift, indicating 
insertion into the hydrophobic membrane.  
 
3.2.2 – A54145A1-Asn3-Asp9 (Peptide 3.1) 
 
3.2.2.1 – Proposed Synthesis of A54145A1-Asn3-Asp9 (3.1) 
 
 After establishing that compound 3.2 was not biologically active, in contradiction with 
the results of Kopp et al.78, we turned our attention to compound 3.1, which contains Thr4 
instead of DAPA4. It was suspected that if this compound exhibited good activity, a library of 




 We envisioned a synthesis of peptide 3.1 analogous to the published syntheses of 
daptomycin analogs by Barnawi et al., who used TentaGel Trt-Cl and exclusively Fmoc-
protected amino acids in their synthesis.82 Dipeptide 1.34 would be elaborated by standard 
Fmoc-SPPS  yielding linear peptide 3.17 (Scheme 3.6). The depsi-bond would be attempted 
using DIC and DMAP in the presence or absence of Triton X-100, yielding 3.18, and further 
Fmoc-SPPS would yield peptide 3.19. Allyl deprotection followed by on-resin cyclization 
using the conditions used for uncyclized peptide 3.16 (PyAOP/HOAt/2,4,6-collidine), and then 
global deprotection and resin cleavage would yield peptide 3.1. 
 




3.2.2.2 – First Attempted Synthesis of Compound 3.1. 
 
 At this time in the Taylor lab, conditions were developed that significantly decreased 
the amino acid coupling times. In the synthesis of peptide 3.2, amino acids were coupled using 
4-hour reactions with DIC/HOBt, or 4-hour reactions with HOBt/PyBOP/DIPEA. It was found 
by Dr. Chuda Lohani, a former post-doctoral fellow in the Taylor group, that peptide coupling 
times could be reduced to 1 hour by using 2-(6-chloro-1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU)/N-methylmorpholine (NMM). 
Accordingly, the synthesis of linear peptide 3.17 from dipeptide 1.34 was attempted employing 
HCTU/NMM as coupling reagents, using 2-ClTrt-Cl-PS resin. 
 Linear peptide 3.17 was synthesized using HCTU/NMM as coupling agents, and the 
resulting crude peptide was analyzed by HPLC. To our dismay, numerous  peaks were present 
in the HPLC chromatogram of the crude mixture (Figure 3.6A). The crude mixture was also 
analyzed by LRMS, and a complex mass spectrum was obtained (Figure 3.6B); however, 
several sets of peaks in the spectrum were separated by consistent mass differences. For 
example, the 44 amu difference between the peak at m/z = 1300.6 and m/z = 1344.6; m/z = 
1199.5 and m/z = 1243.5; m/z = 1085.5 and m/z = 1129.5; and m/z = 956.5 and m/z = 1000.4 is 
indicative of a temporary CO2-deprotection adduct on four different peptides, the result of the 
stepwise removal of Trp1’s Boc-protecting group (Scheme 3.4). The difference between the 
peak at m/z = 1300.6 and m/z = 1199.5 is indicative of a peptide that lacks the threonine residue. 
The difference between the peak at m/z = 1300.6 and m/z = 1085.5 is indicative of a peptide 
lacking two amino acids: threonine and asparagine. Finally, the difference between the peak at 
m/z = 1300.6 and m/z 956.5 corresponds to lacking three amino acids: threonine, asparagine, 




Figure 3.6: Problematic synthesis of linear peptide 3.17 using HCTU/NMM. (A) RP-HPLC 
chromatogram of crude peptide 3.17 indicates side-reactions occurred. (B) LRMS of crude 
peptide 3.17 indicating presence of side-products (target m/z = 1300.6). 
 
 From the analysis of the crude mass spectrum, it was apparent that Thr4, Asn3, and D-





reasons why this might be the case. Firstly, it was possible that Fmoc-deprotection of sarcosine 
was not 100% effective and the treatments with 20% 4-MP in DMF (v/v) did not ensure 
quantitative Fmoc-deprotection. Supporting this hypothesis was the observation that resin-
bound FmocSar required extended deprotection times to completely remove the Fmoc group 
in our synthesis of A54145D (Figure 2.9, Section 2.2.3.2). Admittedly, this issue was not 
observed in the synthesis of peptide 3.2. Alternatively, it was possible that the new coupling 
conditions were not conducive to ensuring quantitative coupling onto sarcosine. As an N-
methylated amino acid, the N-methyl group may sterically hinder the amine nucleophile, thus 
reducing its nucleophilicity. Perhaps complete coupling does not take place in the reduced 
reaction times. Either of these two possibilities could account for a crude mass-spectrum 
similar to what was observed (Figure 3.6B). 
 Since we had not encountered this issue in our synthesis of compound 3.2, linear 
hexapeptide 3.20 was resynthesized using HCTU/NMM as coupling reagents until Sar5, and 
then Thr4 was incorporated using the previous coupling reagents DIC/HOBt, yielding 
heptapeptide 3.21 in a near quantitative yield (Scheme 3.7). This indicated that the issue 
observed in Figure 3.6 was due to inefficient amino acid coupling onto the secondary amine 
of sarcosine under HCTU/NMM conditions, and not due to inefficient Fmoc-deprotection of 
sarcosine.
 




 Also present in Figure 3.6B was a peak at m/z = 1282.6, which is 18 amu less than the 
target peak at 1300.6, signifying possible dehydration of Asn. Dehydration was observed 
previously when PyBOP/HOBt/DIPEA were used as coupling reagents for D-Asn11 in the 
synthesis of peptide 3.2. This problem was addressed by employing Fmoc-D-Asn(Trt)OH 
instead of Fmoc-D-AsnOH. It was suspected that these new coupling reagents, in addition to 
failing to quantitatively couple amino acids onto sarcosine, were also mediating the 
dehydration of Asn3. However, we were concerned that protecting Asn3 with a Trt group 
would increase the difficulty of successfully forming the depsi bond, due to steric bulk of the 
peptide. Instead of using FmocAsn(Trt)OH, we returned to using DIC/HOBt as coupling 
reagents. To confirm that Asn-dehydration was occurring during this coupling using 
HCTU/NMM, the analytical HPLC chromatogram of the peptide was obtained before and after 
the incorporation of FmocAsnOH, employing DIC/HOBt as coupling reagents, and employing 
HCTU/NMM as coupling reagents. As we expected, HCTU/NMM facilitated dehydration 
(Figure 3.7). Fortunately, dehydration was avoided when DIC/HOBt were used as coupling 
reagents (Figure 3.7; Scheme 3.8), which meant that we would not need to resort to the 
potentially problematic Trt protecting group, which could interfere with depsi-bond formation. 
Continuing the synthesis, octapeptide 3.24 was elaborated to linear peptide 3.17 employing 
DIC/HOBt as coupling reagents without further issue (Scheme 3.8). Following the completed 
synthesis of linear peptide 3.17, the next step of the synthesis involved the challenging 











Figure 3.7: HPLC chromatograms of the crude octapeptide 3.24 after cleavage from the resin. 
(Left) Crude 3.24 obtained after coupling of FmocAsnOH using HCTU/NMM. (Right) Crude 








 Formation of the depsi-bond in peptide 3.18 was performed using the conditions of 
Barnawi et al.82 FmocIleOH (10 equiv) and DIC (10 equiv) were mixed in dry DCM for 1 h 
before being filtered and added to the peptide cartridge. Then, DMAP (0.1 equiv) was added, 
followed by Triton X-100 to a final concentration of 1% (v/v). After one overnight coupling, 
the depsi-bond was observed to be ~55% complete, as indicated by RP-HPLC analysis. After 
a second attempt, the depsi-bond appeared to be ~70% complete. After a third attempt, the 
depsi-bond appeared to be ~75% complete, and finally, after a fourth attempt, the depsi-bond 
appeared to be ~80% complete (Figure 3.8). Clearly, formation of the depsi-bond is a 
synthetically challenging step. However, since the purpose of making peptide 3.1 at this stage 
in our studies was to compare its biological activity to that of peptide 3.2, we proceeded with 





Figure 3.8: RP-HPLC chromatograms of the crude mixture obtained after coupling of 
FmocIleOH to peptide 3.17 after resin cleavage. Grey peaks correspond to starting material, 
and black peaks correspond to desired product. (A) First o/n coupling; (B) second o/n coupling; 






 Following the formation of the depsi-bond, Fmoc-deprotections were conducted using 
20% 2-MP in DMF (v/v), to reduce possible aminolysis of the newly formed ester bond.85 
Incorporation of Glu12 with DIC/HOBt proceeded without issue, but upon coupling of Fmoc-
D-AsnOH with DIC/HOBt, dehydration of D-asparagine was once again observed (tr = 39.7 
min vs tr = 41.6 min, Figure 3.9A). This was unexpected, as this dehydration was not observed 
with Asn3 with these identical coupling conditions. The reason for this discrepancy is 
unknown, but nevertheless, the problem was once again solved by using Fmoc-D-Asn(Trt)OH 
(tr = 36.0 min, Figure 3.9B).  
   
Figure 3.9: RP-HPLC chromatograms after resin cleavage of the crude mixture obtained after 
using Fmoc-D-AsnOH (A) or Fmoc-D-Asn(Trt)OH (B) to incorporate residue 11. Black peaks 
correspond to desired peptide 3.19. The peak at 29 minutes in each chromatogram corresponds 
to linear peptide 3.17, which lacks the depsi fragment. The peak at 41.6 min in chromatogram 
A corresponds to the peptide resulting from the dehydration of peptide 3.19. 
 
 With peptide 3.19 completed, albeit with some incomplete depsi-bond formation, the 
only remaining steps in the synthesis of compound 3.1 involved removal of the last Fmoc-
protecting group, removal of the allyl group, and the on-resin cyclization. These steps were 
attempted according to the synthesis of compound 3.2 (Scheme 3.5). The completed peptide 
was cleaved from the resin with TFA/TIPS/H2O and HPLC analysis of the final crude peptide 
revealed three rather strong, closely eluting peaks amongst a variety of other less prominent 




corresponded to peptide 3.25. Presumably, a pyrrolidine contaminant originating from 
commercially available PyAOP, or originating from the breakdown of PyAOP in situ, reacted 
with the activated carboxylic acid of linear peptide 3.27 (Scheme 3.9).122  
. 








 The two other strong peaks (Figure 3.10, tr = 34.1 min, tr = 34.6 min) both had masses 
corresponding to the final peptide, suggesting that at some point in the synthesis, epimerization 
had occurred that was only observable upon the completion of the peptide. These compounds 
corresponding to these two peaks were separated by preparative RP-HPLC, and it was found 
that only one of these peptides (tr = 34.6 min) was biologically active against B. subtilis PY79. 
 The presence of the epimeric products in this synthesis, combined with the lack of these 
epimeric products in the synthesis of compound 3.2, suggested to us that epimerization 
occurred during the depsi-bond formation step. This problem was not avoided with the use of 
TentaGel resin, which has been shown by the Taylor lab to facilitate ester bond formation in 
comparison to standard PS resin. It was suspected that the epimerization was the result of the 
extended reaction times that were required for the formation of the depsi-bond. Accordingly, 
efforts were made to improve this step of the synthesis. 
3.2.2.3 – Improving the Synthesis of A54145A1-Asn3-Asp9 (3.1) 
 
 One of the mechanisms by which an amino acid can racemize during SPPS is via the 
oxazolone pathway of carbamate-protected amino acids (Scheme 3.10). It is by this mechanism 
that we suspected epimerization of Ile13 to have occurred during the formation of the depsi 
bond.  
 




 We therefore attempted to make the ester bond using N3IleOH as a building block 
instead of FmocIleOH, anticipating that the less sterically demanding azido group would make 
formation of the ester bond easier. Surprisingly, the formation of the depsi-bond between 
peptide 3.17 and N3IleOH was very sluggish, regardless of the resin used, and after three 
overnight couplings, less than 50% of peptide 3.17 was converted into peptide 3.29 as 
determined by resin-cleavage and analysis by RP-HPLC (Scheme 3.11). Evidently, the 
formation of the depsi-bond had proven itself to be very challenging on full-length peptide 
3.17. 
 
Scheme 3.11: Unsuccessful depsi-bond formation with N3IleOH and peptide 3.17. 
 
 During a previous synthesis of daptomycin, it was demonstrated that formation of the 
ester bond in daptomycin became more difficult as the length of the peptide containing the Thr 
residue increased,85 and was very difficult when the lipid tail was present. Therefore, we 
attempted to form the depsi-bond on truncated peptide 3.24, as demonstrated in Scheme 3.12. 
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Since this synthesis involved the use of a Fmoc-protected N-terminal amino acid, it also 
necessitated the use of orthogonally protected N3IleOH at the branch point. 
 




 Formation of the depsi-bond between peptide 3.17 and N3IleOH depended on the 
choice of resin. With TentaGel Trt-Cl resin, the depsi bond was formed in near quantitative 
yields after 2 overnight couplings. With 2-ClTrt-Cl-PS resin, the depsi-bind was achieved after 
three overnight couplings. Further elaboration of the branched peptide 3.30 using Fmoc-SPPS 
with DIC/HOBt, and 20% 2-MP in DMF to minimize aminolysis of the newly formed ester, 
yielded branched peptide 3.29. The azido group in peptide 3.29 was reduced to the 
corresponding amine 3.31 using PBu3 in 95:5 THF/H2O in the presence of the symmetric 
anhydride of FmocGlu(tBu)OH following literature procedures.103 Further peptide elaboration 
using Fmoc SPPS (DIC/HOBt) and 20% 2-MP in DMF gave peptide 3.19. Fmoc-removal with 
2-MP in DMF, followed by allyl group removal using the same conditions as for peptide for 
peptide 3.16, followed by on-resin cyclization with PyAOP/HOAt/2,4,6-collidine in DMF, and 
then resin cleavage and global deprotection with TFA/H2O/TIPS (95:2.5:2.5), afforded crude 
peptide 3.1. After purification by RP-HPLC, peptide 3.1 was obtained, free from 
epimerization, in 7% yield when TentaGel Trt-Cl resin was used, and 9% yield when 2-ClTrt-
Cl-PS resin was used. The sequence of the peptide was confirmed with MS/MS (See Figures 
D.5 and D.6 in Appendix D). 
3.2.2.4 – Biological activity of Compound 3.1 
 
 The biological activity of compound 3.1 was assessed against B. subtilis PY79 at 1.8 
mM Ca2+. Gratifyingly, A54145A1-Asn3-Asp9 was found to exhibit an MIC against B. subtilis 
PY79 of 32 µg/mL, in close agreement with Kopp et al., which was 25 µg/mL.78 These results, 
in conjunction with the MIC obtained for A54145A1-Asn3-DAPA4-Asp9, are consistent with 
our previous studies on daptomycin, which demonstrate that when the ester bond of 
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daptomycin analogs is replaced with an amide bond, the biological activity is significantly 
reduced.84,117 
3.2.3 – SARs of Position 4 Mutants of A54145A1-Asn3-Asp9 
 
 There are two key structural differences between A54145A1-Asn3-DAPA4-Asp9 (3.2) 
and A54145A1-Asn3-Asp9 (3.1). The first difference is the inherent replacement of the amide-
bond in 3.2 with an ester bond in 3.1. The second difference is the lack of the γ-methyl group 
of threonine in 3.2. To elucidate if one or both of these changes affect biological activity, we 
envisioned the synthesis of two additional A54145A1 analogs (Figure 3.11). The first analog 
was one in which Thr4 in A54145A1-Asn3-Asp9 was replaced with Ser (A54145A1-Asn3-
Ser4-Asp9, 3.32), and the second analog was one in which DAPA4 in A54145A1-Asn3-
DAPA4-Asp9 was replaced with (2S,3R)-2,3-diaminobutyric acid (DABA4) (A54145A1-
Asn3-DABA4-Asp9, 3.33). Assessing the biological activities of these two analogs would 
provide insight into which change most adversely affects the biological activity of A54145A1. 
 





3.2.3.1 – Synthesis of A54145A1-Asn3-Ser4-Asp9 (3.32) 
 
 Serine contains a primary alcohol group and is therefore a better nucleophile than 
threonine, which contains a secondary alcohol group. Because of this, we hypothesized that 
our synthesis of peptide 3.1 would not be applicable toward the synthesis of peptide 3.32 as 
we expected O-acylation of unprotected Ser4 to be a significant issue. We therefore decided to 
use of side-chain protected FmocSer(Trt)OH in our synthesis, which has an acid-labile trityl 
protecting group that can be easily removed under mildly acidic conditions, such as 1% TFA 
in DCM, or 20% hexafluoroisopropanol (HFIP) in DCM. Accordingly, for SPPS synthesis of 
A54145A1-Asn3-Ser4-Asp9, a more acid-resistant Wang linker would be needed, as the 
conditions to remove the trityl protecting group from Ser4 would also facilitate resin cleavage 
from trityl-based resins. We envisioned a modified synthesis in which the initial dipeptide 3.8 
was attached to the resin with DIC and DMAP (Scheme 3.13). Unfortunately, when using 
dipeptide 3.8, this approach suffered from very low resin-loading. We attempted to improve 
the loading by preparing resin-bound dipeptide 1.34 in a stepwise fashion (Scheme 3.14); 












 To avoid the problem of low-resin loading using a Wang resin, we decided to use 
TBDMS-protected serine as a building block, since this allowed us to use TentaGel Trt-Cl 
resin, which is usually much easier to load than a standard PS Wang resin (Scheme 3.15). 
Synthesis of linear peptide 3.38 was successfully achieved using DIC/HOBt-mediated amino 
acid couplings as indicated by RP-HPLC and LRMS. However, after treatment of linear 
peptide 3.38 with 0.1 M TBAF in DMF to remove the TBDMS group (and form peptide 3.35), 
subsequent analyses indicated that a majority of the peptide (>95%) based on relative HPLC 
signals had been cleaved from the resin. 
 
Scheme 3.15: Second proposed route to 3.32. 
 
 We had assumed that the use of side-chain unprotected FmocSerOH in the synthesis of 
A54145A1-Asn3-Ser4-Asp9 would be unsuccessful due to O-acylation. Nevertheless, we 
decided to attempt the synthesis using unprotected FmocSerOH as a building block in the hope 
that O-acylation would not be a major issue (Scheme 3.16). Surprisingly, the use of DIC/HOBt 
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coupling reagents to transform dipeptide 1.34 into linear peptide 3.35 was very successful, as 
the HPLC chromatogram of this sample was analyzed and found to contain a single major peak 
corresponding to peptide 3.35 by LRMS (Figure 3.12). Furthermore, the subsequent depsi-
bond formation attempt with FmocIleOH and DIC/DMAP was observed to go to completion 
after a single overnight coupling. However, after further elaboration with DIC/HOBt 
couplings, followed by allyl deprotection and on-resin cyclization, we were surprised to find 
that, once again, two epimeric products were observed by RP-HPLC. 
 








Figure 3.12: RP-HPLC chromatogram of crude peptide 3.35 after resin cleavage forming 
peptide 3.40. 
 
 Ultimately, we found that the synthesis of 3.32 could be achieved using an approach 
analogous to that used for 3.1 (Scheme 3.17). Truncated peptide 3.39 containing unprotected 
Ser4 was synthesized from dipeptide 1.34. Ester-bond formation with N3IleOH was 
quantitatively achieved after two overnight coupling attempts yielding 3.41, and subsequent 
peptide elaboration using Fmoc-SPPS with DIC/HOBt, and 2-MP in DMF for Fmoc-removal 
yielded 3.42. Reduction of the azido group yielded the corresponding amine 3.43, and further 
Fmoc-SPPS yielded 3.37. Removal of the last Fmoc-group, allyl deprotection, on-resin 
cyclization, and resin-cleavage with TFA/TIPS/H2O (95:2.5:2.5) yielded peptide 3.32 in 7% 
yield after purification by preparative RP-HPLC. No evidence of isoleucine epimerization was 
observed using this approach. As a novel compound, this peptide was characterized using 1D 
NMR experiments including 1H-NMR, and 2D NMR experiments including 1H-13C HSQC, 
1H-COSY, 1H-TOCSY and 1H-ROESY (See Figures A.19 to A.23, and Table A.3 in Appendix 
A). Additionally, the amino acid sequence was confirmed with MS/MS (See Figures D.7 and 










3.2.3.2 – Synthesis of A54145A1-Asn3-DABA4-Asp9 (3.33) 
 
 In addition to A54145A1-Asn3-Ser4-Asp9 (3.32), we synthesized A54145A1-Asn3-
DABA4-Asp9 (3.33), in which DAPA4 was replaced with (2S,3R)-2,3-diaminobutyric acid 
(DABA). Synthesis of this peptide took place as depicted in Scheme 3.5, except Fmoc-(2S,3R)-
2-amino-3-azidobutanoic acid117 (FmocAABA, synthesized by Ryan Moreira of the Taylor 
Group) was used instead of Fmoc-β-azidoAla, and azido group reduction was performed with 
DTT and DIPEA in DMF. However, this required three 1 h iterations to completely reduce the 
azido group to the corresponding amine. Further peptide elaboration using DIC/HOBt was 
readily achieved, and subsequent allyl deprotection, on-resin cyclization, and resin cleavage 
afforded A54145A1-Asn3-DABA4-Asp9 (3.33) after HPLC purification in 15% yield. This 
novel peptide was completely characterized using 1D NMR experiments including 1H-NMR, 
and 2D NMR experiments including 1H-13C HSQC, 1H-COSY, 1H-TOCSY and 1H-ROESY 
(See Figures A.24 to A.28, and Table A.3 in Appendix A) and the amino acid sequence was 
confirmed with MS/MS (See Figures D.9 and D.10 in Appendix D). 
3.2.3.3 – SARs of Position 4 Mutants of A54145A1-Asn3-Asp9 
 
 With the completion of these two additional A54145A1 analogs, we were then poised 
to assess how position 4 affects biological activity. We had previously demonstrated that when 
Thr4 was replaced with DAPA4, biological activity was reduced by at least 4-fold. The 
synthesized peptides A54145A1-Asn3-Ser4-Asp9 and A54145A1-Asn3-DABA4-Asp9 were 
assessed for biological activity and both analogs were shown to have at least a 4-fold reduction 
in biological activity compared to A54145A1-Asn3-Asp9 when assayed against B. subtilis 
PY79 at 1.8 mM Ca2+ (Table 3.1). While we were unable to assess whether the ester bond or 
the γ-methyl group in Thr4 of A54145A1-Asn3-Asp9 was more important for biological 
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activity, we were nevertheless able to conclude that both of these functional groups are crucial 
for biological activity. 
Table 3.1: MICs of Position 4 mutants of A54145A1-Asn3-Asp9 
entry peptide MIC (g/mL) 
  This work Kopp et al.78 
1 A54145A1-Asn3-DAPA4-Asp9 (3.2) >128a 25a 
2 A54145A1-Asn3-Asp9 (3.1) 32a, 8b 25a 
3 A54145A1-Asn3-Ser4-Asp9 (3.32) >128a --- 
4 A54145A1-Asn3-DABA4-Asp9 (3.33) >128a --- 
aAgainst B. subtilis PY79, 1.8 mM Ca2+ present 
bAgainst B. subtilis ATCC 1046, 1.25 mM Ca2+ present 
 Interestingly, when the biological activity of peptide 3.1 was assayed against B. subtilis 
ATCC 1046 at 1.25 mM Ca2+, it was observed to be 4-fold more active compared to its activity 
against B. subtilis PY79. This corresponds to only a 16-fold loss in biological activity relative 
to unmodified A54145D (Table 2.2, Section 2.2.3.3, entries 1 and 3) instead of the 50-fold loss 
in activity we were expecting as per the results of Kopp et al.78 
 Although our initial idea of using A54145A1-Asn3-DAPA4-Asp9 as a starting point for 
library genesis using a split-and-pool approach with macro-beads would ultimately not be 
viable due to the lack of biological activity of A54145A1-Asn3-DAPA4-Asp9, we nevertheless 
developed a synthesis of using A54145A1-Asn3-Asp9 which is amenable for library 
generation. Current preliminary studies in the Taylor lab are working towards making a library 
of daptomycin analogs using a split-and-pool macro-bead approach, and it is likely that this 
approach will be applicable toward the synthesis of A54145A1-Asn3-Asp9. Challenging steps 
involve the formation of the ester bond with N3IleOH, but this has been shown to go to near 




3.2.4 – Assessing the Importance of HOAsn3 and MeOAsp9 to Biological Activity 
 
 A54145D was previously synthesized and found to be very biologically active against 
B. subtilis ATCC 1046 (MIC = 0.5 µg/mL, Table 2.2, Section 2.2.3.3). However, making three 
simultaneous changes to the structure of A54145D to obtain A54145A1-Asn3-Asp9 (8-
methyldecanoyl → decanoyl; HOAsn3 → Asn3; MeOAsp9 → Asp9) resulted in a 16-fold loss 
in biological activity. To determine which of these changes contributed the most to this loss of 
activity, as well as to determine if activity could be restored with only a single substitution to 
A54145D’s structure, we proceeded to synthesize mutants of A54145D which replaced these 
non-proteinogenic amino acids in isolation with their proteinogenic counterparts. This is 
additionally advantageous in the context of synthesizing a library of A54145D analogs. 
Replacement of either of the two non-proteinogenic amino acids would greatly ease the 
synthetic challenges of building such a library. 
 Nguyen et al. prepared a variety of A54145D analogs using a biosynthetic approach 
(section 1.5.3), including one where HOAsn3 was replaced with Asn3, and another in which 
MeOAsp9 was replaced with Asp9.16 Each of these analogs were reported to be 16-fold less 
active than A54145D against a strain of S. aureus, indicating that these two uncommon amino 
acids are important for its biological activity. They also reported an analog in which HOAsn3 
and MeOAsp9 were replaced with both Asn3 and Asp9, which was only 8-fold less active than 
A54145D.16 
 To confirm that the HOAsn residue is indeed essential for good activity, A54145D-
Asn3 (3.44, Figure 3.13) was prepared according to the method employed in synthesizing 
A54145D (Schemes 2.13, 2.14, and 2.15), except that FmocAsnOH was used instead of Fmoc-
tHOAsn(OTBDMS)OH and Fmoc-eMeOAsp(tBu)OH was used instead of Fmoc-
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tMeOAsp(tBu)OH. Accordingly, there was no need for TBDMS removal with TBAF. 
A54145D-Asn3 was obtained in a 10% yield, characterized by MS/MS sequencing (Figures 
D.11 and D.12 in Appendix D). Further, to confirm that the MeOAsp residue is indeed essential 
for good activity, A54145D-Asp9 (3.45, Figure 3.13) was also prepared according to Schemes 
2.13, 2.14, and 2.15 except that FmocAsp(tBu)OH was used instead of Fmoc-
tMeOAsp(tBu)OH. A54145D-Asp9 was obtained in an overall 14% yield, and characterized 
by MS/MS sequencing (Figures D.13 and D.14 in Appendix D).  
 




 In agreement with Nguyen et al.,16 substitution of either of these non-proteinogenic 
amino acids in A54145D resulted in a 16-fold loss of biological activity when tested against 
B. subtilis ATCC 1046 (Table 3.2) – the same degree of activity loss reported with S. aureus 
42. Interestingly, these two compounds were about 4-fold more active against B. subtilis ATCC 
1046 than S. aureus 42. Perhaps even more interestingly, peptides 3.44 and 3.45 were as active 
as the A54145D triple mutant A54145A1-Asn3-Asp (3.1) which suggests a compensatory 
effect of multiple substitutions, and further, implies that peptide 3.1 is a valuable starting point 
for the development of many A54145 analogs. 
Table 3.2: MICs of A54145D, A54145A1, and A54145D analogs  
entry peptide MIC (g/mL) 
  This work Literature 
1 A54145D (1.11) 0.5a 216,b, 2-415,c 
2 A54145D-Asn3 (3.44) 8a 3216,b 
3 A54145D-Asp9 (3.45) 8a 3216,b 
4 A54145A1 (1.7) 2a 4-815,c 
aAgainst B. subtilis ATCC 1046, 1.25 mM Ca2+ present; b Against S. aureus 42, 1.25 mM 
Ca2+ present; c Against several other strains of S. aureus. 
 
3.2.5 – Effect of Acyl Tail Substitutions on A54145D and A54145A1 and Daptomycin 
 
 From the point of view of preparing a large number of A54145D analogs for biological 
evaluation, it would be more convenient if the anteiso-undecanoyl lipid in A54145D could be 
replaced with a lipid that is commercially available and relatively inexpensive. For these 
reasons, anteiso-undecanoic acid must be synthesized (Scheme 2.3). A54145A1 (1.7, Figure 
3.13) is identical to A54145D except that it contains an n-decanoyl lipid instead of an anteiso-
undecanoyl lipid. Counter et al. demonstrated that A54145D possesses biological activity that 
is 2- to 4-fold higher than A54145A1 against various strains of Staphylococcus, but we were 
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interested in assessing how this subtle change affects biological activity against Bacillus 
subtilis.15 
 A54145A1 was synthesized according to Schemes 2.13, 2.14, and 2.15, except that 
commercially available decanoic acid was used to install the lipid (and Fmoc-
eMeOAsp(tBu)OH was used instead of Fmoc-tMeOAsp(tBu)OH). The target compound was 
obtained in overall 12% yield, whose sequence was confirmed with MS/MS sequencing 
(Figures D.15 and D.16 in Appendix D). We found that A54145A1 was 4-fold less active than 
A54145D against B. subtilis ATCC 1046, which is approximately the same relative reduction 
in activity against S. aureus as reported by Counter et al. (Table 3.2).15 This indicates that the 
methyl group at position 8 of the lipid in A54145D can be omitted with only a modest reduction 
in biological activity, and signifies that this lipid tail can be replaced with a decanoyl tail in the 
future development of A54145A1 or A54145D analogs. 
 Eliopoulos et al. reported that the MICs of 8-methyldecanoyl daptomycin (8-MeDec-
Dap), against various strains of Staphylococcus, Streptococcus, and Listeria, were 1 to 4-fold 
less than daptomycin.20,123 We prepared 8-MeDec-Dap via a semi-synthesis approach (Scheme 
3.18). The succinimidyl ester of 8-methyldecanoic acid was coupled to Orn(Boc)-
deacyldaptomycin (Orn(Boc)deacylDap) in the presence of TEA. Orn(Boc)deacylDap was 
generously provided by Cubist Pharmaceuticals Inc, now part of Merck & Co. The Boc-group 
on the Orn residue was removed with TFA/thioanisole scavenger to produce 8-MeDec-Dap, 
which was purified by preparative RP-HPLC. MIC studies with 8-MeDec-Dap against B. 
subtilis revealed that the addition of the methyl group to the 8-position of increased biological 
activity 1.5-fold (Table 3.3), consistent with the studies of Eliopoulos et al.12a,b Hence, it 
appears that substituting the decanoyl lipid in daptomycin with 8-MeDec-Dap does not 
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significantly affect its activity against B. subtilis, but does modestly affect the activity of 
A54145D against B. subtilis. 
 
Scheme 3.18: Synthesis of 8-MeDec-Dap (3.46) from Orn(Boc)DeacylDap. 
 
 The strategy demonstrated in Scheme 3.18 was also used to synthesize two additional 
analogs of daptomycin in which the lipid tail was replaced with a pentadecanoyl tail, or 10-
methyldodecanoyl lipid. Unsurprisingly, these analogs with a longer acyl tail were very 
biologically active, more-so than authentic daptomycin (Table 3.3). Previous literature has 
demonstrated that longer acyl tails on daptomycin provide increased biological activity but 
also increased the toxicity of the analogs in vivo (Table 1.1, section 1.5.1). 
Table 3.3: MICs of daptomycin and daptomycin analogs with alternative lipid tails 
entry peptide MIC (g/mL)a 
1 Daptomycin (1.2) (i.e., decanoyl lipid tail) 0.75 
2 8-methyldecanoyl-daptomycin (3.46) 0.5 
3 10-methyldodecanoyl-daptomycin (3.47) 0.25 
4 pentadecanoyl-daptomycin (3.48) 0.25 
a Against B. subtilis ATCC 1046, 1.25 mM Ca2+ present 
3.3 – Conclusions 
 
 In this chapter, analogs of A54145D and A54145A1 were prepared and evaluated for 
their in vitro biological activity. It was discovered that, contrary to the results obtained by Kopp 
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et al., the activity of A54145A1 is significantly compromised when the ester bond is replaced 
with an amide bond. Both the ester bond and the γ-methyl group in Thr4 of A54145A1-Asn3-
Asp9 were found to be crucial for biological activity. This result is consistent with studies 
performed by the Taylor and Martin groups, who have reported that the activity of daptomycin 
is significantly compromised when the ester bond is replaced with an amide bond, and that 
both the ester bond and the γ-methyl group in Thr4 of daptomycin are crucial for biological 
activity.84,117 Consequently, it will not be prudent to make libraries of the A54145 factors in 
which the ester bond is replaced with an amide bond. However, it might be possible to use the 
route outlined in Schemes 3.7, 3.8, and 3.12 to make libraries of the A54145 factors even 
though the synthetically challenging ester bond will be present. 
 We also performed studies to determine if either of the uncommon amino acids HOAsn 
and MeOAsp could be replaced with their common amino-acid counter-parts. A single 
substitution of HOAsn with Asn, or of MeOAsp with Asp resulted in a 16-fold decrease in 
biological activity. However, a double substitution of HOAsn with Asn and MeOAsp with Asp 
also resulted in a 16-fold loss in biological activity relative to A54145D, but a 4-fold loss in 
biological activity relative to A54145A1. It is unlikely that it will be possible to replace 
MeOAsp with amino acids other than Asp or 3-hydroxyAsp79 as position 9 is part of the Ca2+-
binding DXDG motif, and it has been shown that replacing Asp9 in daptomycin with Asn 
results in complete loss of activity.76  
 In both Chapter 2 and Chapter 3, many challenges in the total synthesis of these A54145 
analogs were encountered, which are summarized in Figure 3.14. The challenges encountered, 
and the strategies employed to overcome them, will also be of value to future total syntheses 
of cyclic lipodepsipeptide antibiotics. 
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Figure 3.14: Summary of issues encountered in the synthesis of A54145D and analogs.  
3.3.1 – Future Studies 
 
 In the development of antibiotics related to A54145, it is possible that small structural 
changes to the structure of A54145D may tune its biological activity in the presence and 
absence of lung surfactant. For this reason, having the total synthesis available for A54145 
analogs containing both MeOAsp9 or Asp9 is advantageous. 
 Future work in the Taylor lab will be to synthesize new analogs of A54145D and 
A54145Al. Substitutions to either MeOAsp9 or HOAsn3 result in a 16-fold loss in biological 
activity in isolation, but the Baltz group has shown that additional substitutions can compensate 
and restore some biological activity (Table 1.2, entries 16 and 17, entries 19 and 25). The 
results reported here comparing peptide 3.1 with A54145A1 (1.7) are in complete agreement 
with the results of the Baltz group, in that both the non-proteinogenic HOAsn and MeOAsp 
can be replaced with Asn3 and Asp9 with only a 4-fold loss in biological activity, relative to 
A54145A1. It may be worthwhile to conduct an alanine scan of peptide 3.1, to determine if 
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there are any amino acids of A54145A1-Asn3-Asp9 that are amenable to substitution, much 
like the alanine scan performed on daptomycin by Barnawi et al.81,82 With a synthetic strategy 
for A54145D analogs containing MeOAsp9 available, in addition to a synthetic strategy for 
A54145D analogs containing Asp9, the synthesis of these analogs are quite feasible. 
 The A54145 family of antibiotics contains 8 different factors, illustrated in Figure 1.4 
(Section 1.1). These factors arise from the inherent flexibility of suitable substrates in 
A54145’s NRPSs. There are three options for the lipid tail (anteiso-undecanoyl, n-decanoyl, 
and iso-decanoyl), two options for position 13 (isoleucine and valine), and two options for 
position 12 (glutamate and 3-methylglutamate). All possible combinations of these variations 
produce, in theory, a total of twelve members in the A54145 family – it is therefore surprising 
that A54145 produces only 8 factors by Streptomyces fradiae. It may be of interest to 
synthesize these remaining A54145 family members (Table 3.4) and assess their biological 
activities.  
Table 3.4: Structures and MICs of the “entire” A54145 family.15 
A54145 
Factor 
Position 12 Position 13 Lipid Tail 
MICa 
(µg/mL) 
B1 MeGlu Ile iso-decanoyl 0.5 – 2.0 
B MeGlu Ile n-decanoyl 0.5 – 2.0 
E MeGlu Ile anteiso-undecanoyl 0.25 – 2.0 
-- MeGlu Val iso-decanoyl --- 
-- MeGlu Val n-decanoyl --- 
C MeGlu Val anteiso-undecanoyl 2.0 – 4.0 
A Glu Ile iso-decanoyl 0.5 – 2.0 
A1 Glu Ile n-decanoyl 1.0 – 8.0 
D Glu Ile anteiso-undecanoyl 0.5 – 4.0 
F Glu Val iso-decanoyl 2.0 – 32 
-- Glu Val n-decanoyl --- 
-- Glu Val anteiso-undecanoyl --- 
a Against several S. aureus strains 
 Daptomycin and A54145D both contain DXDG calcium-binding motifs; however, two 
of the amino acids vary between them: Asp7-D-Lys8-MeOAsp9-Gly10 in A54145, and Asp7-
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D-Ala8-Asp9-Gly10 in daptomycin. It may be of interest to generate hybrid daptomycin-
A54145D analogs, in which the calcium-binding DXDG motif of A54145 (containing 
MeOAsp) is replaced with the DXDG motif of daptomycin (containing Asp). This series of 
substitutions would change the ionization state of the peptide at physiological pH from -3 to -
4, since the basic D-Lys8 is replaced with a neutral D-Ala8, which may affect biological 
activity. To compensate, an additional analog could be synthesized in which position 6 of 
A54145D (Ala) is also replaced by position 6 of daptomycin (Orn), resulting in a peptide with 
the same net charge in solution. With the calcium-binding motif of daptomycin, the hybrid 
peptide may have a higher calcium affinity and therefore increased biological activity, while 
maintaining A54145D’s activity in the presence of lung surfactant. 
 Ultimately, with the synthesis of A54145D in place, we are poised to synthesize many 
more analogs of A54145D or A54145A1, some of which may have improved biological 
activity and may retain biological activity in the presence of lung surfactant. If sufficiently 
active in mouse models, they may find use as an alternative treatment for community-acquired 
pneumonia. 
3.4 – Experimental 
 
3.4.1 – General Experimental 
 
 The membrane binding assay used to study the interaction of A54145A1-Asn3-
DAPA4-Asp9 with model membranes was performed as described in Taylor et al.49  
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3.4.2 – Experimental Procedures for Synthesized Compounds 
 
FmocAsp(tBu)GlyOAllyl (3.7). To dry THF (90 mL) was added the tosylate salt of allyl 
glycine (2.73) (7.0 g, 24.4 mmol, 1 equiv), N-ethylmorpholine (3.08 mL, 24.4 mmol, 1 equiv) 
and HOBt (3.29 g, 24.4 mmol, 1 equiv). The suspension was stirred and cooled to 0 oC. To this 
was added FmocAsp(tBu)OH (10.0 g, 24.4 mmol, 1 equiv) and the resulting mixture was 
stirred vigorously. A solution of DCC (5.54 g, 26.8 mmol, 1.1 equiv) in dry THF (35 mL) was 
added and the mixture allowed to stir at 0 oC for 30 min. The ice bath was removed and the 
mixture was further stirred at room temperature for 16 h. Following the reaction, the DCU by-
product was removed by filtration, and the filtrate concentrated in vacuo. The product was 
purified by column chromatography using 30:70 EtOAc/hexane to yield Compound 3.7 (10.9 
g, 86% yield) as a thick oil. 1H-NMR (300 MHz, CDCl3) δ: 7.74 (2H, t, J = 7.5 Hz), 7.57 (2H, 
d, J = 7.3 Hz), 7.38 (2H, t, J = 7.4 Hz) 7.29 (2H, t, J = 7.4 Hz), 5.95-5.82 (2H, m), 5.29 (1H, 
d, J = 20.2 Hz), 5.23 (1H, d, J = 10.4 Hz), 4.64-4.42 (5H, m), 4.22 (1H, t, J = 6.8 Hz), 4.12-
3.95 (2H, m),  2.89 (1H, d, J = 20.2), 2.65 (1H, dd, J = 16.5, 6.2), 1.44 (9H, s). 13C-NMR (75 
MHz, CDCl3): δ: 171.0, 170.9, 169.0, 156.1, 143.7, 141.3, 131.4, 127.8, 127.1, 125.1, 120.0, 
119.0, 81.9, 67.3, 66.0, 51.1, 47.1, 41.4, 37.4, 28.0. HRMS (ESI+): m/z [M+H]+ calcd for 




FmocAspGlyOAllyl (3.8). FmocAsp(tBu)GlyOAllyl (3.7) (10.9, 21.4 mmol) was added to a 
round-bottom flask and was cooled in an ice bath. Pre-chilled trifluoroacetic acid (50 mL) was 
added and the mixture was stirred at 0 oC for 6 h. The solvent was removed by vacuum, and 
trace TFA removed azeotropically with toluene three times. Toluene was removed 
azeotropically with methanol, and methanol was removed azeotropically with chloroform. The 
crude product was suspended in chloroform and filtered to yield the purified product as a white 
solid (7.7 g, 79%). Characterization data matched the literature.86 1H- NMR (300 MHz, CDCl3) 
δ: 7.78 (2H, d, J = 7.5 Hz), 7.65 (2H, d, J = 7.5 Hz), 7.38 (2H, t, J = 7.3 Hz), 7.29, (2H, t, J = 
7.4 Hz), 5.91 (1H, m), 5.30 (1H, d, J = 17.1 Hz), 5.19 (1H, d, J = 10.4 Hz), 4.61-4.55 (3H, m), 
4.38-4.22 (3H, m), 3.95 (2H, s), 2.83-2.67 (2H, m). 13C-NMR (75 MHz, DMSO-d6): 172.1, 
172.0, 169.8, 156.3, 144.2, 141.1, 132.7, 128.1, 127.5, 125.8, 120.5, 118.3, 66.2, 65.2, 51.6, 
47.0, 41.2, 36.7. HRMS (+ESI) m/z: calcd for C24H25N2O7: 453.16563, found 453.16568. 
 
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-aminopropanoic acid (3.9). 
Compound 3.9 was synthesized using procedures from Picha and coworkers and Lau and 
coworkers.118,119 FmocAsnOH (11.1 g, 31.3 mmol, 1 equiv) was added to a stirring mixture of 
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acetonitrile (50 mL), ethyl acetate (50 mL), and water (25 mL) at room temperature. To the 
stirred suspension was added (diacetoxyiodo)benzene (12.1 g, 37.6 mmol, 1.2 equiv), and the 
reaction was stirred overnight. The solvent was removed in vacuo and the suspension was 
dissolved in water (150 mL). The solution was acidified to pH 1 with concentrated HCl, and 
the acidified solution was washed with ethyl acetate (3 x 100 mL). The aqueous phase as 
adjusted to pH 6 with 2M NaOH, and the precipitated was filtered and washed with water three 
times, chilled ethanol once, and diethyl ether five times. The solid was dried under vacuum to 
give compound 3.9 as a beige solid (5.83 g, 57%). 1H NMR (300 MHz, DMSO) δ: 8.48 (br. s, 
1H), 7.86 (2H, d, J = 7.4 Hz), 7.73 (2H, d, J = 7.2 Hz), 7.39 (2H, t, J = 7.3 Hz), 7.30 (2H, t, J 
= 7.3 Hz), 6.81 (br. s, 1H), 4.30-4.21 (3H, m), 3.71 (1H, m), 2.98 (1H, m), 2.78 (1H, m), 1.88 
(1H, s). 
 
Fmoc-β-azidoalanine-OH (3.10). Compound 3.10 was synthesized according to a previous 
method by Lau et al.118 Compound 3.9 (1.0 g, 3.1 mmol, 1 equiv) was dissolved in a biphasic 
mixture of water (15 mL), MeOH (30 mL) and DCM (25 mL), according to the procedure by 
Lau and Spring.118 To this was added copper(II) sulfate pentahydrate (5 mg, 0.02 mmol, 0.006 
equiv) and compound 2.77 (2.0 g, 9.5 mmol, 3.1 equiv). The mixture was stirred vigorously 
overnight. The mixture was further diluted with additional DCM (30 mL), and the aqueous 
phase was isolated. The organic phase was extracted with saturated NaHCO3 (2 x 50 mL), and 
the combined aqueous phases were washed with diethyl ether (2 x 50 mL). The aqueous phase 
was adjusted to pH 2 with concentrated HCl and extracted with diethyl ether (3 x 60 mL). The 
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ether layers were dried over Na2SO4 and concentrated under reduced pressure to give Fmoc-
β-Ala(N3)OH as a beige, amorphous solid (0.75 g, 72%). 
1H-NMR (300 MHz, CDCl3) δ: 11.0 
(1H, br. s), 7.76 (2H, d, J = 7.5 Hz), 7.60 (2H, d, J = 7.4 Hz), 7.40 (2H, t, J = 7.4 Hz), 7.32 
(2H, t, J = 7.5 Hz), 6.0 (1H, s), 4.62-4.41 (3H, m), 4.22 (1H, t, J = 6.9 Hz), 3.79-2.70 (3H, m). 
13C-NMR (75 MHz, CDCl3) δ: 175.8, 159.2, 146.4, 144.2, 130.8, 130.1, 128.0, 123.0, 70.5, 
56.7, 55.2, 49.9. 
 
A54145A1-Asn3-DAPA4-Asp9 (3.2). 2’-Cl-TrtCl polystyrene resin (theoretical substitution 
= 1.5 mmol/g, 66.7 mg, 0.1 mmol, 1 equiv) was activated in dry DCM with thionyl chloride 
(26 µL, 3.6 equiv) and pyridine (58 µL, 7.2 equiv) under reflux for 2 h. The resin was 
transferred to a disposable peptide cartridge and rinsed 6 x with dry DCM, followed by loading 
with Fmoc-Asp(OH)GlyOAllyl (4 equiv) and DIPEA (8 equiv) in dry DCM for 4 h. The 
cartridge was briefly rinsed with DCM (3 x 5 min), followed by capping with 17:2:1 
DCM/MeOH/DIPEA (3 x 10 min). The resin was rinsed thoroughly with DMF (3 x 5 min) and 
DCM (3 x 5 min), and the loading efficiency estimated to be 1.04 mmol/g. All Fmoc groups 
were removed by treatment with 20% 4-methylpiperidine in DMF (v/v) for 5 minutes, followed 
by a second treatment for 20 minutes. The lipid tail and residues 1-8 were activated (4 equiv) 
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for 5 min using HOBt (4 equiv) and DIC (4 equiv) in DMF (2 mL) and then coupled for 4 h. 
Residues 13-11 were activated (5 equiv) for 5 min with HOBt (5 equiv), PyBOP (5 equiv), and 
DIPEA (10 equiv) in 3:2:2 DCM/DMF/NMP with 1% Triton X-100 (2 mL) and then coupled 
for 4 h. After each Fmoc deprotection and each amino acid coupling, the resin was rinsed with 
DMF (3 x 5 min) and DCM (3 x 5 min). Following the synthesis of linear peptide 3.3, the azido 
group was reduced by treatment with PMe3 (4 equiv) in 1:1 THF/H2O overnight, which 
afforded peptide 3.4. Further elaboration by Fmoc-SPPS resulted in branched peptide 3.16, 
whose allyl group was removed by treatment with Pd(PPh3)4 (0.2 equiv) and DMBA (10 equiv) 
in 3:1 DCM/DMF (v/v) using a N2 gas inlet for agitation. Unreacted palladium was quenched 
by rinsing the resin with 1% (m/v) sodium diethyldithiocarbamate trihydrate in DMF (5 x 3 
min). The resulting peptide was cyclized by two 1.5 h treatments of PyAOP (5 equiv), HOAt 
(5 equiv), and 2,4,6-collidine (10 equiv) in DMF (2 mL). Resin cleavage and global 
deprotection was mediated through treatment with 95:2.5:2.5 TFA/H2O/TIPS (v/v) for 1.5 h. 
The cleavage cocktail was concentrated by N2 stream and the peptide precipitated by the 
addition of chilled diethyl ether. The suspensions were centrifuged, and the pellets resuspended 
in 9:1 H2O/MeCN and purified by preparative RP-HPLC employing an isocratic solution 
gradient of 35:65 CH3CN / H2O (+0.1% TFA). Fractions containing the desired product were 
pooled and concentrated under vacuum. The residue was resuspended in water, frozen, and 
lyophilized affording A54145A1-Asn3-DAPA4-Asp9 (3.2) as a white powder (36 mg, 13% 
based on resin loading), which was judged to be >95% pure by analytical RP-HPLC (Figure 
B.6 in Appendix B). HRMS (ESI+) m/z: [M+2H]2+ Calcd for C70H110N18O24, 792.3886; Found 
792.3911 (Figure C.6 in Appendix C). Limited sequence data using MS/MS was also obtained 




A54145A1-Asn3-Asp9 (3.1). TentaGel TrtCl resin (theoretical loading, 0.23 mmol/g, 435 mg, 
0.1 mmol, 1 equiv) was activated in dry DCM with thionyl chloride (3.6 equiv) and pyridine 
(7.2 equiv) under reflux for 2 h. The resin was transferred to a disposable peptide cartridge and 
rinsed 6 x with dry DCM, followed by loading with FmocAspGlyOAllyl (4 equiv) and DIPEA 
(8 equiv) in dry DCM for 4 h. The cartridge was briefly rinsed with DCM (3 x 5 min), followed 
by capping with 17:2:1 DCM/MeOH/DIPEA (3 x 10 min). The resin was rinsed thoroughly 
with DMF (3 x 5 min) and DCM (3 x 5 min), and loading efficiency was estimated to be 0.17 
mmol/g. Prior to the formation of the depsi bond, all Fmoc groups were removed by treatment 
with 20% 4-MP in DMF (v/v) for 5 minutes, followed by a second treatment for 20 min. All 
Fmoc-amino acids (4 equiv) and the lipid tail (4 equiv) were activated for 5 min using HOBt 
(4 equiv) and DIC (4 equiv) in DMF (2 mL) and then coupled for 4 h. Peptide 3.24 underwent 
on-resin esterification by treatment with N3IleOH (10 equiv), pre-activated with DIC (10 
equiv) by stirring in DCM (2 mL) for 1 h, followed by the addition of DMAP (0.1 equiv), for 
12 h. The progress of the depsi-bond formation was monitored by analytical HPLC until 
peptide 3.30 was obtained in a satisfactory yield. Following the installation of the depsi bond, 
all Fmoc-deprotections were performed using three 10-min iterations of 20% 2-
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methylpiperidine in DMF (v/v). Fmoc-SPPS with DIC/HOBt coupling starting from peptide 
3.30 yielded branched peptide 3.29. The azido group in the peptide 3.29 was reduced by 
treatment of the peptide with PBu3 (3 equiv), and (FmocGlu(tBu)CO)2O (5 equiv) (formed by 
the addition of 10 equiv FmocGlu(tBu)OH and 5 equiv DIC to 2 mL dry THF and stirring for 
1 h) for 5 min, followed by the addition of 0.1 mL H2O and further stirring for 16 h, yielding 
peptide 3.31. Further Fmoc-SPPS allowed the incorporation of the remaining two amino acids, 
yielding peptide 3.19. Removal of the Fmoc group was performed with 20% 2-MP in DMF, 
followed by allyl deprotection with Pd(PPh3)4 (0.2 equiv) and DMBA (10 equiv) in 3:1 
DCM/DMF (v/v) for 1 h using a N2 gas inlet for agitation. Unreacted palladium was quenched 
by rinsing the resin with 1% (m/v) sodium diethyldithiocarbamate trihydrate in DMF (5 x 3 
min). The resulting peptide was cyclized by two 1.5 h treatments of PyAOP (5 equiv), HOAt 
(5 equiv), and 2,4,6-collidine (10 equiv) in DMF (2 mL). Resin cleavage and global 
deprotection was mediated through treatment with 95:2.5:2.5 TFA/H2O/TIPS (v/v) for 1.5 h. 
The cleavage cocktail was concentrated by N2 stream and the peptide precipitated by the 
addition of chilled diethyl ether. The suspensions were centrifuged, and the pellets resuspended 
in 9:1 H2O/MeCN. The target compound was purified by preparative RP-HPLC employing a 
linear gradient of 37% CH3CN/63% H2O (+0.1% TFA) to 38% CH3CN/62% H2O (+ 0.1% 
TFA) over 50 min. Fractions containing the desired product were pooled and lyophilized 
giving A54145A1-Asn3-Asp9 (3.1) as a white powder (8 mg, 7% based on resin loading), 
which was judged to be >95% pure by analytical RP-HPLC (Figure B.7 in Appendix B). 
HRMS (ESI+) m/z: [M+2H]2+ Calcd for C71H111N17O25, 799.8885; Found 799.8879 (Figure 





NH2-Ser(OTBDMS)-OH (3.49). Compound 3.49 was obtained according to a procedure by 
Luo et al.124 To a stirred suspension of L-serine (2 g, 19.0 mmol, 1 equiv) in DMF (20 mL) 
was added imidazole (2.59 g, 38.1 mmol, 2.0 equiv) and tert-butyldimethylsilyl chloride (3.15 
g, 20.9 mmol, 1.1 equiv). The mixture was stirred over night at room temperature, after which 
the DMF was removed by high-vacuum rotary evaporation. The oily residue was then stirred 
in 1:1 H2O/hexane vigorously for 4 h. The white solid was filtered off, rinsed with hexane, and 
air-dried to give compound 3.49 as a white solid (3.52 g, 84%). 1H-NMR (300 MHz, CDCl3) 
δ: 4.04 (1H, dd, J = 3.9 Hz, J = 11.1 Hz), 3.97 (1H, dd, J = 6.0 Hz, J = 11.0 Hz), 3.60 (1H, m), 
0.92 (9H, s), 0.11 (6H, s). 
 
Fmoc-Ser(OTBDMS)-OH (3.50). Compound 3.50 was obtained according to a procedure by 
Aguda et al.125 To a solution of NH2-Ser(OTBDMS)-OH (3.49) (1 g, 4.6 mmol, 1.0 equiv) in 
a 1:1 mixture of 1,4-dioxane and water (50 mL) was added Na2CO3 (0.966 g, 0.91 mmol, 2.0 
equiv) and Fmoc-OSu (1.69 g, 5.0, 1.1 equiv) at room temperature. The resulting mixture was 
stirred overnight, resulting in a clear solution. This solution was acidified with 2N HCl to pH 
1 and extracted with ethyl acetate (3 x 75 mL). Evaporation of the organic layer afforded the 
crude product as a clear oil. The crude product was purified by column chromatography using 
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a slow gradient of 100% DCM to 97:3 DCM/MeOH, to afford the desired compound 3.50 as 
a yellow amorphous solid  (1.59 g, 79%). 1H NMR (300 MHz, CDCl3) δ: 7.68 (2H, d, J = 7.4 
Hz), 7.55 (2H, d, J = 6.5 Hz), 7.39 (2H, t, J = 7.3), 7.30 (2H, t, J = 7.4), 5.63 (1H, d, J = 8.1 
Hz), 4.44-4.33 (3H, m), 4.24 (1H, t, J = 7.08), 4.14 (1H, d, J = 9.5), 3.87 (1H, d, J = 7.3), 0.89 
(9H, s), 0.06 (6H, s). 
 
A54145A1-Asn3-Ser4-Asp9 (3.32). A54145A1-Asn3-Ser4-Asp9 was synthesized according 
to the procedure for A54145A1-Asn3-Asp9, except that FmocSerOH was used instead of 
FmocThrOH. The target compound was purified by preparative RP-HPLC employing a linear 
gradient of 36% CH3CN/64% H2O (+0.1% TFA) to 37% CH3CN/63% H2O (+ 0.1% TFA) 
over 50 min. Fractions containing the desired product were pooled and lyophilized giving 
A54145A1-Asn3-Ser4-Asp9 (3.32) as a white powder (7 mg, 7% based on resin loading), 
which was judged to be >95% pure by analytical RP-HPLC (Figure B.8 in Appendix B). 
HRMS (ESI+) m/z: [M+2H]2+ calcd for C70H109N17O25, 792.8807; Found 792.8777 (Figure 
C.8 in Appendix C). The peptide was characterized by NMR (Figures A.19 to A.23 and Table 




A54145A1-Asn3-DABA4-Asp9 (3.33). A54145A1-Asn3-DABA4-Asp9 was synthesized 
according to the procedure for A54145A1-Asn3-DAPA4-Asp9 except that Fmoc-(2S,3R)-2-
amino-3-azidobutanoic acid117 (FmocAABA) was used instead of Fmoc-β-azidoAlaOH. The 
reduction of the azido was also slower for this peptide and required three overnight treatments 
with 2 M DTT and 1 M DIPEA in DMF, with the complete azido reduction monitored by 
analytical RP-HPLC. All amino acids were introduced with DIC/HOBt couplings. The target 
compound was purified by preparative RP-HPLC employing a linear gradient of 37% 
CH3CN/63% H2O (+0.1% TFA) to 38% CH3CN/62% H2O (+ 0.1% TFA) over 50 min. 
Fractions containing the desired product were pooled and lyophilized giving A54145A1-Asn3-
DABA4-Asp9 (3.33) as a white powder (42 mg, 15% based on resin loading), which was 
judged to be >95% pure by analytical RP-HPLC (Figure B.9 in Appendix B). HRMS (ESI+) 
m/z: [M+2H]2+ Calcd for C71H110N18O24, 799.3965; Found 799.3948 (Figure C.9 in Appendix 
C). The peptide was characterized by NMR (Figures A.24 to A.28 and Table A.3 in Appendix 





A54145D-Asn3 (3.44). A54145D-Asn3 was synthesized using the procedure we developed 
for the synthesis of A54145D (Chapter 2) except FmocAsnOH was used in place of Fmoc-
tHOAsn(OTBDMS)OH at position 4. The target compound was purified by preparative RP-
HPLC employing a linear gradient of 40% CH3CN/60% H2O (+0.1% TFA) to 41% 
CH3CN/59% H2O (+0.1% TFA) over 40 min. Fractions containing the desired compound were 
pooled and lyophilized giving A54145D-Asn3 (3.44) as a white powder (4 mg, 10% yield 
based on resin loading), judged to be >95% pure by analytical RP-HPLC (Figure B.10 in 
Appendix B). HRMS (ESI+) m/z: [M+2H]2+ calcd for C73H113N17O26 821.9016; Found 
821.9017 (Figure C.10 in Appendix C). Sequence data was obtained by MS/MS (Figures D.11 






A54145D-Asp9 (3.45). A54145D-Asp9 was synthesized using the procedure we developed 
for the synthesis of A54145D (Chapter 2) except FmocAsp(tBu)OH was used in place of 
Fmoc-erythro-MeOAsp(tBu)OH at position 9. The target compound was purified by 
preparative RP-HPLC employing a linear gradient of 39% CH3CN/61% H2O (+0.1% TFA) to 
40% CH3CN/60% H2O (+0.1% TFA) over 40 min. Fractions containing the desired compound 
were pooled and lyophilized giving A54145D-Asp9 (3.45) as a white powder (6 mg, 14 % 
yield based on resin loading), judged to be > 95% pure by analytical RP-HPLC (Figure B.11 
in Appendix B). HRMS (ESI+) m/z: [M+2H]2+ Calcd for C72H111N17O26 814.8938; Found 
814.8965 (Figure C.11 in Appendix C). Sequence data was obtained by MS/MS (Figures D.13 





A54145A1 (1.7). A54145A1 was synthesized using the procedure we developed for the 
synthesis of A54145D (Chapter 2) except commercially available decanoic acid was used to 
install the lipid tail. The target compound was purified by preparative RP-HPLC employing a 
linear gradient of 39% CH3CN/61% H2O (+0.1% TFA) to 40% CH3CN/60% H2O (+0.1% 
TFA) over 40 minutes. Fractions containing the desired compound were pooled and 
lyophilized giving A54145A1 (1.7) as a white powder (5 mg, 12 % yield based on resin 
loading), judged to be > 95% pure by analytical RP-HPLC (Figure B.12 in Appendix B). 
HRMS (ESI+) m/z: [M+2H]2+ calcd for C72H111N17O27 822.8912; Found 822.8910 (Figure 
C.12 in Appendix C). Sequence data was obtained by MS/MS (Figures D.15 and D.16 in 
Appendix D). 
 
8-Methyldecanoic acid succinimidyl ester (3.51).  (±)-8-Methyldecanoic acid (54 mg, 0.29 
mmol, 1 equiv) was added to a 25 mL round-bottom flask. To this was added a solution of N-
hydroxysuccinimide (50 mg, 4.4 mmol, 1.5 equiv) in dry DCM (10 mL) until dissolution. To 
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the stirring solution was added EDC (93 mg, 4.8 mmol, 1.67 equiv) and DMAP (3.5 mg, 0.029 
mmol, 0.1 equiv). The solution was stirred at room temperature overnight, after which TLC 
indicated the reaction was complete. The mixture was diluted with EtOAc (15 mL), and the 
organic phase was washed with 0.1M HCl (aq) (1 x 15 mL), then washed with sat. NaHCO3 
(aq) (1 x 15 mL), and finally washed with brine (1 x 15 mL). The organic phase was dried with 
Na2SO4 and further purified by column chromatography (7:3 hexane/EtOAc). 8-
Methyldecanoic acid succinimidyl ester (3.51) was obtained as a white solid (43 mg, 94%). 1H 
NMR (300 MHz, CDCl3, δ): 2.81 (2H, s), 2.56 (2H, t, J = 7.3 Hz), 1.73 (2H, t, J = 7.1 Hz), 
1.60-1.08 (13H, m), 0.85-0.81 (6H, m). 13C NMR (75 MHz, CDCl3, δ): 172.1, 171.6, 39.4, 
37.2, 33.8, 32.3, 31.7, 29.7, 28.5, 27.5, 22.1, 14.3. HRMS (ESI+) m/z: [M+H]+ calcd for 
C15H26NO4, 284.1856; found, 284.1849. 
 
8-MeDec-Dap (3.46). Orn(Boc)DeacylDap (20 mg, 0.013 mmol, 1 equiv) was added to dry 
DMF (400 µL) in a 7-mL scintered glass vial equipped with a stir bar. To this was added 8-
methyldecanoic acid succinimidyl ester  (3.51) (5.4 mg, 0.019 mmol, 1.5 equiv) and TEA (17.8 
µL, 0.13 mmol, 10 equiv), and the reaction was allowed to stir for 72 h. The reaction was 
concentrated to dryness on a high-vacuum rotary evaporator, resuspended in TFA with 2% 
thioanisole (v/v) for 20 mins at 0 oC to remove the Boc-group. Once again, the solvents were 
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removed by rotary evaporation, and the residue resuspended in water, frozen, and lyophilized. 
Following lyophilization, the residue was resuspended in 9:1 H2O/CH3CN (10 mL). The 
mixture was then purified by preparative RP-HPLC employing a linear gradient of 40% 
CH3CN/60% H2O (+0.1% TFA) to 44% CH3CN/56% H2O (+ 0.1% TFA) over 40 min. 
Fractions containing the desired product were pooled and lyophilized, giving 8-MeDec-Dap as 
an off-white powder (8.7 mg, 42%). The compound was judged to be >95% pure by analytical 
HPLC (Figure B.13 in Appendix B). HRMS (ESI+) m/z: [M+2H]2+ Calcd for C73H105N17O26, 
817.8703; found, 817.8707 (Figure C.13 in Appendix C). 
 
2,5-Dioxopyrrolidin-1-yl 10-methyldodecanoate (3.52). To a 25 mL round-bottom flask was 
added 10-methyldodecanoic acid (25 mg, 0.116 mmol, 1 equiv). To this was added a solution 
of NHS (19.8 mg, 0.172 mmol, 1.5 equiv) in dry DCM (5 mL) until dissolution. The reaction 
was cooled to 0 oC in an ice bath. To the chilled stirring solution was added EDC (37.0 mg, 
0.193 mmol, 1.67 equiv) and DMAP (1.4 mg, 0.012 mmol, 0.1 equiv). The solution was stirred 
at 0 oC for 1 h, after which the ice-bath was removed and the mixture stirred for an additional 
20 h as monitored by TLC. Following the reaction time, the mixture was diluted with EtOAc 
(15 mL). The organic phase was washed with 0.1 M HCl (aq) (1 x 15 mL), then washed with 
sat. NaHCO3 (aq) (1 x 15 mL), and finally washed with brine (1 x 15 mL). The organic phase 
was dried of Na2SO4 and further purified by column chromatography with a mobile phase of 
1:1 EtOAc-hexane, to yield the desired product 3.52 as a white solid (34 mg, 95%). 1H-NMR 
(300 MHz, CDCl3) δ: 2.81 (4H, s), 2.58 (2H, t, J = 7.4 Hz), 1.72 (2H, app. quint., J = 7.2 Hz), 
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1.38-1.04 (16H, m), 0.85-0.81 (6H, m). 13C- NMR (75 MHz, CDCl3) δ: 172.1, 171.6, 39.5, 
37.3, 33.8, 32.8, 32.4, 32.3, 32.0, 31.7, 29.0, 28.5, 27.4, 22.1, 14.3. HRMS (ESI+): m/z 
[M+H+]+ calcd for C17H30NO4: 312.21693, found 312.21668. 
 
10-Methyldodocanoyl-daptomycin (3.47). To a 7 mL glass vial was added 
Orn(Boc)DeacylDap (10 mg, 6.4 µmol, 1 equiv). The vial was equipped with a stir bar, and 
dry DMF (200 µL) was added. To this was added triethylamine (9 µL, 0.065 mmol, 10 equiv) 
and compound 3.52 (2.9 mg, 9.6 µmol, 1.5 equiv) and the suspension was stirred for 72 h. The 
reaction was concentrated on a high-vacuum rotary evaporator and redissolved in water 
followed by lyophilization. Then, the crude product was stirred in a solution of TFA (1 mL) 
containing thioanisole (2% v/v) for 25 min in an ice-bath. The solution was concentrated in 
vacuo, and the residue redissolved in dry DMF, with the solvent being removed once more. 
The oily residue was dissolved in water and lyophilized before purification by preparative 
HPLC using a Clipeus C18 10 µm column employing a linear gradient of 57:43 H2O (+0.1 % 
TFA) / acetonitrile  to 54:46 H2O (+0.1 % TFA) / acetonitrile. Fractions containing the desired 
compound were pooled and concentrated, suspended in water and lyophilized to obtain the 
desired product as a white powder (2.5 mg, 24%), judged to be >95 pure by RP-HPLC (Figure 
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B.14 in Appendix B). HRMS (ESI+): m/z [M+2H+]2+ calcd for C75H109N17O26: 831.88593, 
found 831.88348 (Figure C.14 in Appendix C). 
 
2,5-Dioxopyrrolidin-1-yl pentadecanoate (3.53). Pentadecanoic acid (28 mg, 0.116 mmol, 1 
equiv) was added to a 25 mL round-bottom flask. To this was added a solution of NHS (19.8 
mg, 0.172 mmol, 1.5 equiv) in dry DCM (5 mL) until dissolution. The reaction was cooled to 
0 oC in an ice bath. To the chilled stirring solution was added EDC (37.0 mg, 0.193 mmol, 1.67 
equiv) and DMAP (1.4 mg, 0.012 mmol, 0.1 equiv). The solution was stirred at 0 oC for 1 h, 
after which the ice-bath was removed and the mixture stirred for an additional 20 h as 
monitored by TLC. Following the reaction time, the mixture was diluted with EtOAc (15 mL). 
The organic phase was washed with 0.1 M HCl (aq) (1 x 15 mL), then washed with sat. 
NaHCO3 (aq) (1 x 15 mL), and finally washed with brine (1 x 15 mL). The organic phase was 
dried with Na2SO4 and further purified by column chromatography with a mobile phase of 1:1 
EtOAc-hexane, to yield the desired product 3.53 as a white solid (48 mg, 95%). 1H-NMR (300 
MHz, CDCl3) δ: 2.81 (4H, s), 2.58 (2H, t, J = 7.5 Hz), 1.70 (2H, app. quint., J = 7.2 Hz), 1.38-
1.21 (23H, m), 0.86 (3H, t, J = 6.8 Hz). 13C- NMR (75 MHz, CDCl3) δ: 169.2, 168.7, 31.9, 
30.9, 29.6, 29.5, 29.3, 29.1, 28.8, 25.6, 24.6, 22.7. HRMS (ESI+): m/z [M+H]+ calcd for 





Pentadecanoyl-daptomycin (3.48). To a 7 mL glass vial was added Boc-Deacyl-Dap (10 mg, 
6.4 µmol, 1 equiv). The vial was equipped with a stir bar, and dry DMF (200 µL) was added. 
To this was added triethylamine (9 µL, 0.065 mmol, 10 equiv) and compound 3.52 (3.3 mg, 
9.6 µmol, 1.5 equiv) and the suspension was stirred for 72 hours. The reaction was concentrated 
on a high-vacuum rotary evaporator and redissolved in water followed by lyophilization. Then, 
the crude product was stirred in a solution of TFA (1 mL) containing thioanisole (2% v/v) for 
25 minutes in an ice-bath. The solution was concentrated in vacuo, and the residue redissolved 
in dry DMF, with the solvent being removed once more. The oily residue was dissolved in 
water and lyophilized before purification by preparative HPLC using a Clipeus C18 10 µm 
column employing a linear gradient of 51:49 H2O (0.1 % TFA) / acetonitrile to 50:50 H2O (0.1 
% TFA) / acetonitrile. Fractions containing the desired compound were pooled and 
concentrated, suspended in water and lyophilized to obtain the desired product 3.48 as a white 
powder (2.4 mg, 22%), judged to be >95% pure by RP-HPLC (Figure B.15 in Appendix B). 
HRMS (ESI+): m/z [M+2H+]2+ calcd for C77H113N17O26: 845.90158, found 845.89821 (Figure 
















Chapter 4 – Mechanism Studies of Fluorinated Analogs of Daptomycin  
 
4.1 – Introduction 
 
 It is apparent from the discussion on daptomycin and related antibiotics in Chapter 1 
that there are still many questions concerning their mechanism of action. Fluorescence 
spectroscopy, employing fluorescently labelled daptomycin or using the intrinsic fluorescence 
of daptomycin, has been used extensively, and very effectively, for studying daptomycin’s 
interaction with model and bacterial membranes. However, due to FRET between Trp1 and 
Kyn13, only the Kyn residue can be employed for intrinsic fluorescent studies and, besides the 
lipid tail, the Orn residue is the only residue to which a fluorophore can be attached. It would 
be beneficial for mechanism of action studies if we could monitor the interaction of other 
residues of daptomycin with membranes. 
4.1.1 – 19F-NMR for Studying Biochemical and Biological Systems 
 
 Solid- and solution-state 19F-NMR have been used to study the interaction of proteins 
and peptides, including antimicrobial peptides, with membranes.126–129 The 19F nucleus is a 
particularly useful probe for studying molecular interactions. It is present at 100% isotopic 
abundance and in 19F-NMR, its nucleus has a very wide chemical shift range.126 The fluorine 
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atom is often considered isosteric with hydrogen due to its similar size, and it can often replace 
hydrogen in small molecules with minimal effect on their binding to enzymes and proteins.130 
It is also absent from most biomolecules and biological systems, which allows the 19F-NMR 
spectra of fluorinated compounds in biological systems to be free from extraneous 
signals.126,128  
 Solution state 19F-NMR has been used to study the interaction of fluorinated peptides 
or proteins with biological membranes. Some examples are discussed below. 
 In 2003, Afonin et al. used 19F-NMR to study the interactions of a fluorinated variant 
of PGLa, a cationic antimicrobial peptide, with liposomes.131 It was observed that binding to 
liposomes only occurred when anionic DMPG lipids were present. The T2 (transverse 
relaxation time, or spin-spin relaxation time) of the 19F signal substantially decreased from 298 
milliseconds to <25 milliseconds when DMPG liposomes were present, signifying that the 
PGLa antibiotic had moved from a highly fluid solvent to the less mobile membrane with 
slower tumbling. The authors monitored the 19F-NMR signal of the fluorinated PGLa as a 
function of increasing concentration of DMPG liposomes: when the liposomes were added 
stepwise to the sample tube, the integral of the 19F-NMR signal progressively decreased and 
finally disappeared. They concluded that the observed signal originated from the free form 
only, since any peptide bound to the vesicles would have given rise to a signal that is several 
orders of magnitude broader and could not be distinguished from the baseline. 
 Anderluh et al. observed the interaction of fluorinated equinatoxin II analogs with 
bicelles by solution state 19F-NMR.132 Equinatoxin II is a pore-former, known to require the 
presence of sphingomyelin in membranes for lytic activity. Researchers constructed a strain of 
E. coli that was auxotrophic for tryptophan, and thus could only survive if tryptophan was 
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present in the growth medium. The mutant strain was then grown in the presence of 5-
fluorotryptophan, causing all five Trp residues in equinatoxin II to be replaced with the 
fluorinated amino acid. Incubating the fluorinated equinatoxin II analog with micelles or 
bicelles containing only DMPC resulted in a slight change in chemical shift for some of the 
fluorinated Trp residues, suggesting initial membrane interaction, even in the absence of 
sphingomyelin. Subsequent titration of sphingomyelin lipids caused additional chemical shift 
changes to the signals of specific fluorinated residues, suggesting a conformational change or 
deeper membrane insertion. While it had previously been established that equinatoxin II 
interacts reversibly with membranes containing PC only and irreversibly in membranes 
containing PC and sphingomyelin,133 the changes in frequency of the specific 19F resonances 
using 19F-NMR allowed the researchers to propose several possible orientations of the 
peptide’s insertion into membranes.  
 It has also been shown that the fluorine signal from a water-soluble molecule is 
deshielded by about 0.2 ppm when the solvent is changed from water to deuterium oxide (D2O), 
in which the magnitude of the solvent-induced isotope shift (SIIS) is an indication of the extent 
to which a fluorine nucleus is exposed to solvent.134 Fluorine nuclei exposed to solvent will be 
shifted by about 0.2 ppm, whereas fluorine nuclei buried in a protein, or a membrane, and 
subsequently unexposed to solvent, do not experience any SIIS. Therefore, using a 
combination of deuterated and non-deuterated solvents, in conjunction with chemical shift 
changes expected upon localization in slowly-tumbling chemical environments, the relative 
chemical shift of the 19F signal can shed light on the nature of its chemical environment. The 
Marsh group has used this phenomenon to study membrane protein interactions. 
182 
 
 In 2010 and 2011, the Marsh group introduced trifluoroethylglycine into a known 
membrane-binding protein called MSI-78 and observed shielding of the trifluoromethyl tag 
upon introduction of increasing concentrations of small unilamellar vesicles or bicelles 
containing DMPG and DMPC.135,136 It was observed that upon addition of even low 
concentrations of small unilamellar vesicles (SUVs), peak broadening and chemical shift 
shielding of up to 1.0 ppm was observed, once again suggesting insertion into the membrane 
with slower tumbling. The researchers also observed SIIS effects of these protein analogs and, 
as would be expected, the fluorine signals of residues consistently experienced an upfield shift 
of 0.08 – 0.11 ppm  in the absence of vesicles. However, for fluorine signals of mutant proteins 
in which hydrophobic residues were replaced with trifluoroethylglycine, there were very small 
or completely lacking upfield relative shifts when bicelles were present, signifying that these 
trifluoromethyl tags were not exposed to the deuterated solvent. Finally, while the fluorine 
signals of all fluorinated residues broadened in the presence of model membranes, T2 values 
were smallest for the residues expected to be localized in the hydrophobic interior of the 
bicelle.  
 In 2013, the Marsh group synthesized (perfluoro-tert-butyl)homoserine and introduced 
it to varying locations in MSI-78. Fluorinated MSI-78 analogs were then analyzed in the 
presence of bicelles containing DMPG and DMPC, as discussed above. Once again, the 
researchers observed significant peak-broadening and shielding of the fluorinated tert-butyl 
group ranging from 0.02 ppm to 0.41 ppm, depending upon its location in the peptide.137 The 
key advantage in this work over the previous study was that the fluorinated amino acid used 
contained 9 equivalent fluorine atoms instead of three or less, requiring smaller amounts of 
fluorinated MSI-78 analog for membrane-binding studies.  
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 In 2010, the Pielak group observed a different phenomenon when studying the 
interaction of α-synuclein with small unilamellar vesicles containing varying head groups and 
lipid tails.138 This peptide is associated with Parkinson’s disease and other neurodegenerative 
disorders and is hypothesized to interact with membranes. However, previous studies provided 
contradictory descriptions of the interaction: some results indicated that the N-terminal amino 
acids lie on the surface of the membrane, and other results indicated that the N-terminal amino 
acids are anchored into the membrane. To elucidate the mechanism of membrane interaction, 
researchers replaced the four tyrosine residues of α-synuclein with 3-fluorotyrosine (1 in the 
N-terminal region, 3 in the C-terminal region). They observed that the highly cationic  N-
terminal region bound to SDS micelles and DOPC/DOPG membranes strongly, whereas the 
C-terminal region did not, based upon the complete disappearance of the fluorine signal of 3-
fluorotyrosine of only one of the four fluorinated amino acids. The fluorine signal was 
broadened beyond detection due to the slow tumbling in the interior of the SUVs. Similarly, 
an α-synuclein variant was constructed where four tyrosine residues were replaced with p-
trifluoromethylphenylalanine, whose interactions with SUVs mirrored the above results. These 
fluorinated analogs were used to assess the importance of lipid composition to membrane 
binding, and it was observed (once again based upon broadening beyond detection) that the N-
terminal region is strongly anchored in the SUVs. Additionally, SUV-binding was both head-
group and lipid-specific. The strongest binding was to anionic DOPC/DOPG SUVs, consistent 
with the cationic-nature of the N-terminal region. Interestingly, weakest SUV-binding was 
observed between α-synuclein and DMPG/DMPC lipids, which was attributed to the increase 




4.1.2 – Research Objectives 
 
 Several groups have attempted to study the mechanism of action of daptomycin via 1H- 
or 13C-spectroscopy. All of these groups have reported significant pH-dependent and 
concentration-dependent (both daptomycin and calcium concentration) line-broadening in the 
1H- and 13C spectra of daptomycin, both in the presence and absence of Ca2+.139 Based on these 
results, it has been proposed that daptomycin forms micelles in vivo which deliver daptomycin 
to bacterial membranes.22,139–141 These studies will be discussed in more detail in Section 
4.2.5.1. 
 Besides the finding that daptomycin can form aggregates under certain conditions, little 
else pertaining to daptomycin’s mechanism of action can be inferred from 1H-or 13C-NMR 
studies. Most other mechanism of action studies have involved appending different 
fluorophores to daptomycin, such as to the lipid tail or to the Orn6 residue (See Section 
1.2.3)44,46,49, or using the intrinsically fluorescent Trp1 and Kyn13 residues While effective, 
these strategies are limited to only a few locations on the entire daptomycin structure, and 
accordingly can only provide limited mechanistic insights. 
 The objective of this chapter is to determine if 19F-NMR can be used to probe the 
interaction of fluorinated daptomycin analogs with model membranes, and whether or not it 
can provide new information on the mechanism of action of daptomycin. We anticipate that 
19F-NMR may be used to answer questions such as: (1) Which amino acid residues are 
embedded within the membrane, and which (if any) reside in the aqueous environment 
surrounding the membrane? (2) Which regions of the antibiotic associate with the biological 
membrane first, or initiate interactions between daptomycin and the membrane? We propose 
that these questions can be answered through synthesizing analogs of daptomycin with 
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trifluoromethyl tags at various locations, and subsequently analyzing these compounds in the 
presence of model membranes using 19F-NMR. Answering these questions will provide 
insights regarding the mechanism of daptomycin’s membrane binding, which will hopefully 
lead to the rational development of more potent and clinically valuable antibiotics. 
4.2 – Results and Discussion 
 
4.2.1 –Fluorinated Daptomycin Analogs by Semi-Synthesis 
 
4.2.1.1 – 10,10,10-Trifluorodecanoyl-daptomycin (4.5) 
 
 The first fluorinated analog we chose to synthesize placed the trifluoromethyl tag at the 
end of the lipid tail of daptomycin (Dap-TFDec0 (4.5), Scheme 4.1). Phosphonium bromide salt 
2.12, prepared using a literature procedure,92 reacted with NaHMDS and 4,4,4-trifluorobutanal  
yielding alkene 4.1 in 59% yield. Alkene 4.1 was subjected to hydrogenation to yield alkane 
4.2 in 96% yield, and then the ester moiety in 4.2 was hydrolyzed using 1:1 MeOH/0.6 M 
NaOH (aq) to afford carboxylic acid 4.3 in a 79% yield. Carboxylic acid 4.3 was activated by 
treatment with N-hydroxysuccinimide (NHS), DMAP, and EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide) affording activated ester 4.4 in 82% yield. Compound 4.4 
was coupled to the N-terminus of Orn(Boc)DeacylDap (1.15), and the crude peptide was 
subjected to TFA containing 2% thioanisole as a scavenger which gave target peptide 4.5 in 




Scheme 4.1: Semi-synthesis of peptide 4.5. 
 
4.2.1.2 – Appending fluorinated moieties to Orn6 
 
 The amino group on the Orn residue of daptomycin appears to be necessary for optimal 
biological activity. Hill and co-workers examined the activity of various daptomycin analogs 
in which the Orn residue was acylated (usually with substituted benzoyl groups or amino 
acids).72 In general, analogs containing acyl groups that did not contain a free amino group 
were less active (1.6 to 32-fold) than daptomycin against MSSA, MRSA, and Enterococcus 
faecium, and E. faecalis. When the acyl group contained a free amino group (primary or 
secondary amine), very little or no loss of activity was evident against MSSA or MRSA; 
however, in general, such analogs were less active (sometimes much less active) than 
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daptomycin against E. faecium or E. faecalis. The authors concluded that a free amino group 
was important, but not essential for activity. Additionally, Ghufran Barnawi in the Taylor 
group has shown that replacing the Orn6 residue with alanine results in a 7-fold loss of activity 
against B. subtilis.82 
 It is not unreasonable to expect that the positive charge associated with the basic Orn6 
residue in daptomycin is involved in membrane-binding of the antibiotic to the lipid 
membrane, especially since daptomycin requires the anionic PG to function. Fluorescence 
studies employing daptomycin and daptomycin labelled at the Orn reside with the fluorophore 
acrylodan (acrylodan-Dap) and model membranes suggest that daptomycin’s interactions with 
membranes are initiated by the ornithine residue (section 1.2.3).49,50 However, the acrylodan 
tag had an adverse effect on daptomycin’s activity with acrylodan-dap being approximately 
10-fold less active than daptomycin.13,49 It is possible that interaction of acrylodan-Dap with 
the membranes may have been driven by hydrophobic interactions between the acrylodan 
moiety and the membranes which are not present in unlabeled daptomycin. 19F-NMR studies 
using daptomycin tagged with fluorinated groups on the Orn residue may shed some light as 
to if or at what stage in membrane binding the Orn residue interacts with membranes, and the 
environment surrounding the Orn residue. 
 We envisioned preparing several daptomycin analogs tagged with a trifluoromethyl 
group on the Orn residue (Figure 4.1). By performing 19F-NMR studies on analogs that contain 
a phenyl-based tag (4.6 and 4.8), and those that don’t bear a phenyl group (4.7 and 4.9), we 
would be able to determine if the physical properties of the tags (size and hydrophobicity) 
affect our results. Moreover, in analogs 4.8 and 4.9, the amino group is converted to a non-
basic amide. In analogs 4.6 and 4.7, the primary amino group in Orn6 becomes a secondary 
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amine. The amino group in 4.6 should still be basic enough to be protonated under neutral 
conditions. The amino group in 4.7 may, however, be un-ionized at neutral pH. Considering 
that the pKa of ammonium is 9.25, and the pKa of 2,2,2-trifluoroethylammonium is 5.61, it 
appears that the addition of a trifluoroethyl group reduces the acidity of ammonium species by 
approximately 3.5-4.0 pKA units due to the inductive effect of three fluorine atoms.
142,143 If 
appending a trifluoroethyl group to the protonated Orn residue has an effect of similar 
magnitude, then the pKA of the protonated ornithine residue may decrease from 10.7, as 
reported by Qiu et al.144, to between 6.7 and 7.2. At physiological pH values of 7.4 to 7.5, 
therefore, less than half of the daptomycin molecules in aqueous solution will bear a positive 
charge.  
 
Figure 4.1: Structures of peptides 4.6 to 4.9. 
 
 Analog 4.6 was prepared in moderate yield by reductive amination of p-
trifluoromethylbenzaldehyde (4.10) with daptomycin using sodium triacetoxyborohydride 
(STAB-H) (Scheme 4.2). The synthesis of compound 4.7 was more challenging. Our first 
attempt involved direct alkylation of daptomycin with trifluoroethyl 
trifluoromethanesulfonate. Although some of 4.7 was formed (as determined by MS), the 
major product had a m/z = 1602 (18 Da less than daptomycin), suggesting that daptomycin had 
undergone a dehydration reaction. It is possible that under these conditions, the unprotected 
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alcohol of D-Ser11 reacted with the trifluoroethyl trifluoromethanesulfonate and the resulting 
trifluoroethyl ether was subsequently eliminated by either E2 or E1CB mechanism. We were 
unable to separate this side-product from 4.7 by RP-HPLC. 
 On the basis of several patent procedures,145–148 we attempted to prepare 4.7 by 
reductive amination of the hydrate of trifluoroacetaldehyde or the ethyl hemiacetal of 
trifluoroacetaldehyde with daptomycin in TFA. Unfortunately, the desired product was 
obtained in only trace amounts. Ultimately, the reductive amination conditions that were used 
for preparing 4.6 were applied to the synthesis of 4.7 using the hemiacetal of 
trifluoroacetaldehyde (4.11) (Scheme 4.2). The reductive amination seemed to stop after about 
50% completion, and efforts to drive the reaction to completion by supplementing with 
additional hemiacetal and STAB-H were unsuccessful. Regardless, even though the reaction 
did not go to completion, peptide 4.7 was obtained in 35% yield after purification by 
preparative RP-HPLC. 
 
Scheme 4.2: Synthesis of peptides 4.6 and 4.7. 
 
 Peptides 4.8 and 4.9 were synthesized in moderate yields by reacting daptomycin with 
the succinimidyl ester of trifluoromethylbenzoic acid (4.13) or ethyl trifluoroacetate (4.14) in 




Scheme 4.3: Synthesis of peptides 4.8 and 4.9. 
 
4.2.2 –Fluorinated Daptomycin Analogs by Total Synthesis 
 
 The added value of employing 19F-NMR to study the mechanism by which daptomycin 
interacts with membranes is that fluorine can be introduced in other amino-acid positions, 
instead of just the lipid tail, position 1, and position 6. Based upon the results of previous 
syntheses of daptomycin analogs, we expected that positions would tolerate amino acid 
substitutions with fluorinated amino acids, with a minimal loss in biological activity. For 
example, Ghufran Barnawi, a former graduate student in the Taylor group, performed an 
alanine scan of Dap-Lys6-Glu12-Trp13 (an analog of daptomycin that has activity approaching 
that of daptomycin but does not contain the synthetically challenging MeGlu12 residue, or the 
other two uncommon amino acids, Kyn and Orn). These studies revealed that D-Ser11 can be 
replaced with D-Ala with only a minor loss in biological activity, which suggests that this 
position may be amenable to substitutions with other amino acids, possibly including 
fluorinated ones.81,82 Nguyen produced an analog of daptomycin in which the decanoyl lipid 
tail and D-Ala8 were replaced with 8-methyldecanoyl lipid tail and with D-Ser8, respectively, 
observing only a two-fold loss of activity.16 This also suggests that D-Ala8 may be amenable 
to substitution. More recently, the Taylor group prepared analogs of Dap-Lys6-Glu12-Trp13 
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in which the D-Ala8 was substituted with almost all of the other 19 common amino acids.149 It 
was found that D-Ala8 could be substituted with Ser, Met, or Arg with only a 2.5 to 5-fold loss 
of activity. He et al. revealed that substitution of Trp1 of daptomycin with p-
trifluoromethylphenylalanine produced an analog that was only 2-fold less active than 
daptomycin.74 Since the Taylor lab had already established an efficient synthesis of Dap-Lys6-
Glu12-Trp13, we envisioned introducing fluorinated residues into Dap-Lys6-Glu12-Trp13 at 
positions 1, 8, and 11 by total synthesis.  
4.2.2.1 – Synthesis of Dap-TFMPhe1-Lys6-Glu12-Trp13 (4.15) 
 
 He et al. synthesized daptomycin bearing a p-trifluoromethylphenylalanine residue at 
position 1 (Dap-TFMPhe1) by removing the acyl tail of CBz-protected (Orn-protected) 
daptomycin with a deacylase, yielding 1.16 (Scheme 1.3, Section 1.5.1).74 Following the 
removal of Trp1 by Edman degradation, the N-terminus of the resulting peptide was then 
reacted with an active ester of N-Boc-protected p-trifluoromethylphenylalanine. Removal of 
the Boc-protecting group followed by introduction of the decanoyl tail and subsequent CBz-
group removal gave Dap-TFMPhe1 in an overall yields ranging from 10% to 25% starting from 
daptomycin. Due to limited quantities of daptomycin available, we decided it would be more 
prudent to synthesize the analogous Dap-TMFPhe1-Lys6-Glu12-Trp13 (4.15, Figure 4.2) by 
total synthesis employing Fmoc-SPPS as per Scheme 1.12 (Section 1.6.4). For this, Fmoc-




Figure 4.2. Structures of Dap-TMFPhe1-Lys6-Glu12-Trp13 (4.15) and Fmoc-TFMPheOH 
(4.16). 
 
 While amino acid 4.16 is commercially available, it is prohibitively expensive. In 2000, 
Chris Kotoris, a former graduate student in the Taylor group, developed a synthesis of Fmoc-
TFMPheOH (Scheme 4.4).150 Although the overall yield was only 8.1%, the starting material 
and reagents were relatively inexpensive, so we decided to prepare 4.16 using this procedure 
(Scheme 4.5). For reasons unknown, we were able to obtain a much higher yield than Kotoris 
on the first step of the synthesis. We were also able to significantly increase the yield of racemic 
N-acetylTFMPheOH (4.19) by reversing the order of hydrogenation and hydrolysis steps and 
using an acetone-water mixture for the hydrolysis step. However, we were unable to reproduce 
Kotoris’ yield (50% - essentially quantitative) with regards to the acylase step to get 4.20. The 
deacetylation of 4.19 using acylase 1 from Aspergillus niger at 42 oC was slow as determined 
by analytical RP-HPLC, requiring a two-week reaction time, continually monitoring the pH of 
the reaction and supplying fresh enzyme. Purification of the zwitterionic product was also 
problematic, and ultimately required purification by preparative RP-HPLC. The desired amino 
acid was obtained in a very poor yield of 7% (14% of the desired enantiomer). We are unable 




Scheme 4.4: Synthesis of 4.16 via the route developed by Kotoris and Taylor.150 
 
 
Scheme 4.5: Synthesis of 4.20 via the route developed by Kotoris and Taylor150 with 
modifications. 
 
 One particularly effective way to prepare chiral phenylalanine derivatives is by using 
Williams’ lactone as a chiral auxiliary (4.24 in Scheme 4.6). This auxiliary has been used 
before in the Taylor group to prepare highly enantioenriched (>97% enantiomeric excess, ee) 
phenylalanine derivatives.151 Although there are several other literature syntheses of 
TFMPheOH,152–155 and Williams’ lactone had never been used to prepare 4.16, we chose to 
prepare 4.16 using Williams’ lactone as the route is short, straightforward, and provides amino 
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acids in very high ee.151,156–158 Williams’ lactone (4.24) is commercially available but very 
expensive. We synthesized this lactone according to a modified procedure from Dastlik and 
co-workers (Scheme 4.6).159 Subjecting the auxiliary to NaHMDS and then p-
trifluoromethylbenzyl bromide gave 4.26 in 54% yield. Hydrogenolysis of 4.26 gave 4.20. 
Crude compound 4.20 was subjected to Fmoc-OSu in biphasic 1,4-dioxane and saturated 
NaHCO3 (aq) to afford compound 4.16 in 67% yield (two steps). The overall yield was 27%. 
To determine the ee of this compound, an aliquot of crude 4.20 was subjected to the 
pentafluorophenyl ester of R-Mosher’s acid under Schotten-Baumann conditions overnight, 
and another aliquot subjected to the pentafluorophenyl ester of racemic Mosher’s acid. The 
crude mixture was analyzed by 19F-NMR and based upon the integrations of the Mosher’s acid 
CF3 groups of the corresponding amides, the ee of compound 4.20, and correspondingly 4.16, 
was determined to be 97% (Figure 4.3).  
 






Figure 4.3: Establishing the ee of TFMPheOH. Coupling of 4.20 to the pentafluorophenyl ester 
of racemic Mosher’s acid (red trace) revealed two diastereomeric 19F-NMR signals, and 
coupling of 4.20 to the pentafluorophenyl ester of R-Mosher’s acid demonstrates that the ee of 
4.20, and subsequently 4.16, is 97%. 
 
 With the enantomerically enriched amino acid in hand, we were poised to introduce 
this amino acid into daptomycin via Fmoc-SPPS. The route employed by Barnawi et al. in their 
synthesis of daptomycin analogs was used (see Scheme 1.12, section 1.6.4). Peptide 4.15 was 
obtained in a 10% yield after purification by semi-preparative RP-HPLC. 
4.2.2.2 – Synthesis of Dap-Lys6-D-Ser(CF3)11-Glu12-Trp13 (4.38) 
 
 Barnawi and co-workers reported in 2018 that D-Ser11 of Dap-Lys6-Glu12-Trp13 
could be replaced with D-Ala with only a minor decrease (~4-fold) in biological activity 
against B. subtilis ATCC 1046.82 We anticipated that replacement of D-Ser with D-Ser(CF3) 
would not significantly affect biological activity. In 2015, Liu et al. reported the synthesis of 
BocSer(CF3)OMe (4.30) in 56% yield via silver-mediated trifluoromethylation of BocSerOMe 
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(Scheme 4.7). We anticipated that we could use this approach to prepare Fmoc-D-Ser(CF3)OH 
(4.36, Scheme 4.8). This was advantageous, as it allowed for us to buy our enantiomerically 
pure starting material in the form of Boc-D-SerOMe. 
 
Scheme 4.7: Liu et al.’s synthesis of 4.30.160 
 
 Boc-D-SerOMe was converted to Boc-D-Ser(CF3)OMe in 35% yield using Liu et al.’s 
procedure (Scheme 4.8).160 The Boc-protecting group was removed with TFA; however, 
hydrolysis of methyl ester 4.33 with LiOH was unsuccessful, producing a complex mixture of 
products. We suspected that the treatment with LiOH to hydrolyze the methyl ester might be 
causing some unknown side-reactions (possibly elimination of CF3O- and formation of a 
dehydroalanine derivative, which may have decomposed to form other species). We were also 
concerned that treatment with LiOH might result in racemization. Therefore, we instead 
elected to use Boc-D-SerOtBu (4.32) as a starting material. Fortuitously, this was converted 
into Boc-D-Ser(CF3)OtBu (4.34) in 51% yield using the conditions reported by Liu et al. 
(Scheme 4.8). The Boc-group and tert-butyl group were cleanly removed by TFA, and the 
resulting crude product converted to Fmoc-D-Ser(CF3)OH (4.36) with Fmoc-OSu under basic 




Scheme 4.8: Successful synthesis of Fmoc-D-Ser(CF3)OH (4.36). 
 
 With the desired amino acid in hand, we attempted to synthesize Dap-Lys6-D-
Ser(CF3)11-Glu12-Trp13 (4.38), using the same route that was used for making Dap-
TFMPhe1-
Lys6-Glu12-Trp13 (Scheme 1.12, Section 1.6.4). The HPLC chromatogram of the crude 
material showed many peaks (Figure 4.4). One of the major products had a mass corresponding 
to the desired product 4.38 (m/z = 1684) while the other had a mass corresponding to 4.37, 
specifically with a loss of 84 Da (m/z = 1600). We suspected that CF3O
- was eliminated from 
peptide 4.39 during removal of the Fmoc group during 20% 2-MP in DMF, yielding resin-
bound dehydroalanine peptide 4.41 (Scheme 4.9). Upon cleavage from the resin and global 
deprotection using TFA, H2O, and the reducing agent TIPS, the dehydroalanine was reduced 
to D/L alanine to give peptide 4.37 as a mixture of epimers at Ala11. The extent of elimination, 
as determined by peak areas of the two products, was about 55%. The desired product was 




          . 
Figure 4.4: HPLC chromatogram of crude Dap-Lys6-D-Ser(CF3)11-Glu12-Trp13 (4.38). 
 
Scheme 4.9: Proposed sequence of side reactions resulting in peptide 4.37.  
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 Barnawi et al. reported that substitution of D-Ala8 with L-Ala8 was detrimental to 
biological activity, which suggested to us that the stereochemistry of amino acids in the 8-
position of daptomycin must be of the D-configuration. We initially hoped that Fmoc-D-
Ser(CF3)OH could be introduced to position 8, allowing for the synthesis of Dap-Lys6-D-
Ser(CF3)8-Glu12-Trp13, but due to the issues faced in the synthesis of peptide 4.38, this was 
not attempted. In Barnawi’s route to Dap-Lys6-Glu12-Trp13, the D-Ser resiude at position 11 
is subjected to a single treatment of 2-MP in DMF. The position 8 amino acid, D-Ala, is 
subjected to 11 treatments of 2-MP or 4-MP during the course of the synthesis, and so little or 
no Dap-Lys6-D-Ser(CF3)8-Glu12-Trp13 would have been present at the end of the synthesis, 
especially since a single treatment resulted in about 55% elimination. Accordingly, we turned 
our attention to an amino acid that would avoid elimination of the trifluoromethyl tag. 
4.2.2.3 – Synthesis of Dap-Lys6-D-hCys(CF3)8-Glu12-Trp13 (4.55) 
 
 Michael Noden and Julian Marlyn, a graduate student and a former undergraduate 
student in the Taylor group, respectively, have shown that when D-Ala8 in Dap-Lys6-Glu12-
Trp13 is replaced with D-Met, only a 2.5-fold decrease in activity results.149 Therefore, we 
decided to replace D-Ala8 with D-trifluoromethylhomocysteine (D-hCys(CF3)OH, also known 
as trifluoromethionine). This required the synthesis of Fmoc-D-hCys(CF3)OH (4.52). 
 In 2014, Brown et al. reported the synthesis of Fmoc-L-hCys(CF3)OH by electrophilic 
trifluoromethylation of Fmoc-L-hCys(Trt)OH, 4.42, using Togni’s reagent.161 Briefly, 4.42 
was subjected to TFA and TIPS to remove the Trt group (Scheme 4.10). The residue was 
dissolved in a mixture of DCM and methanol and subjected to Togni’s reagent (4.44), and 
stirred overnight, yielding Fmoc-L-hCys(CF3)OH (4.45). While this strategy could have been 
applied to the synthesis of Fmoc-D-hCys(CF3)OH, the starting materials Fmoc-D-
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hCys(Trt)OH and Togni’s reagent were prohibitively expensive and instead we decided to 
pursue a different route. 
 
Scheme 4.10: Synthesis of Fmoc-hCys(CF3)OH by Brown et al.
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  In 1997, the Honek group reported the synthesis of L-hCys(CF3)OH (4.49) from 
racemic homocysteine thiolactone (4.46), employing acylase 1 at the end of their synthesis, 
which catalyzes the hydrolysis of N-acetyl groups for L-amino acids only (Scheme 4.11).162 
This route was appealing to us as the reagents were relatively inexpensive and the route was 
short and straightforward. However, in our case, we required the D-amino acid, so acylase 1 
could not be used. Fortunately, Amano Enzyme Inc. has a D-amino acid acylase available, 
which catalyzes the hydrolysis of N-acetyl groups and is highly selective for D-amino acids. 
Further, its optimal substrate (both in terms of activity and stereoselectivity) is DL-N-
acetylmethionine. Since N-acetylmethionine and N-acetyl-hCys(CF3) are very similar, we 
anticipated that D-aminoacylase would be very effective in the chiral resolution of our desired 
D-amino acid. 
 





 Accordingly, amino acid 4.52 was synthesized beginning from the hydrochloride salt 
of homocysteine thiolactone and acetic anhydride at reflux (Scheme 4.12), yielding 4.46 in a 
73% yield. Compound 4.46 was subjected to NaOMe in MeOH and subsequently treated with 
CF3I under UV radiation yielding 4.48 in a 72% yield. The methyl ester was hydrolyzed with 
NaOH (aq), and the resulting mixture was adjusted to pH 7.5 with 0.1 M HCl (aq). The solution 
was brought to 30 oC and then subjected to D-aminoacylase for 3 days. The crude product, 
4.51, used without further purification, was treated with Fmoc-OSu under alkaline conditions, 
which yielded the desired compound 4.52, in 30% yield over two steps. To determine the ee 
of this compound, an aliquot of crude 4.51 was subjected to the pentafluorophenyl ester of R-
Mosher’s acid under Schotten-Baumann conditions overnight, and another aliquot subjected 
to the pentafluorophenyl ester of racemic Mosher’s acid. The crude mixture was analyzed by 
19F-NMR and based upon the integrations of the Mosher’s acid CF3 groups of the 
corresponding amides, the ee of compound 4.51, and subsequently 4.52, was determined to be 
94.2% (Figure 4.5).  
 







Figure 4.5: Establishing the ee of D-hCys(CF3). Coupling of 4.51 to the pentafluorophenyl 
ester of racemic Mosher’s acid (red trace) revealed two diastereomeric 19F-NMR signals, and 
coupling of 4.51 to the pentafluorophenyl ester of R-Mosher’s acid demonsrates that the ee of 
4.51, and subsequently 4.52, is 94.2%.  
 
 With 4.52 in hand, we then synthesized Dap-Lys6-D-hCys(CF3)8-Glu12-Trp13 (4.55, 
Figure 4.6) using the route outlined in Scheme 1.12 (Section 1.6.4). Unlike the incorporation 
of D-Ser(CF3), no products resulting from elimination were observed, and after purification by 
RP-HPLC, peptide 4.55 was obtained in 11% yield based on resin loading. 
 




 Additionally, we synthesized Dap-Lys6-D-hCys(CF3)11-Glu12-Trp13 (4.56, Figure 
4.6) using the route outlined in Scheme 1.12 (Section 1.6.4). Once again, elimination was not 
an issue, and the desired product was obtained after purification by RP-HPLC in 2% yield 
based on resin loading. 
4.2.2.4 – Synthesis of Dap-TFDec0-Lys6-Glu12-Trp13 (4.57) 
 
 We also prepared Dap-Lys6-Glu12-Trp13 bearing a 10,10,10-trifluorodecanoyl 
residue (Dap-TFDec0-Lys6-Glu12-Trp13, 4.57, Figure 4.6) by total synthesis (11% yield) 
according to procedures for the other Dap-Lys6-Glu12-Trp13 analogs described above (i.e., 
Scheme 1.12), except that 10,10,10-trifluorodecanoic acid (4.3) was used in place of decanoic 
acid. 
4.2.3 – Biological Studies 
 
 The MICs of the fluorinated daptomycin analogs were determined against B. subtilis 
ATCC 1046 using a standard broth dilution assay. The results are presented in Table 4.1. 
 Peptides bearing a 10,10,10-trifluorodecanoyl lipid (4.5 (entry 2) and 4.57 (entry 8)) 
exhibited the same activity as their decanoyl counter parts (entries 1 and 7). The daptomycin 
analog containing the p-TFMbenzyl group (4.6, entry 3) on Orn6 was only 2.7-fold less active 
than daptomycin, whereas the analog containing the p-TFMbenzoyl group on Orn6 (4.8, entry 
4) was 5.3-fold les active than daptomycin. In this case, the presence of an amino group is 
slightly beneficial for activity, or, the carbonyl moiety in the benzoyl group is slightly 
detrimental to activity. The TFethyl (4.7, entry 5) and TFacetyl (4.9, entry 6) daptomycin 
derivatives were both 5.3-fold less active than daptomycin. Peptide 4.7 was 2-fold less active 
than its benzyl-counterpart, but peptide 4.9 had the same activity as its benzoyl-counterpart, 
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indicating that, in this case, the type of linkage to the Orn residue (amine versus amide) does 
not affect activity. In any case, all of these daptomycin analogs (4.5 to 4.9) exhibited similar 
biological activity as daptomycin. In addition, all of the Dap-Lys6-Glu12-Trp13 analogs 
containing fluorinated amino acids (4.38, 4.55, and 4.56) exhibited similar biological activity, 
being only 2- to 5-fold less active than their parent compound, Dap-Lys6-Glu12-Trp13 (1.47). 
Table 4.1: MICs of fluorinated daptomycin analogs against B. subtilis ATCC 1046. 
a 1.25 mM Ca2+ added. 
b Blue shaded cells represent deviations from daptomycin corresponding to peptide 1.47, 
Dap-Lys6-Glu12-Trp13. 
 
4.2.4 – Trifluoroacetate counter-ion (TFA-) after RP-HPLC Purification 
 
 In all of the 19F-NMR studies described in this thesis, the solvent is H2O, with D2O in 
a glass insert used for a lock signal. All 19F-NMR spectra showed two fluorine signals, one of 
which was determined to be the trifluoroacetate (TFA-) counter-ion (δ = -76 ppm) as a result 
of purification by RP-HPLC (water containing 0.1% TFA was employed as part of the mobile 
phase).  For example, Figure 4.7 shows the 19F-NMR spectra of compound 4.5 after HPLC 





















Trp Orn --- D-Ala D-Ser MeGlu Kyn 0.75 
3 4.6 decanoyl Trp Orn p-TFMbenzyl D-Ala D-Ser MeGlu Kyn 2 
4 4.8 decanoyl Trp Orn p-TFMbenzoyl D-Ala D-Ser MeGlu Kyn 4 
5 4.7 decanoyl Trp Orn TFethyl D-Ala D-Ser MeGlu Kyn 4 
6 4.9 decanoyl Trp Orn TFacetyl D-Ala D-Ser MeGlu Kyn 4 




Trp Lys --- D-Ala D-Ser Glu Trp 1.5 
9 4.15 decanoyl TFMPhe Lys --- D-Ala D-Ser Glu Trp 8 
10 4.55 decanoyl Trp Lys --- D-hCys(CF3) D-Ser Glu Trp 4 
11 4.56 decanoyl Trp Lys --- D-Ala D-hCys(CF3) Glu Trp 2 
12 4.38 decanoyl Trp Lys --- D-Ala D-Ser(CF3) Glu Trp 8 
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subjected to HPLC. The 19F-NMR spectrum of compound 4.5 shows the peak due to the CF3 
group on the lipid tail at approximately -66 ppm and a peak at about -76 ppm due to TFA-. The 
19F-NMR spectrum of daptomycin, after being subjected to HPLC, only shows a single peak 
at -76 ppm, corresponding to TFA-. The 19F-NMR spectrum of daptomycin that was not 
subjected to HPLC shows no peaks. 
 
Figure 4.7: 19F-NMR spectrum of (A) compound 4.5 after HPLC purification; (B) daptomycin 
after being subjected to HPLC, and of (C) daptomycin that was not subjected to HPLC. The 
TFA counterion appears at -76 ppm. 
 
4.2.5 – 19F-NMR Studies of Fluorinated Analogs 
 
4.2.5.1 – 19F-NMR Studies on Daptomycin Aggregation 
 
 It has been shown that, under certain conditions, daptomycin can form aggregates. 
NMR spectroscopy has been used to study the aggregation of apo-Dap (Ca2+-free daptomycin) 
by examining line-broadening in the 1H- and 13C-NMR spectra of apo-Dap as a function of 
apo-Dap concentration and pH. The effect of pH on apo-Dap aggregation has been studied by 






of 0.8 mM apo-Dap at pH 7.8 exhibited little or no line broadening. Decreasing the pH to 5.2 
and 2.4 resulted in increasing line broadening, characteristic of aggregation, such that the 
spectrum at pH 2.4 was difficult to analyze. This was particularly true at elevated apo-Dap 
concentrations of 3-5 mM. 
 Qiu and Kirsch reported that at pH 6.5, even when the concentration of apo-Dap was 
very high (21.2 mM), no significant line broadening in the 1H-NMR spectrum was evident.163 
Qiu and Kirsch also studied the effect of pH on apo-Dap oligomerization using fluorescence 
spectroscopy and dynamic light scattering (DLS). Since daptomycin possesses intrinsically 
fluorescent Kyn13, whose fluorescence intensity increases in non-polar environments 
compared with polar, aqueous ones, an increase in fluorescence intensity signifies localization 
in a hydrophobic environment. The critical aggregation concentration (CAC) values of apo-
Dap were identified by an upward inflection of the fluorescence emission intensity for Kyn13 
and were also found to be pH-dependent. At pH 3-5, the CAC was determined to be 0.12-0.2 
mM of apo-Dap. At pH values of 5.5-6.5, no upward inflections were detected up to 0.3 mM 
apo-Dap. Using DLS, they also determined that the hydrodynamic radius of apo-Dap at pH 4.0 
above 0.2 mM increased, indicating aggregation. At pH 6.5, the hydrodynamic radius remained 
constant up to 7.32 mM, suggesting a lack of aggregation. 
 The tendency for apo-Dap to oligomerize under acidic conditions can be explained by 
the ionization state of apo-Dap. Between pH 2.5-4, apo-Dap exists primarily as a neutral or 
monoanionic species. As the pH increases to 7, the dianionic and trianionic forms dominate. 
Based on pKA values assigned to the acidic residues, deprotonation of the Asp3 and MeGlu12 
residues occurs as pH increased from 4 to 7 and these residues are located near the hydrophobic 
portions of daptomycin’s amphipathic structure.144 Since the structure of the monoanionic 
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species has been compared to a surfactant, ionization of the acid residues close to the lipid tail 
and hydrophobic portions of daptomycin would destabilize aggregates formed by hydrophobic 
interactions, and thus reduce aggregation.163  
 In summary, apo-Dap aggregates under acidic conditions at concentrations above 0.12 
– 0.20 mM but does not appear to aggregate at neutral or near neutral pH, even at very high 
concentrations. 
 Since daptomycin is known to require calcium for biological activity, NMR studies 
have also been performed on daptomycin with calcium present. It has been shown that 
significant line broadening in the 1H-NMR spectrum occurs upon the addition of just 0.3 
equivalents of Ca2+ to 0.8 mM daptomycin at pH 5.0.139 The Hancock and Straus groups 
reported that an aqueous solution of 2 mM daptomycin at pH 6.6 exhibited well-resolved 
resonances in the 1H- and 13C-NMR spectra; however, the addition of 5 mM Ca2+ resulted in 
significant line broadening.22 Using ultracentrifugation, the Hancock and Straus groups 
reported that a 2.5 mM solution of daptomycin containing 1 molar equivalent of Ca2+ at pH 
7.0 forms micelles consisting of 14 daptomycin monomers.164 On the basis of these results, the 
Hancock and Straus groups suggested that daptomycin forms micelles in vivo, and the micelles 
act as vehicles to deliver daptomycin to the bacterial membrane, where the daptomycin micelle 
dissociates into monomers which allows daptomycin insertion into the bilayer. 
 Qiu and Kirsch also studied the effect of Ca2+ on daptomycin oligomerization using 
fluorescence spectroscopy (using the intrinsic fluorescence of the Trp and Kyn residues).163 At 
pH 6.5, in the presence of 10 mM Ca2+, the CAC of daptomycin was determined to be 0.50 
mM. Limited studies were also performed using 1.0 mM Ca2+ in phosphate-buffered saline at 
pH 7.4 at daptomycin concentrations ranging from 0.011 to 0.0157 mM. As daptomycin 
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concentrations increased from 0.011 to 0.026 mM, the fluorescence spectral patterns or Trp 
and Kyn were not changed, except for an increase in emission intensity from these residues 
with increasing daptomycin concentration. When the daptomycin concentrations increased 
from 0.065 to 0.157 mM, there was an increase of the emission intensity from Kyn13 and a 
decrease in emission intensity from Trp1, suggesting that increased FRET between Trp1 and 
Kyn13 was occurring. The increased FRET occurring may suggest aggregation, although it 
should be noted that the slight increase in Kyn fluorescence seemed to parallel the slight 
increase observed when the Ca2+ concentration was increased from 0.011 to 0.026 mM – that 
is to say, Kyn13 emission intensity might not have been increasing between 0.065 and 0.157 
mM Ca2+ because of FRET from Trp. Nevertheless, the researchers interpreted these 
fluorescence changes as being due to daptomycin aggregation and concluded that daptomycin 
forms aggregates at physiological plasma concentrations of 0.06 mM165,166 (or 100 µg/mL) and 
physiological Ca2+ concentration (1.25 mM), and that daptomycin aggregation is critical for 
achieving its therapeutic effect. However, it has been pointed out by Taylor and Palmer that 
such daptomycin concentrations still substantially exceed daptomycin’s MIC (0.75 µg/mL), 
and would only occur in human plasma immediately after application of the drug, as 90% of 
the total amount of daptomycin is protein-bound, most likely in its monomeric form.167,168 
 Although the above studies indicate that daptomycin undergoes oligomerization in the 
presence of calcium, these studies were conducted using daptomycin concentrations that were 
far greater than MIC values of daptomycin. More recently, Muraih et al. have examined 
daptomycin oligomerization at concentrations close to those required for antibacterial activity 
using fluorescence spectroscopy.44 Because kynurenine has a very low fluorescence intensity 
in aqueous solution, both in the presence and absence of Ca2+, Muraih et al. elected to use a 
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highly sensitive FRET assay to study daptomycin oligomerization and used daptomycin 
labelled at Orn6 with NBD (NBD-Dap, 4.58, Figure 4.8) or Alexa Fluor 350 (Alexa-Dap, 4.59, 
Figure 4.8). These fluorophores allow for FRET from Alexa-Dap to NBD-Dap if the two 
moieties are found in close proximity, and due to their high fluorescence intensity, could be 
studied at very low concentrations (0.175 µM Alexa-Dap, 0.88 µM NBD-Dap; corresponding 
to 0.3 µg/mL and 1.4 µg/mL of daptomycin, respectively). They found that no FRET between 
Alexa-Dap and NBD-Dap occurred in solution in both the absence and presence of Ca2+. In 
contrast, strong FRET was observed only in the presence of both Ca2+ and DMPC/DMPG 
liposomes, suggesting that daptomycin only oligomerizes on membranes in the presence of 
Ca2+ These studies suggest that daptomycin does not form aggregates in solution at its MIC 
concentration, which indicates that pre-aggregation of daptomycin in solution is not necessary 
for daptomycin to interact with membranes and exert its biological effects. 
 
Figure 4.8: Structures of NBD-Dap (4.58) and Alexa-Dap (4.59). 
 
 We wished to determine if 19F-NMR can be used to study daptomycin aggregation. We 
began these studies using an unbuffered solution of peptide 4.5, at concentrations ranging from 





Figure 4.9: 19F-NMR spectra of peptide 4.5 (0.01-0.500 mM) in Milli-Q water. 
 
 The chemical shift remained the same at all daptomycin concentrations. Qualitatively, 
broadening of the peaks was observed at approximately 0.25 mM of the peptide. Figure 4.10A 
shows the relationship between peak area (relative to the TFA counter-ion) and peptide 
concentration, Figure 4.10B shows the relationship between peak height (relative to the TFA 
counter-ion) and peptide concentration, and Figure 4.10C shows the relationship between 
peptide concentration and the width of the peak at half of the height of the peak, signifying 
broadening. Peak area (panel A) does not change with peptide concentration. Peak height does 
not begin to diminish significantly until the peptide concentration is greater than 0.20 mM. The 
peak width at half-height is constant up to 0.20 mM but then begins to increase in a linear 
fashion up to 0.45 mM. From the plot of the peak width at half-height versus peptide 
concentration, we are able to determine the critical aggregation concentration of daptomycin 
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under these conditions. These results are consistent with those of Qiu and Kirsch (discussed 
above) who, using fluorescence spectroscopy, determined the CAC of daptomycin to be 0.20 
mM at pH 5.0. 
 
Figure 4.10: The effect of concentration of peptide in Milli-Q water on peptide 4.5 19F-NMR 
signal characteristics. (A) Total peak area, (B) peak height, and (C) peak width at half height. 
In panel C, where the two lines intersect represents the critical aggregation concentration of 
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 For obvious reasons, a solution of daptomycin in Milli-Q water (approximate pH = 4.8) 
does not represent biologically relevant conditions. Human plasma contains ions like sodium 
and calcium and is buffered at approximately pH = 7.4. Accordingly, we sought to determine 
the critical aggregation concentrations of compound 4.5 in buffered solutions in the presence 
and absence of calcium. 
 A solution of peptide 4.5 in 20 mM HEPES (pH 7.4) containing 150 mM NaCl was 
analyzed 19F-NMR at 37 oC, both with and without the physiological concentration of 
daptomycin (1.25 mM CaCl2). The chemical shift remained the same at all daptomycin 
concentrations. Unlike in unbuffered Milli-Q water, the peaks did not broaden at the higher 
concentrations, but remained relatively constant (Figure 4.11). Although the Hancock and 
Straus groups reported that the 1H-NMR spectrum of an aqueous solution of daptomycin at pH 
6.6 containing Ca2+ exhibited significant line broadening, the concentration of daptomycin 
used in their experiment (2 mM) was much greater than daptomycin’s MIC (approximately 1.5 
µM) and the concentration of Ca2+ (2.5 to 5 mM) was well above physiological concentrations 
(1.25 mM), making these results meaningless in terms of their relevance to daptomycin’s 
mechanism of action.167,168 Our results support the findings of Muraih et al.44 that indicate that, 
at MIC concentrations of daptomycin and in the presence of physiological concentrations of 
Ca2+, daptomycin does not form aggregates in solution under physiological conditions, and 
that pre-aggregation of daptomycin in solution is probably not necessary for daptomycin to 





Figure 4.11: The effect of the concentrations of peptide 4.5 in buffered aqueous solution on 
19F-NMR peak characteristics in the presence (1.25 mM, orange line) and absence (green line) 
of Ca2+. (A) Total peak area, (B) peak height, and (C) peak width at half-height. No aggregation 
of peptide 4.5 is observed, up to concentrations of 0.5 mM, ten times higher than concentrations 
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4.2.5.2 – 19F-NMR Studies of Peptide 4.5 in the Presence of Liposomes 
 
 Our next step was to obtain 19F-NMR spectra of peptide 4.5 in the presence of model 
membranes. To this end, 19F-NMR spectra of 0.025 mM solutions of peptide 4.5 in HEPES 
buffer (20 mM, pH 7.4, 150 mM NaCl) containing liposomes (0.250 mM total lipid) and 
varying amounts of Ca2+ were recorded. One liposome sample consisted of a 1:1 mixture of 
DOPG and DOPC, while another liposome consisted of only DOPC lipids. Since daptomycin 
is known to require PG in its mechanism of action, interactions with liposomes containing 
DOPC were not expected. 
 The 19F-NMR spectra of peptide 4.5 in solutions containing the DOPG/DOPC (1:1) 
liposomes and varying amounts of Ca2+ are shown in Figure 4.12. The 19F-NMR spectra of 
peptide 4.5 in solutions containing the DOPC liposomes and varying amounts of Ca2+ are 
shown in Figure 4.13. Neither the chemical shift, nor the peak width at half-height (Figure 
4.14B) changes as a function of Ca2+ concentration with either the DOPG/DOPC or DOPC 
liposomes. The peak area does not change as a function of Ca2+ concentration with the DOPC; 
however, the peak area does change as a function of Ca2+ concentration with the DOPG/DOPC 
liposomes (Figure 4.14A). Clearly, the peptide is not interacting with the DOPC liposomes, 
which is consistent with the mechanism of action of daptomycin in liposomes. It is interesting 
that with the DOPG/DOPC liposomes, that the peak width-at half-height (used to represent 
peak broadening) does not change while peak area decreases. This suggests that we are 
observing only the free, unbound form of the peptide. Any peptide bound to the liposomes 
should give rise to a signal that is broader (and possibly not observable) and probably has a 
chemical shift that is different from the free, unbound form. A similar phenomenon has been 
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reported by Afonin et al. during their 19F-NMR studies on the interaction of PGLa, and by 
Pielak and co-workers during their 19F-NMR studies on α-synuclein, mentioned above.131,138  
 
Figure 4.12: 19F-NMR spectra of peptide 4.5 (0.025 mM) in HEPES buffer (pH 7.4, 150 mM 
NaCl, containing DOPG/DOPC (1:1) liposomes (0.250 mM) and varying amounts of Ca2+. 
 
 
Figure 4.13: 19F-NMR spectra of peptide 4.5 (0.025 mM) in HEPES buffer (pH 7.4, 150 mM 






Figure 4.14: 19F-NMR spectra characteristics of peptide 4.5 in buffered (pH 7.4) solutions 
containing lipids as a function of calcium concentration. Orange lines represent DOPG/DOPC 
(1:1) liposomes, blue lines represent DOPC liposomes. (A) Total peak area, (B) peak width at 
half-height. 
 
4.2.5.3 – 19F-NMR Studies of Peptide 4.6 in the Presence of Liposomes 
 
 Next, we examined the interaction of ornithine analog 4.6 with membranes using 19F-
NMR. 19F-NMR spectra of 0.025 mM solutions of peptide 4.6 in HEPES buffer (20 mM, pH 
7.4, 150 mM NaCl) containing liposomes (0.250 mM) and varying amounts of Ca2+ were 
recorded. One liposome consisted of a 1:1 mixture of DOPG and DOPC, while another 






















A. Area of 19F-signal of 4.5 in model 





















B. Peak Width at half-height of 19F signal of 4.5
in model membranes at increasing [Ca2+]
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 The 19F-NMR spectra of peptide 4.6 in the presence of DOPC liposomes did not change 
significantly with Ca2+ concentration, indicating that this peptide was not interacting strongly 
with these liposomes (Figure 4.15). In contrast, the 19F-NMR spectra of peptide 4.6 in the 
presence of the DOPG/DOPC liposomes changed dramatically with Ca2+ concentration (Figure 
4.16). First, we noticed that even in the absence of Ca2+ that the height of the peak 
corresponding to peptide 4.6 in the presence of DOPG/DOPC liposomes was significantly less 
than the height of the peak corresponding to peptide 4.6 in the presence of DOPC liposomes 
(28% relative to the TFA peak versus 43% relative to the TFA peak). This suggests that, even 
in the absence of Ca2+, the Orn residue is interacting with PG. This may be due to the 
electrostatic interactions between peptide 4.6, which still bears a protonated amino group on 
the Orn residue, and the negative charge on PG. Due to the small size of the peaks in the 
DOPG/DOPC spectra (Figure 4.16), it was challenging to accurately determine the peak width 
at half-height; nevertheless, it appears that in the presence of the DOPG/DOPC liposomes that 
this characteristic does not change with increasing Ca2+ concentration. In contrast, in 
DOPG/DOPC liposomes, peak area decreases dramatically with Ca2+ concentrations, and the 
peak is undetectable at just 0.100 mM Ca2+ (Figure 4.17). These results again suggest that we 
are observing only the free, unbound form of the peptide. It can be concluded that the 





Figure 4.15: 19F-NMR spectra of peptide 4.6 (0.025 mM) in HEPES buffer (pH 7.4, 150 mM 
NaCl), containing DOPC liposomes (0.250 mM) and varying amounts of Ca2+. 
 
 
Figure 4.16: 19F-NMR spectra of peptide 4.6 (0.025 mM) in HEPES buffer (pH 7.4, 150 mM 





Figure 4.17: Areas of the peaks of peptide 4.6 in buffered (pH 7.4) solutions containing lipids 
as a function of calcium concentration. Orange lines represent DOPG/DOPC (1:1) liposomes, 
blue lines represent DOPC liposomes. 
 
 The interaction of peptide 4.6 with DOPG/DOPC liposomes was observed at calcium 
concentrations much lower than those observed with compound 4.5. A graph illustrating the 
dependency of the peak area on Ca2+ concentration for both peptides 4.5 and 4.6 is shown in 
Figure 4.18. The area of the 19F-signal of compound 4.6 decreased rapidly at concentrations 
between 0 and 0.05 mM Ca2+ and was completely undetectable at just 0.100 mM Ca2+. In 
contrast, with peptide 4.5, it takes considerably higher calcium concentrations for the area of 
the 19F signal in peptide 4.5 to decrease, and even at the highest Ca2+ concentration examined, 
0.250 mM, the peak did not completely disappear. Indeed, between 0.100 and 0.250 mM of 
Ca2+, the peak area does not change appreciably. It is possible that the peak does not completely 
disappear because we did not use sufficiently high concentrations of Ca2+ to promote complete 
association of the lipid portion of peptide 4.5 with the liposome. Daptomycin exhibits maximal 
antibacterial activity at 1.25 mM Ca2+. It will be interesting to see whether the peak area of 


























mM and 1.25 mM. If so, then this would suggest that daptomycin interacts with membranes 
via two successive Ca2+ binding events as has been suggested by Palmer and Taylor groups 
(section 1.2.3).49,51 
 Previous results published by the Palmer and Taylor groups in the changes in 
fluorescence of daptomycin and of fluorescently labelled daptomycin suggested that the Orn 
residue initiates daptomycin interactions (section 1.2.3).49 Our results are entirely consistent 
with these findings in that the trifluoromethylbenzyl moiety on the Orn residue in peptide 4.6 
interacts with liposomes prior to the trifluoromethyl tag of compound 4.5 (Figure 4.18). 
Extending this to unlabeled daptomycin, one can conclude that the Orn residue interacts with 
membranes before the lipid tail. 
 
 
Figure 4.18: Peak area of the 19F-signal of peptides 4.5 and 4.6 as a function of calcium in 
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4.3 – Summary and Conclusions 
 
 A total of ten fluorinated analogs of daptomycin were prepared. Analogs containing the 
trifluoromethyl group at either the lipid tail or Orn6 were prepared via semi-synthesis. Analogs 
containing the trifluoromethyl group at positions 1, 8, or 11 were prepared via total synthesis, 
as well as a Dap-Lys6-Glu12-Trp13 analog which contained the trifluoromethyl group on the 
lipid tail. All of the analogs were found to retain good biological activity against B. subtilis 
ATCC 1046 in comparison to their parent compounds (daptomycin or Dap-Lys6-Glu12-
Trp13). 
 Using 19F-NMR and peptide 4.5, which bears a CF3 group at the end of the lipid tail, 
we demonstrated that under physiological pH and physiological Ca2+ concentration, that 
daptomycin does not form aggregates at daptomycin concentrations up to at least 0.5 mM. 
These results support the findings of Muraih et al.44, that at MIC concentrations of daptomycin, 
and in the presence of physiological concentrations of Ca2+,  daptomycin does not form 
aggregates in solution, and that preaggregation of daptomycin in solution is probably not 
necessary for daptomycin to interact with membranes and exert its biological effects. 
 19F-NMR studies with peptides 4.5 and 4.6 suggest that the Orn6 residue of daptomycin 
interacts with biological membranes before the lipid tail does, as made evident by the 
observation that the trifluoromethyl signal for peptide 4.6 broadens beyond detection at Ca2+ 
concentrations lower than that observed for peptide 4.5. 
 Due to time constraints, it was not possible to probe the interaction of peptides 4.7 to 
4.9, 4.15, 4.38, or 4.55 to 4.57 with model membranes using 19F-NMR. Nevertheless, one of 
our objectives, which was to determine if 19F-NMR can be used to probe the interaction of 
daptomycin with model membranes, has been achieved. It is clear from the above studies that 
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19F-NMR can indeed be used to study daptomycin’s interaction with model membranes. 
Whether or not it can provide new information on the mechanisms of action of daptomycin 
remains to be seen. We anticipate that future 19F-NMR studies on all of the peptides 
synthesized in this chapter will indeed provide new information. A summary of these future 
studies is presented below. 
4.3.1 – Future Studies 
 
 The studies involving the interaction of fluorinated analogs 4.5 and 4.6 with model 
membranes were performed on a Bruker 500 MHz NMR Spectrometer, and to obtain the 
spectra shown above with an acceptable signal-to-noise ratio, fluorinated daptomycin analogs 
were analyzed at concentrations of 0.025 mM, which is higher than the concentration of free 
daptomycin seen in vivo. Additionally, these NMR experiments involved 8000 scans requiring 
12-hour NMR experiments. To support future 19F-NMR studies on these compounds, the 
University of Waterloo received a grant for the purchase an installation of a 19F-probe for a 
Bruker 600 MHz Spectrometer, which will assist future 19F-NMR studies in terms of reduced 
time required for each NMR experiment, and additionally, reduced concentration of 
daptomycin analogs needed. The Taylor group is anxiously waiting for this new probe to be 
installed before 19F-NMR studies will continue. 
 In the performed experiments, fluorinated analogs in the presence of lipids and 
increasing calcium concentration were analyzed by 19F-NMR, and higher calcium resulted in 
a smaller magnitude of 19F signal present in DOPG/DOPC membranes only, with no 
observable change in DOPC membranes. These studies were performed up to calcium 
concentrations of at most 0.4 mM, which is less than the physiological concentration of Ca2+ 
(1.25 mM). Accordingly, with DOPC membranes, it will be necessary to increase the 
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concentration of Ca2+ to at least 1.25 mM, to be absolutely certain that this method can be used 
to corroborate the overwhelming scientific consensus that daptomycin does not interact with 
DOPC liposomes under physiological concentrations of free calcium. 
 All synthesized peptides will be analyzed by 19F-NMR in the presence of liposomes 
containing DOPG/DOPC as presented in Section 4.2.5.2 and 4.2.5.3. So far, the 
trifluoromethyl tags studied reside on a hydrophobic lipid tail, and on a hydrophobic benzyl 
group, and indicate localization within the hydrophobic bilayer of model membranes. It is 
possible that the trifluoromethyl tag of other fluorinated daptomycin analogs will demonstrate 
localization in the aqueous surroundings to the membranes. The placement of trifluoromethyl 
tags at varying locations of daptomycin’s structure will hopefully shed light on the chemical 
environments associated with the different amino acid residues of daptomycin.  
 Instead of increasing calcium concentrations, an alternative version of this experiment 
can involve studying the fluorinated analogs in the presence of calcium and increasing the lipid 
concentration present. In doing so, we would expect to see a slow disappearance of the 19F 
signal as liposomes are added, signifying membrane insertion, analogous to the observations 
of Afonin et al., who saw a decrease in the 19F-signal of fluorinated α-synuclein upon addition 
of negatively charged liposomes.131 In the studies performed in this thesis, the total peptide to 
lipid ratio is 1:10 (thus a 1:5 ratio of peptide to DOPG). Starting the experiments with no 
liposomes present and slowly increasing the amount of liposomes present would provide 
valuable information of the stoichiometry of daptomycin-DOPG binding. Additionally, the 
ratio of DOPG to DOPC can be varied to observe how this affects membrane binding using 
19F-NMR, in addition to including cardiolipin, or lipids with myristoyl acyl groups instead of 
oleoyl acyl groups. 
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 Typically T2 relaxation times are determined from measuring the peak-width at half 
height (λ, λ = 2R2, and R2 = 1/T2 → T2 = 2 λ).
169 In our studies, this is not possible due to the 
observed disappearance of the peaks of interest. To solve this problem, we can determine the 
T2 values using CPMG T2 experiments, as performed by the Marsh group for fluorinated 
analogs of MSI-78, an antimicrobial peptide.135–137  
 Additionally, these studies can be repeated with D2O as the solvent instead of H2O to 
observe the solvent induced isotopic shift (SIIS) effect. Trifluoromethyl tags on residues that 
are found in an aqueous environment will display a change in chemical shift of about 0.2 ppm 
in D2O relative to water, but trifluoromethyl tags residing in a hydrophobic environment will 
not experience any SIIS effect.170 
 In this chapter, fluorinated analogs of daptomycin were synthesized. With the synthesis 
available for analogs of A54145A1 and A54145D (Chapter 2 and 3), we are also poised to 
synthesize fluorinated analogs of A54145D and conduct the same studies to shed greater 
insights on the mechanism of action of A54145D as well. It is assumed to behave in a similar 
fashion to daptomycin, but due to some differences in the locations of its charged residues 
(e.g., D-Asn2 and Asp3 in daptomycin, vs. D-Glu2 and HOAsn3 in A54145; as well as Orn6 
and D-Ala8 in daptomycin, vs. Ala6 and D-Lys8 in A54145), subtle differences in their 
membrane binding patterns may be expected. 
4.4 – Experimental 
 
4.4.1 – Procedure for 19F-NMR studies 
 
 All NMR of fluorinated daptomycin analogs presented in this thesis were obtained on 
a Bruker 500 MHz NMR spectrometer with temperature set to 37 oC. For self-aggregation 
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studies in water, a 400-µL sample was prepared at the desired concentration of analog, added 
to an NMR tube, and a glass insert with D2O was inserted. Samples with analog concentrations 
of 0.025 mM or less were subjected to 8000 scans with a delay time of 5 seconds, and samples 
with a higher concentration were subjected to 1000 scans.  
 All 19F-NMR studies involving model membranes were performed at a final analog 
concentration of 0.025 mM, and accordingly subjected to 8000 scans with a relaxation time of 
5 seconds. For these studies, liposomes were prepared by Dr. Robert Taylor, previously of the 
Taylor and Palmer lab, following previously reported procedures.49,51,63 Each individual NMR 
experiment was performed on a freshly prepared solution of liposomes, buffer, calcium, and 
fluorinated analog. 
4.4.2 – Procedure for ee Determination of Synthesized Fluorinated Amino Acids 
 
For Trifluoromethylphenylalanine: 
 Following hydrogenation of 4.26 yielding 4.20, an aliquot of the crude product (1 mg) 
was suspended in 1:1 H2O/MeCN (200 µL). To this was added the pentafluorophenyl ester of 
R-Mosher’s acid, or the pentafluorophenyl ester of R/S-Mosher’s acid in excess (4 mg, >2 eq) 
and triethylamine (2 µL, >3 eq) (accounting for the mass of the bi-benzyl by-product after 
hydrogenation, the actual mass of unprotected trifluoromethylphenylalanine was necessarily 
less than 1 mg). The reaction was stirred at room temperature overnight. Following the 
reaction, the entire crude mixture was suspended in CDCl3 and analyzed by 
19F-NMR. Peaks 
were observed that corresponded to unreacted starting Mosher’s pentafluorophenyl ester, and 
hydrolyzed Mosher’s acid and pentafluorophenol. The presence of unreacted Mosher’s acid 
pentafluorophenyl ester indicated that all of the amino acid had been converted to its 
corresponding Mosher’s amide. To elucidate the ee of compound 4.20, and subsequently 4.16, 
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the relative integrations of the diastereomeric Mosher’s acid CF3 signals were compared (See 
Figure 4.3). 
For Trifluoromethylhomocysteine: 
 Following the enzymatic resolution to obtain crude 4.51, an aliquot of the crude product 
(1 mg) was suspended in 1:1 H2O/MeCN (200 µL). To this was added the pentafluorophenyl 
ester of R-Mosher’s acid, or the pentafluorophenyl ester of R/S-Mosher’s acid in excess (4 mg, 
>2 eq) and triethylamine (2 µL, >3 eq) (accounting for the mass of unreacted N-acetyl-L-
trifluoromethylhomocysteine, the actual mass of unprotected D-trifluoromethylhomocysteine 
was necessarily less than 1 mg). The reaction was stirred at room temperature overnight. 
Following the reaction, the entire crude mixture was suspected in CDCl3 and analyzed by 
19F-
NMR. Peaks were observed that corresponded to unreacted starting Mosher’s 
pentafluorophenyl ester, and hydrolyzed Mosher’s acid and pentafluorophenol. To elucidate 
the ee of compound 4.51, and subsequently 4.52, the relative integrations of the diastereomeric 
Mosher’s acid -CF3 signals were compared (See Figure 4.5). 
 
4.4.3 – Experimental Procedures for Synthesized Compounds 
 
Ethyl 10,10,10-trifluorodec-6-enoate (4.1). To a 100 mL round-bottom flask was added 
phosphonium salt 2.12 (1.02 g, 2.1 mmol, 1.0 eq.) and purged with argon gas. Dry THF (50 
mL) was added and the mixture was cooled to -78 oC in a slurry of dry ice in acetone. Sodium 
hexamethyldisilazide (1 mol/L in THF, 2.1 mL, 2.1 mmol, 1.0 eq.) was slowly added and the 
resulting brown solution was stirred for 30 minutes at -78 oC. A solution of 4,4,4-
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trifluorobutyraldehyde (0.265 g, 2.0 mmol, 1.0 equiv) was dissolved in THF (5 mL) and 
transferred to the reaction mixture. The solution was allowed to warm to room temperature and 
was stirred overnight. The reaction was quenched with saturated sodium bicarbonate and the 
product was extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, dried 
with sodium sulfate, and concentrated in vacuo. The residue was purified by flash 
chromatography with 95:5 hexane/ethyl acetate, yielding compound 4.1 as a clear oil (0.312 g, 
59%). 1H-NMR (300 MHz, CDCl3) δ: 5.43 (1H, dt, J = 10.4, 7.5 Hz), 5.32 (1H, dt, J = 10.9, 
6.8 Hz), 4.11 (2H, d, J = 7.1 Hz), 2.31-2.24 (4H, m), 2.14-2.01 (4H, m), 1.59 (2H, app. quint., 
J = 7.6 Hz), 1.37 (2H, app. quint., J = 7.7 Hz), 1.24 (3H, t,  J = 7.1 Hz). 13C-NMR (75 MHz, 
CDCl3) δ: 173.6, 131.4, 128.7, 126.4, 60.1, 34.2, 33.8, 28.9, 26.7, 24.5, 19.9, 14.2. 
19F-NMR 
(282 MHz, CDCl3) δ: -66.8 (t, J = 10.0 Hz). HRMS (ESI+): m/z [M+H]
+
 calcd for C12H20F3O2: 
253.14099; found 253.14094. 
 
Ethyl 10,10,10-trifluorodecanoate (4.2). Compound 4.1 (245.5 mg, 0.97 mmol, 1 equiv) was 
added to a 50 mL round-bottom flask purged with argon. To this was added 10% Pd/C (37 mg) 
and the flask was re-purged with argon gas. The flask was then flushed with hydrogen gas and 
allowed to stir overnight at room temperature. The mixture was filtered over celite and the 
filtrate was concentrated. The hydrogenated product was obtained as a clear oil (239 mg, 96%). 
1H-NMR (300 MHz, CDCl3) δ: 4.11 (2H, q, J = 7.1 Hz), 2.28 (2H, t, J = 7.5 Hz), 2.12-1.96 
(2H, m), 1.62-1.48 (4H, m), 1.30-1.22 (11H, m). 13C-NMR (75 MHz, CDCl3): δ: 173.6, 127.2, 
60.0, 34.1 (2C), 33.5, 28.9 (2C), 28.5, 24.8, 21.7, 14.0. 19F-NMR (282 MHz, CDCl3) δ: -66.7 
228 
 
(t, J = 10.9 Hz). HRMS (ESI+): m/z [M+H]+ calcd for C12H22F3O2: 255.15664, found 
255.15646.  
 
10,10,10-Trifluorodecanoic acid (4.3). Compound 4.2 (168 mg, 0.66 mmol) was dissolved in 
a 1:1 solution of methanol and 0.6 M NaOH (8 mL), and reaction completion was monitored 
by TLC. After 3 h, the reaction was acidified with 1 M HCl and the product was extracted with 
ethyl acetate twice. The organic layers were dried and evaporated yielding compound 4.3 as a 
beige solid (118 mg, 79%). 1H-NMR (300 MHz, CDCl3) δ: 11.26 (1H, br. s), 2.34 (2H, t, J = 
7.1 Hz), 2.12-1.96 (2H, m), 1.65-1.48 (4H, m), 1.31-1.24 (8H, m). 13C-NMR (75 MHz, CDCl3) 
δ: 180.6, 127.2, 34.0, 33.6, 28.90, 28.86, 28.6, 24.5, 21.8. 19F-NMR (282 MHz, CDCl3) δ: -
66.7 (t, J = 10.6 Hz). HRMS (ESI+): m/z [M+H]+ calcd for C10H18F3O2: 225.10969, found 
225.10992.  
 
2,5-Dioxopyrrolidin-1-yl 10,10,10-trifluorodecanoate (4.4). Compound 4.3 (112.9 mg, 
0.499 mmol, 1 equiv) was added to a 50 mL round-bottom flask. To this was added a solution 
of N-hydroxysuccinimide (NHS; 96 mg, 0.834 mmol, 1.67 equiv) in dry DCM (8 mL) until 
dissolution. The reaction as cooled to 0 oC in an ice bath. To the chilled stirring solution was 
added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC; 114 mg, 0.734 mmol, 1.47 
equiv) and DMAP (6 mg, 0.050 mmol, 0.1 equiv). The solution was stirred at 0 oC for 1 h, 
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after which the ice-bath was removed and the mixture stirred for an additional 20 h as 
monitored by TLC. Following the reaction time, the mixture was diluted with EtOAc (15 mL). 
The organic phase was washed with 0.1 M HCl (aq) (1 x 15 mL), then washed with sat. 
NaHCO3 (1 x 15 mL), and finally washed with brine (1 x 15 mL). The organic phase was dried 
of Na2SO4 and further purified by column chromatography with a mobile phase of 1:1 EtOAc-
hexane, to yield the desired product as a white solid (132.6 mg, 82%). 1H-NMR (300 MHz, 
CDCl3) δ: 2.82 (4H, s), 2.59 (2H, d, J = 7.3 Hz), 2.12-1.95 (2H, m), 1.73 (2H, app. quint, J = 
7.2 Hz), 1.52-1.23 (10 H, m). 13C- NMR (75 MHz, CDCl3) δ: 169.2, 168.6, 127.2, 33.4, 30.8, 
28.74, 28.65, 28.46, 28.41, 25.5, 24.4, 21.7. 19F-NMR (282 MHz, CDCl3) δ: -66.7 (t, J = 10.6 
Hz). HRMS (ESI+): m/z [M+H]+ calcd for C14H21F3NO4: 324.14172, found 324.14168. 
 
10,10,10-Trifluorodecanoyl-daptomycin (4.5). To a 7 mL glass vial was added Boc-Deacyl-
Dap (10 mg, 6.4 µmol, 1 equiv). The vial was equipped with a stir bar, and dry DMF (200 µL) 
was added. To this was added triethylamine (9 µL, 0.065 mmol, 10 equiv) and compound 4.4 
(3.1 mg, 9.6 µmol, 1.5 equiv) and the suspension was stirred for 72 h. The reaction was 
concentrated on a high-vacuum rotary evaporator and redissolved in water followed by 
lyophilization. Then, the crude product was stirred in a solution of TFA (1 mL) containing 
thioanisole (2% v/v) for 25 minutes in an ice-bath. The solution was concentrated in vacuo, 
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and the residue redissolved in dry DMF, with the solvent being removed once more. The oily 
residue was dissolved in water and lyophilized before purification by preparative HPLC using 
a Clipeus C18 10 µm column employing an isocratic gradient of 63% H2O (0.1 % TFA) to 
37% acetonitrile. Fractions containing the desired compound were pooled and concentrated, 
suspended in water and lyophilized to obtain the desired product as a white powder (2.7 mg, 
25%), judged to be >95% pure by RP-HPLC (Figure B.16 in Appendix B). HRMS (ESI+): m/z 
[M+H]+ calcd for C72H98F3N17O26: 1674.68938, found 1674.69360; m/z [M+2H]
2+ calcd for 
C72H100FN17O26: 837.84833, found 837.84793 (Figure C.16 in Appendix C). 
 
Dap-Orn(TFMBenzyl)6 (4.6): Daptomycin (50 mg, 0.031 mmole, 1.0 equiv) was added to 
DMF (1 mL) in a scintered-glass vial equipped with a stirbar. To the stirring suspension was 
added p-trifluoromethylbenzaldehyde (4.10, 10.7 mg, 0.062 mmole, 2.0 equiv) and sodium-
triacetoxyborohydride (STAB-H, 13.1 mg, 0.062 mmole, 2.0 equiv). Glacial acetic acid (1.7 
µL, 0.031 mmole, 1.0 equiv) was added. The reaction was stirred at room temperature for 72 
h, after which the solution was removed in vacuo. The residue was dissolved in water and 
lyophilized before purification by preparative HPLC using a Clipeus C18 10 µm column 
employing an isocratic gradient of 59% H2O (0.1 % TFA) / 41% acetonitrile to 51% H2O (0.1 
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% TFA) / 49% acetonitrile over 40 min. Fractions containing the desired compound were 
pooled and concentrated, suspended in water and lyophilized to obtain the desired product as 
a slightly yellow powder (28.2 mg, 51%), judged to be >95% pure by RP-HPLC (Figure B.17 
in Appendix B). HRMS (ESI+): m/z [M+2H]+ calcd for C80H108F3N17O26: 889.87963, found 
889.87801 (Figure C.17 in Appendix C). 
 
Dap-Orn(TFethyl)6 (4.7). Daptomycin (50 mg, 0.031 mmol, 1 equiv) was suspended in DMF 
(1 mL) in a scintered glass vial equipped with a stir bar. To this was added ethyl 
trifluoroacetalydehyde hemiacetal (9.9 µL, 0.062 mmol, 2 equiv) and STAB-H (13.1 mg, 0.062 
mmole, 2 equiv). Glacial acetic acid (1.7 µL, 0.031 mmol, 1 equiv) was added, the reaction 
allowed to stir at room temperature for 72 h. To increase the completion of the reaction, further 
aliqouts of STAB-H (1 equiv) and ethyl-trifluoroacetaldehyde hemiacetal (1 equiv) were added 
but as determined by analytical HPLC, the reaction ceased after 50% completion. The solvent 
was removed by rotary evaporation, and the peptide was resuspended in H2O and concentrated 
to dryness once more. The crude product was redissolved in H2O, frozen, and lyophilized. The 
crude product was purified by preparative HPLC using a Clipeus C18 10 µm column 
employing a linear gradient of 59 % H2O (0.1 % TFA) / 41% acetonitrile to 52 % H2O (0.1 % 
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TFA) / 48 % acetonitrile over 40 min. Fractions containing the desired compound were pooled 
and concentrated, suspended in water and lyophilized to obtain the desired product as a white 
powder (18.4 mg, 35%), judged to be >95% pure by RP-HPLC (Figure B.18 in Appendix B). 
HRMS (ESI+): m/z [M+2H]2+ calcd for C74H104F3N17O26: 851.86398, found 851.86551 (Figure 
C.18 in Appendix C). 
 
2,5-Dioxopyrrolidin-1-yl 4-(trifluoromethyl)benzoate (4.13). Compound 4.13 was 
synthesized modified from a procedure developed by Rubin et al.171 To a 25-mL round-bottom 
flask was added 4-(trifluoromethyl)benzoic acid (4.12, 200 mg, 1.05 mmol, 1.0 equiv), N-
hydroxysuccinimide (202 mg, 1.76 mmol, 1.67 equiv), and DCM (6 mL). To the vigorously 
stirred solution was added EDC (296 mg, 1.55 mmol, 1.5 equiv) and DMAP (12.8 mg, 0.11 
mmole, 0.1 equiv). The suspension was stirred at room temperature overnight. Following the 
reaction time, the mixture was diluted with EtOAc (15 mL). The organic phase was washed 
with 0.1 M HCl (aq) (1 x 15 mL), then washed with Sat. NaHCO3 (1 x 15 mL), and finally 
washed with brine (1 x 15 mL). The organic phase was dried of Na2SO4 and further purified 
by column chromatography with a mobile phase of 1:1 EtOAc-hexane, to yield the desired 
product as a white solid (280 mg, 93%). 1H-NMR (300 MHz, CDCl3) δ: 8.26 (2H, d, J = 7.8 
Hz), 7.79 (2H, d, J = 8.0 Hz), 2.92 (4H, s). 19F-NMR (282 MHz, CDCl3) δ: -63.7 (s). 
13C-NMR 
(75 MHz, CDCl3) δ: 171.8, 163.8, 139.0, 133.9, 131.4, 128.8, 126.1, 28.5. HRMS (ESI+): m/z 





Dap-Orn(TFMBenzoyl)6 (4.8). Native daptomycin (50 mg, 0.031 mmol, 1 equiv) was added to 
a 7-mL scintillation vial containing dry DMF (1 mL). To this was added compound 4.13 (13.3 
mg, 0.046 mmol, 1.5 equiv), and triethylamine (43 µL, 0.31 mmol, 10 equiv) and the reaction 
mixture was allowed to stir for 48 h at room temperature, after which the reaction progress was 
confirmed complete by HPLC. Following the reaction, the mixture was dissolved in 50 mL of 
Milli-Q water and concentrated. This process was repeated leaving an oily residue, which was 
suspended in water, and subsequently frozen and lyophilized to yield crude 4.8 as a yellow 
powder. The crude product was purified by preparative HPLC using a Clipeus C18 10 µm 
column employing a linear gradient of 60 % H2O (0.1 % TFA) / 40% acetonitrile to 50 % H2O 
(0.1 % TFA) / 50% acetonitrile over 40 min. Fractions containing the desired compound were 
pooled and concentrated, suspended in water and lyophilized to obtain the desired product as 
a white powder (30.5 mg, 55%), judged to be >95% pure by RP-HPLC (Figure B.19 in 
Appendix B). HRMS (ESI+): m/z [M+2H]2+ calcd for C80H106F3N17O27: 896.86296, found 




Dap-Orn(TFacetyl)6 (4.9). Native daptomycin (25 mg, 0.015 mmol, 1 equiv) was added to a 
7-mL scintillation vial equipped with a stir bar, followed by the addition of DMF (1 mL). To 
this was added DIPEA (3.9 µL, 0.039 mmol, 2.5 equiv), and ethyl trifluoroacetate (2.6 µL, 
0.02 mmol, 1.4 equiv). The mixture was stirred for 16 h at room temperature and the reaction 
completion monitored by HPLC. The solvent was removed by rotary evaporation, and the 
peptide was resuspended in H2O and concentrated to dryness once more. The crude product 
was redissolved in H2O, frozen, and lyophilized. The crude product was purified by preparative 
HPLC using a Clipeus C18 10 µm column employing a linear gradient of 60 % H2O (0.1 % 
TFA) / 40% acetonitrile to 52 % H2O (0.1 % TFA) / 48 % acetonitrile over 40 min. Fractions 
containing the desired compound were pooled and concentrated, suspended in water and 
lyophilized to obtain the desired product as a white powder (11.9 mg, 45%), judged to be >95% 
pure by RP-HPLC (Figure B.20 in Appendix B). HRMS (ESI+): m/z [M+2H]2+ calcd for 




(E)-2-Methyl-4-(4-(trifluoromethyl)benzylidene)oxazol-5(4H)-one (4.18). To a round-
bottom flask was added p-trifluoromethylbenzaldehyde (1.5 mL, 3.66 mmol, 1 equiv), acetic 
anhydride (1.72 mL, 18.3 mmol, 5.0 equiv), N-acetylglycine (557 mg, 4.76 mmol, 1.3 equiv), 
and sodium acetate (395 mg, 4.76 mmol, 1.3 equiv). The solution was stirred at reflux under 
argon for 1 h. Following the reaction time, the reaction was quenched with the addition of ice 
(10 g), and the reaction further stirred for 1h. The precipitous product was filtered and the 
obtained as a yellow solid (818 mg, 93%). Characterization data matched literature data.172 1H-
NMR (300 MHz, CDCl3) δ: 8.18 (2H, d, J = 8.2 Hz), 7.68 (2H, d, J = 8.3 Hz), 7.13 (1H, s), 
2.43 (3H, s). 19F-NMR (282 MHz, CDCl3) δ: -63.3 (s).  
 
(E)-2-Acetamido-3-(4-(trifluoromethyl)phenyl)acrylic acid (4.21). Compound 4.18 (800 
mg, 3.13 mmole) was added to reagent grade acetone (20 mL) and water (20 mL) in a round-
bottom flask and heated to reflux for 12 h. Following the reaction, the reaction mixture was 
acidified with 1M HCl, and the product extracted with ethyl acetate (3 x mL). The organic 
phases were dried over sodium sulfate and concentrated, leaving the product as a yellow 
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residue without future purification (821 mg, 96%). Characterization data matched the 
literature.173 1H-NMR (300 MHz, DMSO-d6) δ: 9.53 (1H, s), 7.71 (4H, app. s), 7.17 (1H, s) 
1.95 (3H, s). 19F-NMR (282 MHz, DMSO-d6) δ: -61.4 (s). 
 
2-Acetamido-3-(4-(trifluoromethyl)phenyl)propanoic acid (4.19). Compound 4.21 (750 
mg, 2.75 mmole, 1 equiv) was dissolved in methanol, and 10% Pd/C (90 mg, 0.08 mmole, 0.03 
equiv) was added. The reaction vessel was purged with hydrogen gas and equipped with a 
hydrogen balloon, and the reaction stirred overnight. The reaction was filtered over celite and 
solvents removed in vacuo to yield target product 4.19 as a yellow solid (726 mg, 96%). 
Characterization data matched the literature.153 1H-NMR (300 MHz, DMSO-d6) δ: 8.19 (1H, 
d, J = 8.2 Hz), 7.62 (2H, d, J = 8.2 Hz), 7.42 (2H, d, J = 8.1 Hz), 4.42 (1H, m), 3.11 (1H, dd, 
J = 13.6 Hz, J = 4.7 Hz), 2.91 (2H, dd, J = 13.2 Hz, J = 9.5 Hz), 1.75 (3H, s). 19F-NMR (282 
MHz, DMSO-d6) δ: -61.0 (s). 
 
(S)-2-Amino-3-(4-(trifluoromethyl)phenyl)propanoic acid (4.20). To Compound 4.19 (700 
mg, 2.54 mmole, 1 equiv) in water (20 mL) was added Acylase 1 from Aspergillus niger (1 
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mg). The reaction mixture was brought to 42 oC and adjusted to pH 7.5 with NaHCO3 (aq). 
Over the course of two weeks, the pH was manually readjusted to 7.5 with NaHCO3 (aq), and 
fresh enzyme continually added. After 2 weeks, the reaction appeared 50% complete by 
analytical RP-HPLC. The mixture was made acidic through the addition of 1 M HCl, and the 
solution washed with ethyl acetate to remove the unreacted D-enantiomer starting material. 
The aqueous phase was neutralized with NaHCO3, and the aqueous phase concentrated by 
high-vacuum rotary evaporation. The residue was resuspended in 9:1 H2O/MeCN and purified 
by RP-HPLC employing a linear gradient of 90 % H2O (0.1 % TFA) / 10% acetonitrile to 10 
% H2O (0.1 % TFA) / 90 % acetonitrile over 50 min. The desired amino acid was obtained as 
a white powder (41.4 mg, 7%). Characterization data matched the literature.155  1H-NMR (300 
MHz, D2O) δ: 7.62 (2H, d, J = 8.1 Hz), 7.38 (2H, d, J = 8.0 Hz), 4.23 (1H, app. t, J = 6.7 Hz), 
3.31 (1H, dd, J = 14.6 Hz, J = 5.9 Hz), 3.19 (1H, dd, J = 14.6 Hz, J = 7.5 Hz).  
 
Benzyl (2R,3S)-6-oxo-2,3-diphenylmorpholine-4-carboxylate (4.24). Williams’ lactone was 
synthesized according to a modified procedure from Dastlik et al.159 Dry THF (22 mL) was 
added to (1R,2S)-2-amino-1,2-diphenylethanol (2.12 g, 10 mmol, 1 equiv) and stirred to form 
a suspension under argon. To this was added NEt3 (2.2 mL, 15.5 mmol, 1.55 equiv), followed 
by the dropwise addition of ethyl bromooacetate (1.65 mL, 15.5 mmol, 1.55 equiv) over 1 h. 
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After the addition of ethyl chloroacetate, the mixture was stirred for an additional hour at room 
temperature, before being cooled to 0 oC and filtered. The precipitate was rinsed with chilled 
THF and the filtrates were evaporated to dryness to yield a white solid. This was diluted with 
DCM (25 mL) and saturated NaHCO3 (25 mL) and cooled on ice. Benzyl chloroformate (1.66 
mL, 11 mmol, 1.1 equiv) was added to the vigorously stirred solution over 1 h, after which the 
mixture stirred for an additional 1 h. The two layers were separated by liquid-liquid extraction, 
and the aqueous layer was extracted with DCM. Combined organic layers were dried with 
sodium sulfate and evaporated to dryness. The residue was dissolved in toluene (22 mL) and 
p-TsOH·H2O (190 mg, 1.0 mmol, 0.1 equiv) was added. The solution was concentrated to 
approximately half the initial volume and then cooled to room temperature. The crystals were 
collected by suction filtration and rinsed with toluene and hexane. Then, the product was 
further purified by flash chromatography with 20% EtOAc in hexane, affording Compound 
4.24 as a white solid (2.97 g, 76%). 1H-NMR (500 MHz, DMSO-d6, 120 
oC) δ: 7.35-7.10 (13H, 
m), 6.74 (1H, s), 6.72 (1H, s), 6.23 (1H, s), 5.33 (1H, s), 5.12 (1H, d, J = 7.6 Hz), 5.07 (1H, d, 
J = 7.6 Hz), 4.66 (1H, d, J = 10.7 Hz), 4.60 (1H, d, J = 10.6 Hz). 13C-NMR (123.3 MHz, 
DMSO-d6, 120 
oC) δ: 166.4, 153.1, 135.7, 135.5, 134.1, 127.52, 127.46, 127.3, 127.0, 126.8, 





carboxylate (4.26). Compound 4.24 (1.03 g, 2.66 mmole, 1 equiv) was dissolved in anhydrous 
THF (50 mL) and cooled to -78 oC in an acetone-dry ice bath under argon. To the stirring 
solution was added dropwise a solution of NaHMDS in THF (1 M, 2.66 mL, 2.66 mmole 1 
equiv) dropwise and the reaction allowed to stir at -78 oC for 30 minutes. Then, p-
trifluoromethylbenzyl bromide (4.25, 700 mg, 2.93 mmole, 1.1 equiv) as a solution in 
anhydrous THF (20 mL) was added dropwise, and the stirring suspension allowed to warm 
slowly to room temperature, followed by additional overnight stirring. Ethyl acetate (20 mL) 
was added followed by sat. NaHCO3 (aq) (30 mL) to quench the reaction. The mixture was 
transferred to a separatory funnel and the layers separated. The aqueous phase was washed 
with ethyl acetate (3 x 50 mL), and the organic phase was dried over sodium sulfate and 
concentrated. The residue was then purified by column chromatography with 9:1 
hexane/EtOAc. Purified fractions were pooled and concentrated yielding compound 4.26 as a 
white solid (785 mg, 54%). 1H-NMR (500 MHz, DMSO-d6, 120 
oC) δ: 7.67 (2H, d, J = 7.6 
Hz), 7.53 (2H, d), 7.30-7.15 (7H, m), 7.10 (2H, t, J = 7.6 Hz), 6.98 (2H, d, J = 7.1 Hz), 6.61 
(2H, d, J = 7.5 Hz), 5.88 (1H, s), 5.29 (1H, d, J = 3.1 Hz), 5.16 (1H, dd, J = 8.6, 4.6 Hz), 5.03 
(2H, s), 3.61 (1H, dd, J = 13.8, 8.7 Hz), 3.53 (1H, dd, J = 13.9, 4.5 Hz). 13C-NMR (125.8 MHz, 
DMSO-d6, 120 
oC) δ: 166.7, 140.7, 135.4, 133.9, 129.6, 127.5, 127.1, 126.9, 126.8, 126.7, 
125.7, 124.5, 77.6, 66.5, 59.5, 57.9. 19F-NMR (470.6 MHz, DMSO-d6, 120 
oC) δ: -61.4. HRMS 






(trifluoromethyl)phenyl)propanoic acid (4.16). Compound 4.26 (751 mg, 1.37 mmole, 1 
equiv) was dissolved in ethanol and PdCl2 (7.3 mg, 0.041 mmole, 0.03 equiv) was added. The 
reaction vessel was purged with hydrogen gas, and equipped with a hydrogen balloon, followed 
by overnight stirring. The following day, the mixture was filtered over celite and the solvents 
removed to obtain a residue which was immediately resuspended in 1,4-dioxane (30 mL) and 
sat. NaHCO3 (aq) (30 mL). To this mixture was added Fmoc-OSu (462 mg, 1.37 mmole, 1 
equiv) and the mixture allowed to stir at room temperature overnight. The mixture was 
acidified with 1 M HCl (aq) to pH 1 and the desired product extracted to ethyl acetate (3 x 25 
mL). The organic phase was dried over Na2SO4 and the solvent removed by rotary evaporation. 
The residue was then subjected to column chromatography with 9:1 hexane/EtOAc + 0.5% 
acetic acid. The purified compound was then dissolved in toluene to azeotropically remove 
trace acetic acid, yielding the desired compound as a white solid (420 mg, 67%). The ee of 
4.16 was determined to be 97%, as described in section 4.4.2. Characterization data agreed 
with the literature.152 1H-NMR (300 MHz, MeOD-d3) δ: 7.75 (2H, d, J = 7.4 Hz), 7.58-7.49 
(4H, m), 7.41-7.32 (4H, m), 7.25 (2H, t, J = 6.33 Hz), 4.45-4.10 (4H, m), 3.29 (1H, m), 3.05-
2.95 (1H, m). 13C-NMR (75 MHz, MeOD-d3) δ: 159.8, 146.6, 145.0, 44.0, 132.5, 131.4, 130.2, 
129.6, 127.7, 122.4, 69.4, 49.7, 39.7. 19F-NMR (282 MHz, MeOD-d3) δ: -64.1. HRMS (ESI+): 




Dap-TFMPhe1-Lys6-Glu12-Trp13 (4.15). 2-ClTrt-Cl-PG resin (theoretical substitution = 1.5 
mmol/g, 66.7 mg, 0.1 mmol, 1 equiv) was activated in dry DCM with thionyl chloride (26 µL, 
3.6 equiv) and pyridine (58 µL, 7.2 equiv) under reflux for 2 h. The resin was transferred to a 
disposable peptide cartridge and rinsed 6 x with dry DCM, followed by loading with 
FmocAsp(OH)GlyOallyl (3.8, 4 equiv) and DIPEA (8 equiv) in dry DCM. The resin was 
capped with 17:2:1 DCM/MeOH/DIPEA (3 x 10 min) and the loading efficiency determined 
to be 1.21 mmol/g. Removal of the Fmoc groups were performed with 20% 4-MP in DMF 
(v/v, 1 x 5 min, 1 x 20 min) before the formation of the depsi bond, and 20% 2-MP in DMF 
(v/v, 3 x 10 min) after the formation of the depsi bond). All Fmoc-amino acids including 4.16 
(4 equiv) and the lipid tail (4 equiv) were activated for 5 min using HOBt (4 equiv) and DIC 
(4 equiv) in DMF (2 mL) and then coupled for 4 h. Following installation of the decanoyl tail, 
the depsi-bond formation was achieved FmocTrp(Boc)OH (10 equiv) with DIC (10 equiv) and 
DMAP (0.1 equiv). Residues 12 and 11 were introduced using standard coupling procedures. 
Deprotection of the allyl group was achieved with Pd(PPh3)4 (0.2 equiv) and DMBA (10 equiv) 
in 3:1 DCM/DMF for 1 h. On-resin cyclization was afforded by treating the peptide to PyAOP 
(5 equiv), HOAt (5 equiv) and 2,4,6-collidine (10 equiv), and the peptide was cleaved with 
95:2.5:2.5 TFA/TIPS/H2O. The deprotection cocktail was removed under an N2 stream, and 
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the peptide resuspended in 4:1 H2O/MeCN (v/v). The crude product was purified by 
preparative HPLC using a Clipeus C18 10 µm column employing a linear gradient of 58 % 
H2O (0.1 % TFA) / 42% acetonitrile to 51 % H2O (0.1 % TFA) / 49 % acetonitrile over 40 
minutes. Fractions containing the desired compound were pooled and concentrated, suspended 
in water and lyophilized to obtain the desired product as a white powder (15 mg, 10% based 
on resin loading), judged to be >95% pure by RP-HPLC (Figure B.21 in Appendix B). HRMS 
(ESI+): m/z [M+2H]2+ calcd for C72H99F3N16O25: 823.35324, found 823.35421 (Figure C.21 in 
Appendix C). 
 
Methyl N-(tert-butoxycarbonyl)-O-(trifluoromethyl)-D-serinate (4.33). Compound 4.33 
was obtained according to the procedure by Liu et al., performed in a N2 box at room 
temperature.160 To a round-bottomed flask containing anhydrous ethyl acetate (10 mL) 
equipped with a stirbar was added Boc-D-SerOMe (0.439 g, 2.0 mmole, 1 equiv), AgOTf (1.54 
g, 6.0 mole, 3 equiv), SelectfluorTM (1.06 g, 3.0 mmole, 1.5 equiv), KF (0.465 g, 8.0 mmole, 4 
equiv), 2-fluoropyridine (0.516 mL, 6.0 mmole, 3.0 equiv), and trifluoromethyl trimethylsilane 
(0.886 mL, 6.0 mmole, 3.0 equiv). The reaction was stirred overnight at room temperature, 
after which the vessel was removed from the N2 box. The reaction was filtered through a plug 
of silica, eluted with ethyl acetate, and concentrated, and the product purified by column 
chromatography with (9:1 hexane/EtOAc, yielding the desired product as a clear oil (201 mg, 
35% yield). 1H-NMR (300 MHz, CDCl3) δ: 5.34 (1H, d, J = 7.2 Hz), 4.55 (1H, app. d, J = 7.8 




tert-Butyl N,N'-diisopropylcarbamimidate (4.58). To a flame-dried purged flask equipped 
with a stir-bar was added tert-butanol (4.9 mL, 51.6 mmol, 1.3 equiv) and N,N’-
diisopropylcarbodiimide (6.13 mL, 39.6 mmol, 1.0 equiv). To this was added copper (I) 
chloride (75 mg, 0.76 mmol, 0.02 equiv) and the reaction vessel was sealed. The reaction was 
stirred at room temperature for 20 h, after which the reaction progress was monitored by 1H-
NMR to reveal no remaining diisopropylcarbodiimide. The vessel was concentrated in vacuo 
to remove any remaining tert-butanol and subsequently distilled over reduced pressure to 
obtain the purified product as a clear oil (5.28 g, 66.5%, mixture of E/Z isomers). Compound 
4.58 was stored in a freezer until use. 1H-NMR (300 MHz, CDCl3) δ: 3.73-3.59 (1H, m), 3.24-
3.08 (1H, m), 1.48-1.34 (9H, m), 1.10-1.01 (12H, m).  
 
tert-Butyl (tert-butoxycarbonyl)-D-serinate (4.32). To a solution of Boc-D-serine (1.25 g, 
6.1 mmole, 1 equiv) in THF (20 mL) was added compound 4.58 (1.83 g, 9.1 mmole, 1.5 equiv).  
The mixture was refluxed for 2.5 h after which a second addition of compound 4.58 occurred 
(1.83 g, 9.1 mmole, 1.5 equiv). The reaction was stirred at reflux overnight. The mixture was 
cooled to room temperature, filtered to remove the diisopropylurea by-product, and 
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concentrated in vacuo. The crude product was then purified by flash chromatography 
employing a gradient of 1:1 hexane/ethyl acetate, yielding the desired compound 4.32 as a 
clear oil (1.02 g, 51%). Characterization data matched with the literature.174 1H-NMR (300 
MHz, CDCl3) δ: 5.40 (1H, br. s), 4.23 (1H, br. s), 3.88 (2H, br. s), 2.35 (1H, br. s), 1.47 (9H, 
s), 1.44 (9H, s). 13C-NMR (75 MHz, CDCl3): δ: 169.9, 155., 82.3, 79.9,77.5, 77.1, 76.6, 63.7, 
56.3, 28.3, 27.9. HRMS (ESI+): m/z [M+H]+ calcd for C12H24NO5: 262.16490, found 
262.16492. 
 
tert-Butyl N-(tert-butoxycarbonyl)-O-(trifluoromethyl)-D-serinate (4.34). Compound 4.34 
was obtained according to the procedure by Liu et al., performed in a N2 box at room 
temperature.160 To a round-bottomed flask containing anhydrous ethyl acetate (30 mL) 
equipped with a stirbar was added 4.32 (2.26 g, 8.7 mmole, 1 equiv), AgOTf (6.67 g, 26.0 
mole, 3 equiv), SelectfluorTM (4.60 g, 13.0 mmole, 1.5 equiv), KF (2.01 g, 34.6 mmole, 4 
equiv), 2-fluoropyridine (2.24 mL, 26.0 mmole, 3.0 equiv), and trifluoromethyl trimethylsilane 
(3.84 mL, 26.0 mmole, 3.0 equiv). The reaction was stirred overnight at room temperature, 
after which the vessel was removed from the N2 box. The reaction was filtered through a plug 
of silica, eluted with ethyl acetate, and concentrated, and the product purified by column 
chromatography with (9:1 hexane/EtOAc, yielding the desired product as a clear oil (1.45 g, 
51% yield). 1H-NMR (300 MHz, CDCl3) δ: 5.33 (1H, br. s), 4.39 (1H, m), 4.32 (1H, d, J = 9.5 
Hz), 4.19 (1H, d, J = 9.2 Hz), 1.45 (9H, s), 1.43 (9H, s). 13C-NMR (75 MHz, CDCl3): δ: 167.5, 
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155.1, 121.4, 83.3, 80.3, 67.5, 53.2, 28.2, 27.8. 19F-NMR (282 MHz, CDCl3) δ: -61.5 (s).  
HRMS (ESI+): m/z [M+H]+ calcd for C13H23F3NO5; 330.15228, found 330.15231. 
 
N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-O-(trifluoromethyl)-D-serine (4.36). 
Compound 4.34 (600 mg, 1.8 mmole, 1 equiv) was suspended in TFA (30 mL) and stirred for 
4 h at room temperature. The reaction completion was monitored by 1H-NMR spectroscopy, 
and following the reaction, the solvent was removed by rotary evaporation. The residue was 
resuspended in 1,4-dioxane (20 mL) and sat. NaHCO3 (aq) (20 mL), followed by the addition 
of Fmoc-OSu (614 mg, 1.8 mmole, 1 equiv). The reaction was stirred at room temperature 
overnight after which the reaction mixture was acidified to pH = 1 with 1 M HCl. The reaction 
mixture was extracted with ethyl acetate (3 x 30 mL), and the organic layer was dried over 
Na2SO4 and concentrated. The residue was then purified by column chromatography 
employing a slow gradient of DCM to 5% MeOH in DCM, yielding the desired product as a 
white solid (453 mg, 63% over two steps). 1H-NMR (300 MHz, MeOD-d3) δ: 7.70 (2H, d, J = 
7.4 Hz), 7.60 (2H, d, J = 7.1 Hz), 7.32 (2H, t, J = 7.3 Hz), 7.24 (2H, t, J = 7.4 Hz), 4.57 (1H, 
t, J = 4.1 Hz), 4.45-4.25 (4H, m), 4.14 (1H, t, J = 7.0 Hz). 13C-NMR (75 MHz, MeOD-d3): 
δ:170.2, 157.0, 143.8, 141.1, 127.4, 126.8, 124.9, 121.6, 119.5, 66.9, 53.1, 48.5, 46.9. 19F-
NMR (282 MHz, MeOD-d3) δ: -62.5 (s). HRMS (ESI+): m/z [M+H]
+ calcd for C19H17F3NO5; 




Dap-Lys6-D-Ser(CF3)11-Glu12-Trp13 (4.38). Peptide 4.38 was synthesized in the same 
manner as 4.15, except that FmocTrp(Boc)OH was used instead of amino acid 4.16, and Fmoc-
D-Ser(CF3)OH was used instead of Fmoc-D-SerOH. The crude product was purified by 
preparative HPLC using a Clipeus C18 10 µm column employing a linear gradient of 60 % 
H2O (0.1 % TFA) / 40% acetonitrile to 56 % H2O (0.1 % TFA) / 44 % acetonitrile over 40 
min. Fractions containing the desired compound were pooled and concentrated, suspended in 
water and lyophilized to obtain the desired product as a white powder (5.7 mg, 4% based on 
resin loading), judged to be >95% pure by RP-HPLC (Figure B.22 in Appendix B). HRMS 
(ESI+): m/z [M+2H]2+ calcd for C74H102F3N17O25: 842.85869, found 842.86197 (Figure C.22 






(±)-N-(2-Oxotetrahydrothiophen-3-yl)acetamide (4.46). To reagent-grade acetone (50 mL) 
was added DL-homocysteine thiolactone hydrochloride (1.0 g, 6.51 mmol, 1.0 equiv), 
NaHCO3 (1.15 g, 13.7 mmol, 2.1 equiv), and acetic anhydride (1.23 mL, 13.0 mmol, 2.0 
equiv). The suspension was brought to reflux for 3 h, after which the reaction was filtered, and 
the filtrate concentrated by rotary evaporation. Trace acetic acid by-product was removed 
azeotropically with toluene. Trace toluene was removed azeotropically with methanol, and 
trace methanol was removed azeotropically with chloroform, yielding the desired product 4.46 
as a white solid (1.34 g, 73%). Characterization data matched the literature.175 1H-NMR (300 
MHz, CDCl3) δ: 6.77 (1H, br. s), 4.53 (1H, m), 3.29-3.14 (2H, m), 2.73-2.66 (1H, m), 2.00-
1.85 (4H, m). 13C- NMR (75 MHz, CDCl3) δ: 208.8, 174.2, 62.1, 34.2, 30.3, 25.7, 25.0, 24.0.  
 
(±)-N-Acetyltrifluoromethionine methyl ester (4.48). Sodium metal (1.80 g, 78.3 mmol, 2.5 
equiv) was added portion-wise to dried methanol (155 mL) in a 250 mL round bottom flask 
over ice and stirred until dissolution occurred. To this was added compound 4.46 (5.0 g, 31.4 
mmol, 1 equiv) and the reaction was stirred at 0 oC for 40 minutes. The mixture was equipped 
with a dry-ice condenser and CF3I (g) (18.5 g, 94.4 mmol, 3 equiv) was added. The mixture 
was then irradiated by UV light (350 nm) for 1 h. Following this reaction time, another 
installment of CF3I (g) (6.2 g, 31.5 mmol, 1 equiv) was added, and the reaction further 
subjected to UV light for an additional 1 h. The solvent was removed in vacuo and redissolved 
in DCM (200 mL) and subsequently washed with sat. NaHCO3 (1 x 100 mL) and brine (1 x 
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100 mL). The organic layer was dried over Na2SO4 and concentrated. The residue was further 
purified by chromatography in silica gel using 3:1 EtOAC/hexane as the mobile phase. 
Purification using this method afforded the desired compound 4.48  (5.86 g, 72%) as a clear 
oil. Characterization data matched with the literature.176 1H-NMR (300 MHz, CDCl3) δ: 6.12 
(1H, br. s), 4.72 (1H, dt, J = 7.7, 5.0 Hz), 3.77 (3H, s), 2.92-2.86 (2H, m), 2.32-2.23 (1H, m), 
2.08-1.99 (4H, m). 13C- NMR (75 MHz, CDCl3) δ: 172.0, 170.6, 130.8, 52.6, 51.1, 32.7, 26.0, 
22.8. 19F-NMR (282 MHz, CDCl3) δ: -41.6.  
 
N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-S-(trifluoromethyl)-D-homocysteine (4.52). 
Compound 4.48 (1.99 g, 7.68 mmole, 1 equiv) was suspended in water (20 mL) in a 50 mL 
round-bottom flask equipped with a stir bar. To this was added NaOH(s) (338 mg, 8.44 mmole, 
1.1 equiv), and the reaction was stirred for 1 h at room temperature to hydrolyze the methyl 
ester and the reaction monitored by TLC. At the completion of hydrolysis, the solution was 
then adjusted to pH 7.5 with HCl (aq) and heated to 30 oC followed by the addition of D-
aminoacylase (50 mg). The reaction was gently stirred at 30 oC for 24 h. After the reaction 
time, the solution was made basic by the addition of NaHCO3(s) (1.5 g), and an equal volume 
of MeCN was added. To the stirring suspension was added Fmoc-OSu (1.29 g, 3.84 mmole, 
0.5 equiv), and the reaction stirred vigorously overnight. The mixture was made acidic (pH = 
1) through the addition of 1 M HCl (aq), and the product extracted to ethyl acetate (3 x 50 mL). 
The organic layer was dried over Na2SO4 and concentrated. The residue was then purified by 
column chromatography, with a mobile phase of 9:1 hexane/EtOAc + 0.5% acetic acid, 
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yielding compound 4.52 as a slightly yellow solid (986 mg, 30% yield, 60% yield of desired 
enantiomer). The ee of 4.52 was determined to be 94.2%, described in Section 4.4.2. 
Characterization data closely matched that for the enantiomeric compound.161 1H-NMR (300 
MHz, MeOD-d3) δ: 7.68(2H, d, J = 7.4 Hz), 7.58 (2H, app. t, J = 6.2 Hz), 7.30 (2H, t, J = 7.3 
Hz), 7.23 (2H, t, J = 7.3 Hz), 4.31 (2H, d, J = 7.0 Hz), 4.10 (1H, t, J = 6.8 Hz), 3.05-2.85 (2H, 
m), 2.30-1.95 (2H, m). 13C-NMR (75 MHz, MeOD-d3): δ: 176.2, 160.1, 146.8/146.5, 144.1, 
134.2, 130.3, 129.6, 127.7, 122.4, 69.4, 55.4, 49.9, 34.6. 19F-NMR (282 MHz, MeOD-d3) δ: -
43.0 (s). HRMS (ESI+): m/z [M+H]+ calcd for C20H19F3NO4S; 426.09814, found 426.09879. 
 
Dap-Lys6-D-hCys(CF3)8-Glu12-Trp13 (4.55). Peptide 4.55 was synthesized in the same 
manner as (4.16), except that FmocTrp(Boc)OH was used instead of amino acid 4.16, and 
Fmoc-D-hCys(CF3)OH was used instead of Fmoc-D-AlaOH. The crude product was purified 
by preparative HPLC using a Clipeus C18 10 µm column employing an isocratic gradient of 
57 % H2O (0.1 % TFA) / 43% acetonitrile over 40 min. Fractions containing the desired 
compound were pooled and concentrated, suspended in water and lyophilized to obtain the 
desired product as a white powder (2.9 mg, 2% based on resin loading), judged to be >95% 
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pure by RP-HPLC (Figure B.23 in Appendix B). HRMS (ESI+): m/z [M+2H]2+ calcd for 
C75H104F3N17O25S: 865.85355, found 865.85547 (Figure C.23 in Appendix C). 
 
Dap-Lys6-D-hCys(CF3)11-Glu12-Trp13 (4.56). Peptide 4.56 was synthesized in the same 
manner as (4.16), except that FmocTrp(Boc)OH was used instead of amino acid 4.16, and 
Fmoc-D-hCys(CF3)OH was used instead of Fmoc-D-SerOH. The crude product was purified 
by preparative HPLC using a Clipeus C18 10 µm column employing an isocratic gradient of 
56 % H2O (0.1 % TFA) / 44% acetonitrile over 40 min. Fractions containing the desired 
compound were pooled and concentrated, suspended in water and lyophilized to obtain the 
desired product as a white powder (16 mg, 11% based on resin loading), judged to be >95% 
pure by RP-HPLC (Figure B.24 in Appendix B). HRMS (ESI+): m/z [M+2H]2+ calcd for 





Dap-TFDec0-Lys6-Glu12-Trp13 (4.57). Peptide 4.57 was synthesized in the same manner as 
4.15, except that FmocTrp(Boc)OH was used instead of amino acid 4.16, and 10,10,10-
decanoic acid (4.3) was used instead of decanoic acid. The crude product was purified by 
preparative HPLC using a Clipeus C18 10 µm column employing an isocratic gradient of 61 
% H2O (0.1 % TFA) / 39% acetonitrile over 40 min. Fractions containing the desired 
compound were pooled and concentrated, suspended in water and lyophilized to obtain the 
desired product as a white powder (16 mg, 11% based on resin loading), judged to be >95% 
pure by RP-HPLC (Figure B.25 in Appendix B). HRMS (ESI+): m/z [M+2H]2+ calcd for 
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Appendix A: NMR Characterization Data for A54145D 
 
 
Figure A.1: 1H-NMR spectrum of A54145D-nucleus (600 MHz, D2O). 
 
 




















Figure A.6: 1H-ROESY spectrum of A54145D-nucleus (600 MHz, D2O).  
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Table A.1: HSQC/HMBC peak correlations for A54145D-nucleus 























CαH 4.35 55.4 
eMeOAsp9 
CαH 4.05 55.7 
CβH2 3.25, 3.43 28.6 CβH 4.86 72.6 
C2H 7.10 127.2 O-CH3 3.38 59.9 
C3 --- 107.9 Gly10 CαH2 3.90 44.1 
C3a --- 128.5 
D-Asn11 
CαH 4.76 52.8 
C4H 7.50 [7.58]a 119.9 CβH2 2.80, 2.86 41.1 
C5H 7.18 121.5 
Glu12 
CαH 4.61 54.1 
C6H 7.28 124.2 CβH2 2.01, 2.20 28.9 
C7H 7.53 114.1 CγH2 2.53 [2.48]a 32.1 [32.3]a 
C7a --- 138.0 
Ile13 
CαH 3.95 59.4 
D-Glu2 
CαH 4.13 56.0 CβH 1.67 [1.86]a 37.8 
CβH2 1.89 27.1 CγH2 1.10 [1.23]a 27.5 [26.7]a 
CγH2 2.09 31.5 CδH3 0.80 [0.86] a 12.9 [12.23]a 
tHOAsn3 
CαH 4.95 58.0 CγH3 0.80 [0.86] a 16.2 [15.32]a 
CβH 4.79 72.5     
Thr4 
CαH 5.30 [5.26]a 54.8     
CβH 5.50 [5.40]a 72.1 [73.4]a     
CγH3 1.24 [1.33]a 18.30     
Sar5 
Nα-CH3 3.17 38.6     
CαH2 3.80, 4.28 53.8     
Ala6 
CαH 4.40 51.3     
CβH3 1.43 18.5     
Asp7 
CαH 4.70 52.8     
CβH2 2.90 [2.95]a 37.4     
D-Lys8 
CαH 4.53 [4.48]a 55.3 [54.8]a     
CβH2 1.78, 1.86 32.6     
CγH2 1.43 23.7     
CδH2 1.70 28.0     









Figure A.7: 1H-NMR spectrum of A54145D-tHOAsn3-eMeOAsp9 (600 MHz, d6-DMSO). 
 
 

































































(600 MHz, DMSO) 
 
A54145D-tHOAsn3-eMeOAsp9  
(600 MHz, DMSO) 
  1H 13C   1H 13C 
Trp1 
Nα-H 7.83 ---  Nα-H 7.84 --- 
CαH 4.54 54.27  CαH 4.56 54.25 
CβH2 3.09, 2.92 28.38  CβH2 3.07, 2.92 28.45 
N1H 10.68 ---  N1H 10.69 --- 
C2H 7.08 124.16  C2H 7.08 124.07 
C3 --- 110.70  C3 --- 110.76 
C3a --- 127.93  C3a --- 127.86 
C4H 7.56 118.83  C4H 7.56 118.81 
C5H 6.94 118.49  C5H 6.94 118.54 
C6H 7.01 121.27  C6H 7.02 121.30 
C7H 7.28 111.73  C7H 7.28 111.80 
C7a --- 136.62  C7a --- 136.67 
D-Glu2 
Nα-H 8.09 ---  Nα-H 8.11 --- 
CαH 4.28 52.95  CαH 4.27 52.82 
CβH2 1.67, 1.85 27.76  CβH2 1.66, 1.84 27.70 
CγH2 2.08 30.29  CγH2 2.05 30.29 
COOH 12.1   COOH 12.1  
HOAsn3 
Nα-H 7.79 ---  Nα-H 7.76 --- 
CαH 4.66 56.12  CαH 4.67 54.88 
CβH 4.33 71.52  CβH 4.33 71.52 
OH 5.31 ---  OH 5.33 --- 
CONH2 5.81 [5.87]a ---  CONH2 5.79 [5.90]a --- 
Thr4 
Nα-H 7.73 [7.60]a ---  Nα-H 7.79 [7.58]a --- 
CαH 5.13 [4.91]a 49.92  CαH 5.11 [4.92]a 50.91 
CβH 5.13 [5.03]a 70.40  CβH 5.14 [5.03]a 70.51 
CγH3 1.19 [1.14]a 15.35  CγH3 1.18 [1.13]a 15.77 
Sar5 
Nα-CH3 3.07 [2.83]a 
37.16 
[35.49]a 











Nα-H 8.06 ---  Nα-H 8.10 --- 
CαH 4.30 49.43  CαH 4.23 49.56 
CβH3 1.25 18.19  CβH3 1.26 18.90 
Asp7 
Nα-H 7.82 ---  Nα-H 7.80 --- 
CαH 4.61 49.91  CαH 4.58 50.28 
CβH2 2.37, 2.55b 38.39  CβH2 2.43b, 2.55b 38.07 
COOH 12.1   COOH 12.1  
D-Lys8 
Nα-H 7.72 ---  Nα-H 7.85 --- 
CαH 4.31 53.93  CαH 4.27 52.82 
CβH2 1.51, 1.67 31.00  CβH2 1.52, 1.66 31.25 
CγH2 1.25 21.89  CγH2 1.25 22.53 
CδH2 1.46 27.33  CδH2 1.47 27.18 
CεH2 2.71, 2.76 38.95  CεH2 2.74 39.23 









(600 MHz, DMSO) 
 
A54145D-tHOAsn3-eMeOAsp9  
(600 MHz, DMSO) 




Nα-H 7.83 ---  Nα-H 7.78 --- 
CαH 4.66 56.12  CαH 4.67 55.83 
CβH 4.33 71.52  CβH 4.33 71.33 
O-CH3 3.26c 58.20  O-CH3 3.29c 58.73 
COOH 12.1 ---  COOH 12.1 --- 
Gly10 




42.85  CαH2 3.70, 3.80 42.87 
D-Asn11 
Nα-H 7.81 ---  Nα-H 7.80 --- 
CαH 4.58 49.35  CαH 4.56 50.49 
CβH2 2.30, 2.50b 36.85  CβH2 2.50b, 2.42 36.51 
CONH2 6.81, 7.24 ---  CONH2 6.80, 7.24 --- 
Glu12 
Nα-H 8.00 ---  Nα-H 7.99 --- 
CαH 4.47 51.84  CαH 4.35 52.25 
CβH2 1.84, 1.74 28.00  CβH2 1.89, 1.73 27.85 
CγH2 2.14 30.33  CγH2 2.19 30.51 
COOH 12.1 ---  COOH 12.1 --- 
Ile13 
Nα-H 8.07 ---  Nα-H 7.89 --- 
CαH 4.22 [4.11]a 57.33  CαH 4.14 57.62 
CβH 1.74 36.44  CβH 1.75 36.36 
CγH2 1.36, 1.06 29.33  CγH2 1.37, 1.11 29.33 
CδH3 0.80 12.77  CδH3 0.80 12.89 
CγH3 0.83 15.88  CγH3 0.83 15.77 
MeDec0 
C2H2 2.06 35.65  C2H2 2.05 35.70 
C3H2 1.36 25.44  C3H2 1.37 25.40 
C4H2 1.10 25.39  C4H2 1.11 25.18 
C5H2 1.14 27.01  C5H2 1.13 27.00 
C6H2 1.14 27.01  C6H2 1.13 27.00 
C7H2 1.01, 1.19 36.37  C7H2 1.01, 1.17 36.40 
C8H 1.26 34.18  C8H 1.25 34.18 
C8’H3 0.80 19.64  C8’H3 0.80 19.67 
C9H2 1.08, 1.13 29.19  C9H2 1.13, 1.08 29.10 
C10H3 0.80 11.81  C10H3 0.80 11.78 
Note: bolded peaks overlap with one or more other peaks. 
a square brackets denote the minor conformer’s chemical shift. 
b Partial overlap with DMSO-d6 solvent residual peak. 






Figure A.19: 1H-NMR spectrum of peptide 3.32 (500 MHz, DMSO-d6). 
 
 





Figure A.21: 1H-COSY spectrum of peptide 3.32 (500 MHz, DMSO-d6). 
 
 














Figure A.25: 1H-13C HSQC spectrum of peptide 3.33 (500 MHz, DMSO-d6). 
 
 





Figure A.27: 1H-TOCSY spectrum of peptide 3.33 (500 MHz, DMSO-d6). 
 
 












(500 MHz, DMSO) 
  1H 13C   1H 13C 
Trp1 
Nα-H 7.98 ---  Nα-H 7.86 --- 
CαH 4.45 55.0  CαH 4.54 50.2 
CβH2 2.99, 3.11 27.9  CβH2 3.11, 2.96 28.2 
N1H 10.71 ---  N1H 10.70 --- 
C2H 7.20 124.5  C2H 7.09 123.9 
C4H 7.56 118.8  C4H 7.55 119.0 
C5H 6.95 118.7  C5H 6.95 118.5 
C6H 7.03 121.4  C6H 7.02 121.5 
C7H 7.31 111.8  C7H 7.29 111.7 
D-Glu2 
Nα-H 8.45 ---  Nα-H 8.10 --- 
CαH 4.03 53.3  CαH 4.12 [4.05] 53.2 
CβH2 1.84, 1.65 26.6  CβH2 1.83, 1.66 27.9 
CγH2 2.00 30.4  CγH2 2.04 30.3 
COOH 12.1 ---  COOH 12.1 --- 
Asn3 
Nα-H 8.12 ---  Nα-H 8.10 --- 
CαH 4.42 50.8  CαH 4.55 50.1 
CβH 2.66, 2.43 a 36.9  CβH2 2.65-2.45 36.6/37.7 




Nα-H 7.19 ---  Nα-H 8.10 [8.01] --- 
CαH 4.89 52.4  CαH 5.00 [4.90] 48.1 





[63.6] CγH3 1.07 17.3  
Nγ-H 7.21 ---  --- --- --- 
Sar5 
Nα-CH3 3.03 36.0  Nα-CH3 3.06 36.7 
CαH2 4.04, 4.26 53.0  CαH2 3.63, 4.39 54.1 
Ala6 
Nα-H 8.02 ---  Nα-H 7.96 [7.93] --- 
CαH 4.41 48.7  CαH 4.24 [4.32] 49.2 
CβH3 1.26 18.3  CβH3 1.21 [1.24] 18.2 
Asp7 
Nα-H 8.30 ---  Nα-H 8.10 --- 
CαH 4.56 49.9  CαH 4.55 50.1 
CβH2 2.59, 2.54 a 38.0  CβH2 2.65-2.45 36.6/37.7 
COOH 12.1 ---  COOH 12.1 --- 
D-Lys8 
Nα-H 8.05 ---  Nα-H 7.87 --- 
CαH 4.25 53.0  CαH 4.17 53.1 
CβH2 1.64, 1.56 32.0  CβH2 1.59, 1.52 31.1 
CγH2 1.25 22.4  CγH2 1.28 22.4 
CδH2 1.50 27.2  CδH2 1.50 27.1 
CεH2 2.73 39.2  CεH2 2.73 39.3 
NεH2 7.60 ---  NεH2 7.60 --- 
Asp9 
Nα-H 7.83 ---  Nα-H 8.10 --- 
CαH 4.71 50.0  CαH 4.55 50.1 
CβH2 2.59, 2.49 a 38.0  CβH2 2.65-2.45 36.6/37.7 







Table A.3 (continued): HSQC Peak Coordinates for peptides 3.32 and 3.33. 
 
A5A1-Asn3-DABA4-Asp9 (5) 
(500 MHz, DMSO) 
 
A5A1-Asn3-S4-Asp9 (6) 
(500 MHz, DMSO) 
  1H 13C   1H 13C 
Gly10 
Nα-H 8.26 ---  Nα-H 7.96 --- 
CαH2 3.69 42.9  CαH2 3.65, 3.76 42.8 
D-Asn11 
Nα-H 8.44 ---  Nα-H 8.10 --- 
CαH 4.40 48.7  CαH 4.55 50.1 
CβH2 2.61, 2.54a 36.0  CβH2 2.65-2.45 36.6/37.7 
CONH2 6.83, 7.10 ---  CONH2 7.23, 6.81 --- 
Glu12 
Nα-H 8.07 ---  Nα-H 8.29 --- 
CαH 4.68 52.4  CαH 4.33 52.3 
CβH2 1.84, 1.74 28.1  CβH2 1.73, 1.89 27.9 
CγH2 2.17 30.3  CγH2 2.17 31.0 
COOH 12.1 ---  COOH 12.1 --- 
Ile13 
Nα-H 8.04 ---  Nα-H 7.96 --- 
CαH 4.22 57.5  CαH 4.29 52.2 
CβH 1.63 27.5  CβH 1.77 27.9 
CγH2 1.40, 1.01 25.3  CγH2 1.38, 1.12 25.6 
CδH3 0.78 11.6  CδH3 0.80 [0.77] 11.7 
CγH3 0.77 15.5  CγH3 0.80 15.6 
Dec0 
C2H2 2.21, 2.03 35.3  C2H2 2.04 35.8 
C3H2 1.37 25.5  C3H2 1.37 25.6 
C4H2 1.2-1.1 31.7/29.2  C4H2 1.2-1.1 31.7/29.1 
C5H2 1.2-1.1 31.7/29.2  C5H2 1.2-1.1 31.7/29.1 
C6H2 1.2-1.1 31.7/29.2  C6H2 1.2-1.1 31.7/29.1 
C7H2 1.2-1.1 31.7/29.2  C7H2 1.2-1.1 31.7/29.1 
C8H2 1.2-1.1 31.7/29.2  C8H2 1.2-1.1 31.7/29.1 
C9H2 1.23 22.4  C9H2 1.24 22.4 
C10H3 0.83 14.5  C10H3 0.83 14.4 
Note: bolded peaks overlap with one or more other peaks. 









Figure B.1: HPLC chromatogram of pure A54145D-tHOAsn3-tMeOAsp9. Gradient: 30:70 




Figure B.2: HPLC chromatogram of pure synthetic A54145D (1.11). This peptide corresponds 
to A54145D-tHOAsn3-eMeOAsp9. Gradient: 30:70 MeCN:H2O (+0.1% TFA) to 50:50 







Figure B.3: HPLC chromatogram of pure A54145D-(8S)-anteiso. Gradient: 30:70 





Figure B.4: HPLC chromatogram of pure A54145D-(8R)-anteiso. Gradient: 30:70 







Figure B.5: HPLC chromatogram of pure A54145D-nucleus. Gradient: 10:90 MeCN:H2O 




Figure B.6: HPLC chromatogram of pure A54145A1-Asn3-DAPA4-Asp9 (3.2). Gradient: 







Figure B.7: HPLC chromatogram of pure A54145A1-Asn3-Asp9 (3.3). Gradient: 10:90 
MeCN:H2O (+0.1% TFA) to 90:10 MeCN:H2O (+ 0.1% TFA) in 40 min (λ = 220 nm). 
 
\  
Figure B.8: HPLC chromatogram of pure A54145A1-Asn3-Ser4-Asp9 (3.32). Gradient: 10:90 




Figure B.9: HPLC chromatogram of pure A54145A1-Asn3-DABA4-Asp9 (3.33). Gradient: 
10:90 MeCN:H2O (+0.1% TFA) to 90:10 MeCN:H2O (+ 0.1% TFA) in 40 min (λ = 220 nm). 
 
 
Figure B.10: HPLC chromatogram of pure A54145D-Asn3 (3.44). Gradient: 10:90 




Figure B.11: HPLC chromatogram of pure A54145D-Asp9 (3.45). Gradient: 10:90 
MeCN:H2O (+0.1% TFA) to 90:10 MeCN:H2O (+ 0.1% TFA) in 40 min (λ = 220 nm). 
 
 
Figure B.12: HPLC chromatogram of pure synthetic A54145A1 (1.7). Gradient: 10:90 





Figure B.13: HPLC chromatogram of pure 8-methyldecanoyl-daptomycin (3.46).  Gradient: 
10:90 MeCN:H2O (+0.1% TFA) to 90:10 MeCN:H2O (+ 0.1% TFA) in 40 min (λ = 220 nm). 
 
 
Figure B.14: HPLC chromatogram of pure 10-methyldodecanoyl-daptomycin (3.47). 








Figure B.15: HPLC chromatogram of pure pentadecanoyl-daptomycin (3.48). Gradient: 40:60 
MeCN:H2O (+0.1% TFA) to 70:30 MeCN:H2O (+ 0.1% TFA) in 40 min (λ = 220 nm). 
 
 
Figure B.16: HPLC chromatogram of pure 10,10,10-trifluorodecanoyl-daptomycin (4.5). 






Figure B.17: HPLC chromatogram of pure Dap(TFMbenzyl)Orn6-daptomycin (4.6). Gradient: 
10:90 MeCN:H2O (+0.1% TFA) to 90:10 MeCN:H2O (+ 0.1% TFA) in 40 min (λ = 220 nm). 
 
 
Figure B.18: HPLC chromatogram of pure Dap(TFethyl)Orn6-daptomycin (4.7). Gradient: 




Figure B.19: HPLC chromatogram of pure Dap-(TFMbenzoyl)Orn6 (4.8). Gradient: 10:90 




Figure B.20: HPLC chromatogram of pure Dap-(TFacetyl)Orn6 (4.9). Gradient: 10:90 






Figure B.21: HPLC chromatogram of pure Dap-TFMPhe1-Lys6-Glu12-Trp13 (4.15). Gradient: 





Figure B.22: HPLC chromatogram of pure Dap-Lys6-D-Ser(CF3)11-Glu12-Trp13 (4.38). 









Figure B.23: HPLC chromatogram of pure Dap-Lys6-D-hCys(CF3)8-Glu12-Trp13 (4.55). 





Figure B.24: HPLC chromatogram of pure Dap-Lys6-D-hCys(CF3)11-Glu12-Trp13 (4.56). 





Figure B.25: HPLC chromatogram of pure Dap-TFDec0-Lys6-Glu12-Trp13 (4.57). Gradient: 










Figure C.1: HRMS data for A54145D-tHOAsn3-tMeOAsp9. (A) ESI+ HRMS for A54145D-
tHOAsn3-tMeOAsp9. The peak at m/z = 829.89924 corresponds to the [M+2H]+ species. The 
peak at m/z = 838.41221 corresponds to the [M+H+NH4]
+
 species. The peak at m/z = 840.88916 
corresponds to the [M+H+Na]+ species. The peak at m/z = 848.87611 corresponds to the 








Figure C.2: HRMS data for synthetic A54145D. This peptide corresponds to A54145D-
tHOAsn3-eMeOAsp9. (A) ESI+ HRMS for A54145D. The peak at m/z = 829.90104 
corresponds to the [M+2H]+ species. The peak at m/z = 838.41318 corresponds to the 
[M+H+NH4]
+
 species. The peak at m/z = 840.89057 corresponds to the [M+H+Na]
+
 species. 
The peak at m/z = 848.87565 corresponds to the [M+H+K]+ species. (B) HRMS data for the 








Figure C.3: HRMS data for A54145D-(8S)-anteiso. (A) ESI+ HRMS for A54145D-(8S)-
anteiso. The peak at m/z = 829.89861 corresponds to the [M+2H]2+ species. The peak at m/z = 
838.41153 corresponds to the [M+H+NH4]
2+
 species. The peak at m/z = 840.88937 corresponds 
to the [M+H+Na]2+ species. The peak at m/z = 848.87362 corresponds to the [M+H+K]
2+
 










Figure C.4: HRMS data for A54145D-(8R)-anteiso. (A) ESI+ HRMS for A54145D-(8R)-
anteiso. The peak at m/z = 829.89908 corresponds to the [M+2H]2+ species. The peak at m/z = 
838.41259 corresponds to the [M+H+NH4]
2+
 species. The peak at m/z = 840.89065 corresponds 
to the [M+H+Na]2+ species. The peak at m/z = 848.87423 corresponds to the [M+H+K]
2+
 









Figure C.5: HRMS data for A54145D-nucleus. (A) ESI+ HRMS for A54145D-nucleus. The 
peak at m/z = 745.82333 corresponds to the [M+2H]+ species. (B) HRMS data for the peak at 










Figure C.6: HRMS data for A54145A1-Asn3-DAPA4-Asp9 (3.2). (A) ESI+
 HRMS of pure 
A54145A1-Asn3-DAPA4-Asp9. The peak at m/z = 792.3911 corresponds to the [M+2H]
2+ 
species. The peak at m/z = 800.9001 corresponds to the [M+H+NH4]
2+ species. The peak at 
m/z = 803.3774 corresponds to the [M+H+Na]2+ species. The peak at m/z = 811.3632 









Figure C.7: HRMS data for A54145A1-Asn3-Asp9 (3.1). (A) ESI+ HRMS of pure A54145A1-
Asn3-Asp9. The peak at m/z = 799.88785 corresponds to the [M+2H]2+ species. The peak at 
m/z = 808.40007 corresponds to the [M+H+NH4]
2+ species. The peak at m/z = 810.87805 
corresponds to the [M+H+Na]2+ species. The peak at m/z = 818.86229 corresponds to the 








Figure C.8: HRMS data for A54145A1-Asn3-Ser4-Asp9 (3.32). (A) ESI+ HRMS of pure 
A54145A1-Asn3-Ser4-Asp9. The peak at m/z = 792.87766 corresponds to the [M+2H]
2+ 
species. The peak at m/z = 801.39163 corresponds to the [M+H+NH4]
2+ species. (B) HRMS 







Figure C.9: HRMS data for A54145A1-Asn3-DABA4-Asp9 (3.33). (A) ESI+ HRMS of pure 
A54145A1-Asn3-DABA4-Asp9. The peak at m/z = 799.39478 corresponds to the [M+2H]
2+ 
species. The peak at m/z = 807.90747 corresponds to the [M+H+NH4]
2+ species. The peak at 
m/z = 810.38331 corresponds to the [M+H+Na]2+ species. The peak at m/z = 818.37092 








Figure C.10: HRMS data for A54145D-Asn3 (3.44). (A) ESI+ HRMS of pure A54145D-
Asn3. The peak at m/z = 821.90167 corresponds to the [M+2H]2+ species. The peak at m/z = 
830.41403 corresponds to the [M+H+NH4]
2+ species. The peak at m/z = 832.89229 
corresponds to the [M+H+Na]2+ species. The peak at m/z = 840.87936 corresponds to the 








Figure C.11: HRMS data for A54145D-Asp9 (3.45). (A) ESI+ HRMS of pure A54145D-
Asp9. The peak at m/z = 814.8965 corresponds to the [M+2H]2+ species. The peak at m/z = 
823.4063 corresponds to the [M+H+NH4]
2+ species. The peak at m/z = 825.8834 corresponds 
to the [M+H+Na]2+ species. The peak at m/z = 833.8686 corresponds to the [M+H+K]2+ 









Figure C.12: HRMS data for synthetic A54145A1 (1.7). (A) ESI+ HRMS of pure A54145A1. 
The peak at m/z = 822.89099 corresponds to the [M+2H]2+ species. The peak at m/z = 
831.40258 corresponds to the [M+H+NH4]
2+ species. The peak at m/z = 833.87995 
corresponds to the [M+H+Na]2+ species. The peak at m/z = 841.85948 corresponds to the 







Figure C.13: HRMS data for 8-methyldecanoyl-daptomycin (3.46). (A) ESI+ HRMS of pure 
8-methyldecanoyl-daptomycin. The peak at m/z = 817.87072 corresponds to the [M+2H]2+ 
species. The peak at m/z = 828.86030 corresponds to the [M+H+Na]2+ species. The peak at m/z 
= 836.84922 corresponds to the [M+H+K]2+ species. (B) HRMS data for the peak at m/z = 









Figure C.14: HRMS data for 10-methyldodecanoyl-daptomycin (3.47). (A) ESI+ HRMS of 
pure 10-methyldodecanoyl-daptomycin. The peak at m/z = 831.88348 corresponds to the 
[M+2H]2+ species. The peak at m/z = 842.87397 corresponds to the [M+H+Na]2+ species. The 
peak at m/z = 850.85755 corresponds to the [M+H+K]2+ species. (B) HRMS data for the peak 








Figure C.15: HRMS data for pentadecanoyl-daptomycin (3.48). (A) ESI+ HRMS of pure 
pentadecanoyl-daptomycin. The peak at m/z = 845.89821 corresponds to the [M+2H]2+ 
species. The peak at m/z = 856.88856 corresponds to the [M+H+Na]2+ species. The peak at m/z 
= 864.871315 corresponds to the [M+H+K]2+ species. (B) HRMS data for the peak at m/z = 







Figure C.16: HRMS data for 10,10,10-trifluorodecanoyl-daptomycin (4.5). (A) ESI+ HRMS 
Data for 10,10,10-trifluorodecanoyl-daptomycin. The peak at m/z = 837.84793 corresponds to 
the [M+2H]2+ species. The peak at m/z = 848.83892 corresponds to the [M+H+Na]2+ species. 
The peak at m/z = 856.82278 corresponds to the [M+H+K]2+ species. (B) HRMS data for the 






Figure C.17: HRMS data for Dap-(TFMBenzyl)Orn6 (4.6). (A) ESI+ HRMS Data for Dap-
(TFMBenzyl)Orn6. The peak at m/z = 889.87801 corresponds to the [M+2H]2+ species. The 
peak at m/z = 908.85117 corresponds to the [M+H+K]2+ species. (B) HRMS data for the peak 








Figure C.18: HRMS data for Dap-(TFethyl)Orn6 (4.7). (A) ESI+ HRMS Data for Dap-
(TFethyl)Orn6. The peak at m/z = 851.86551 corresponds to the [M+2H]2+ species. The peak at 
m/z = 862.85599 corresponds to the [M+H+Na]2+ species. The peak at m/z = 870.84063 









Figure C.19: HRMS data for Dap-(TFMbenzoyl)Orn6 (4.8). (A) ESI+ HRMS data for Dap-
(TFMbenzoyl)Orn6. The peak at m/z = 896.87057 corresponds to the [M+2H]2+ species. The 
peak at m/z = 907.86011 corresponds to the [M+H+Na]2+ species. The peak at m/z = 915.84590 









Figure C.20: HRMS data for Dap-(TFacetyl)Orn6 (4.9). (A) ESI+ HRMS data for Dap-
(TFacetyl)Orn6. The peak at m/z = 858.85537 corresponds to the [M+2H]2+ species. The peak 
at m/z = 867.36823 corresponds to the [M+H+NH4]
2+ species. The peak at m/z = 869.84568 
corresponds to the [M+H+Na]2+ species. The peak at m/z = 877.82979 corresponds to the 









Figure C.21: HRMS data for Dap-TFMPhe1-Lys6-Glu12-Trp13 (4.15). (A) ESI+ HRMS data 
for Dap-TFMPhe1-Lys6-Glu12-Trp13. The peak at m/z = 823.35421 corresponds to the 
[M+2H]2+ species. The peak at m/z = 831.86580 corresponds to the [M+H+NH4]
2+ species. 
The peak at m/z = 834.34296 corresponds to the [M+H+Na]2+ species. The peak at m/z = 
842.33253 corresponds to the [M+H+K]2+ species. (B) HRMS data for the peak at m/z = 









Figure C.22: HRMS data for Dap-Lys6-D-Ser(CF3)11-Glu12-Trp13 (4.38). (A) ESI+ HRMS 
data for Dap-Lys6-D-Ser(CF3)11-Glu12-Trp13. The peak at m/z = 842.86197 corresponds to 
the [M+2H]2+ species. The peak at m/z = 866.37077 corresponds to the [M+H+NH4]
2+ species. 
The peak at m/z = 868.84772 corresponds to the [M+H+Na]2+ species. The peak at m/z = 
876.83324 corresponds to the [M+H+K]2+ species. (B) HRMS data for the peak at m/z = 








Figure C.23: HRMS data for Dap-Lys6-D-hCys(CF3)8-Glu12-Trp13 (4.55). (A) ESI+ HRMS 
data for Dap-Lys6-D-hCys(CF3)8-Glu12-Trp13. The peak at m/z = 865.85547 corresponds to 
the [M+2H]2+ species. The peak at m/z = 874.36784 corresponds to the [M+H+NH4]
2+ species. 
The peak at m/z = 876.84544 corresponds to the [M+H+Na]2+ species. The peak at m/z = 
884.83094 corresponds to the [M+H+K]2+ species. (B) HRMS data for the peak at m/z = 








Figure C.24: HRMS data for Dap-Lys6-D-hCys(CF3)11-Glu12-Trp13 (4.56). (A) ESI+ 
HRMS data for Dap-Lys6-D-hCys(CF3)11-Glu12-Trp13. The peak at m/z = 857.85792 
corresponds to the [M+2H]2+ species. The peak at m/z = 866.37077 corresponds to the 
[M+H+NH4]
2+ species. The peak at m/z = 868.84772 corresponds to the [M+H+Na]2+ species. 
The peak at m/z = 876.83324 corresponds to the [M+H+K]2+ species. (B) HRMS data for the 








Figure C.25: HRMS data for Dap-TFDec0-Lys6-Glu12-Trp13 (4.57). (A) ESI+ HRMS Data 
for Dap-TFDec0-Lys6-Glu12-Trp13. The peak at m/z = 835.85226 corresponds to the 
[M+2H]2+ species. The peak at m/z = 844.36651 corresponds to the [M+H+NH4]
2+ species. 
The peak at m/z = 854.83339 corresponds to the [M+H+K]2+ species. (B) HRMS data for the 











ion molecular formula 
Observed mass of fragment 
(Calculated mass) (Da) 
[M+H-H2O]+ C73H110N17O26+ 1640.7 (1640.8) 
[M+H-NH3]+ C73H109N16O27+ 1641.7 (1641.8) 
y9 + 18 C38H64N11O18+ 962.5 (962.4) 
y10 C42H69N12O19+ 1045.5 (1045.5) 
y11 C45H75N14O22+ 1175.5 (1175.5) 
y12 C51H82N15O25+ 1304.6 (1304.6) 
 
Figure D.1: MS/MS sequencing of synthetic A54145D. This peptide is also referred to as 
A54145D-tHOAsn3-eMeOAsp9. Shown are single bond fragmentations corresponding to y10, 




















[M+H-H2O]+ C73H112N17O27+ 1658.8 (1658.8)  y6 C28H49N8O13+ 705.4 (705.3) 
[M+H-NH3]+ C73H111N16O28+ 1659.8 (1659.8)  y7 C32H54N9O16+ 820.4 (820.4) 
b9 C56H85N12O20+ 1245.6 (1245.6)  y8 C35H59N10O17+ 891.5 (891.4) 
b10 C58H88N13O21+ 1302.7 (1302.6)  y9 C38H64N11O18+ 962.5 (962.4) 
b11 C62H94N15O23+ 1416.7 (1416.7)  y10 C42H71N12O20+ 1063.6 (1063.5) 
b12 C67H101N16O26+ 1545.7 (1545.7)  y11 C46H77N14O23+ 1193.6 (1193.5) 
y5 – CO2 C21H35N6O10+ 531.3 (531.2)  y12 C51H84N15O26+ 1322.6 (1322.6) 
 
Figure D.2: MS/MS sequencing of hydrolyzed synthetic A54145D. The peptide was 
hydrolyzed with 0.1 M LiOH (aq). The fragment associated with y5 was not observed, due to 





ion molecular formula 
Observed mass of fragment 
(Calculated mass) (Da) 
[M+H-H2O]+ C70H105N18O23+ 1565.7 (1565.8) 
[M+H-NH3]+ C70H104N17O24+ 1566.7 (1566.7) 
y9 + 18 C37H62N11O17+ --- (932.4) 
y10 C40H66N13O17+ 1000.5 (1000.5) 
y11 C44H72N15O19+ 1114.5 (1114.5) 
y12 C49H79N16O22+ 1243.5 (1243.6) 
 
Figure D.3: MS/MS sequencing of A54145A1-Asn3-DAPA4-Asp9 (3.2). Shown are single 
bond fragmentations corresponding to y10, y11, and y12. The lack of observation of a signal with 
m/z = 932.4 is indicative of an amide bond between DAPA4 and Ile13, as simultaneous 
cleavage of two amide bonds is less likely than simultaneous cleavage of an amide and ester 





















[M+H-H2O]+ C70H107N18O24+ --- (1583.8)  y6 C27H47N8O12+ --- (675.3) 
[M+H-NH3]+ C70H106N17O25+ --- (1584.8)  y7 C31H52N9O15+ --- (790.4) 
b9 C53H80N13O17+ --- (1170.6)  y8 C34H57N10O16+ --- (861.4) 
b10 C55H83N14O18+ --- (1227.6)  y9 C37H62N11O17+ --- (932.4) 
b11 C59H89N16O20+ --- (1341.6)  y10 C40H68N13O18+ --- (1018.5) 
b12 C64H96N17O23+ --- (1470.7)  y11 C44H74N15O20+ --- (1132.5) 
y5 – CO2 C20H33N6O9+ --- (501.2)  y12 C49H81N16O23+ --- (1261.6) 
 
Figure D.4: MS/MS after attempted hydrolysis of A54145A1-Asn3-DAPA4-Asp9 (3.2). After 
subjecting A54145A1-Asn3-DAPA4-Asp9 to 0.1 M LiOH (aq) for 24 h, no hydrolyzed product 
was observed, confirming that the side-chain of DAPA4 is attached to the α-carboxylic acid of 





ion molecular formula 
Observed mass of fragment 
(Calculated mass) (Da) 
[M+H-H2O]+ C71H106N17O24+ 1580.7 (1580.8) 
[M+H-NH3]+ C71H105N16O25+ 1581.7 (1581.7) 
y9 + 18 C37H62N11O17+ 932.5 (932.4) 
y10 C41H67N12O19+ 1015.5 (1015.5) 
y11 C45H73N14O20+ 1129.5 (1129.5) 
y12 C50H80N15O23+ 1258.5 (1258.6) 
 
Figure D.5: MS/MS sequencing of A54145A1-Asn3-Asp9 (3.1). Shown are single bond 
fragmentations corresponding to y10, y11, and y12, as well as simultaneous cleavage of the ester 





















[M+H-H2O]+ C71H108N17O25+ 1598.8 (1598.8)  y6 C27H47N8O12+ 675.5 (675.3) 
[M+H-NH3]+ C71H107N16O26+ 1599.8 (1599.8)  y7 C31H52N9O15+ 790.4 (790.4) 
b9 C54H81N12O18+ 1185.6 (1185.6)  y8 C34H57N10O16+ 861.5 (861.4) 
b10 C56H84N13O19+ 1242.6 (1242.6)  y9 C37H62N11O17+ 932.5 (932.4) 
b11 C60H90N14O21+ 1356.7 (1356.7)  y10 C41H69N12O19+ 1033.5 (1033.5) 
b12 C65H97N16O24+ 1485.7 (1485.7)  y11 C45H75N14O21+ 1147.6 (1147.5) 
y5 – CO2 C20H33N6O9+ 501.3 (501.2)  y12 C50H82N15O24+ 1276.6 (1276.6) 
 
Figure D.6: MS/MS sequencing of hydrolyzed A54145A1-Asn3-Asp9 (3.1). The peptide was 
hydrolyzed with 0.1 M LiOH (aq). The fragment associated with y5 was not observed, due to 





ion molecular formula 
Observed mass of fragment 
(Calculated mass) (Da) 
[M+H-H2O]+ C70H104N17O24+ 1566.7 (1566.7) 
[M+H-NH3]+ C70H103N16O25+ 1567.6 (1567.7) 
y9 + 18 C37H62N11O17+ 932.4 (932.4) 
y10 C40H65N12O19+ 1001.5 (1001.5) 
y11 C44H71N14O20+ 1115.5 (1115.5) 
y12 C49H78N15O23+ 1244.5 (1244.5) 
 
Figure D.7: MS/MS sequencing of A54145A1-Asn3-Ser4-Asp9 (3.32). Shown are single bond 
fragmentations corresponding to y10, y11, and y12, as well as simultaneous cleavage of the ester 





















[M+H-H2O]+ C70H106N17O25+ 1584.8 (1584.8)  y6 C27H47N8O12+ 675.5 (675.3) 
[M+H-NH3]+ C70H105N16O26+ 1585.7 (1585.7)  y7 C31H52N9O15+ 790.4 (790.4) 
b9 C53H79N12O18+ 1171.6 (1171.6)  y8 C34H57N10O16+ 861.5 (861.4) 
b10 C55H82N13O19+ 1228.6 (1228.6)  y9 C37H62N11O17+ 932.5 (932.4) 
b11 C59H88N14O21+ 1342.7 (1342.6)  y10 C40H67N12O19+ 1019.5 (1019.5) 
b12 C64H95N16O24+ 1471.7 (1471.7)  y11 C44H73N14O21+ 1133.5 (1133.5) 
y5 – CO2 C20H33N6O9+ 501.3 (501.2)  y12 C49H80N15O24+ 1262.6 (1262.6) 
 
Figure D.8: MS/MS sequencing of hydrolyzed A54145A1-Asn3-Ser4-Asp9 (3.32). The 
peptide was hydrolyzed with 0.1 M LiOH (aq). The fragment associated with y5 was not 





ion molecular formula 
Observed mass of fragment 
(Calculated mass) (Da) 
[M+H-H2O]+ C71H107N18O23+ 1579.7 (1579.8) 
[M+H-NH3]+ C71H104N17O24+ 1580.7 (1580.8) 
y9 + 18 C37H62N11O17+ --- (932.4) 
y10 C41H68N13O17+ 1014.5 (1014.5) 
y11 C45H74N15O19+ 1128.6 (1128.5) 
y12 C50H81N16O22+ 1257.5 (1257.6) 
 
Figure D.9: MS/MS sequencing of A54145A1-Asn3-DABA4-Asp9 (3.33). Shown are single 
bond fragmentations corresponding to y10, y11, and y12. The lack of observation of a signal with 
m/z = 932.5 is indicative of an amide bond between DABA4 and Ile13, as simultaneous 






















[M+H-H2O]+ C71H109N18O24+ --- (1597.8)  y6 C27H47N8O12+ --- (675.3) 
[M+H-NH3]+ C71H108N17O25+ --- (1598.8)  y7 C31H52N9O15+ --- (790.4) 
b9 C54H82N13O17+ --- (1184.6)  y8 C34H57N10O16+ --- (861.4) 
b10 C56H85N14O18+ --- (1241.6)  y9 C37H62N11O17+ --- (932.4) 
b11 C60H91N16O20+ --- (1355.7)  y10 C41H70N13O18+ --- (1032.5) 
b12 C65H98N17O23+ --- (1484.7)  y11 C45H76N15O20+ --- (1146.5) 
y5 – CO2 C20H33N6O9+ --- (501.2)  y12 C50H83N16O23+ --- (1275.6) 
 
Figure D.10: MS/MS after attempted hydrolysis of A54145A1-Asn3-DABA4-Asp9 (3.33). 
After subjecting A54145A1-Asn3-DABA4-Asp9 to 0.1 M LiOH (aq) for 24 h, no hydrolyzed 
product was observed, confirming that the side-chain of DABA4 is attached to the α-carboxylic 






ion molecular formula 
Observed mass of fragment 
(Calculated mass) (Da) 
[M+H-H2O]+ C73H110N17O25+ 1624.7 (1624.8) 
[M+H-NH3]+ C73H109N16O26+ 1625.7 (1625.8) 
y9 + 18 C38H64N11O18+ 962.4 (962.4) 
y10 C42H69N12O19+ 1045.5 (1045.5) 
y11 C46H75N14O21+ 1159.6 (1159.5) 
y12 C51H82N15O24+ 1288.6 (1288.6) 
 
Figure D.11: MS/MS sequencing of A54145D-Asn3 (3.44). Shown are single bond 
fragmentations corresponding to y10, y11, and y12, as well as simultaneous cleavage of the ester 




















[M+H-H2O]+ C73H112N17O26+ 1642.7 (1642.8)  y6 C28H49N8O13+ 705.4 (705.3) 
[M+H-NH3]+ C73H111N16O27+ 1643.7 (1643.7)  y7 C32H54N9O16+ 820.4 (820.4) 
b9 C56H85N12O19+ 1229.5 (1229.6)  y8 C35H59N10O17+ 891.4 (891.4) 
b10 C58H88N13O20+ 1286.6 (1286.6)  y9 C38H64N11O18+ 962.5 (962.4) 
b11 C62H94N14O22+ 1400.7 (1400.7)  y10 C42H71N12O20+ 1063.4 (1063.5) 
b12 C67H101N16O25+ 1529.7 (1529.7)  y11 C46H77N14O22+ 1177.5 (1177.5) 
y5 – CO2 C21H35N6O10+ 531.3 (531.2)  y12 C51H84N15O25+ 1306.5 (1306.6) 
 
Figure D.12: MS/MS sequencing of hydrolyzed A54145D-Asn3 (3.44). The peptide was 
hydrolyzed with 0.1 M LiOH (aq). The fragment associated with y5 was not observed, due to 





ion molecular formula 
Observed mass of fragment 
(Calculated mass) (Da) 
[M+H-H2O]+ C72H108N17O25+ 1610.7 (1610.8) 
[M+H-NH3]+ C72H107N16O26+ 1611.7 (1611.8) 
y9 + 18 C37H62N11O18+ 932.5 (932.4) 
y10 C41H67N12O19+ 1015.5 (1015.5) 
y11 C45H73N14O21+ 1145.6 (1145.5) 
y12 C50H80N15O24+ 1274.5 (1274.6) 
 
Figure D.13: MS/MS sequencing of cyclic A54145D-Asp9 (3.45). Shown are single bond 
fragmentations corresponding to y10, y11, and y12, as well as simultaneous cleavage of the ester 





















[M+H-H2O]+ C72H110N17O26+ 1628.7 (1628.8)  y6 C27H47N8O12+ 675.4 (675.3) 
[M+H-NH3]+ C72H109N16O27+ 1629.7 (1629.8)  y7 C31H52N9O15+ 790.4 (790.4) 
b9 C55H83N12O19+ 1215.5 (1215.6)  y8 C34H57N10O16+ 861.3 (861.4) 
b10 C57H86N13O20+ 1272.5 (1272.6)  y9 C37H62N11O17+ 932.4 (932.4) 
b11 C61H92N14O22+ 1386.6 (1386.7)  y10 C41H69N12O19+ 1033.5 (1033.5) 
b12 C66H99N16O25+ 1515.6 (1515.7)  y11 C45H75N14O22+ 1163.5 (1163.5) 
y5 – CO2 C20H33N6O9+ 501.3 (501.2)  y12 C50H82N15O25+ 1292.5 (1292.6) 
 
Figure D.14: MS/MS sequencing of hydrolyzed A54145D-Asp9 (3.45). The peptide was 
hydrolyzed with 0.1 M LiOH (aq). The fragment associated with y5 was not observed, due to 





ion molecular formula 
Observed mass of fragment 
(Calculated mass) (Da) 
[M+H-H2O]+ C72H108N17O26+ 1626.7 (1626.8) 
[M+H-NH3]+ C72H107N16O27+ 1627.7 (1627.8) 
y9 + 18 C38H64N11O18+ 962.5 (962.4) 
y10 C42H69N12O19+ 1045.6 (1045.5) 
y11 C45H75N14O22+ 1175.5 (1175.5) 
y12 C51H82N15O25+ 1304.6 (1304.6) 
 
Figure D.15: MS/MS sequencing of A54145A1 (1.7). Shown are single bond fragmentations 





















[M+H-H2O]+ C72H110N17O27+ 1644.8 (1644.8)  y6 C28H49N8O13+ 705.5 (705.3) 
[M+H-NH3]+ C72H109N16O28+ 1645.8 (1645.8)  y7 C32H54N9O16+ 820.4 (820.4) 
b9 C55H83N12O20+ 1231.6 (1231.6)  y8 C35H59N10O17+ 891.5 (891.4) 
b10 C57H86N13O21+ 1288.6 (1288.6)  y9 C38H64N11O18+ 962.5 (962.4) 
b11 C61H92N15O23+ 1402.6 (1402.7)  y10 C42H71N12O20+ 1063.6 (1063.5) 
b12 C66H99N16O26+ 1531.7 (1531.7)  y11 C46H77N14O23+ 1193.6 (1193.5) 
y5 – CO2 C21H35N6O10+ 531.3 (531.2)  y12 C51H84N15O26+ 1322.6 (1322.6) 
 
Figure D.16: MS/MS sequencing of hydrolyzed A54145A1 (1.7). The peptide was hydrolyzed 
with 0.1 M LiOH (aq). The fragment associated with y5 was not observed, due to further 




Appendix E: Letters of Copyright Permission 
 






Permission for Figure 1.5: 
Figure 1.5 was borrowed from Section 11.4.1 of Dr. Michael Palmer’s online course notes for 
CHEM 731 - Biochemical Pharmacology. Dr. Michael Palmer gave written permission for this 
figure to be used in this thesis. 
 








Permission for Figure 1.7: 
 
Direct link to journal article: 
https://pubs.acs.org/doi/10.1021/bi500779g 
 

















































(1)  Clatworthy, A. E.; Pierson, E.; Hung, D. T. Targeting Virulence: A New Paradigm for 
Antimicrobial Therapy. Nat. Chem. Biol. 2007, 3 (9), 541–548. 
(2)  Palumbi, S. R. Humans as the World’s Greatest Evolutionary Force. Science 2001, 
293, 1786–1791. 
(3)  Yocum, R. R.; Rasmussen, J. R.; Strominger, J. L. The Mechanism of Action of 
Penicillin. J. Biol. Chem. 1980, 255 (9), 3977–3986. 
(4)  Silver, L. L. Challenges of Antibacterial Discovery. Clin. Microbiol. Revews 2011, 24 
(1), 71–109. 
(5)  Venugopal, A. A.; Johnson, S. Fidaxomicin: A Novel Macrocyclic Antibiotic 
Approved for Treatment of Clostridium Difficile Infection. Clin. Infect. Dis. 2012, 54, 
568–574. 
(6)  Fox, G. J.; Menzies, D. A Review of the Evidence for Using Bedaquiline (TMC207) 
to Treat Multi-Drug Resistant Tuberculosis. Infect. Deseases Ther. 2013, 2, 123–144. 
(7)  Fernandes, P.; Martens, E. Antibiotics in Late Clinical Development. Biochem. 
Pharmacol. 2017, 133 (2017), 152–163. 
(8)  Swaney, S. M.; Aoki, H.; Ganoza, M. C.; Shinabarger, D. L. The Oxazolidinone 
Linezolid Inhibits Initiation of Protein Synthesis in Bacteria. Antimicrob. Agents 
Chemother. 1998, 42 (12), 3251–3255. 
(9)  Jones, R. N.; Fritsche, T. R.; Sader, H. S.; Ross, J. E. Activity of Retapamulin (SB-
275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci. 
Antimicrob. Agents Chemother. 2006, 50 (7), 2583–2586. 
(10)  Srivastava, A.; Talaue, M.; Liu, S.; Degen, D.; Ebright, R. Y.; Sineva, E.; 
Chakraborty, A.; Druzhinin, S. Y.; Chatterjee, S.; Ebright, Y. W.; Zozula, A.; Shen, J.; 
Sengupta, S.; Rong, R.; Xin, C.; Kaneko, T.; Irschik, H.; Jansen, R.; Donadio, S.; 
Connell, N.; Ebright, R. H. New Target for Inhibition of Bacterial RNA Polymerase: 
“Switch Region.” Curr. Opin. Microbiol. 2012, 14 (5), 532–543. 
(11)  Yadav, S.; Rawal, G.; Baxi, M. Bedaquiline: A Novel Antitubercular Agent for the 
Treatment of Multidrug- Resistant Tuberculosis. J. Clin. Diagnostic Res. 2016, 10 (8), 
FM01–FM02. 
(12)  Alanis, A. J. Resistance to Antibiotics: Are We in the Post-Antibiotic Era? Arch. Med. 
Res. 2005, 36, 697–705. 
(13)  Taylor, S. D.; Palmer, M. The Action Mechanism of Daptomycin. Bioorganic Med. 
Chem. 2016, 24, 6253–6268. 
(14)  Eisenstein, B. I.; Oleson, F. B.; Baltz, R. H. Daptomycin: From the Mountain to the 
Clinic, with Essential Help from Francis Tally, MD. Clin. Infect. Dis. 2010, 50 Suppl 1 
(Suppl 1), S10–S15. 
(15)  Counter, F. T.; Allen, N. E.; Fukuda, D. S.; Hobbs, J. N.; Ott, J.; Ensminger, P. W.; 
Mynderse, J. S.; Preston, D. A.; Wu, C. Y. E. A54145 a New Lipopeptide Antibiotic 
342 
 
Complex: Microbiological Evaluation. J. Antibiot. (Tokyo). 1990, 43, 616–622. 
(16)  Nguyen, K. T.; He, X.; Alexander, D. C.; Li, C.; Gu, J. Q.; Mascio, C.; Van Praagh, 
A.; Mortin, L.; Chu, M.; Silverman, J. a.; Brian, P.; Baltz, R. H. Genetically 
Engineered Lipopeptide Antibiotics Related to A54145 and Daptomycin with 
Improved Properties. Antimicrob. Agents Chemother. 2010, 54 (4), 1404–1413. 
(17)  Alexander, D. C.; Rock, J.; Gu, J.; Mascio, C.; Chu, M.; Brian, P.; Baltz, R. H. 
Production of Novel Lipopeptide Antibiotics Related to A54145 by Streptomyces 
fradiae Mutants Blocked in Biosynthesis of Modified Amino Acids and Assignment 
of LptJ, LptK and LptL Gene Functions. J. Antibiot. (Tokyo). 2010, 64 (1), 79–87. 
(18)  Liu, L.; Oza, S.; Hogan, D.; Perin, J.; Rudan, I.; Lawn, J. E.; Cousens, S.; Mathers, C.; 
Black, R. E. Global, Regional, and National Causes of Child Mortality in 2000–13 , 
with Projections to Inform Post-2015 Priorities: An Updated Systematic Analysis. 
Lancet 2015, 385, 430–440. 
(19)  Silverman, J. A.; Mortin, L. I.; Vanpraagh, A. D. G.; Li, T.; Alder, J. Inhibition of 
Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J. 
Infect. Dis. 2005, 191 (12), 2149–2152. 
(20)  Eliopoulos, G. M.; Thauvin, C.; Gerson, B.; Moellering, R. C. In Vitro Activity and 
Mechanism of Action of A21978C1, a Novel Cyclic Lipopeptide Antibiotic. 
Antimicrob. Agents Chemother. 1985, 27 (3), 357–362. 
(21)  Lakey, J. H.; Lea, E. J. A. The Role of Acyl Chain Character and Other Determinants 
on the Bilayer Activity of A21978C an Acidic Lipopeptide Antibiotic. Biochim. 
Biophys. Acta 1986, 859, 219–226. 
(22)  Jung, D.; Rozek, A.; Okon, M.; Hancock, R. E. W. Structural Transitions as 
Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin. Chem. 
Biol. 2004, 11, 949–957. 
(23)  Palmer, M. Biochemical Pharmacology. University of Waterloo: Waterloo 2012. 
(24)  Allen, N. E.; Hobbs, J. N.; Alborn, W. E. Inhibition of Peptidoglycan Biosynthesis in 
Gram-Positive Bacteria by LY146032. Antimicrob. Agents Chemother. 1987, 31 (7), 
1093–1099. 
(25)  Mengin-Lecreulx, D.; Allen, N. E.; Hobbs, J. N.; van Heijenoort, J. Inhibition of 
Peptidoglycan Biosynthesis in Bacillus megaterium by Daptomycin. FEMS Microbiol. 
Lett. 1990, 69, 245–248. 
(26)  Boaretti, M.; Canepari, P.; del Mar Lleo, M.; Satta, G. The Activity of Daptomycin on 
Enterococcus faecium Protoplasts: Indirect Evidence Supporting a Novel Mode of 
Action on Lipoteichoic Acid Synthesis. J. Antimicrob. Chemother. 1993, 31, 227–235. 
(27)  Canepari, P.; Boaretti, M.; del Mar Lleo, M.; Satta, G. Lipoteichoic Acid as a New 
Target for Activity of Antibiotics: Mode of Action of Daptomycin (LY146032). 
Antimicrob. Agents Chemother. 1990, 34 (6), 1220–1226. 
(28)  Boaretti, M.; Canepari, P. Identification of Daptomycin-Binding Proteins in the 




(29)  Boaretti, M.; Canepari, P. Purification of Daptomycin Binding Proteins (DBPS) from 
the Membrane of Enterococcus hirae. Microbiologica 2000, 23, 305–317. 
(30)  Laganas, V.; Alder, J.; Silverman, J. A. In Vitro Bactericidal Activities of Daptomycin 
against Staphylococcus aureus and Enterococcus faecalis Are Not Mediated by 
Inhibition of Lipoteichoic Acid Biosynthesis. Antimicrob. Agents Chemother. 2003, 47 
(8), 2682–2684. 
(31)  Wehrli, W. Rifampin: Mechanisms of Action and Resistance. Rev. Infect. Dis. 1983, 5, 
S407–S411. 
(32)  Wale, L. J.; Shelton, A. P.; Greenwood, D. Scanning Electronmicroscopy of 
Staphylococcus aureus and Enterococcus faecalis Exposed to Daptomycin. J. Med. 
Microbiol. 1989, 30, 45–49. 
(33)  Cotroneo, N.; Harris, R.; Perlmutter, N.; Beveridge, T.; Silverman, J. A. Daptomycin 
Exerts Bactericidal Activity without Lysis of Staphylococcus aureus. Antimicrob. 
Agents Chemother. 2008, 52 (6), 2223–2225. 
(34)  Jung, D.; Paul, J.; Straus, S. K.; Hancock, R. E. W. Lipid-Specific Binding of the 
Calcium-Dependent Antibiotic Daptomycin Leads to Changes in Lipid Polymorphism 
of Model Membranes. Chem. Phys. Lipids 2008, 154, 120–128. 
(35)  Pogliano, J.; Pogliano, N.; Silverman, J. a. Daptomycin-Mediated Reorganization of 
Membrane Architecture Causes Mislocalization of Essential Cell Division Proteins. J. 
Bacteriol. 2012, 194 (17), 4494–4504. 
(36)  Chen, Y.; Sun, T.; Sun, Y.; Huang, H. W. Interaction of Daptomycin with Lipid 
Bilayers: A Lipid Extracting Effect. Biochemistry 2014, 53, 5384–5392. 
(37)  Müller, A.; Wenzel, M.; Strahl, H.; Grein, F.; Saaki, T. N. V; Kohl, B.; Siersma, T.; 
Bandow, J. E.; Sahl, H.-G.; Schneider, T.; Hamoen, L. W. Daptomycin Inhibits Cell 
Envelope Synthesis by Interfering with Fluid Membrane Microdomains. Proc. Natl. 
Acad. Sci. U. S. A. 2016, 113 (45), E7077–E7086. 
(38)  Lee, M.-T.; Yang, P.-Y.; Charron, N. E.; Hseih, M.-H.; Chang, Y.-Y.; Huang, H. W. 
Comparison of the Effects of Daptomycin on Bacterial and Model Membranes. 
Biochemistry 2018, 57 (38), 5629–5639. 
(39)  Lakey, J. H.; Ptak, M. Fluorescence Indicates a Calcium-Dependent Interaction 
between the Lipopeptide Antibiotic LY 146032 and Phospholipid Membranes. 
Biochemistry 1988, 27, 4639–4645. 
(40)  Alborn, W. E.; Allen, N. E.; Preston, D. A. Daptomycin Disrupts Membrane-Potential 
in Growing Staphylococcus aureus. Antimicrob. Agents Chemother. 1991, 35 (11), 
2282–2287. 
(41)  Allen, N. E.; Alborn, W. E.; Hobbs, J. N. Inhibition of Membrane Potential-Dependent 
Amino Acid Transport by Daptomycin. Antimicrob. Agents Chemother. 1991, 35 (12), 
2639–2642. 
(42)  Silverman, J. A.; Perlmutter, N. G.; Howard, M.; Shapiro, H. M. Correlation of 
Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus 
aureus. Antimicrob. Agents Chemother. 2003, 47 (8), 2538–2544. 
344 
 
(43)  Seydlová, G.; Sokol, A.; Liskova, P.; Konopasek, I.; Fiser, R. Daptomycin Pore 
Formation and Stoichiometry Depend on Membrane Potential of Target Membrane. 
Antimicrob. Agents Chemother. 2018, 63 (1), e01589-18. 
(44)  Muraih, J. K.; Pearson, A.; Silverman, J.; Palmer, M. Oligomerization of Daptomycin 
on Membranes. Biochim. Biophys. Acta 2011, 1808, 1154–1160. 
(45)  Muraih, J. K.; Harris, J.; Taylor, S. D.; Palmer, M. Characterization of Daptomycin 
Oligomerization with Perylene Excimer Fluorescence: Stoichiometric Binding of 
Phosphatidylglycerol Triggers Oligomer Formation. BBA - Biomembr. 2012, 1818, 
673–678. 
(46)  Muraih, J. K.; Palmer, M. Estimation of the Subunit Stoichiometry of the Membrane-
Associated Daptomycin Oligomer by FRET. Biochim. Biophys. Acta - Biomembr. 
2012, 1818 (7), 1642–1647. 
(47)  Zhang, T.; Muraih, J. K.; MacCormick, B.; Silverman, J.; Palmer, M. Daptomycin 
Forms Cation- and Size-Selective Pores in Model Membranes. Biochim. Biophys. Acta 
2014, 1838, 2425–2430. 
(48)  Zhang, T.; Muraih, J. K.; Herskowitz, J.; Victor, R. L.; Silverman, J.; Uwumarenogie, 
S.; Taylor, S. D.; Palmer, M.; Zhang, T.; Muraih, J. K.; Tishbi, N.; Herskowitz, J.; 
Victor, R. L.; Silverman, J.; Uwumarenogie, S.; Taylor, S. D.; Palmer, M.; Mintzer, E. 
Cardiolipin Prevents Membrane Translocation and Permeabilization by Daptomycin. 
J. Biol. Chem. 2014, 289, 11584–11591. 
(49)  Taylor, R.; Butt, K.; Scott, B.; Zhang, T.; Muraih, J. K.; Mintzer, E.; Taylor, S.; 
Palmer, M. Two Successive Calcium-Dependent Transitions Mediate Membrane 
Binding and Oligomerization of Daptomycin and the Related Antibiotic A54145. BBA 
- Biomembr. 2016, 1858 (9), 1999–2005. 
(50)  Zhang, T.; Taylor, S. D.; Palmer, M.; Duhamel, J. Membrane Binding and 
Oligomerization of the Lipopeptide A54145 Studied by Pyrene Fluorescence. Biophys. 
J. 2016, 111, 1267–1277. 
(51)  Taylor, R.; Beriashvili, D.; Taylor, S.; Palmer, M. Daptomycin Pore Formation Is 
Restricted by Lipid Acyl Chain Composition. ACS Infect. Dis. 2017, 3, 797–801. 
(52)  Beriashvili, D.; Taylor, R.; Kralt, B.; Mazen, N. A.; Taylor, S. D.; Palmer, M. 
Mechanistic Studies on the Effect of Membrane Lipid Acyl Chain Composition on 
Daptomycin Pore Formation. Chem. Phys. Lipids 2018, 216, 73–79. 
(53)  Kreutzberger, M. A.; Pokorny, A.; Almeida, P. F. Daptomycin–Phosphatidylglycerol 
Domains in Lipid Membranes. Langmuir 2017, 33 (47), 13669–13679. 
(54)  Friedman, L.; Alder, J. D.; Silverman, J. a. Genetic Changes That Correlate with 
Reduced Susceptibility to Daptomycin in Staphylococcus aureus. Antimicrob. Agents 
Chemother. 2006, 50 (6), 2137–2145. 
(55)  Peleg, A. Y.; Miyakis, S.; Ward, D. V; Earl, A. M.; Rubio, A.; Cameron, D. R.; Pillai, 
S.; Moellering, R. C.; Eliopoulos, G. M. Whole Genome Characterization of the 
Mechanisms of Daptomycin Resistance in Clinical and Laboratory Derived Isolates of 
Staphylococcus aureus. PLoS One 2012, 7, e28316. 
345 
 
(56)  Ernst, C. M.; Staubitz, P.; Mishra, N. N.; Yang, S.; Hornig, G.; Bayer, A. S.; Kraus, 
D.; Peschel, A. The Bacterial Defensin Resistance Protein MprF Consists of Separable 
Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion. PLoS One 
2009, 5 (11), e1000660. 
(57)  Ernst, C. M.; Peschel, A. Broad-Spectrum Antimicrobial Peptide Resistance by MprF-
Mediated Aminoacylation and Flipping of Phospholipids. Mol. Microbiol. 2011, 80 
(2), 290–299. 
(58)  Yang, S.-J.; Mishra, N. N.; Rubio, A.; Bayer, A. S. Causal Role of Single Nucleotide 
Polymorphisms within the MprF Gene of Staphylococcus aureus in Daptomycin 
Resistance. Antimicrob. Agents Chemother. 2013, 57 (11), 5658–5664. 
(59)  Yang, S.-J.; Xiong, Y. Q.; Dunman, P. M.; Schrenzel, J.; Francois, P.; Peschel, A.; 
Bayer, A. S. Regulation of MprF in Daptomycin-Nonsusceptible Staphylococcus 
aureus Strains. Antimicrob. Agents Chemother. 2016, 53 (6), 2636–2637. 
(60)  Mishra, N. N.; Bayer, A. S. Correlation of Cell Membrane Lipid Profiles with 
Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus. Antimicrob. 
Agents Chemother. 2013, 57 (2), 1082–1085. 
(61)  Pillai, S. K.; Gold, H. S.; Sakoulas, G.; Wennersten, C.; Moellering, R. C.; Eliopoulos, 
G. M. Daptomycin Nonsusceptibility in Staphylococcus aureus with Reduced 
Vancomycin Susceptibility Is Independent of Alterations in MprF. Antimicrob. Agents 
Chemother. 2007, 51 (6), 2223–2225. 
(62)  Davlieva, M.; Zhang, W.; Arias, C. A.; Shamoo, Y. Biochemical Characterization of 
Cardiolipin Synthase Mutations Associated with Daptomycin Resistance in 
Enterococci. Antimicrob. Agents Chemother. 2013, 57 (1), 289–296. 
(63)  Taylor, R. M.; Scott, B.; Taylor, S.; Palmer, M. An Acyl-Linked Dimer of 
Daptomycin Is Strongly Inhibited by the Bacterial Cell Wall. ACS Infect. Dis. 2017, 3, 
462–466. 
(64)  Yang, S.; Nast, C. C.; Mishra, N. N.; Yeaman, M. R.; Fey, P. D.; Bayer, A. S. Cell 
Wall Thickening Is Not a Universal Accompaniment of the Daptomycin 
Nonsusceptibility Phenotype in Staphylococcus aureus: Evidence for Multiple 
Resistance Mechanisms. Antimicrob. Agents Chemother. 2016, 54 (8), 3079–3085. 
(65)  D’Costa, V. M.; Mukhtar, T. a.; Patel, T.; Koteva, K.; Waglechner, N.; Hughes, D. 
W.; Wright, G. D.; De Pascale, G. Inactivation of the Lipopeptide Antibiotic 
Daptomycin by Hydrolytic Mechanisms. Antimicrob. Agents Chemother. 2012, 56, 
757–764. 
(66)  Baltz, R. H.; Miao, V.; Wrigley, S. K. Natural Products to Drugs: Daptomycin and 
Related Lipopeptide Antibiotics. Nat. Prod. Rep. 2005, 22, 717–741. 
(67)  Miao, V.; Brost, R.; Chapple, J.; She, K.; Coëffet-Le Gal, M. F.; Baltz, R. H. The 
Lipopeptide Antibiotic A54145 Biosynthetic Gene Cluster from Streptomyces fradiae. 
J. Ind. Microbiol. Biotechnol. 2006, 33, 129–140. 
(68)  Robbel, L.; Marahiel, M. A. Daptomycin, a Bacterial Lipopeptide Synthesized by a 
Nonribosomal Machinery*. J. Biol. Chem. 2010, 285 (36), 27501–27508. 
346 
 
(69)  Debono, M.; Abbott, B. J.; Molloy, R. M.; Fukuda, D. S.; Hunt, A. H.; Daupert, V. 
M.; Counter, F. T.; Ott, J. L.; Carrell, C. B.; Howard, L. C.; Boeck, L. D.; Hamill, R. 
L. Enzymatic and Chemical Modifications of Lipopeptide Antibiotic A21978C: The 
Synthesis and Evaluation of Daptomycin (LY 146032). J. Antibiot. (Tokyo). 1988, 41 
(8), 1093–1105. 
(70)  Fukuda, D. S.; Bus, R. H. Du; Baker, P. J.; Mynderse, J. S.; Berry, D. M. A54145, a 
New Lipopeptide Antibiotic Complex: Isolation and Characterization. J. Antibiot. 
(Tokyo). 1990, 43, 594–600. 
(71)  Fukuda, D. S.; Debono, M.; Molloy, R. M.; Mynderse, J. S. A54145, a New 
Lipopeptide Antibiotic Complex: Microbial and Chemical Modification. J. Antibiot. 
(Tokyo). 1990, 43, 601–606. 
(72)  Hill, J.; Siedlecki, J.; Parr, I.; Morytko, M.; Yu, X.; Zhang, Y.; Silverman, J.; 
Controneo, N.; Laganas, V.; Li, T.; Lai, J.; Keith, D.; Shimer, G.; Finn, J. Synthesis 
and Biological Activity of N-Acylated Ornithine Analogues of Daptomycin. 
Bioorganic Med. Chem. Lett. 2003, 13, 4187–4191. 
(73)  Siedlecki, J.; Hill, J.; Parr, I.; Yu, X.; Morytko, M.; Zhang, Y.; Silverman, J.; 
Controneo, N.; Laganas, V.; Li, T.; Li, J.; Keith, D.; Shimer, G.; Finn, J. Array 
Synthesis of Novel Lipodepsipeptide. Bioorganic Med. Chem. Lett. 2003, 13, 4245–
4249. 
(74)  He, Y.; Li, J.; Yin, N.; Herradura, P. S.; Martel, L.; Zhang, Y.; Pearson, A. L.; 
Kulkarni, V.; Mascio, C.; Howland, K.; Silverman, J. A.; Keith, D. D.; Metcalf, C. A. 
Reduced Pulmonary Surfactant Interaction of Daptomycin Analogs via Tryptophan 
Replacement with Alternative Amino Acids. Bioorg. Med. Chem. Lett. 2012, 22 (19), 
6248–6251. 
(75)  Leese, R. A.; Curran, W. V; Borders, D. B. Lipodepsipeptide Antiobiotics and 
Methods of Preparation. US Pat. 2003, US30224475, 14. 
(76)  Grunewald, J.; Sieber, S. A.; Mahlert, C.; Linne, U.; Marahiel, M. A. Synthesis and 
Derivatization of Daptomycin : A Chemoenzymatic Route to Acidic Lipopeptide 
Antibiotics. J. Am. Chem. Soc. 2004, 126, 17025–17031. 
(77)  Miao, V.; Coeffet-LeGal, M. F.; Brian, P.; Brost, R.; Penn, J.; Whiting, A.; Martin, S.; 
Ford, R.; Parr, I.; Bouchard, M.; Silva, C. J.; Wrigley, S. K.; Baltz, R. H. Daptomycin 
Biosynthesis in Streptomyces roseosporus: Cloning and Analysis of the Gene Cluster 
and Revision of Peptide Stereochemistry. Microbiology 2005, 151 (5), 1507–1523. 
(78)  Kopp, F.; Grunewald, J.; Mahlert, C.; Marahiel, M. A. Chemoenzymatic Design of 
Acidic Lipopeptide Hybrids: New Insights into the Structure-Activity Relationship of 
Daptomycin and A54145. Biochemistry 2006, 45, 10474–10481. 
(79)  Baltz, R. H. Combinatorial Biosynthesis of Cyclic Lipopeptide Antibiotics: A Model 
for Synthetic Biology To Accelerate the Evolution of Secondary Metabolite 
Biosynthetic Pathways. ACS Synth. Biol. 2014, 3, 748–758. 
(80)  Baltz, R. H. Daptomycin and A54145: Structure-Activity Relationship (SAR) Studies 
Enabled by Combinatorial Biosynthesis; Osbourne, A., Goss, R., Carter, G. T., Eds.; 
John Wiley and Sons, Inc.: Hoboken, NJ, 2014. 
347 
 
(81)  Barnawi, G. Structure-Activity Relationship Studies on Daptomycin, 2018. 
(82)  Barnawi, G.; Noden, M.; Taylor, R.; Lohani, C.; Beriashvili, D.; Palmer, M.; Taylor, 
S. D. An Entirely Fmoc Solid Phase Approach to the Synthesis of Daptomycin 
Analogs. Biopolymers 2017, e23094, doi.org/10.1002/bip.23094. 
(83)  Lam, H. Y.; Zhang, Y.; Liu, H.; Xu, J.; Wong, C. T. T.; Xu, C.; Li, X. Total Synthesis 
of Daptomycin by Cyclization via a Chemoselective Serine Ligation. J. Am. Chem. 
Soc. 2013, 135, 6272–6279. 
(84)  ’t Hart, P.; Kleijn, L. H. J.; de Bruin, G.; Oppedijk, S. F.; Kemmink, J.; Martin, N. I. A 
Combined Solid- and Solution-Phase Approach Provides Convenient Access to 
Analogues of the Calcium-Dependent Lipopeptide Antibiotics. Org. Biomol. Chem. 
2014, 12 (6), 913–918. 
(85)  Lohani, C. R.; Taylor, R.; Palmer, M.; Taylor, S. D. Solid-Phase Total Synthesis of 
Daptomycin and Analogs. Org. Lett. 2015, 17, 748–751. 
(86)  Lohani, C. R.; Taylor, R.; Palmer, M.; Taylor, S. D. Solid-Phase Synthesis and in vitro 
Biological Activity of a Thr4 --> Ser4 Analog of Daptomycin. Bioorganic Med. Chem. 
Lett. 2015, 25, 5490–5494. 
(87)  Lohani, C. R.; Rasera, B.; Scott, B.; Palmer, M.; Taylor, S. D. α‑Azido Acids in Solid-
Phase Peptide Synthesis: Compatibility with Fmoc Chemistry and an Alternative 
Approach to the Solid Phase Synthesis of Daptomycin Analogs. J. Org. Chem. 2016, 
81, 2624–2628. 
(88)  Strieker, M.; Kopp, F.; Mahlert, C.; Essen, L.-O.; Marahiel, M. A. Mechanistic and 
Structural Basis of Stereospecific Cβ-Hydroxylation in Calcium-Dependent 
Antibiotic, a Daptomycin-Type Lipopeptide. ACS Chem. Biol. 2007, 2 (3), 187–196. 
(89)  von Eckardstein, L.; Petras, D.; Dang, T.; Cociancich, S.; Sabri, S.; Kerwat, D.; Seidel, 
M.; Pesic, A.; Dorrestein, P. C.; Royer, M.; Weston, J. B.; Sussmuth, R. D. Total 
Synthesis and Biological Assessment of Novel Albicidins Discovered by Mass 
Spectrometric Networking. Chem. - A Eur. J. 2017, 2017 (23), 15316–15321. 
(90)  Imashiro, R.; Seki, M. A Catalytic Asymmetric Synthesis of Chiral Glycidic Acid 
Derivatives through Chiral Dioxirane-Mediated Catalytic Asymmetric Epoxidation of 
Cinnamic Acid Derivatives. J. Org. Chem. 2004, 69, 4216–4226. 
(91)  Moreira, R.; Taylor, S. D. Asymmetric Synthesis of Fmoc-Protected β‑Hydroxy and 
β‑Methoxy Amino Acids via a Sharpless Aminohydroxylation Reaction Using 
FmocNHCl. Org. Lett. 2018, 20, 7717–7720. 
(92)  Motoshima, K.; Ishikawa, M.; Hashimoto, Y.; Sugita, K. Peroxisome Proliferator-
Activated Receptor Agonists with Phenethylphenylphthalimide Skeleton Derived from 
Thalidomide-Related Liver X Receptor Antagonists: Relationship between Absolute 
Configuration and Subtype Selectivity. Bioorganic Med. Chem. 2011, 19 (10), 3156–
3172. 
(93)  Siow, A.; Opiyo, G.; Kavianinia, I.; Li, F. F.; Furkert, D. P.; Harris, P. W. R.; Brimble, 
M. A. Total Synthesis of the Highly N-Methylated Acetylene-Containing Anticancer 
Peptide Jahanyne. Org. Lett. 2018, 20, 788–791. 
348 
 
(94)  Pedroso, E.; Grandas, A.; de las Heras, X.; Eritja, R.; Giralt, E. Diketopiperazine 
Formation in Solid Phase Peptide Synthesis Using p-Alkoxybenzyl Ester Resins and 
Fmoc-Amino Acids. Tetrahedron Lett. 1986, 27 (6), 743–746. 
(95)  Purdie, J. E.; Benoiton, N. L. Piperazinedione Formation from Esters of Dipeptides 
Containing Glycine, Alanine, and Sarcosine: The Kinetics in Aqueous Solution. J. 
Chem. Soc. Perkin Trans. 1 1973, 1845–1853. 
(96)  Gude, M.; Ryf, J.; White, P. D. An Accurate Method for the Quantitation of Fmoc-
Derivatized Solid Phase Supports. Lett. Pept. Sci. 2003, 9, 203–206. 
(97)  Thieriet, N.; Alsina, J.; Giralt, E.; Guibe, F.; Albericio, F. Use of Alloc-Amino Acids 
in Solid-Phase Peptide Synthesis. Tandem Deprotection-Coupling Reactions Using 
Neutral Conditions. Tetrahedron Lett. 1997, 38 (41), 7275–7278. 
(98)  Zorn, C.; Gnad, F.; Salmen, S.; Herpin, T.; Reiser, O. Deprotection of N-Alloc Amines 
by Pd(0)/DABCO—an Efficient Method for in situ Peptide Coupling of Labile Amino 
Acids. Tetrahedron 2001, 42, 7049–7053. 
(99)  Malakoutikhah, M.; Teixidó, M.; Giralt, E. Toward an Optimal Blood-Brain Barrier 
Shuttle by Synthesis and Evaluation of Peptide Libraries. J. Med. Chem. 2008, 51, 
4881–4889. 
(100)  Kim, H.; Cho, J. K.; Aimoto, S.; Lee, Y.-S. Solid-Phase Staudinger Ligation from a 
Novel Core-Shell-Type Resin: A Tool for Facile Condensation of Small Peptide 
Fragments. Org. Lett. 2006, 8 (6), 1149–1151. 
(101)  Goddard-Borger, E. D.; Stick, R. V. An Efficient, Inexpensive, and Shelf-Stable 
Diazotransfer Reagent: Imidazole-1-Sulfonyl Azide Hydrochloride. Org. Lett. 2007, 9 
(19), 3797–3800. 
(102)  Ji, L.; Zhou, G.-Q.; Qian, C.; Chen, X.-Z. Synthesis of 1,2,3-Triazoles from Azide-
Derivatised Aminocyclitols by Catalytic Diazo Transfer and CuAAC Click Chemistry. 
European J. Org. Chem. 2014, 2014, 3622–3636. 
(103)  Lohani, C. R.; Soley, J.; Kralt, B.; Palmer, M.; Taylor, S. D. α‑Azido Esters in 
Depsipeptide Synthesis: C−O Bond Cleavage during Azido Group Reduction. J. Org. 
Chem. 2016, 81, 11831–11840. 
(104)  Wong, D.; Taylor, C. M. Asymmetric Synthesis of Erythro-β-Hydroxyasparagine. 
Tetrahedron Lett. 2009, 50, 1273–1275. 
(105)  Boeck, L. D.; Fukuda, D. S.; Mynderse, J. S.; Hoen, M. M.; Kastner, R. E.; Papiska, 
H. R. A54145 Antibiotics and Process for Their Production. US Pat. 1991, 4994270, 
30. 
(106)  Fukuda, D. S.; Mynderse, J. S. A54145 Cyclic Peptides. US Pat. 1991, US5039789, 
23. 
(107)  Kaneda, T. Iso- and Anteiso-Fatty Acids in Bacteria: Biosynthesis, Function, and 
Taxonomic Significance. Microbiol. Rev. 1991, 55 (2), 288–302. 
(108)  Boeck, L. D.; Wetzel, R. W. A54145, a New Lipopeptide Antibiotic Complex: Factor 




(109)  Wuster, T.; Kaczybura, N.; Bruckner, R.; Keller, M. Synthesis of Enantiomerically 
Pure Model Compounds of the Glucose-6-Phosphate-T1-Translocase Inhibitors 
Kodaistatins A-D. Inferences with Regard to the Stereostructure of the Natural 
Products. Tetrahedron 2013, 69, 7785–7809. 
(110)  Yang, Z.; Ma, M.; Yang, C.-H.; Gao, Y.; Zhang, Q.; Chen, Y. Determination of the 
Absolute Configurations of Microtermolides A and B. J. Nat. Prod. 2016, 79, 2408–
2412. 
(111)  Chen, D.; Chow, H. Y.; Po, K. H. L.; Ma, W.; Leung, E. L. Y.; Sun, Z.; Liu, M.; Chen, 
S.; Li, X. Total Synthesis and Structural Establishment/Revision of Antibiotics 
A54145. Org. Lett. 2019, 21, 5639–5644. 
(112)  Wiegand, I.; Hilpert, K.; Hancock, R. E. W. Agar and Broth Dilution Methods to 
Determine the Minimal Inhibitory Concentration (MIC) of Antimicrobial Substances. 
Nat. Protoc. 2008, 3 (2), 163–175. 
(113)  Hedenstrom, E.; Nguyen, B.-V.; Silks, L. A. I. Do Enzymes Recognise Remotely 
Located Stereocentres? Highly Enantioselective Candida rugosa Lipase-Catalysed 
Esterification of the 2- to 8-Methyldecanoic Acids. Tetrahedron: Asymmetry 2002, 13, 
835–844. 
(114)  Paulsen, H.; Merz, G.; Brockhausen, I. Synthese von L-Prolin-Haltigen O-
Glycopeptiden. Liebigs Ann. der Chemie 1990, 1990 (8), 719–739. 
(115)  Groth, T.; Grøtli, M.; Meldal, M. Diffusion of Reagents in Macrobeads. J. Comb. 
Chem. 2001, 3, 461–468. 
(116)  Dartois, V.; Sanchez-Quesada, J.; Cabezas, E.; Chi, E.; Dubbelde, C.; Dunn, C.; 
Granja, J.; Gritzen, C.; Weinberger, D.; Ghadiri, M. R.; Parr, T. R. Systemic 
Antibacterial Activity of Novel Synthetic Cyclic Peptides. Antimicrob. Agents 
Chemother. 2005, 49 (8), 3302–3310. 
(117)  Moreira, R.; Barnawi, G.; Beriashvili, D.; Palmer, M.; Taylor, S. D. The Effect of 
Replacing the Ester Bond with an Amide Bond and of Overall Stereochemistry on the 
Activity of Daptomycin. Bioorganic Med. Chem. 2019, 27, 240–246. 
(118)  Lau, Y. H.; Spring, D. R. Efficient Synthesis of Fmoc-Protected Azido Amino Acids. 
Synlett 2011, 1917–1919. 
(119)  Pícha, J.; Budesinsky, M.; Machackova, K.; Collinsová, M.; Jiracek, J. Optimized 
Syntheses of Fmoc Azido Amino Acids for the Preparation of Azidopeptides. J. Pept. 
Sci. 2017, 23, 202–214. 
(120)  Thakkar, A.; Trinh, T. B.; Pei, D. Global Analysis of Peptide Cyclization Efficiency. 
ACS Comb. Sci. 2013, 15, 120–129. 
(121)  Knerr, P. J.; van der Donk, W. A. Chemical Synthesis and Biological Activity of 
Analogues of the Lantibiotic Epilancin 15X. J. Am. Chem. Soc. 2012, 134, 7648–7651. 
(122)  Alsina, J.; Barany, G.; Albericio, F.; Kates, S. A. Pyrrolidide Formation as a Side 
Reaction during Activation of Carboxylic Acids by Phosphonium Salt Coupling 
350 
 
Reagents. Lett. Pept. Sci. 1999, 6, 243–245. 
(123)  Eliopoulos, G. M.; Willey, S.; Reiszner, E.; Spitzer, P. G.; Caputo, G.; Moellering, R. 
C. In vitro and in vivo Activity of LY 146032, a New Cyclic Lipopeptide Antibiotic. 
Antimicrob. Agents Chemother. 1986, 30 (4), 532–535. 
(124)  Luo, Y.; Evindar, G.; Fishlock, D.; Lajoie, G. A. Synthesis of N-Protected N-Methyl 
Serine and Threonine. Tetrahedron Lett. 2001, 42, 3807–3809. 
(125)  Aguda, A. H.; Lavallee, V.; Cheng, P.; Bott, T. M.; Meimetis, L. G.; Law, S.; Nguyen, 
N. T.; Williams, D. E.; Kaleta, J.; Villanueva, I.; Davies, J.; Andersen, R. J.; Brayer, 
G. D.; Bromme, D. Affinity Crystallography: A New Approach to Extracting High-
Affinity Enzyme Inhibitors from Natural Extracts. J. Nat. Prod. 2016, 79, 1962–1970. 
(126)  Su, Y.; Degrado, W. F.; Hong, M. Orientation, Dynamics, and Lipid Interaction of an 
Antimicrobial Arylamide Investigated by 19F and 31P Solid-State NMR Spectroscopy. 
J. Am. Chem. Soc. 2010, 132 (1), 9197–9205. 
(127)  Afonin, S.; Dürr, U. H. N.; Glaser, R. W.; Ulrich, A. S. ’Boomerang’-like Insertion of 
a Fusogenic Peptide in a Lipid Membrane Revealed by Solid-State 19F NMR. Magn. 
Reson. Chem. 2004, 42, 195–203. 
(128)  Cobb, S. L.; Murphy, C. D. 19F NMR Applications in Chemical Biology. J. Fluor. 
Chem. 2009, 130, 132–143. 
(129)  Prosser, R. S.; Evanics, F.; Kitevski, J. L.; Patel, S. The Measurement of Immersion 
Depth and Topology of Membrane Proteins by Solution State NMR. Biochim. 
Biophys. Acta 2007, 1768, 3044–3051. 
(130)  Marsh, E. N. G.; Suzuki, Y. Using 19F NMR to Probe Biological Interactions of 
Proteins and Peptides. ACS Chem. Biol. 2014, 9, 1242–1250. 
(131)  Afonin, S.; Glaser, R. W.; Berditchevskaia, M.; Wadhwani, P.; Guhrs, K.-H.; 
Mollmann, U.; Perner, A.; Ulrich, A. S. 4-Fluorophenylglycine as a Label for 19F 
NMR Structure Analysis of Membrane-Associated Peptides. ChemBioChem 2003, 4, 
1151–1163. 
(132)  Anderluh, G.; Razpotnik, A.; Podlesek, Z.; Macek, P.; Separovic, F.; Norton, R. S. 
Interaction of the Eukaryotic Pore-Forming Cytolysin Equinatoxin II with Model 
Membranes: 19 F NMR Studies. J. Mol. Biol. 2005, 347, 27–39. 
(133)  Caaveiro, J. M. M.; Echabe, I.; Gutierrez-Aguirre, I.; Nieva, J. L.; Arrondo, J. L. R.; 
Gonzalez-Manas, J. M. Differential Interaction of Equinatoxin II with Model 
Membranes in Response to Lipid Composition. Biophys. J. 2001, 80, 1343–1353. 
(134)  Li, C.; Lutz, E. A.; Slade, K. M.; Ruf, R. A. S.; Wang, G.-F.; Pielak, G. J. 19F NMR 
Studies of α-Synuclein Conformation and Fibrillation. Biochemistry 2009, 48, 8578–
8584. 
(135)  Buer, B. C.; Chugh, J.; Al-hashimi, H. M.; Marsh, E. N. G. Using Fluorine Nuclear 
Magnetic Resonance To Probe the Interaction of Membrane-Active Peptides with the 
Lipid Bilayer. Biochemistry 2010, 49, 5760–5765. 
(136)  Suzuki, Y.; Buer, B. C.; Al-hashimi, H. M.; Marsh, E. N. G. Using Fluorine Nuclear 
351 
 
Magnetic Resonance to Probe Changes in the Structure and Dynamics of Membrane-
Active Peptides Interacting with Lipid Bilayers. Biochemistry 2011, 50, 5979–5987. 
(137)  Buer, B. C.; Levin, B. J.; Marsh, E. N. G. Perfluoro-tert-Butyl-Homoserine as a 
Sensitive 19F NMR Reporter for Peptide–Membrane Interactions in Solution. J. Pept. 
Sci. 2013, 19, 308–314. 
(138)  Wang, G.; Li, C.; Pielak, G. J. 19F NMR Studies of α-Synuclein-Membrane 
Interactions. Protein Sci. 2010, 19, 1686–1691. 
(139)  Ball, L.-J.; Goult, C. M.; Donarski, J. A.; Micklefield, J.; Ramesh, V. NMR Structure 
Determination and Calcium Binding Effects of Lipopeptide Antibiotic Daptomycin. 
Org. Biomol. Chem. 2004, 2, 1872–1878. 
(140)  Rotondi, K. S.; Gierasch, L. M. A Well-Defined Amphipathic Conformation for the 
Calcium-Free Cyclic Lipopeptide Antibiotic, Daptomycin, in Aqueous Solution. 
Biopolymers 2005, 80, 374–385. 
(141)  Scott, W. R. P.; Baek, S.; Jung, D.; Hancock, R. E. W.; Straus, S. K. NMR Structural 
Studies of the Antibiotic Lipopeptide Daptomycin in DHPC Micelles. Biochim. 
Biophys. Acta 2007, 1768, 3116–3126. 
(142)  Graton, J.; Laurence, C.; Berthelot, M.; Questel, J.-Y. Le; Besseau, F.; Raczynska, E. 
D. Hydrogen-Bond Basicity pKHB Scale of Aliphatic Primary Amines. J. Chem. Soc. 
Perkin Trans. 2 1999, 2, 997–1001. 
(143)  Konermann, L. Addressing a Common Misconception: Ammonium Acetate as Neutral 
pH “Buffer” For Native Electrospray Mass Spectrometry. J. Am. Soc. Mass Spectrom. 
2017, 28, 1827–1835. 
(144)  Qiu, J.; Yu, L.; Kirsch, L. E. Estimated pKA Values for Specific Amino Acid Residues 
in Daptomycin. J. Pharm. Sci. 2010, 100 (10), 4225–4233. 
(145)  Haidle, A. M.; Burch, J.; Guay, D.; Gauthier, J. Y.; Robichaud, J.; Fournier, J. F.; 
Ellis, J. M.; Christopher, M.; Kattar, S. D.; Smith, G.; Northrup, A. B. Substituted 
Phenyl Spleen Tyrosine Kinase (Syk) Inhibitors. WO Pat. 2014, WO20140314, 115. 
(146)  Bijan, P.; Shuo, Z.; Yixing, S.; van Oeveren, A.; Zhi, L. A1 Androgen Receptor 
Modulator Compounds and Methods. US Pat. 2009, US20093002. 
(147)  Van Oeveren, A.; Motamedi, M.; Mani, N. S.; Marschke, K. B.; Lopez, F. J.; 
Schrader, W. T.; Negro-Vilar, A.; Zhi, L. 4-Trifluoromethylquinolin-2-(1H)-one as a 
Novel Selective Androgen Receptor Modulator. J. Med. Chem. 2006, 49, 6143–6146. 
(148)  van Oeveren, A.; Pio, B. A.; Tegley, C. M.; Higuchi, R. I.; Wu, M.; Zhi, L.; Jones, T. 
K.; Marschke, K. B.; Negro-Vilar, A.; Zhi, L. Discovery of an Androgen Receptor 
Modulator Pharmacophore Based on 2-Quinolinones. Bioorganic Med. Chem. Lett. 
2007, 17, 1523–1526. 
(149)  Noden, M.; Marlyn, J.; Taylor, S. Unpublished Results. 
(150)  Kotoris, C. C. The Synthesis of Novel Organofluorines by Electrophilic Fluorination 




(151)  Hill, B.; Ahmed, V.; Bates, D.; Taylor, S. D. Enantioselective Synthesis of Protected 
L-4-[Sulfonamido(Difluoromethyl)]Phenylalanine and L-4-
[Sulfonamido(Methyl)]Phenylalanine and an Examination of Hexa-and Tripeptide 
Platforms for Evaluating PTyr Mimics for PTP1B Inhibition. J. Org. Chem. 2006, 71, 
8190–8197. 
(152)  Chen, G.; Shigenari, T.; Jain, P.; Zhang, Z.; Jin, Z.; He, J.; Li, S.; Mapelli, C.; Miller, 
M. M.; Poss, M. A.; Scola, P. M.; Yeung, K.-S.; Yu, J.-Q. Ligand-Enabled β‑C−H 
Arylation of α‑Amino Acids Using a Simple and Practical Auxiliary. J. Am. Chem. 
Soc. 2015, 137, 3338–3351. 
(153)  Combret, Y.; Duflos, J.; Dupas, G.; Bourguignon, J.; Queguiner, G. Variations of the 
Nature of the Chiral Auxiliary with a Highly Enantioselective Chiral NADH Model. 
Tetrahedron: Asymmetry 1993, 4 (7), 1635–1644. 
(154)  Lovelock, S. L.; Lloyd, R. C.; Turner, N. J. Phenylalanine Ammonia Lyase Catalyzed 
Synthesis of Amino Acids by an MIO-Cofactor Independent Pathway. Angew. Chemie 
Int. Ed. 2014, 53, 4652–4656. 
(155)  Parmeggiani, F.; Lovelock, S. L.; Weise, N. J.; Ahmed, S. T.; Turner, N. J. Synthesis 
of D- and L-Phenylalanine Derivatives by Phenylalanine Ammonia Lyases: A 
Multienzymatic Cascade Process. Angew. Chemie Int. Ed. 2015, 54, 4608–4611. 
(156)  Williams, R. M.; Im, M.-N. Assymetric Synthesis of Monosubstituted and α,α-
Disubstituted α-Amino Acids via Diastereoselective Glycine Enolate Alkylations. J. 
Am. Chem. Soc. 1991, 113, 9276–9286. 
(157)  Van Den Nieuwendijk, A. M. C. H.; Kriek, N. M. A. J.; Brussee, J.; Van Boom, J. H.; 
van der Gen, A. Stereoselective Synthesis of (2R,5R)- and (2S,5R)-5-Hydroxylysine. 
European J. Org. Chem. 2000, 2000, 3683–3691. 
(158)  Allevi, P.; Anastasia, M. A Practical and Simple Synthesis of (2S,5R)- and (2S,5S)-5-
Hydroxylysine and of a Related α-Amino Acid Required for the Synthesis of the 
Collagen Cross-Link Pyridinoline. Tetrahedron: Asymmetry 2004, 15, 2091–2096. 
(159)  Dastlik, K. A.; Sundermeier, U.; Johns, D. M.; Chen, Y.; Williams, R. M. An 
Improved Synthesis of Optically Pure 4-Boc-5,6-diphenylmorpholin-2-one and 4-Cbz-
5,6-diphenylmorpholin-2-one. Synlett 2005, 2005 (4), 693–696. 
(160)  Liu, J.; Xu, X.-H.; Qing, F.-L. Silver-Mediated Oxidative Trifluoromethylation of 
Alcohols to Alkyl Trifluoromethyl Ethers. Org. Lett. 2015, 17, 5048–5051. 
(161)  Brown, Z. Z.; Muller, M. M.; Jain, S. U.; Allis, C. D.; Lewis, P. W.; Muir, T. W. 
Strategy for “Detoxification” of a Cancer-Derived Histone Mutant Based on Mapping 
Its Interaction with the Methyltransferase PRC2. J. Am. Chem. Soc. 2014, 136, 13498–
13501. 
(162)  Duewel, H.; Daub, E.; Robinson, V.; Honek, J. F. Incorporation of 
Trifluoromethionine into a Phage Lysozyme: Implications and a New Marker for Use 
in Protein 19F NMR. Biochemistry 1997, 36, 3404–3416. 
(163)  Qiu, J.; Kirsch, L. E. Evaluation of Lipopeptide (Daptomycin) Aggregation Using 
Fluorescence, Light Scattering, and Nuclear Magnetic Resonance Spectroscopy. J. 
353 
 
Pharm. Sci. 2014, 103, 853–861. 
(164)  Ho, S. W.; Jung, D.; Calhoun, J. R.; Lear, J. D.; Okon, M.; Scott, W. R. P.; Hancock, 
R. E. W.; Straus, S. K. Effect of Divalent Cations on the Structure of the Antibiotic 
Daptomycin. Eur. Biophys. J. 2008, 37, 421–433. 
(165)  Wenisch, J. M.; Meyer, B.; Fuhrmann, V.; Saria, K.; Zuba, C.; Dittrich, P.; 
Thalhammer, F. Multiple-Dose Pharmacokinetics of Daptomycin during Continuous 
Venovenous Haemodiafiltration. J. Antimicrob. Chemother. 2012, 67, 977–983. 
(166)  Vilay, A. M.; Grio, M.; Depestel, D. D.; Sowinski, K. M.; Gao, L.; Heung, M.; 
Salama, N. N.; Mueller, B. A.; Nct, I.; Care, C. Daptomycin Pharmacokinetics in 
Critically Ill Patients Receiving Continuous Venovenous Hemodialysis. Crit. Care 
Med. 2011, 39 (1), 19–25. 
(167)  Benvenuto, M.; Benziger, D. P.; Yankelev, S.; Vigliani, G. Pharmacokinetics and 
Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body 
Weight Once Daily in Healthy Volunteers. Antimicrob. Agents Chemother. 2006, 50 
(10), 3245–3249. 
(168)  Dvorchik, B. H.; Brazier, D.; Debruin, M. F.; Arbeit, R. D. Daptomycin 
Pharmacokinetics and Safety Following Administration of Escalating Doses Once 
Daily to Healthy Subjects Daptomycin Pharmacokinetics and Safety Following 
Administration of Escalating Doses Once Daily to Healthy Subjects. Antimicrob. 
Agents Chemother. 2003, 47 (4), 1318–1323. 
(169)  Kleckner, I. R.; Foster, M. P. An Introduction to NMR-Based Approaches for 
Measuring Protein Dynamics. Biochim. Biophys. Acta - Proteins Proteomics 2011, 
1814, 942–968. 
(170)  Kreutz, C.; Micura, R. Investigations on Fluorine-Labelled Ribonucleic Acids by 19F 
NMR Spectroscopy. In Modified Nucleosides; 2008; pp 3–20. 
(171)  Rubin, H.; Cockrell, J.; Morgan, J. B. Scalable Synthesis of N‑Acylaziridines from 
N‑Tosylaziridines. J. Org. Chem. 2013, 78, 8865–8871. 
(172)  Busca, P.; Paradisi, F.; Moynihan, E.; Maguire, A. R.; Engel, P. C. Enantioselective 
Synthesis of Non-Natural Amino Acids Using Phenylalanine Dehydrogenases 
Modified by Site-Directed Mutagenesis. Org. Biomol. Chem. 2004, 2, 2684–2691. 
(173)  Takrouri, K.; Chen, T.; Papadopoulos, E.; Sahoo, R.; Kabha, E.; Chen, H.; Cantel, S.; 
Wagner, G.; Halperin, J. A.; Aktas, B. H.; Chorev, M. Structure-Activity Relationship 
Study of 4EGI-1, Small Molecule EIF4E/EIF4G Protein-Protein Interaction Inhibitors. 
Eur. J. Med. Chem. 2014, 77, 361–377. 
(174)  Lopez-Tapia, F.; Brotherton-Pleiss, C.; Yue, P.; Murakami, H.; Carolina Costa Araujo, 
A.; Reis dos Santos, B.; Ichinotsubo, E.; Rabkin, A.; Shah, R.; Lantz, M.; Chen, S.; 
Tius, M. A.; Turkson, J. Linker Variation and Structure–Activity Relationship 
Analyses of Carboxylic Acid-Based Small Molecule STAT3 Inhibitors. ACS Med. 
Chem. Lett. 2018, 9, 250–255. 
(175)  Yang, L.; Zhang, Z.; Cheng, B.; You, Y.; Wu, D.; Hong, C. Two Tandem 
Multicomponent Reactions for the Synthesis of Sequence-Defined Polymers. Sci. 
354 
 
China Chem. 2015, 58, 1734–1740. 
(176)  Langlois, B.; Montegre, D.; Roidot, N. Synthesis of S-Trifluoromethyl-Containing α-
Amino Acids from Sodium Trifluoromethanesulfinate and Dithio-Amino Acids. J. 
Fluor. Chem. 1994, 68, 63–66. 
 
 
 
 
